Our O
data O
suggest O
that O
lipoxygenase B
metabolites I
activate O
ROI O
formation O
which O
then O
induce O
IL B
- I
2 I
expression O
via O
NF B
- I
kappa I
B I
activation O
. O

This O
is O
the O
first O
description O
of O
an O
HIV B
- I
2 I
enhancer I
element I
which O
displays O
such O
monocyte O
specificity O
, O
and O
no O
comparable O
enhancer B
element I
has O
been O
clearly O
defined O
for O
HIV O
- O
1 O
. O

While O
a O
nuclear B
factor I
( O
s O
) O
from O
both O
peripheral O
blood O
monocytes O
and O
T O
cells O
binds O
the O
peri B
- I
kappa I
B I
site I
, O
electrophoretic O
mobility O
shift O
assays O
suggest O
that O
either O
a O
different O
protein O
binds O
to O
this O
site O
in O
monocytes O
versus O
T O
cells O
or O
that O
the O
protein O
recognizing O
this O
enhancer B
element I
undergoes O
differential O
modification O
in O
monocytes O
and O
T O
cells O
, O
thus O
supporting O
the O
transfection O
data O
. O

While O
a O
nuclear B
factor I
( O
s O
) O
from O
both O
peripheral O
blood O
monocytes O
and O
T O
cells O
binds O
the O
peri B
- I
kappa I
B I
site I
, O
electrophoretic O
mobility O
shift O
assays O
suggest O
that O
either O
a O
different O
protein O
binds O
to O
this O
site O
in O
monocytes O
versus O
T O
cells O
or O
that O
the O
protein O
recognizing O
this O
enhancer B
element I
undergoes O
differential O
modification O
in O
monocytes O
and O
T O
cells O
, O
thus O
supporting O
the O
transfection O
data O
. O

Distinct O
signaling O
properties O
identify O
functionally O
different O
CD4 B
epitopes I
. O

ER B
- O
mediated O
repression O
of O
GATA B
- I
1 I
activity O
occurs O
on O
an O
artificial B
promoter I
containing O
a O
single O
GATA B
- I
binding I
site I
, O
as O
well O
as O
in O
the O
context O
of O
an O
intact B
promoter I
which O
is O
normally O
regulated O
by O
GATA B
- I
1 I
. O

ER B
- O
mediated O
repression O
of O
GATA B
- I
1 I
activity O
occurs O
on O
an O
artificial B
promoter I
containing O
a O
single O
GATA B
- I
binding I
site I
, O
as O
well O
as O
in O
the O
context O
of O
an O
intact B
promoter I
which O
is O
normally O
regulated O
by O
GATA B
- I
1 I
. O

Rather O
, O
EBV O
remains O
in O
a O
linear O
configuration O
from O
which O
replicative B
genes I
are O
transcribed O
. O

We O
demonstrate O
, O
through O
the O
deletion O
of O
the O
human B
UDG I
promoter I
sequences I
, O
that O
expression O
of O
E2F B
- I
1 I
activates O
the O
UDG B
promoter I
through O
several O
E2F B
sites I
. O

We O
demonstrate O
, O
through O
the O
deletion O
of O
the O
human B
UDG I
promoter I
sequences I
, O
that O
expression O
of O
E2F B
- I
1 I
activates O
the O
UDG B
promoter I
through O
several O
E2F B
sites I
. O

In O
addition O
, O
IL B
- I
2 I
but O
not O
IL B
- I
12 I
induced O
nuclear B
factors I
NF B
- I
kappa I
B I
and O
AP1 B
, O
and O
regulation O
of O
the O
nuclear O
levels O
of O
these O
two O
DNA B
binding I
protein I
complexes I
is O
correlated O
with O
IFN O
- O
gamma O
and O
GM O
- O
CSF O
gene O
expression O
. O

alpha B
B I
is O
the O
mouse B
homologue I
of O
human B
AML1 I
gene I
detected O
at O
the O
breakpoints O
of O
t O
( O
8 O
; O
21 O
) O
and O
t O
( O
3 O
; O
21 O
) O
myeloid O
leukemias O
. O

alpha B
B I
is O
the O
mouse B
homologue I
of O
human B
AML1 I
gene I
detected O
at O
the O
breakpoints O
of O
t O
( O
8 O
; O
21 O
) O
and O
t O
( O
3 O
; O
21 O
) O
myeloid O
leukemias O
. O

We O
examined O
alpha B
A1 I
( O
an O
alpha B
A I
- I
gene I
product I
) O
and O
alpha B
B1 I
and O
alpha B
B2 I
( O
two O
alpha B
B I
- I
encoded I
isomers I
) O
for O
their O
effects O
on O
the O
GM B
- I
CSF I
promoter I
. O

We O
examined O
alpha B
A1 I
( O
an O
alpha B
A I
- I
gene I
product I
) O
and O
alpha B
B1 I
and O
alpha B
B2 I
( O
two O
alpha B
B I
- I
encoded I
isomers I
) O
for O
their O
effects O
on O
the O
GM B
- I
CSF I
promoter I
. O

We O
examined O
alpha B
A1 I
( O
an O
alpha B
A I
- I
gene I
product I
) O
and O
alpha B
B1 I
and O
alpha B
B2 I
( O
two O
alpha B
B I
- I
encoded I
isomers I
) O
for O
their O
effects O
on O
the O
GM B
- I
CSF I
promoter I
. O

Although O
further O
studies O
are O
required O
to O
determine O
the O
precise O
role O
of O
PEBP2 B
in O
the O
GM B
- I
CSF I
promoter O
activity O
, O
the O
present O
findings O
suggested O
the O
importance O
of O
the O
relative O
ratio O
of O
different O
PEBP2 B
isoforms I
in O
regulating O
the O
levels O
of O
the O
promoter O
activity O
. O

The O
induction O
of O
cytokine B
expression O
in O
monocytes O
/ O
macrophages O
by O
bacterial B
endotoxin I
or O
lipopolysaccharide O
is O
a O
critical O
, O
highly O
regulated O
host O
defence O
response O
. O

H O
- O
89 O
substantially O
suppressed O
LPS O
- O
induced O
TNF B
mRNA I
accumulation O
in O
unprimed O
cells O
, O
but O
had O
no O
effect O
on O
primed O
monocytes O
following O
LPS O
stimulation O
. O

A O
Myc B
- I
associated I
zinc I
finger I
protein I
binding I
site I
is O
one O
of O
four O
important O
functional B
regions I
in O
the O
CD4 B
promoter I
. O

A O
Myc B
- I
associated I
zinc I
finger I
protein I
binding I
site I
is O
one O
of O
four O
important O
functional B
regions I
in O
the O
CD4 B
promoter I
. O

Since O
the O
terminal O
events O
of O
erythropoiesis O
are O
controlled O
by O
the O
glycoprotein B
hormone I
erythropoietin I
( O
Epo B
) O
, O
we O
investigated O
whether O
the O
expression O
or O
activity O
of O
the O
TAL1 B
gene I
and O
its O
protein B
products I
were O
affected O
by O
Epo B
in O
splenic O
erythroblasts O
from O
mice O
infected O
with O
an O
anemia O
- O
inducing O
strain O
of O
Friend O
virus O
( O
FVA O
cells O
) O
. O

Since O
the O
terminal O
events O
of O
erythropoiesis O
are O
controlled O
by O
the O
glycoprotein B
hormone I
erythropoietin I
( O
Epo B
) O
, O
we O
investigated O
whether O
the O
expression O
or O
activity O
of O
the O
TAL1 B
gene I
and O
its O
protein B
products I
were O
affected O
by O
Epo B
in O
splenic O
erythroblasts O
from O
mice O
infected O
with O
an O
anemia O
- O
inducing O
strain O
of O
Friend O
virus O
( O
FVA O
cells O
) O
. O

Interestingly O
, O
when O
we O
mutated O
the O
Sp1 B
site I
, O
resulting O
in O
a O
marked O
decrease O
in O
hEpoR B
promoter I
activity O
, O
we O
could O
restore O
transactivation O
by O
increasing O
GATA B
- I
1 I
levels O
in O
OCIM1 O
cells O
. O

Interestingly O
, O
when O
we O
mutated O
the O
Sp1 B
site I
, O
resulting O
in O
a O
marked O
decrease O
in O
hEpoR B
promoter I
activity O
, O
we O
could O
restore O
transactivation O
by O
increasing O
GATA B
- I
1 I
levels O
in O
OCIM1 O
cells O
. O

These O
data O
suggest O
that O
while O
GATA B
- I
1 I
can O
transactivate O
the O
EpoR B
promoter I
, O
the O
level O
of O
hEpoR B
gene I
expression O
does O
not O
depend O
on O
GATA B
- I
1 I
alone O
. O

These O
data O
suggest O
that O
while O
GATA B
- I
1 I
can O
transactivate O
the O
EpoR B
promoter I
, O
the O
level O
of O
hEpoR B
gene I
expression O
does O
not O
depend O
on O
GATA B
- I
1 I
alone O
. O

The O
deduced O
amino O
acid O
sequence O
similarity O
to O
the O
proteins O
encoded O
by O
these O
two O
latter O
genes O
is O
approximately O
65 O
% O
and O
includes O
domains O
and O
amino O
acid O
residues O
( O
the O
leucine B
zipper I
- I
like I
and O
the O
RGD B
domain I
, O
a O
serine O
and O
a O
histidine O
residue O
in O
the O
NH2 B
- I
and O
in O
the O
COOH B
- I
terminal I
portion I
of O
the O
protein O
, O
respectively O
) O
postulated O
to O
be O
important O
for O
nm23 B
function O
. O

The O
deduced O
amino O
acid O
sequence O
similarity O
to O
the O
proteins O
encoded O
by O
these O
two O
latter O
genes O
is O
approximately O
65 O
% O
and O
includes O
domains O
and O
amino O
acid O
residues O
( O
the O
leucine B
zipper I
- I
like I
and O
the O
RGD B
domain I
, O
a O
serine O
and O
a O
histidine O
residue O
in O
the O
NH2 B
- I
and O
in O
the O
COOH B
- I
terminal I
portion I
of O
the O
protein O
, O
respectively O
) O
postulated O
to O
be O
important O
for O
nm23 B
function O
. O

Genomic O
sequence O
upstream O
of O
the O
Fc B
gamma I
RIC I
gene I
was O
cloned O
and O
subjected O
to O
primer O
extension O
analysis O
, O
which O
demonstrated O
a O
single O
transcription B
initiation I
site I
without O
a O
TATA B
box I
. O

Double B
- I
stranded I
GIRE I
sequence I
, O
but O
not O
a O
scrambled B
sequence I
, O
was O
specifically O
bound O
by O
nuclear B
proteins I
from O
IFN O
- O
gamma O
treated O
U937 O
cells O
. O

Double B
- I
stranded I
GIRE I
sequence I
, O
but O
not O
a O
scrambled B
sequence I
, O
was O
specifically O
bound O
by O
nuclear B
proteins I
from O
IFN O
- O
gamma O
treated O
U937 O
cells O
. O

In O
HTLV O
- O
I O
- O
infected O
cord O
blood O
lymphocytes O
, O
the O
transition O
from O
IL B
- I
2 I
- O
dependent O
to O
IL B
- I
2 I
- O
independent O
growth O
correlated O
with O
the O
acquisition O
of O
a O
constitutively O
activated O
Jak B
- B
STAT I
pathway O
, O
which O
suggests O
that O
this O
pathway O
participates O
in O
HTLV O
- O
I O
- O
mediated O
T O
cell O
transformation O
. O

Nitric O
oxide O
selectively O
reduces O
endothelial O
expression O
of O
adhesion B
molecules I
and O
proinflammatory B
cytokines I
. O

Nitric O
oxide O
selectively O
reduces O
endothelial O
expression O
of O
adhesion B
molecules I
and O
proinflammatory B
cytokines I
. O

Murine B
macrophage I
inflammatory I
protein I
1 I
alpha I
( O
MIP B
- I
1 I
alpha I
) O
and O
its O
human B
equivalent I
( O
GOS19 B
, O
LD78 B
, O
or O
AT464 B
) O
are O
members O
of O
the O
- B
C I
- I
C I
family I
of O
low B
- I
molecular I
- I
weight I
chemokines I
. O

We O
provide O
evidence O
for O
an O
additional O
binding B
site I
, O
the O
MIP B
- I
1 I
alpha I
nuclear I
protein I
( I
MNP I
) I
site I
, O
which O
overlaps O
the O
ICK B
- I
1 I
site I
. O

The O
signal O
is O
subsequently O
propagated O
through O
the O
activation O
of O
Raf B
- I
1 I
, O
MEK B
, O
and O
MAP B
kinases I
as O
shown O
by O
their O
increased O
autophosphorylation O
in O
vitro O
and O
phosphorylation O
in O
situ O
. O

We O
conclude O
that O
IL B
- I
5 I
induced O
signals O
are O
propagated O
through O
two O
distinct O
pathways O
: O
( O
1 O
) O
Lyn B
- O
- O
> O
Ras B
- O
- O
> O
Raf B
- I
1 I
- O
- O
> O
MEK B
- O
- O
> O
MAP B
kinase I
and O
( O
2 O
) O
Jak2 B
- O
- O
> O
STAT1 B
. O

We O
found O
that O
the O
retinoblastoma B
susceptibility I
gene I
product I
( O
Rb B
) O
dramatically O
suppressed O
this O
IE2 B
transactivation O
of O
various B
promoters I
. O

And O
there O
was O
no O
statistically O
significant O
difference O
in O
NDP B
kinase I
expression O
between O
SCC O
with O
metastasis O
and O
SCC O
without O
metastasis O
. O

Retinoblastoma B
protein I
( O
RB B
) O
is O
a O
tumor O
suppressor O
and O
functions O
as O
a O
transcriptional B
repressor I
by O
binding O
and O
inactivating O
the O
transactivator B
E2F I
- I
I I
. O

Retinoblastoma B
protein I
( O
RB B
) O
is O
a O
tumor O
suppressor O
and O
functions O
as O
a O
transcriptional B
repressor I
by O
binding O
and O
inactivating O
the O
transactivator B
E2F I
- I
I I
. O

Furthermore O
, O
we O
show O
that O
IL B
- I
12 I
stimulates O
formation O
of O
a O
DNA B
- I
binding I
complex I
that O
recognizes O
a O
DNA O
sequence O
previously O
shown O
to O
bind O
STAT B
proteins I
and O
that O
this O
complex O
contains O
STAT4 B
. O

DESIGN O
: O
The O
effects O
of O
hypercortisolaemia O
, O
hyperthermia O
and O
cellular O
composition O
on O
number O
of O
glucocorticoid B
receptors I
per O
cell O
and O
their O
affinity O
were O
evaluated O
, O
both O
in O
vitro O
and O
in O
vivo O
, O
in O
peripheral O
blood O
mononuclear O
leucocytes O
of O
control O
subjects O
and O
in O
patients O
with O
sepsis O
or O
septic O
shock O
. O

RESULTS O
: O
Hypercortisolaemia O
, O
in O
vitro O
, O
resulted O
in O
a O
decreased O
affinity O
and O
a O
decreased O
binding O
capacity O
of O
the O
glucocorticoid B
receptor I
. O

To O
determine O
if O
New O
World O
primates O
express O
an O
inhibitor O
that O
influences O
glucocorticoid B
receptor I
( O
GR B
) O
binding O
characteristics O
, O
we O
examined O
[ O
3H O
] O
dexamethasone O
binding O
in O
cytosol O
prepared O
from O
B95 O
- O
8 O
lymphoid O
cells O
, O
derived O
from O
the O
cotton O
top O
tamarin O
( O
Saguinus O
oedipus O
) O
, O
in O
combination O
with O
cytosol O
prepared O
from O
human O
or O
rat O
tissues O
. O

The O
results O
further O
demonstrated O
the O
activation O
of O
S6 B
kinase I
( O
pp90rsk B
) O
, O
evidenced O
by O
phosphorylation O
of O
S6 B
and O
serum O
response O
factor O
( O
SRF O
) O
peptides O
, O
in O
PWM O
treated O
B O
cells O
. O

We O
have O
recently O
found O
a O
novel O
conserved B
motif I
in O
the O
promoters B
of O
several O
T B
- I
cell I
- I
expressed I
cytokines I
[ O
human B
interleukin I
- I
2 I
, I
- I
4 I
, I
- I
5 I
and I
- I
13 I
and O
human B
and I
mouse I
granulocyte I
/ I
macrophage I
- I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
] O
. O

In O
transfection O
assays O
, O
the O
human B
GM I
- I
CSF I
element I
has O
a O
strong O
positive O
effect O
on O
the O
expression O
of O
a O
reporter B
gene I
by O
the O
human O
T O
cell O
line O
Jurkat O
J6 O
upon O
stimulation O
. O

In O
different O
genes B
, O
the O
core B
sequences I
are O
separated O
by O
integer O
numbers O
of O
helical O
turns O
. O

The O
5 B
' I
flanking I
region I
of O
the O
human B
alpha I
- I
globin I
gene I
is O
highly O
G O
+ O
C O
rich O
and O
contains O
multiple O
copies O
of O
the O
consensus B
sequence I
for O
the O
Sp1 B
binding I
site I
. O

Finally O
, O
we O
show O
by O
both O
footprint O
analysis O
and O
functional O
assays O
that O
the O
ability O
of O
the O
G B
+ I
C I
- I
rich I
region I
to O
increase O
alpha B
- I
globin I
promoter I
activity O
from O
a O
stably O
integrated O
alpha B
- I
globin I
gene I
is O
mediated O
by O
its O
multiple B
binding I
sites I
for O
the O
transcription B
factor I
Sp1 B
. O

The O
Ah B
receptor I
recognizes O
DNA B
binding I
sites I
for O
the O
B B
cell I
transcription I
factor I
, O
BSAP B
: O
a O
possible O
mechanism O
for O
dioxin O
- O
mediated O
alteration O
of O
CD19 B
gene I
expression O
in O
human O
B O
lymphocytes O
. O

The O
Ah B
receptor I
recognizes O
DNA B
binding I
sites I
for O
the O
B B
cell I
transcription I
factor I
, O
BSAP B
: O
a O
possible O
mechanism O
for O
dioxin O
- O
mediated O
alteration O
of O
CD19 B
gene I
expression O
in O
human O
B O
lymphocytes O
. O

In O
addition O
, O
the O
Ah B
receptor I
complex I
recognized O
a O
DNA B
binding I
site I
for O
B B
cell I
lineage I
- I
specific I
activator I
protein I
( O
BSAP B
) O
in O
the O
promoter B
region I
of O
the O
human O
CD19 B
gene I
which O
is O
similar O
to O
the O
consensus B
Ah I
receptor I
DNA I
binding I
site I
. O

In O
addition O
, O
the O
Ah B
receptor I
complex I
recognized O
a O
DNA B
binding I
site I
for O
B B
cell I
lineage I
- I
specific I
activator I
protein I
( O
BSAP B
) O
in O
the O
promoter B
region I
of O
the O
human O
CD19 B
gene I
which O
is O
similar O
to O
the O
consensus B
Ah I
receptor I
DNA I
binding I
site I
. O

We O
recently O
identified O
a O
differentiation B
inhibitory I
factor I
( O
I B
- I
factor I
) O
in O
mouse O
myeloid O
leukemia O
M1 O
cells O
as O
a O
murine B
homolog I
of O
the O
human B
nm23 I
- I
H2 I
gene I
product I
. O

In O
the O
present O
experiment O
, O
we O
examined O
the O
effect O
of O
nm23 B
proteins I
on O
various O
differentiation O
induction O
systems O
of O
human O
leukemic O
cells O
including O
HL O
- O
60 O
, O
U937 O
, O
HEL O
/ O
S O
, O
KU812F O
, O
K562 O
, O
and O
HEL O
cells O
. O

Delayed O
administration O
of O
rBPI21 B
also O
affected O
LPS O
- O
mediated O
activation O
of O
the O
nuclear B
factor I
, O
NF B
- I
kappa I
B I
. O

3 O
. O
Danazol O
decreased O
the O
transcription O
rate O
of O
ER B
gene I
to O
approximately O
50 O
% O
in O
monocytes O
in O
a O
run O
- O
on O
assay O
. O

From O
nuclear O
runoff O
experiments O
, O
we O
found O
that O
one O
subunit O
in O
particular O
, O
the O
B2 B
isoform I
( O
Mr O
= O
56 O
, O
000 O
) O
, O
was O
amplified O
primarily O
by O
transcriptional O
means O
. O

These O
results O
imply O
that O
at O
least O
three O
signals O
are O
required O
to O
activate O
the O
GM B
- I
CSF I
proximal I
promoter I
, O
and O
that O
the O
signals O
impinge O
on O
distinct O
transcription B
factors I
that O
bind O
to O
the O
hCLEO B
and I
NF I
- I
kappa I
B I
regions I
of O
the O
promoter B
. O

In O
this O
report O
, O
we O
show O
that O
in O
monocytes O
and O
T O
cells O
IL B
- I
10 I
stimulates O
tyrosine O
phosphorylation O
of O
the O
signal B
transducers I
and O
activators B
of I
transcription I
, O
STAT1 B
alpha I
and O
STAT3 B
, O
in O
a O
differential O
manner O
such O
that O
the O
relative O
formation O
of O
homo B
- I
and I
heterodimers I
varies O
between O
the O
two O
cell O
types O
. O

In O
this O
report O
, O
we O
show O
that O
in O
monocytes O
and O
T O
cells O
IL B
- I
10 I
stimulates O
tyrosine O
phosphorylation O
of O
the O
signal B
transducers I
and O
activators B
of I
transcription I
, O
STAT1 B
alpha I
and O
STAT3 B
, O
in O
a O
differential O
manner O
such O
that O
the O
relative O
formation O
of O
homo B
- I
and I
heterodimers I
varies O
between O
the O
two O
cell O
types O
. O

They O
also O
display O
constitutively O
high O
levels O
of O
p59fyn B
and O
CD3 B
zeta I
tyrosine O
phosphorylation O
. O

We O
demonstrate O
that O
cross O
- O
linking O
CD30 B
with O
an O
anti O
- O
CD30 B
- O
specific O
monoclonal O
antibody O
, O
which O
mimics O
the O
described O
biological O
activities O
of O
the O
CD30 B
ligand I
( O
CD30L B
) O
, O
results O
in O
HIV O
expression O
. O

Transient O
transfections O
using O
reporter B
constructs I
with O
multiples O
of O
transcription B
factor I
binding I
sites I
from O
the O
IL B
- I
2 I
promoter I
[ O
distal B
nuclear I
factor I
( I
NF I
) I
- I
AT I
, O
proximal B
NF I
- I
AT I
, O
AP B
- I
1 I
/ I
Octamer I
( O
UPS B
) O
or O
NF B
- I
chi I
B I
( O
TCEd B
) O
sites O
] O
were O
performed O
. O

Latent B
membrane I
protein I
- I
1 I
induces O
cyclin B
D2 I
expression O
, O
pRb B
hyperphosphorylation O
, O
and O
loss O
of O
TGF B
- I
beta I
1 I
- O
mediated O
growth O
inhibition O
in O
EBV O
- O
positive O
B O
cells O
. O

Does O
thyroidectomy O
, O
radioactive O
iodine O
therapy O
, O
or O
antithyroid O
drug O
treatment O
alter O
reactivity O
of O
patients O
' O
T O
cells O
to O
epitopes O
of O
thyrotropin B
receptor I
in O
autoimmune O
thyroid O
diseases O
? O

TSHR B
antibody I
and O
microsomal B
antibody I
levels O
decreased O
after O
surgery O
, O
but O
increased O
after O
RAI O
therapy O
. O

TSHR B
antibody I
and O
microsomal B
antibody I
levels O
decreased O
after O
surgery O
, O
but O
increased O
after O
RAI O
therapy O
. O

We O
have O
identified O
an O
in O
vivo O
footprint O
over O
the O
PuF B
site I
on O
the O
translocated O
c B
- I
myc I
allele I
in O
Burkitt O
' O
s O
lymphoma O
cells O
. O

Transfection O
experiments O
with O
c B
- I
myc I
promoter I
constructs I
in O
both O
DHL O
- O
9 O
and O
Raji O
cells O
revealed O
that O
the O
PuF B
site I
functioned O
as O
a O
positive B
regulatory I
element I
in O
B O
cells O
with O
a O
drop O
in O
activity O
with O
mutation O
of O
this O
site O
. O

In O
contrast O
, O
introduction O
of O
a O
phosphoserine O
mimetic O
at O
these O
sites O
rectified O
this O
functional O
defect O
, O
a O
finding O
consistent O
with O
a O
causal O
linkage O
between O
the O
phosphorylation O
status O
and O
proteolytic O
stability O
of O
this O
cytoplasmic B
inhibitor I
. O

Human O
peripheral O
blood O
monocytes O
responded O
to O
stimulation O
of O
platelet B
- I
activating I
factor I
( O
PAF B
) O
with O
up O
- O
regulation O
of O
the O
transcript O
for O
heparin B
- I
binding I
epidermal I
growth I
factor I
- I
like I
growth I
factor I
( O
HB B
- I
EGF I
) O
, O
a O
potent B
mitogen I
for O
vascular O
smooth O
muscle O
cells O
. O

Moreover O
, O
replacement O
of O
the O
DQB B
X2 I
- I
box I
with O
the O
DRA B
X2 I
- I
box I
markedly O
diminished O
the O
activity O
of O
the O
DQB B
promoter I
in O
the O
mutant O
cell O
. O

ZEBRA B
is O
a O
bZIP B
transcriptional I
activator I
which O
binds O
as O
a O
dimer O
to O
7 B
- I
bp I
response I
elements I
within O
EBV B
promoters I
and O
is O
directly O
involved O
in O
the O
stimulation O
of O
virus O
replication O
at O
the O
EBV B
lytic I
origin I
. O

These O
activation O
domains O
restored O
ZEBRA B
' O
s O
ability O
to O
induce O
early B
antigen I
and O
to O
stimulate O
origin O
replication O
to O
levels O
that O
were O
equal O
to O
or O
greater O
than O
those O
of O
wild O
type O
. O

Because O
these O
are O
the O
characteristics O
of O
a O
signal B
transducer I
and I
activator I
of I
transcription I
( I
Stat I
) I
protein I
, O
we O
determined O
whether O
antibodies B
to I
Stat I
proteins I
will O
interfere O
with O
gel O
mobility O
shift O
and O
found O
that O
antibodies B
to I
IL I
- I
4 I
Stat I
, O
also O
known O
as O
Stat6 B
, O
but O
not O
antibodies B
to O
other O
Stat B
proteins I
, O
interfere O
with O
the O
formation O
of O
the O
IL B
- I
4 I
NAF I
complex I
. O

Monoallelic O
expression O
of O
TAL1 B
was O
observed O
in O
the O
leukemic O
cells O
of O
all O
patients O
( O
8 O
of O
8 O
) O
bearing O
a O
TAL1 B
gene I
rearrangement O
. O

Acute O
megakaryoblastic O
leukaemia O
( O
M7 O
) O
and O
transient O
myeloproliferative O
disorder O
in O
Down O
' O
s O
syndrome O
( O
TMD O
) O
are O
characterized O
by O
rapid O
growth O
of O
abnormal O
blast O
cells O
which O
express O
megakaryocytic B
markers I
. O

The O
incubation O
with O
transforming B
growth I
factor I
beta I
1 I
and O
1 O
alpha O
, O
25 O
- O
dihydroxyvitamin O
D3 O
resulted O
in O
a O
5 O
- O
to O
7 O
- O
fold O
increase O
of O
AhR B
mRNA I
. O

In O
vitro O
translated O
Spi B
- I
B I
protein I
can O
bind O
to O
PU B
. I
1 I
binding I
sites I
in O
myeloid B
promoters I
and O
transactivate O
these O
promoters B
in O
nonmyeloid O
cells O
. O

These O
results O
indicate O
selective O
functions O
for O
different O
PKC B
isotypes I
in O
T O
cells O
. O

Moreover O
, O
the O
data O
comparing O
the O
effects O
of O
activated B
Ras I
and O
PKC B
mutants I
suggest O
that O
PKC B
- I
alpha I
, O
p21ras B
, O
and O
PKC B
- I
epsilon I
are O
not O
positioned O
linearly O
on O
a O
single O
signal O
transduction O
pathway O
. O

Moreover O
, O
the O
data O
comparing O
the O
effects O
of O
activated B
Ras I
and O
PKC B
mutants I
suggest O
that O
PKC B
- I
alpha I
, O
p21ras B
, O
and O
PKC B
- I
epsilon I
are O
not O
positioned O
linearly O
on O
a O
single O
signal O
transduction O
pathway O
. O

Differences O
in O
binding O
of O
glucocorticoid B
receptor I
to O
DNA O
in O
steroid O
- O
resistant O
asthma O
. O

We O
examined O
the O
ability O
of O
nuclear O
translocated O
glucocorticoid B
receptors I
to O
bind O
to O
their O
DNA B
binding I
sites I
( O
GRE B
) O
using O
electrophoretic O
mobility O
shift O
assays O
in O
PBMC O
from O
patients O
with O
steroid O
- O
sensitive O
and O
steroid O
- O
resistant O
asthma O
. O

Scatchard O
analysis O
of O
glucocorticoid B
receptor I
- O
GRE B
binding O
showed O
no O
change O
in O
binding O
affinity O
but O
did O
show O
a O
reduced O
number O
of O
receptors B
available O
for O
DNA O
binding O
in O
the O
steroid O
- O
resistant O
patients O
. O

Interleukin B
- I
5 I
signaling O
in O
human O
eosinophils O
involves O
JAK2 B
tyrosine I
kinase I
and O
Stat1 B
alpha I
. O

Signaling O
by O
a O
wide O
variety O
of O
cytokines B
, O
including O
interferons B
, O
interleukins B
, O
and O
growth B
factors I
, O
involves O
activation O
of O
JAK B
kinases I
and O
Stat B
( I
Signal I
transducers I
and I
activators I
of I
transcription I
) I
proteins I
. O

Signaling O
by O
a O
wide O
variety O
of O
cytokines B
, O
including O
interferons B
, O
interleukins B
, O
and O
growth B
factors I
, O
involves O
activation O
of O
JAK B
kinases I
and O
Stat B
( I
Signal I
transducers I
and I
activators I
of I
transcription I
) I
proteins I
. O

From O
supershift O
experiments O
it O
was O
concluded O
that O
one O
DNA B
- I
binding I
complex I
contained O
Stat1 B
alpha I
, O
probably O
as O
a O
homodimer O
. O

It O
was O
found O
that O
the O
propagation O
of O
the O
Tat B
mutants I
containing O
wild B
- I
type I
LTRs I
was O
less O
efficient O
than O
that O
of O
the O
LTR B
- I
modified I
Tat I
mutants I
. O

Here O
we O
show O
that O
the O
lymphoid B
- I
specific I
transcription I
factor I
Oct I
- I
2A I
plays O
a O
critical O
role O
in O
HLA B
- I
DRA I
gene I
expression O
in O
class O
II O
- O
positive O
B O
cell O
lines O
, O
and O
that O
the O
high B
mobility I
group I
protein I
( O
HMG B
) O
I B
/ I
Y I
binds O
to O
multiple O
sites O
within O
the O
DRA B
promoter I
, O
including O
the O
Oct B
- I
2A I
binding I
site I
. O

We O
conclude O
that O
distinct O
sets O
of O
transcription B
factors I
are O
involved O
in O
the O
two O
modes O
of O
HLA B
- I
DRA I
expression O
, O
and O
that O
HMG B
I I
/ I
Y I
may O
be O
important O
for O
B O
cell O
- O
specific O
expression O
, O
and O
is O
essential O
for O
IFN B
- I
gamma I
induction O
. O

In O
lymphoblastoid O
cell O
lines O
, O
six O
EBV B
- I
encoded I
nuclear I
antigens I
( O
EBNA1 B
, I
2 I
, I
3A I
, I
3B I
, I
3C I
, I
- I
LP I
) O
, O
three O
latent B
membrane I
proteins I
( O
LMP1 B
, O
2A B
, O
2B B
) O
, O
and O
two O
nuclear B
RNAs I
( O
EBERs B
) O
are O
expressed O
. O

Three O
different O
isoforms O
of O
CBF B
beta I
were O
also O
tested O
for O
transcriptional O
activity O
on O
the O
SL3 B
enhancer I
. O

Three O
different O
isoforms O
of O
CBF B
beta I
were O
also O
tested O
for O
transcriptional O
activity O
on O
the O
SL3 B
enhancer I
. O

However O
, O
no O
combination O
of O
CBF B
alpha I
and O
CBF B
beta I
subunits O
that O
we O
tested O
was O
able O
to O
distinguish O
the O
1 O
- O
bp O
difference O
in O
transcription O
assays O
. O

However O
, O
no O
combination O
of O
CBF B
alpha I
and O
CBF B
beta I
subunits O
that O
we O
tested O
was O
able O
to O
distinguish O
the O
1 O
- O
bp O
difference O
in O
transcription O
assays O
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

Using O
electrophoretic O
mobility O
shift O
assays O
( O
EMSA O
) O
, O
we O
now O
show O
that O
, O
in O
monocytes O
stimulated O
with O
LPS O
or O
TNF B
alpha I
, O
IL B
- I
10 I
inhibits O
nuclear O
stimulation O
of O
nuclear B
factor I
kappa I
B I
( O
NF B
kappa I
B I
) O
, O
a O
transcription B
factor I
involved O
in O
the O
expression O
of O
inflammatory B
cytokine I
genes I
. O
Several O
other O
transcription B
factors I
including O
NF O
- O
IL B
- I
6 I
, O
AP B
- I
1 I
, O
AP B
- I
2 I
, O
GR B
, O
CREB B
, O
Oct B
- I
1 I
, O
and O
Sp B
- I
1 I
are O
not O
affected O
by O
IL B
- I
10 I
. O

In O
HeLa O
cells O
stably O
transfected O
with O
the O
HIV B
- I
1 I
tat I
gene I
( O
HeLa O
- O
tat O
cells O
) O
, O
expression O
of O
the O
Tat B
protein I
enhanced O
both O
TNF B
- O
induced O
activation O
of O
NF B
- I
kappa I
B I
and O
TNF B
- O
mediated O
cytotoxicity O
. O

EBNA B
- I
2 I
is O
known O
to O
interact O
with O
the O
cellular B
DNA I
- I
binding I
protein I
J B
kappa I
and O
is O
recruited O
to O
promoters B
containing O
the O
GTGGGAA O
J B
kappa I
recognition I
sequence I
. O

The O
minimal B
EBNA I
- I
2 I
- I
responsive I
LMP I
- I
1 I
promoter I
includes O
one O
J B
kappa I
- I
binding I
site I
, O
and O
we O
now O
show O
that O
mutation O
of O
that O
site O
, O
such O
that O
J B
kappa I
can O
not O
bind O
, O
reduces O
EBNA B
- I
2 I
responsiveness O
by O
60 O
% O
. O

We O
hypothesized O
that O
lymphocyte B
GCII I
is O
altered O
in O
adolescent O
MDD O
and O
could O
serve O
as O
a O
marker O
for O
response O
to O
SRIs O
. O

EBNA B
- I
2 I
is O
able O
to O
trans O
- O
activate O
the O
expression O
of O
the O
LMP B
gene I
in O
several O
cell O
lines O
. O

Various O
reports O
have O
delineated O
the O
cis B
- I
acting I
elements I
of O
the O
LMP B
promoter I
through O
which O
EBNA B
- I
2 I
mediates O
trans O
- O
activation O
. O

Enhanced O
Ig B
synthesis O
is O
a O
result O
of O
coordinated O
transcriptional O
activation O
of O
Ig B
genes I
without O
promoter O
or O
isotype O
specificity O
, O
and O
differential O
accumulation O
of O
the O
mRNA B
encoding O
the O
secreted O
form O
of O
Ig B
heavy I
chain I
. O

We O
also O
examined O
the O
function O
of O
the O
IL B
- I
3 I
CK I
- I
1 I
/ I
CK I
- I
2 I
elements I
that O
are O
present O
in O
many O
cytokine B
genes I
and O
found O
that O
they O
acted O
as O
a O
repressor O
of O
basal O
level O
expression O
when O
cloned O
upstream O
of O
a O
heterologous B
promoter I
but O
were O
also O
inducible O
by O
PMA O
/ B
PHA I
. O

We O
also O
examined O
the O
function O
of O
the O
IL B
- I
3 I
CK I
- I
1 I
/ I
CK I
- I
2 I
elements I
that O
are O
present O
in O
many O
cytokine B
genes I
and O
found O
that O
they O
acted O
as O
a O
repressor O
of O
basal O
level O
expression O
when O
cloned O
upstream O
of O
a O
heterologous B
promoter I
but O
were O
also O
inducible O
by O
PMA O
/ B
PHA I
. O

We O
also O
examined O
the O
function O
of O
the O
IL B
- I
3 I
CK I
- I
1 I
/ I
CK I
- I
2 I
elements I
that O
are O
present O
in O
many O
cytokine B
genes I
and O
found O
that O
they O
acted O
as O
a O
repressor O
of O
basal O
level O
expression O
when O
cloned O
upstream O
of O
a O
heterologous B
promoter I
but O
were O
also O
inducible O
by O
PMA O
/ B
PHA I
. O

Glucocorticoids O
have O
an O
inhibitory O
effect O
on O
inflammatory O
and O
immune O
responses O
, O
and O
this O
may O
be O
through O
the O
modulation O
of O
transcription B
factor I
binding O
to O
DNA O
. O

Using O
a O
highly O
sensitive O
mutation O
screening O
assay O
of O
the O
DNA B
- I
and I
the I
steroid I
- I
binding I
region I
, O
none O
of O
the O
treated O
patients O
revealed O
any O
mutation O
, O
suggesting O
that O
the O
glucocorticoid B
receptor I
in O
the O
CLL O
patients O
tested O
is O
not O
altered O
in O
these O
domains O
. O

Expression O
of O
the O
kappa O
immunoglobulin O
light O
chain O
gene O
requires O
developmental O
- O
and O
tissue O
- O
specific O
regulation O
by O
trans B
- I
acting I
factors I
which O
interact O
with O
two O
distinct O
enhancer B
elements I
. O

Methylation O
studies O
indicated O
that O
the O
tal B
- I
15 I
' I
GC I
- I
rich I
region I
behaves O
like O
a O
CpG B
island I
, O
hypomethylated O
in O
normal O
cells O
, O
and O
methylated O
de O
novo O
on O
transcriptionally B
inactive I
alleles I
in O
established O
cell O
lines O
. O

Transient O
chloramphenicol B
acetyltransferase I
assay O
revealed O
that O
the O
region O
containing O
E2F B
binding I
site I
had O
a O
strong O
promoter O
activity O
, O
and O
introduction O
of O
the O
mutation O
at O
the O
E2F B
binding I
site I
resulted O
in O
a O
significant O
loss O
of O
the O
activity O
. O

The O
NFATd B
element I
, O
which O
binds O
the O
transcription B
factor I
NFAT B
- I
1 I
and O
is O
very O
active O
in O
T O
cells O
, O
is O
only O
weakly O
active O
in O
one O
B O
clone O
and O
not O
at O
all O
in O
another O
. O

The O
NFATd B
element I
, O
which O
binds O
the O
transcription B
factor I
NFAT B
- I
1 I
and O
is O
very O
active O
in O
T O
cells O
, O
is O
only O
weakly O
active O
in O
one O
B O
clone O
and O
not O
at O
all O
in O
another O
. O

Insertion O
of O
this O
chimeric B
promoter I
( O
ISG15 B
LTR I
) O
upstream O
of O
the O
human B
IFNA2 I
gene I
directed O
high O
levels O
of O
IFN B
synthesis O
in O
Tat O
- O
expressing O
cells O
, O
while O
this O
promoter O
was O
not O
responsive O
to O
tumor B
necrosis I
factor I
alpha I
- O
mediated O
activation O
. O

Insertion O
of O
this O
chimeric B
promoter I
( O
ISG15 B
LTR I
) O
upstream O
of O
the O
human B
IFNA2 I
gene I
directed O
high O
levels O
of O
IFN B
synthesis O
in O
Tat O
- O
expressing O
cells O
, O
while O
this O
promoter O
was O
not O
responsive O
to O
tumor B
necrosis I
factor I
alpha I
- O
mediated O
activation O
. O

Selected O
transfected O
clones O
produced O
low O
levels O
of O
IFN B
A I
( O
IFNA B
) O
constitutively O
, O
and O
their O
abilities O
to O
express O
interleukin B
- I
2 I
and O
interleukin B
- I
2 I
receptor I
upon O
stimulation O
with O
phytohemagglutinin B
and O
phorbol O
myristate O
acetate O
were O
retained O
. O

In O
extracts O
from O
nonstimulated O
cells O
the O
receptor O
is O
recovered O
in O
an O
inducible O
cytoplasmic O
form O
associated O
with O
the O
90 B
- I
kDa I
heat I
shock I
protein I
( O
hsp90 B
) O
, O
a O
molecular B
chaperone I
. O

It O
was O
not O
possible O
to O
reconstitute O
dioxin B
receptor I
function O
with O
proteins O
expressed O
in O
wheat O
germ O
lysate O
. O

In O
line O
with O
these O
observations O
, O
reticulocyte O
lysate O
but O
not O
wheat O
germ O
lysate O
promoted O
the O
association O
of O
de O
novo O
synthesized O
dioxin B
receptor I
with O
hsp90 B
. O

Induction O
of O
transcription B
factors I
in O
human O
T O
lymphocytes O
by O
aspirin O
- O
like O
drugs O
. O

Apart O
from O
stat3 B
, O
another O
cytoplasmic B
protein I
was O
tyrosine O
phosphorylated O
and O
subsequently O
translocated O
to O
the O
nucleus O
in O
response O
to O
IL B
- I
2 I
. O

This O
protein O
had O
an O
apparent O
molecular O
mass O
of O
84 O
kDa O
and O
was O
not O
recognized O
by O
stat3 B
or O
stat1 B
mAb I
or O
antisera O
. O

The O
tax O
gene O
product O
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
is O
a O
potent O
transcriptional B
activator I
that O
both O
stimulates O
viral O
gene O
expression O
and O
activates O
an O
array O
of O
cellular B
genes I
involved O
in O
T O
- O
cell O
growth O
. O

The O
tax O
gene O
product O
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
is O
a O
potent O
transcriptional B
activator I
that O
both O
stimulates O
viral O
gene O
expression O
and O
activates O
an O
array O
of O
cellular B
genes I
involved O
in O
T O
- O
cell O
growth O
. O

In O
this O
paper O
we O
describe O
results O
using O
mRNA B
differential O
display O
reverse B
transcriptase I
PCR O
( O
DDPCR O
) O
to O
identify O
and O
isolate O
short O
cDNA O
sequence O
tags O
from O
thymocyte O
and O
prostate O
cells O
under O
various O
hormone O
conditions O
. O

This O
function O
was O
a O
result O
of O
the O
interaction O
of O
EBV O
with O
its O
receptor O
, O
CD21 B
, O
but O
was O
caused O
by O
infection O
rather O
than O
surface O
signaling O
, O
because O
neither O
specific B
mAb I
nor O
the O
P3HR O
- O
1 O
strain O
of O
virus O
mimicked O
the O
effect O
of O
B95 O
- O
8 O
. O

The O
cis B
- I
acting I
region I
, O
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
( O
positions B
- I
95 I
and O
- B
73 I
) O
, O
within O
the O
murine B
GM I
- I
CSF I
gene I
promoter I
is O
required O
for O
maximal O
induction O
by O
stimulation O
with O
phorbol O
- O
12 O
- O
myristate O
acetate O
( O
PMA O
) O
and O
calcium O
ionophore O
( O
A23187 O
) O
in O
T O
cells O
. O

It O
encodes O
a O
protein O
predicted O
to O
contain O
688 O
amino O
acid O
residues O
, O
including O
11 O
zinc B
finger I
motifs I
of O
the O
C2H2 B
type I
in O
the O
C B
- I
terminal I
region I
, O
that O
are O
Kruppel O
- O
like O
in O
the O
conservation O
of O
the O
H B
/ I
C I
link I
sequence I
connecting O
them O
. O

One O
of O
the O
Drosophila B
sequences I
, O
ttk B
, O
is O
a O
developmental B
control I
gene I
, O
while O
a O
second O
does O
not O
contain O
a O
zinc B
finger I
region I
but O
encodes O
a O
structure O
important O
in O
oocyte O
development O
. O

We O
also O
show O
that O
both O
Fos B
and O
Jun B
components O
of O
the O
AP B
- I
1 I
factors O
participate O
in O
the O
OAP40 B
complex I
. O

Therefore O
, O
we O
propose O
that O
the O
TPA O
/ O
calcium O
- O
activated O
AP B
- I
1 I
/ B
OAP I
element O
is O
the O
main O
target O
of O
positive O
or O
negative O
regulatory O
signals O
influencing O
the O
IL B
- I
2 I
octamer I
motif I
, O
through O
synergism O
with O
Oct B
- I
2 I
and O
antagonism O
by O
RAR B
. O

Two O
gel B
shift I
complexes I
( O
Mono B
A I
and O
Mono B
B I
) O
were O
formed O
with O
separate O
sequence O
elements O
within O
this O
region O
. O

Two O
gel B
shift I
complexes I
( O
Mono B
A I
and O
Mono B
B I
) O
were O
formed O
with O
separate O
sequence O
elements O
within O
this O
region O
. O

PKC O
- O
zeta O
cells O
expressed O
a O
more O
differentiated O
phenotype O
as O
assessed O
by O
changes O
in O
morphology O
, O
surface O
antigen O
expression O
, O
and O
lysosomal B
enzyme I
activities O
and O
were O
distinct O
from O
parental O
U937 O
cells O
stimulated O
to O
differentiate O
by O
exposure O
to O
phorbol O
esters O
. O

OBF B
- I
1 I
, O
a O
novel B
B I
cell I
- I
specific I
coactivator I
that O
stimulates O
immunoglobulin B
promoter I
activity O
through O
association O
with O
octamer B
- I
binding I
proteins I
. O

The O
first O
early O
- O
induced O
peak O
was O
transient O
and O
likely O
corresponds O
to O
the O
well O
documented O
typical O
junB B
mRNA I
, O
stimulated O
in O
response O
to O
numerous O
growth B
factors I
, O
including O
IL B
- I
6 I
. O

The O
first O
early O
- O
induced O
peak O
was O
transient O
and O
likely O
corresponds O
to O
the O
well O
documented O
typical O
junB B
mRNA I
, O
stimulated O
in O
response O
to O
numerous O
growth B
factors I
, O
including O
IL B
- I
6 I
. O

Second O
, O
tyrphostin O
, O
a O
tyrosine O
kinase O
inhibitor O
, O
impaired O
the O
expression O
of O
the O
first O
but O
not O
the O
second O
junB B
mRNA I
peak O
. O

Erythropoietin B
( O
Epo B
) O
, O
granulocyte B
/ I
macrophage I
colony I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
interleukin B
3 I
( O
IL B
- I
3 I
) O
promoted O
the O
growth O
of O
NS O
- O
Meg O
cells O
. O

In O
contrast O
, O
SCL B
mRNA I
levels O
did O
not O
decrease O
significantly O
between O
day O
7 O
and O
day O
14 O
cells O
, O
suggesting O
that O
posttranscriptional O
mechanisms O
are O
largely O
responsible O
for O
the O
decrease O
in O
SCL B
protein I
observed O
. O

In O
contrast O
, O
SCL B
mRNA I
levels O
did O
not O
decrease O
significantly O
between O
day O
7 O
and O
day O
14 O
cells O
, O
suggesting O
that O
posttranscriptional O
mechanisms O
are O
largely O
responsible O
for O
the O
decrease O
in O
SCL B
protein I
observed O
. O

In O
BFU O
- O
E O
- O
derived O
colonies O
cultured O
with O
Steel B
factor I
, O
colony O
size O
was O
significantly O
increased O
compared O
to O
control O
. O

Tumor B
necrosis I
factor I
alpha I
( O
TNF B
alpha I
) O
is O
particularly O
important O
in O
this O
process O
because O
of O
its O
ability O
to O
regulate O
other O
inflammatory O
mediators O
in O
an O
autocrine O
and O
paracrine O
fashion O
. O

We O
present O
data O
to O
show O
that O
the O
expression O
of O
TNF B
alpha I
is O
regulated O
by O
the O
transcription B
factor I
C B
/ I
EBP I
beta I
( O
NF B
- I
IL6 I
) O
. O

We O
present O
data O
to O
show O
that O
the O
expression O
of O
TNF B
alpha I
is O
regulated O
by O
the O
transcription B
factor I
C B
/ I
EBP I
beta I
( O
NF B
- I
IL6 I
) O
. O

Calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
II I
downregulates O
both O
calcineurin O
and O
protein O
kinase O
C O
- O
mediated O
pathways O
for O
cytokine B
gene I
transcription O
in O
human O
T O
cells O
. O

We O
have O
used O
mutants O
of O
these O
kinases B
and O
phosphatases B
( O
gamma B
B I
* I
CaM I
- I
K I
and O
delta B
CaM I
- I
AI I
, O
respectively O
) O
to O
explore O
their O
relative O
role O
in O
cytokine B
gene I
transcription O
and O
their O
interactions O
with O
PKC B
- O
dependent O
signaling O
systems O
. O

Induction O
of O
TaxI B
in O
a O
human O
T O
- O
cell O
line O
Jurkat O
carrying O
the O
TaxI B
gene I
under O
the O
metallothionein B
promoter I
led O
to O
increases O
in O
mRNA B
and O
surface O
expression O
of O
ICAM B
- I
I I
. O

Induction O
of O
TaxI B
in O
a O
human O
T O
- O
cell O
line O
Jurkat O
carrying O
the O
TaxI B
gene I
under O
the O
metallothionein B
promoter I
led O
to O
increases O
in O
mRNA B
and O
surface O
expression O
of O
ICAM B
- I
I I
. O

Infection O
with O
Theileria O
annulata O
induces O
expression O
of O
matrix B
metalloproteinase I
9 I
and O
transcription B
factor I
AP B
- I
1 I
in O
bovine O
leucocytes O
. O

We O
generated O
conditional O
EBV O
mutants O
by O
expressing O
EBNA2 B
as O
chimeric B
fusion I
protein I
with O
the O
hormone O
binding O
domain O
of O
the O
estrogen B
receptor I
on O
the O
genetic O
background O
of O
the O
virus O
. O

These O
data O
suggest O
that O
EBV O
is O
using O
a O
common O
pathway O
for O
B O
- O
cell O
activation O
bypassing O
the O
requirement O
for O
antigen O
, O
T O
- O
cell O
signals O
and O
growth B
factors I
. O

The O
synergistic O
antigen B
receptor I
initiated O
signals O
are O
mediated O
through O
protein B
kinase I
C I
because O
they O
can O
be O
mimicked O
by O
the O
phorbol O
ester O
, O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
, O
but O
not O
with O
calcium O
ionophores O
; O
and O
are O
staurosporine O
sensitive O
but O
cyclosporine O
resistant O
. O

Computer O
analysis O
of O
the O
SM B
protein I
sequence O
showed O
a O
C B
terminal I
section I
of O
SM B
to O
be O
related O
to O
genome B
positional I
homologues I
of O
four O
other O
herpesviruses O
and O
revealed O
consensus B
CKII I
sites I
near O
the O
N B
termini I
of O
the O
EBV B
SM I
protein I
, O
the O
herpes B
simplex I
virus I
( I
HSV I
) I
ICP27 I
protein I
and O
the O
herpesvirus B
saimiri I
( I
HVS I
) I
open I
reading I
frame I
57 I
protein I
. O

Computer O
analysis O
of O
the O
SM B
protein I
sequence O
showed O
a O
C B
terminal I
section I
of O
SM B
to O
be O
related O
to O
genome B
positional I
homologues I
of O
four O
other O
herpesviruses O
and O
revealed O
consensus B
CKII I
sites I
near O
the O
N B
termini I
of O
the O
EBV B
SM I
protein I
, O
the O
herpes B
simplex I
virus I
( I
HSV I
) I
ICP27 I
protein I
and O
the O
herpesvirus B
saimiri I
( I
HVS I
) I
open I
reading I
frame I
57 I
protein I
. O

The O
serum B
response I
element I
( O
SRE B
) O
in O
the O
c B
- I
fos I
regulatory I
region I
participates O
in O
induction O
of O
transcription O
by O
various O
growth B
factors I
and O
by O
phorbol O
esters O
and O
subsequent O
squelching O
of O
transcription O
. O

Band B
A I
contains O
the O
serum B
response I
factor I
plus O
additional O
factor O
( O
s O
) O
. O

Thus O
, O
the O
use O
of O
DNase B
I I
allowed O
us O
, O
for O
the O
first O
time O
, O
to O
correlate O
the O
AIR B
- I
1 I
locus I
defect I
with O
class B
II I
promoter I
occupancy O
alterations O
and O
distinguish O
these O
alterations O
from O
the O
ones O
observed O
in O
phenotypically O
similar O
but O
genetically O
distinct O
MHC O
class O
II O
- O
negative O
cells O
. O

The O
expression O
of O
the O
QR B
gene I
is O
regulated O
by O
the O
transcription B
factor I
AP B
- I
1 I
. O

The O
expression O
of O
the O
QR B
gene I
is O
regulated O
by O
the O
transcription B
factor I
AP B
- I
1 I
. O

One O
gene O
, O
two O
transcripts B
: O
isolation O
of O
an O
alternative O
transcript O
encoding O
for O
the O
autoantigen B
La I
/ I
SS I
- I
B I
from O
a O
cDNA B
library I
of O
a O
patient O
with O
primary O
Sjogrens O
' O
syndrome O
. O

In O
contrast O
, O
TPCK O
and O
TLCK O
did O
not O
block O
induction O
of O
an O
immediate B
- I
early I
gene I
encoding O
the O
transcription B
factor I
, O
Egr B
- I
1 I
. O

Changes O
of O
calcitriol B
receptors I
in O
primary O
and O
secondary O
hyperparathyroidism O
could O
magnify O
the O
consequences O
of O
disturbances O
in O
serum O
concentration O
of O
calcitriol O
itself O
and O
might O
play O
an O
important O
role O
in O
the O
development O
of O
secondary O
hyperparathyroidism O
in O
uremia O
. O

Studies O
of O
these O
females O
show O
that O
the O
XIST B
locus I
on O
their O
tiny B
ring I
X I
chromosomes I
is O
either O
not O
present O
or O
not O
expressed O
. O

As O
XIST B
transcription O
is O
well O
correlated O
with O
inactivation O
of O
the O
X B
chromosome I
in O
female O
somatic O
cells O
and O
spermatogonia O
, O
nonexpression O
of O
the O
locus O
even O
when O
it O
is O
present O
suggests O
that O
these O
chromosomes B
are O
transcriptionally O
active O
. O

We O
examined O
the O
transcriptional O
activity O
of O
ring O
X B
chromosomes I
lacking O
XIST B
expression O
( O
XISTE O
- O
) O
, O
from O
three O
females O
with O
severe O
phenotypes O
. O

The O
activity O
of O
constructs O
containing O
5 B
' I
deletion I
mutants I
of O
the O
alpha B
4 I
gene I
promoter I
was O
compared O
in O
transfection O
assays O
into O
cell O
lines O
that O
express O
alpha B
4 I
and O
cell O
lines O
that O
do O
not O
. O

The O
sequence O
between O
position O
- B
42 I
and I
- I
76 I
base I
pairs I
( O
bp O
) O
was O
required O
for O
efficient O
transcription O
in O
cells O
that O
express O
alpha B
4 I
, O
but O
it O
showed O
no O
activity O
in O
HeLa O
cells O
, O
which O
do O
not O
express O
alpha B
4 I
. O

The O
sequence O
between O
position O
- B
42 I
and I
- I
76 I
base I
pairs I
( O
bp O
) O
was O
required O
for O
efficient O
transcription O
in O
cells O
that O
express O
alpha B
4 I
, O
but O
it O
showed O
no O
activity O
in O
HeLa O
cells O
, O
which O
do O
not O
express O
alpha B
4 I
. O

When O
all O
three O
sites O
were O
present O
, O
a O
second O
complex O
` O
` O
a O
' O
' O
was O
detected O
, O
which O
contains O
an O
unknown O
member O
of O
the O
Ets B
family I
. O

This O
arrangement O
of O
Ets B
sites I
, O
coupled O
with O
the O
tissue O
- O
and O
developmental O
- O
specific O
expression O
of O
Ets B
members I
, O
likely O
play O
a O
key O
role O
in O
defining O
the O
pattern O
of O
alpha B
4 I
integrin I
. O

This O
arrangement O
of O
Ets B
sites I
, O
coupled O
with O
the O
tissue O
- O
and O
developmental O
- O
specific O
expression O
of O
Ets B
members I
, O
likely O
play O
a O
key O
role O
in O
defining O
the O
pattern O
of O
alpha B
4 I
integrin I
. O

Antiandrogens O
result O
in O
protection O
of O
both O
the O
hinge B
region I
and O
C B
- I
terminus I
of O
the O
androgen B
receptor I
agonist O
proteolytic O
attack O
, O
whereas O
other O
studies O
showed O
that O
antiestrogens O
and O
antiprogestagens O
expose O
the O
C B
- I
terminal I
end I
of O
the O
ligand B
binding I
domain I
of O
their O
respective O
receptors O
to O
protease B
. O

Antiandrogens O
result O
in O
protection O
of O
both O
the O
hinge B
region I
and O
C B
- I
terminus I
of O
the O
androgen B
receptor I
agonist O
proteolytic O
attack O
, O
whereas O
other O
studies O
showed O
that O
antiestrogens O
and O
antiprogestagens O
expose O
the O
C B
- I
terminal I
end I
of O
the O
ligand B
binding I
domain I
of O
their O
respective O
receptors O
to O
protease B
. O

To O
identify O
ets B
- I
related I
transcriptional I
regulators I
expressed O
in O
pre O
- O
B O
lymphocytes O
that O
may O
interact O
with O
either O
the O
pi B
or O
the O
microB B
site I
, O
we O
have O
used O
a O
PCR O
approach O
with O
degenerate O
oligonucleotides O
encoding O
conserved O
sequences O
in O
all O
members O
of O
the O
ets B
family I
. O

To O
identify O
ets B
- I
related I
transcriptional I
regulators I
expressed O
in O
pre O
- O
B O
lymphocytes O
that O
may O
interact O
with O
either O
the O
pi B
or O
the O
microB B
site I
, O
we O
have O
used O
a O
PCR O
approach O
with O
degenerate O
oligonucleotides O
encoding O
conserved O
sequences O
in O
all O
members O
of O
the O
ets B
family I
. O

Our O
experiments O
also O
show O
that O
activated O
PR B
does O
not O
confer O
direct O
transcriptional O
control O
on O
the O
dPRL B
promoter I
. O

One O
of O
the O
nuclear B
factors I
( O
NFs B
) O
that O
regulates O
the O
response O
of O
the O
IL B
- I
5 I
promoter I
to O
cAMP O
and O
PMA O
has O
properties O
similar O
to O
NF B
for O
activated O
t O
cell O
. O

Full O
activation O
of O
the O
MAP B
kinases I
that O
phosphorylate O
the O
Jun B
activation I
domain I
, O
JNK1 B
and O
JNK2 B
, O
required O
costimulation O
of O
T O
cells O
with O
either O
TPA O
and O
Ca2 O
+ O
ionophore O
or O
antibodies O
to O
TCR B
and O
CD28 B
. O

OBJECTIVE O
: O
To O
determine O
whether O
activation O
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
replication O
in O
tumour O
cells O
of O
AIDS O
- O
related O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
ARNHL O
) O
is O
correlated O
with O
CD4 B
+ I
cell O
counts O
and O
influences O
antibody O
response O
to O
EBV O
[ O
anti B
- I
Z I
Epstein I
- I
Barr I
replicative I
activator I
( O
ZEBRA B
) O
, O
anti B
- I
early I
antigen I
( O
EA B
) O
, O
anti B
- I
viral I
capsid I
antigen I
( O
VCA B
) O
] O
. O

DESIGN O
: O
Retrospective O
study O
based O
on O
immunohistochemistry O
and O
in O
situ O
hybridization O
to O
detect O
EBV O
replicative O
gene O
products O
in O
tissue O
samples O
from O
patients O
affected O
by O
ARNHL O
and O
correlation O
with O
CD4 B
+ I
cell O
counts O
and O
results O
of O
EBV O
serology O
( O
including O
anti O
- O
ZEBRA B
activity O
) O
in O
sera O
from O
the O
same O
patients O
. O

In O
contrast O
, O
analysis O
of O
pp90rsk B
activity O
by O
phosphorylation O
of O
a O
peptide O
derived O
from O
S6 B
protein I
demonstrated O
stimulation O
of O
this O
kinase B
in O
TPA O
- O
treated O
U O
- O
937 O
, O
and O
not O
TUR O
, O
cells O
. O

We O
have O
identified O
a O
` B
` I
two I
- I
handed I
' I
' I
zinc I
finger I
protein I
, O
denoted O
ZEB B
, O
the O
DNA O
- O
binding O
specificity O
of O
which O
mimics O
that O
of O
the O
cellular B
repressor I
. O

By O
employing O
a O
derivative O
E B
box I
that O
binds O
ZEB B
but O
not O
E2A B
, O
we O
have O
shown O
that O
the O
repressor B
is O
active O
in O
B O
cells O
and O
the O
IgH B
enhancer I
is O
silenced O
in O
the O
absence O
of O
binding O
competition O
by O
bHLH B
proteins I
. O

By O
employing O
a O
derivative O
E B
box I
that O
binds O
ZEB B
but O
not O
E2A B
, O
we O
have O
shown O
that O
the O
repressor B
is O
active O
in O
B O
cells O
and O
the O
IgH B
enhancer I
is O
silenced O
in O
the O
absence O
of O
binding O
competition O
by O
bHLH B
proteins I
. O

By O
employing O
a O
derivative O
E B
box I
that O
binds O
ZEB B
but O
not O
E2A B
, O
we O
have O
shown O
that O
the O
repressor B
is O
active O
in O
B O
cells O
and O
the O
IgH B
enhancer I
is O
silenced O
in O
the O
absence O
of O
binding O
competition O
by O
bHLH B
proteins I
. O

In O
order O
to O
elucidate O
the O
role O
of O
c B
- I
myb I
gene I
in O
erythroid O
differentiation O
of O
K562 O
cell O
induced O
by O
hemin B
( O
Hm B
) O
and O
erythropoietin B
( O
Epo B
) O
, O
we O
constructed O
recombinant B
plasmid I
that O
could O
produce O
antisense B
myb I
RNA I
after O
induction O
with O
dexamethasone O
. O

Fos B
kinase I
may O
play O
a O
role O
in O
transcriptional O
regulation O
through O
its O
capacity O
to O
phosphorylate O
c B
- I
Fos I
at O
a O
site O
required O
for O
expression O
of O
the O
transcriptional O
transrepressive O
activity O
of O
this O
molecule O
. O

We O
studied O
genomic B
DNA I
and O
RNA O
extracted O
from O
the O
patient O
' O
s O
peripheral O
leucocytes O
in O
order O
to O
determine O
the O
origin O
of O
the O
basophils O
. O

The O
RAR B
alpha I
rearranged O
band O
in O
the O
Southern O
blot O
analysis O
and O
a O
chimaeric B
product I
of O
PML B
- I
RAR I
alpha I
by O
polymerase O
chain O
reaction O
were O
strongly O
visible O
before O
ATRA O
treatment O
, O
but O
at O
the O
time O
of O
maximal O
basophilia O
both O
of O
them O
were O
markedly O
diminished O
. O

The O
RAR B
alpha I
rearranged O
band O
in O
the O
Southern O
blot O
analysis O
and O
a O
chimaeric B
product I
of O
PML B
- I
RAR I
alpha I
by O
polymerase O
chain O
reaction O
were O
strongly O
visible O
before O
ATRA O
treatment O
, O
but O
at O
the O
time O
of O
maximal O
basophilia O
both O
of O
them O
were O
markedly O
diminished O
. O

In O
this O
regard O
, O
the O
cytokine B
interleukin B
6 I
( O
IL B
- I
6 I
) O
may O
play O
a O
role O
in O
the O
clinical O
manifestations O
and O
pathological O
events O
of O
tuberculosis O
infection O
. O

This O
region O
contains O
two O
binding B
sites I
for O
the O
Sp1 B
transcription I
factor I
. O

This O
nuclear B
complex I
was O
activated O
by O
LPS O
with O
kinetics O
that O
preceded O
induction O
of O
the O
TF B
gene I
. O

This O
nuclear B
complex I
was O
activated O
by O
LPS O
with O
kinetics O
that O
preceded O
induction O
of O
the O
TF B
gene I
. O

Human O
immunodeficiency O
virus O
type O
1 O
Nef O
protein O
down O
- O
regulates O
transcription B
factors I
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
in O
human O
T O
cells O
in O
vitro O
after O
T O
- O
cell O
receptor O
stimulation O
. O

This O
allows O
us O
to O
characterize O
these O
two O
granule O
populations O
with O
regard O
to O
their O
content O
of O
membrane B
proteins I
, O
which O
become O
incorporated O
into O
the O
plasma O
membrane O
during O
exocytosis O
. O

Hence O
, O
PPAR B
can O
positively O
or O
negatively O
influence O
TH O
action O
depending O
on O
TRE B
structure O
and O
THR B
isotype I
. O

Retinoic O
acid O
- O
induced O
expression O
of O
CD38 B
antigen I
in O
myeloid O
cells O
is O
mediated O
through O
retinoic B
acid I
receptor I
- I
alpha I
. O

Thus O
antioxidants O
vary O
widely O
in O
potency O
as O
inhibitors O
of O
the O
activation O
of O
transcription B
factors I
and O
of O
the O
transcription O
of O
genes B
for O
pro B
- I
inflammatory I
cytokines I
. O

Such O
observations O
indicate O
that O
IL B
- I
4 I
Stat I
has O
the O
same O
functional B
domain I
for O
both O
receptor O
coupling O
and O
dimerization O
. O

Lung O
disease O
associated O
with O
disorders O
such O
as O
cystic O
fibrosis O
( O
CF O
) O
may O
be O
amenable O
to O
somatic O
gene O
therapy O
in O
which O
there O
is O
delivery O
of O
the O
normal B
gene I
directly O
to O
the O
respiratory O
epithelium O
using O
E1a O
- O
adenovirus O
( O
Ad O
) O
type O
2 O
- O
or O
5 O
- O
based O
vectors O
. O

Tumor O
cells O
showed O
an O
overexpression O
of O
p53 B
protein I
and O
were O
estrogen B
receptor I
- O
positive O
. O

Tumor O
cells O
showed O
an O
overexpression O
of O
p53 B
protein I
and O
were O
estrogen B
receptor I
- O
positive O
. O

The O
magnitude O
and O
time O
kinetics O
of O
the O
LIF B
effects O
were O
similar O
to O
interleukin B
1 I
( O
IL B
- I
1 I
) O
, O
IL B
- I
6 I
, O
and O
tumor B
necrosis I
factor I
( O
TNF B
) O
, O
other O
cytokines O
known O
to O
induce O
HIV O
replication O
in O
this O
cell O
line O
. O

To O
characterize O
mechanisms O
responsible O
for O
these O
LIF B
effects O
, O
levels O
of O
HIV B
mRNA I
, O
activation O
of O
the O
DNA B
binding I
protein I
nuclear I
factor I
( B
NF I
) I
- I
kB I
, O
signal O
transduction O
pathways O
, O
and O
potential O
interactions O
with O
other O
cytokines B
were O
analyzed O
. O

In O
order O
to O
study O
CD14 B
gene I
regulation O
, O
the O
human B
CD14 I
gene I
was O
cloned O
from O
a O
partial O
EcoRI B
digested I
chromosome I
5 I
library I
. O

Four O
regions O
in O
this O
DNA B
fragment I
interact O
with O
nuclear B
proteins I
isolated O
from O
monocytic O
cells O
. O

Four O
regions O
in O
this O
DNA B
fragment I
interact O
with O
nuclear B
proteins I
isolated O
from O
monocytic O
cells O
. O

The O
Sp1 B
transcription B
factor I
bound O
to O
three O
different O
regions O
in O
the O
CD14 B
promoter I
. O

The O
Sp1 B
transcription B
factor I
bound O
to O
three O
different O
regions O
in O
the O
CD14 B
promoter I
. O

Stimulation O
of O
the O
CD28 B
cell I
surface I
molecule I
delivers O
costimulatory O
signals O
essential O
for O
lymphokine B
production O
in O
activated O
T O
cells O
via O
a O
conserved B
sequence I
element I
found O
in O
the O
promoter B
of O
several O
lymphokine B
genes I
. O

Diminished O
glucocorticoid B
receptors I
do O
not O
result O
in O
glucocorticoid O
resistance O
. O

Thrombin B
and O
thrombin B
receptor I
agonist O
peptide O
induce O
early O
events O
of O
T O
cell O
activation O
and O
synergize O
with O
TCR B
cross O
- O
linking O
for O
CD69 B
expression O
and O
interleukin O
2 O
production O
. O

We O
therefore O
reexamined O
this O
issue O
by O
using O
two O
different O
experimental O
approaches O
that O
allowed O
LMP1 B
- O
induced O
effects O
to O
be O
monitored O
immediately O
following O
expression O
of O
the O
viral O
protein O
and O
in O
the O
absence O
of O
selective O
pressures O
; O
activation O
of O
the O
NF B
- I
kappa I
B I
transcription B
factor I
and O
upregulation O
of O
the O
cell B
adhesion I
molecule I
ICAM B
- I
1 I
were O
used O
as O
early O
indices O
of O
LMP1 B
function O
. O

We O
found O
that O
tyrosine B
kinase I
activity O
was O
similar O
for O
both O
mAbs B
over O
a O
period O
of O
hours O
. O

Furthermore O
, O
the O
present O
results O
demonstrate O
clearly O
that O
mycoplasma B
products I
can O
have O
a O
profound O
impact O
on O
the O
activation O
status O
of O
eukaryotic O
cells O
. O

Analysis O
of O
the O
chromatin O
organization O
of O
the O
integrated O
human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
genome I
has O
previously O
revealed O
a O
major B
constitutive I
DNase I
I I
- I
hypersensitive I
site I
associated O
with O
the O
pol B
gene I
( O
E O
. O
Verdin O
, O
J O
. O
Virol O
. O
65 O
: O
6790 O
- O
6799 O
, O
1991 O
) O
. O

Site B
D I
( O
nt B
4816 I
to I
4851 I
) O
specifically O
bound O
a O
ubiquitously B
expressed I
factor I
. O

NF B
- I
kappa I
B I
is O
a O
rapidly O
inducible O
transcriptional B
activator I
that O
responds O
to O
a O
variety O
of O
signals O
and O
influences O
the O
expression O
of O
many O
genes O
involved O
in O
the O
immune O
response O
. O

Sequence O
analyses O
show O
that O
this O
protein O
has O
significant O
homology O
with O
the O
human B
cytomegalovirus I
UL44 I
gene I
coding O
for O
the O
ICP36 B
family I
of O
early B
- I
late I
- I
class I
phosphoprotein I
. O

CD14 B
- O
mediated O
translocation O
of O
nuclear B
factor I
- I
kappa I
B I
induced O
by O
lipopolysaccharide O
does O
not O
require O
tyrosine B
kinase I
activity O
. O

The O
stimulatory O
effects O
of O
gp160 O
are O
mediated O
through O
the O
CD4 B
molecule I
, O
since O
pretreatment O
with O
soluble O
CD4 B
abrogates O
its O
activity O
. O

No O
evidence O
for O
the O
expression O
of O
the O
progesterone B
receptor I
on O
peripheral O
blood O
lymphocytes O
during O
pregnancy O
[ O
see O
comments O
] O

A O
role O
for O
the O
progesterone B
receptor I
in O
the O
mechanism O
of O
the O
known O
effect O
of O
progesterone O
on O
peripheral O
blood O
lymphocytes O
is O
also O
excluded O
. O

The O
CD14 B
LPS O
receptor O
is O
, O
however O
, O
up O
- O
regulated O
( O
not O
down O
- O
regulated O
) O
in O
tolerant O
cells O
, O
and O
LPS O
can O
, O
in O
fact O
, O
still O
lead O
to O
activation O
of O
tolerant O
cells O
as O
evidenced O
by O
mobilization O
of O
the O
transcription B
factor I
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
. O

Resolution O
of O
the O
NF B
- I
kappa I
B I
complex I
in O
gel O
shift O
analysis O
shows O
that O
the O
binding B
protein I
, O
mobilized O
in O
naive O
Mono O
Mac O
6 O
cells O
, O
consists O
mainly O
of O
p50 B
- I
p65 I
heterodimers I
, O
while O
in O
tolerant O
cells O
, O
the O
p50 B
homodimer I
is O
predominant O
. O

Resolution O
of O
the O
NF B
- I
kappa I
B I
complex I
in O
gel O
shift O
analysis O
shows O
that O
the O
binding B
protein I
, O
mobilized O
in O
naive O
Mono O
Mac O
6 O
cells O
, O
consists O
mainly O
of O
p50 B
- I
p65 I
heterodimers I
, O
while O
in O
tolerant O
cells O
, O
the O
p50 B
homodimer I
is O
predominant O
. O

This O
increase O
in O
p50 B
homodimers I
coincides O
with O
an O
increase O
in O
p105 B
mRNA I
, O
suggestive O
of O
a O
transcriptional O
up O
- O
regulation O
of O
p50 B
. O

This O
increase O
in O
p50 B
homodimers I
coincides O
with O
an O
increase O
in O
p105 B
mRNA I
, O
suggestive O
of O
a O
transcriptional O
up O
- O
regulation O
of O
p50 B
. O

In O
addition O
, O
a O
new O
combination O
isoform O
containing O
Oct2a B
' I
s I
amino I
terminal I
insert I
( O
exon B
7a I
) O
and O
Oct2b B
' I
s I
carboxy I
terminal I
insert I
( O
exon B
13 I
) O
was O
found O
that O
created O
a O
novel O
large O
isoform O
, O
Oct2ab B
. O

In O
addition O
, O
a O
new O
combination O
isoform O
containing O
Oct2a B
' I
s I
amino I
terminal I
insert I
( O
exon B
7a I
) O
and O
Oct2b B
' I
s I
carboxy I
terminal I
insert I
( O
exon B
13 I
) O
was O
found O
that O
created O
a O
novel O
large O
isoform O
, O
Oct2ab B
. O

Positive O
regulators O
of O
the O
lineage O
- O
specific O
transcription B
factor I
GATA B
- I
1 I
in O
differentiating O
erythroid O
cells O
. O

Analyses O
with O
cultured O
cells O
and O
cell O
- O
free O
systems O
have O
provided O
strong O
evidence O
that O
GATA B
- I
1 I
is O
involved O
in O
control O
of O
globin B
gene I
expression O
during O
erythroid O
differentiation O
. O

We O
have O
previously O
shown O
that O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
expressed O
surface B
IgM I
( O
sIgM B
) O
and O
surface B
IgD I
( O
sIgD B
) O
, O
and O
that O
crosslinking O
of O
sIgM B
and O
sIgD B
by O
anti B
- I
IgM I
antibody I
( I
Ab I
) I
and O
anti B
- I
IgD I
Ab I
, O
respectively O
, O
induced O
Ca2 O
+ O
influx O
to O
almost O
the O
same O
degree O
, O
whereas O
only O
sIgM B
- O
crosslinking O
caused O
B104 O
cell O
death O
. O

We O
have O
previously O
shown O
that O
a O
human O
B O
lymphoma O
cell O
line O
, O
B104 O
, O
expressed O
surface B
IgM I
( O
sIgM B
) O
and O
surface B
IgD I
( O
sIgD B
) O
, O
and O
that O
crosslinking O
of O
sIgM B
and O
sIgD B
by O
anti B
- I
IgM I
antibody I
( I
Ab I
) I
and O
anti B
- I
IgD I
Ab I
, O
respectively O
, O
induced O
Ca2 O
+ O
influx O
to O
almost O
the O
same O
degree O
, O
whereas O
only O
sIgM B
- O
crosslinking O
caused O
B104 O
cell O
death O
. O

Treatment O
of O
human O
erythrocytes O
with O
10 O
microM O
sodium O
orthovanadate O
( O
NaOV O
) O
, O
an O
inhibitor O
of O
plasma B
membrane I
Ca I
- I
ATPase I
and O
phosphotyrosine B
phosphatase I
, O
decreased O
parasitemia O
by O
30 O
% O
. O

Because O
erythrocytes O
are O
anucleated O
, O
these O
results O
are O
discussed O
as O
evidence O
for O
biochemical O
changes O
by O
TCDD O
without O
requiring O
the O
activation O
of O
gene B
products I
. O

Electrophoretic O
mobility O
shift O
assays O
indicate O
that O
MS B
- I
2beta I
and O
MS B
- I
2gamma I
interact O
with O
nuclear B
factors I
that O
are O
induced O
during O
U937 O
differentiation O
. O

These O
factors O
are O
detected O
at O
the O
time O
the O
CD11b B
promoter I
is O
activated O
. O

Acetylsalicylic O
acid O
and O
sodium O
salicylate O
inhibit O
LPS O
- O
induced O
NF B
- I
kappa I
B I
/ I
c I
- I
Rel I
nuclear O
translocation O
, O
and O
synthesis O
of O
tissue B
factor I
( O
TF B
) O
and O
tumor B
necrosis I
factor I
alfa I
( O
TNF B
- I
alpha I
) O
in O
human O
monocytes O
. O

Neutral B
sphingomyelinase I
( O
SMase B
) O
can O
be O
activated O
by O
extracellular O
signals O
to O
produce O
ceramide O
, O
which O
may O
affect O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
activities O
. O

PMA O
acted O
synergistically O
with O
ionomycin O
to O
activate O
JNK B
MAPKs I
in O
Jurkat O
and O
EL4 O
within O
10 O
minutes O
. O

Distinct O
patterns O
of O
chromosome B
1 I
abnormalities O
were O
found O
among O
the O
histologic O
types O
of O
breast O
carcinoma O
. O

In O
this O
study O
, O
we O
have O
investigated O
the O
mechanisms O
by O
which O
the O
R24 B
mAb I
affects O
T O
cell O
functions O
. O

We O
have O
observed O
that O
the O
R24 B
mAb I
stimulates O
GD3 O
+ O
T O
cell O
proliferation O
, O
cytotoxicity O
, O
and O
surface O
marker O
expression O
of O
IL B
- I
2R I
alpha I
- I
chain I
, O
IL B
- I
2R I
beta I
- I
chain I
, O
HLA B
- I
DR I
, O
CD11a B
, O
and O
CD11c B
. O

Additionally O
, O
herbimycin O
A O
, O
a O
tyrosine B
kinase I
inhibitor O
, O
blocked O
the O
R24 B
- O
stimulated O
increase O
in O
proliferation O
but O
not O
cytotoxicity O
at O
concentrations O
consistent O
with O
specificity O
for O
tyrosine B
kinases I
. O

Additionally O
, O
herbimycin O
A O
, O
a O
tyrosine B
kinase I
inhibitor O
, O
blocked O
the O
R24 B
- O
stimulated O
increase O
in O
proliferation O
but O
not O
cytotoxicity O
at O
concentrations O
consistent O
with O
specificity O
for O
tyrosine B
kinases I
. O

Using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
, O
we O
show O
here O
that O
the O
genes B
encoding O
the O
TATA B
- I
box I
binding I
protein I
( O
TBP B
) O
, O
TFIIB B
, O
TFIIE B
alpha I
, O
TFIIE B
beta I
, O
RAP30 B
, O
RAP74 B
and O
the O
62 B
kDa I
subunit I
, O
of O
TFIIH B
are O
located O
at O
the O
human B
chromosomal I
bands I
6q26 I
- I
27 I
, I
1p21 I
- I
22 I
, I
3q21 I
- I
24 I
, I
8p12 I
, I
13q14 I
, I
19p13 I
. I
3 I
and I
11p14 I
- I
15 I
. I
1 I
, O
respectively O
. O

Using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
, O
we O
show O
here O
that O
the O
genes B
encoding O
the O
TATA B
- I
box I
binding I
protein I
( O
TBP B
) O
, O
TFIIB B
, O
TFIIE B
alpha I
, O
TFIIE B
beta I
, O
RAP30 B
, O
RAP74 B
and O
the O
62 B
kDa I
subunit I
, O
of O
TFIIH B
are O
located O
at O
the O
human B
chromosomal I
bands I
6q26 I
- I
27 I
, I
1p21 I
- I
22 I
, I
3q21 I
- I
24 I
, I
8p12 I
, I
13q14 I
, I
19p13 I
. I
3 I
and I
11p14 I
- I
15 I
. I
1 I
, O
respectively O
. O

To O
further O
elucidate O
the O
role O
of O
this O
variant O
octamer B
motif I
in O
the O
regulation O
of O
germline B
transcription O
from O
the O
unrearranged O
kappa B
locus I
, O
we O
have O
quantitated O
the O
relative O
binding O
affinity O
of O
Oct B
- I
1 I
and O
Oct B
- I
2 I
for O
the O
variant O
octamer B
motif I
and O
determined O
the O
functional O
role O
of O
this O
octamer B
motif I
in O
transcriptional O
activation O
. O

To O
further O
elucidate O
the O
role O
of O
this O
variant O
octamer B
motif I
in O
the O
regulation O
of O
germline B
transcription O
from O
the O
unrearranged O
kappa B
locus I
, O
we O
have O
quantitated O
the O
relative O
binding O
affinity O
of O
Oct B
- I
1 I
and O
Oct B
- I
2 I
for O
the O
variant O
octamer B
motif I
and O
determined O
the O
functional O
role O
of O
this O
octamer B
motif I
in O
transcriptional O
activation O
. O

To O
further O
elucidate O
the O
role O
of O
this O
variant O
octamer B
motif I
in O
the O
regulation O
of O
germline B
transcription O
from O
the O
unrearranged O
kappa B
locus I
, O
we O
have O
quantitated O
the O
relative O
binding O
affinity O
of O
Oct B
- I
1 I
and O
Oct B
- I
2 I
for O
the O
variant O
octamer B
motif I
and O
determined O
the O
functional O
role O
of O
this O
octamer B
motif I
in O
transcriptional O
activation O
. O

To O
further O
elucidate O
the O
role O
of O
this O
variant O
octamer B
motif I
in O
the O
regulation O
of O
germline B
transcription O
from O
the O
unrearranged O
kappa B
locus I
, O
we O
have O
quantitated O
the O
relative O
binding O
affinity O
of O
Oct B
- I
1 I
and O
Oct B
- I
2 I
for O
the O
variant O
octamer B
motif I
and O
determined O
the O
functional O
role O
of O
this O
octamer B
motif I
in O
transcriptional O
activation O
. O

The O
mechanism O
of O
inhibition O
is O
related O
to O
the O
surface O
expression O
of O
several O
cell O
adhesion B
molecules I
. O

The O
monoclonal B
antibody I
( O
mAb B
) O
J393 B
induces O
apoptosis O
in O
Jurkat O
T O
- O
cells O
. O

NH2 B
- O
terminal O
amino O
acid O
sequence O
analysis O
identified O
the O
140 B
- I
kDa I
surface I
antigen I
for O
mAb B
J393 I
as O
CD43 B
/ I
leukosialin I
, O
the O
major O
sialoglycoprotein B
of O
leukocytes O
. O

While O
Jurkat O
cells O
co O
- O
expressed O
two O
discrete O
cell B
- I
surface I
isoforms I
of O
CD43 B
, O
recognized O
by O
mAb B
J393 I
and O
mAb B
G10 I
- I
2 I
, O
respectively O
, O
only O
J393 B
/ I
CD43 I
signaled O
apoptosis O
. O

Tyrosine B
kinase I
inhibition O
by O
herbimycin O
A O
diminished O
J393 B
/ I
CD43 I
- O
mediated O
apoptosis O
, O
whereas O
inhibition O
of O
phosphotyrosine B
phosphatase I
activity O
by O
bis O
( O
maltolato O
) O
oxovanadium O
- O
IV O
enhanced O
cell O
death O
. O

Tyrosine B
kinase I
inhibition O
by O
herbimycin O
A O
diminished O
J393 B
/ I
CD43 I
- O
mediated O
apoptosis O
, O
whereas O
inhibition O
of O
phosphotyrosine B
phosphatase I
activity O
by O
bis O
( O
maltolato O
) O
oxovanadium O
- O
IV O
enhanced O
cell O
death O
. O

Consequently O
, O
the O
present O
study O
was O
addressed O
to O
understand O
this O
phenomenon O
and O
revealed O
the O
existence O
of O
a O
unique B
47 I
kDa I
protein I
factor I
having O
affinity O
for O
this O
SRE B
sequence I
in O
lymphocytes O
from O
normal O
subjects O
as O
well O
as O
its O
absence O
in O
lymphocytes O
from O
untreated O
CML O
patients O
. O

The O
SCL B
protein I
displays O
cell O
- O
specific O
heterogeneity O
in O
size O
. O

The O
restricted O
pattern O
of O
SCL B
protein I
synthesis O
is O
consistent O
with O
the O
restricted O
expression O
of O
SCL B
mRNA I
documented O
previously O
. O

The O
restricted O
pattern O
of O
SCL B
protein I
synthesis O
is O
consistent O
with O
the O
restricted O
expression O
of O
SCL B
mRNA I
documented O
previously O
. O

This O
effect O
required O
surface O
expression O
of O
the O
CD45 B
PTPase I
and O
was O
not O
observed O
in O
CD45 O
- O
deficient O
variants O
of O
Jurkat O
cells O
. O

Pervanadate B
activated I
NF I
- I
kappa I
B I
, O
as O
shown O
by O
an O
increase O
in O
DNA O
- O
binding O
activity O
of O
this O
transcription B
factor I
. O

Signals O
transduced O
via O
the O
TCR B
activate O
the O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
, O
which O
, O
in O
turn O
, O
is O
critical O
to O
the O
transcriptional O
induction O
of O
many O
genes O
important O
for O
the O
proliferation O
and O
expression O
of O
a O
differentiated O
phenotype O
. O

Therefore O
, O
to O
evaluate O
the O
mechanism O
of O
TPA O
responsiveness O
of O
the O
SNE B
motifs I
and O
of O
a O
related O
16 O
- O
bp O
SEE B
( O
SRF B
/ I
ETS I
element I
) O
motif O
found O
in O
the O
HCMV B
and I
chimpanzee I
CMV I
MIE I
enhancers I
, O
we O
have O
examined O
the O
functional O
responses O
and O
protein O
binding O
properties O
of O
multimerized B
wild I
- I
type I
and I
mutant I
elements I
added O
upstream O
to O
the O
SCMV B
MIE I
or O
simian B
virus I
40 I
minimal I
promoter I
regions I
in O
the O
U O
- O
937 O
, O
K O
- O
562 O
, O
HL O
- O
60 O
, O
THP O
- O
1 O
, O
and O
Jurkat O
cell O
lines O
. O

Therefore O
, O
to O
evaluate O
the O
mechanism O
of O
TPA O
responsiveness O
of O
the O
SNE B
motifs I
and O
of O
a O
related O
16 O
- O
bp O
SEE B
( O
SRF B
/ I
ETS I
element I
) O
motif O
found O
in O
the O
HCMV B
and I
chimpanzee I
CMV I
MIE I
enhancers I
, O
we O
have O
examined O
the O
functional O
responses O
and O
protein O
binding O
properties O
of O
multimerized B
wild I
- I
type I
and I
mutant I
elements I
added O
upstream O
to O
the O
SCMV B
MIE I
or O
simian B
virus I
40 I
minimal I
promoter I
regions I
in O
the O
U O
- O
937 O
, O
K O
- O
562 O
, O
HL O
- O
60 O
, O
THP O
- O
1 O
, O
and O
Jurkat O
cell O
lines O
. O

Furthermore O
, O
the O
physical O
interaction O
of O
Tax B
with O
p100 B
leads O
to O
the O
inhibition O
of O
Tax B
- O
induced O
activation O
of O
the O
HTLV O
- O
I O
and O
human B
immunodeficiency I
virus I
type I
1 I
long I
terminal I
repeats I
, O
reflecting O
p100 B
- O
mediated O
cytoplasmic O
sequestration O
of O
the O
normally O
nuclearly O
expressed O
Tax B
protein I
. O

We O
present O
here O
the O
results O
on O
the O
recognition O
of O
several O
pml O
/ O
RAR O
- O
alpha O
peptides O
by O
APL O
patients O
expressing O
HLA B
DR11 I
. O

The O
proximal O
element O
is O
a O
composite O
site O
that O
binds O
members O
of O
the O
CREB B
/ I
ATF I
, O
AP B
- I
1 I
, O
and O
octamer B
families I
of O
transcription B
factors I
. O

The O
proximal O
element O
is O
a O
composite O
site O
that O
binds O
members O
of O
the O
CREB B
/ I
ATF I
, O
AP B
- I
1 I
, O
and O
octamer B
families I
of O
transcription B
factors I
. O

The O
predicted O
amino O
acid O
sequence O
of O
the O
amino B
- I
terminal I
portion I
of O
Sp140 B
was O
similar O
to O
Sp100 B
, O
a O
previously O
identified O
NB B
protein I
. O

Inhibition O
of O
RANTES B
expression O
did O
not O
appear O
to O
be O
secondary O
to O
IL B
- I
2 I
inhibition O
and O
required O
binding O
to O
the O
intracellular O
glucocorticoid B
receptor I
. O

TRAF1 B
, O
TRAF2 B
, O
and O
TRAF3 B
bind O
to O
a O
single O
site O
in O
the O
LMP1 B
CT I
corresponding O
to O
amino O
acids O
( O
aa O
) O
199 O
to O
214 O
, O
within O
a O
domain O
which O
is O
important O
for O
B O
- O
lymphocyte O
growth O
transformation O
( O
aa O
187 O
to O
231 O
) O
. O

NF B
- I
kappaB I
activation O
by O
LMP1 B
( O
1 O
- O
231 O
) O
is O
likely O
to O
be O
mediated O
by O
TRAF1 B
/ B
TRAF2 I
heteroaggregates O
since O
TRAF1 B
is O
unique O
among O
the O
TRAFs B
in O
coactivating O
NF B
- I
kappaB I
with O
LMP1 B
( O
1 O
- O
231 O
) O
, O
a O
TRAF2 B
dominant O
- O
negative O
mutant O
can O
block O
LMP1 B
( O
1 O
- O
231 O
) O
- O
mediated O
NF B
- I
kappaB I
activation O
as O
well O
as O
TRAF1 B
coactivation O
, O
and O
30 O
% O
of O
TRAF2 B
is O
associated O
with O
TRAF1 B
in O

The O
gene O
encoding O
the O
Epstein B
- I
Barr I
virus I
( I
EBV I
) I
- I
specific I
dUTPase I
was O
amplified O
from O
virus B
DNA I
by O
PCR O
. O

Two O
pp56 B
( I
lck I
) I
mutants I
lacking O
either O
the O
entire O
catalytic B
domain I
or O
the O
entire O
NH2 B
regulatory B
domain I
were O
generated O
, O
and O
their O
abilities O
to O
trigger O
transactivation O
of O
the O
TCR B
- I
regulated I
nuclear I
factor I
of I
activated I
T I
cells I
( I
NF I
- I
AT I
) I
region I
of O
the O
IL B
- I
2 I
promoter I
were O
compared O
. O

Two O
pp56 B
( I
lck I
) I
mutants I
lacking O
either O
the O
entire O
catalytic B
domain I
or O
the O
entire O
NH2 B
regulatory B
domain I
were O
generated O
, O
and O
their O
abilities O
to O
trigger O
transactivation O
of O
the O
TCR B
- I
regulated I
nuclear I
factor I
of I
activated I
T I
cells I
( I
NF I
- I
AT I
) I
region I
of O
the O
IL B
- I
2 I
promoter I
were O
compared O
. O

Interleukin B
2 I
( O
IL B
- I
2 I
) O
stimulates O
IL B
- I
2R I
alpha I
. O

Tumor B
necrosis I
factor I
receptor I
- I
1 I
( O
TNFR B
- I
1 I
) O
and O
CD95 B
( O
also O
called O
Fas B
or O
APO B
- I
1 I
) O
are O
cytokine B
receptors I
that O
engage O
the O
apoptosis O
pathway O
through O
a O
region O
of O
intracellular O
homology O
, O
designated O
the O
` O
` O
death B
domain I
. O
' O
' O
Another O
death B
domain I
- I
containing I
member I
of O
the O
TNFR B
family I
, O
death B
receptor I
3 I
( O
DR3 B
) O
, O
was O
identified O
and O
was O
shown O
to O
induce O
both O
apoptosis O
and O
activation O
of O
nuclear B
factor I
kappaB I
. O

Tumor B
necrosis I
factor I
receptor I
- I
1 I
( O
TNFR B
- I
1 I
) O
and O
CD95 B
( O
also O
called O
Fas B
or O
APO B
- I
1 I
) O
are O
cytokine B
receptors I
that O
engage O
the O
apoptosis O
pathway O
through O
a O
region O
of O
intracellular O
homology O
, O
designated O
the O
` O
` O
death B
domain I
. O
' O
' O
Another O
death B
domain I
- I
containing I
member I
of O
the O
TNFR B
family I
, O
death B
receptor I
3 I
( O
DR3 B
) O
, O
was O
identified O
and O
was O
shown O
to O
induce O
both O
apoptosis O
and O
activation O
of O
nuclear B
factor I
kappaB I
. O

Tumor B
necrosis I
factor I
receptor I
- I
1 I
( O
TNFR B
- I
1 I
) O
and O
CD95 B
( O
also O
called O
Fas B
or O
APO B
- I
1 I
) O
are O
cytokine B
receptors I
that O
engage O
the O
apoptosis O
pathway O
through O
a O
region O
of O
intracellular O
homology O
, O
designated O
the O
` O
` O
death B
domain I
. O
' O
' O
Another O
death B
domain I
- I
containing I
member I
of O
the O
TNFR B
family I
, O
death B
receptor I
3 I
( O
DR3 B
) O
, O
was O
identified O
and O
was O
shown O
to O
induce O
both O
apoptosis O
and O
activation O
of O
nuclear B
factor I
kappaB I
. O

The O
IRF B
- I
2 I
promoter B
region I
contains O
a O
CpG O
island O
, O
with O
several O
GC B
boxes I
, O
a O
putative O
NF B
- I
kappa I
B I
- I
binding I
site I
, O
and O
a O
CAAT B
box I
, O
but O
no O
TATA B
box I
. O

The O
IRF B
- I
2 I
promoter B
region I
contains O
a O
CpG O
island O
, O
with O
several O
GC B
boxes I
, O
a O
putative O
NF B
- I
kappa I
B I
- I
binding I
site I
, O
and O
a O
CAAT B
box I
, O
but O
no O
TATA B
box I
. O

The O
IRF B
- I
2 I
promoter B
region I
contains O
a O
CpG O
island O
, O
with O
several O
GC B
boxes I
, O
a O
putative O
NF B
- I
kappa I
B I
- I
binding I
site I
, O
and O
a O
CAAT B
box I
, O
but O
no O
TATA B
box I
. O

The O
IRF B
- I
2 I
promoter B
region I
contains O
a O
CpG O
island O
, O
with O
several O
GC B
boxes I
, O
a O
putative O
NF B
- I
kappa I
B I
- I
binding I
site I
, O
and O
a O
CAAT B
box I
, O
but O
no O
TATA B
box I
. O

When O
the O
promoter B
region I
was O
linked O
with O
a O
heterologous B
reporter I
gene I
, O
we O
found O
that O
the O
promoter B
region I
is O
inducible O
by O
both O
interferons B
( O
interferon B
- I
alpha I
and I
- I
gamma I
) O
and O
interferon B
regulatory I
factor I
1 I
. O

When O
the O
promoter B
region I
was O
linked O
with O
a O
heterologous B
reporter I
gene I
, O
we O
found O
that O
the O
promoter B
region I
is O
inducible O
by O
both O
interferons B
( O
interferon B
- I
alpha I
and I
- I
gamma I
) O
and O
interferon B
regulatory I
factor I
1 I
. O

Interferon B
alpha I
selectively O
affects O
expression O
of O
the O
human B
myeloid I
cell I
nuclear I
differentiation I
antigen I
in O
late O
stage O
cells O
in O
the O
monocytic O
but O
not O
the O
granulocytic O
lineage O
. O

Although O
, O
the O
level O
of O
MNDA B
mRNA I
in O
primary O
monocytes O
is O
very O
low O
it O
was O
up O
- O
regulated O
at O
6 O
h O
following O
the O
addition O
of O
interferon B
alpha I
. O

Although O
, O
the O
level O
of O
MNDA B
mRNA I
in O
primary O
monocytes O
is O
very O
low O
it O
was O
up O
- O
regulated O
at O
6 O
h O
following O
the O
addition O
of O
interferon B
alpha I
. O

This O
reduced O
level O
of O
mRNA B
could O
then O
be O
elevated O
with O
subsequent O
interferon B
alpha I
treatment O
. O

We O
identified O
a O
protein O
, O
p37 O
, O
which O
specifically O
bound O
to O
DRE B
1 I
. O

In O
these O
cells O
, O
nuclear B
factors I
involved O
in O
activation O
of O
the O
HIV B
- I
1 I
LTR I
, O
which O
contains O
the O
transcriptional B
control I
elements I
of O
the O
virus O
, O
are O
unknown O
. O

Cell O
specific O
expression O
of O
human B
Bruton I
' I
s I
agammaglobulinemia I
tyrosine I
kinase I
gene I
( O
Btk B
) O
is O
regulated O
by O
Sp1 B
- I
and O
Spi B
- I
1 I
/ I
PU I
. I
1 I
- I
family I
members I
. O

Thus O
, O
the O
tyrosine B
kinase I
activated O
by O
G B
- I
CSF I
appears O
to O
directly O
transduce O
a O
signal O
to O
a O
protein O
which O
functions O
as O
a O
transcriptional B
regulator I
. O

Thus O
, O
the O
tyrosine B
kinase I
activated O
by O
G B
- I
CSF I
appears O
to O
directly O
transduce O
a O
signal O
to O
a O
protein O
which O
functions O
as O
a O
transcriptional B
regulator I
. O

In O
addition O
, O
analysis O
of O
EBV O
protein O
expression O
by O
IH O
revealed O
a O
heterogeneous O
pattern O
of O
EBV B
gene I
expression O
at O
the O
single O
- O
cell O
level O
consisting O
of O
both O
LMP1 O
+ O
and O
LMP1 O
- O
tumour O
cells O
, O
suggesting O
a O
mixture O
of O
latency O
I O
and O
II O
. O

Moreover O
, O
ZK161422 O
, O
but O
not O
ZK157202 O
, O
showed O
preference O
for O
gene O
activation O
from O
a O
promoter B
carrying O
a O
VD B
response I
element I
with O
a O
palindromic O
arrangement O
of O
two O
hexameric B
receptor I
binding I
sites I
spaced O
by O
9 O
nucleotides O
( O
IP9 O
) O
rather O
than O
for O
activation O
from O
a O
response B
element I
formed O
by O
a O
direct O
repeat O
spaced O
by O
3 O
nucleotides O
( O
DR3 O
) O
. O

The O
process O
of O
activation O
involves O
calcium O
mobilization O
, O
activation O
of O
protein B
kinase I
C I
( O
PKC B
) O
, O
and O
phosphorylation O
of O
tyrosine B
kinases I
. O

The O
expression O
of O
activated O
p21 B
( I
ras I
) I
negatively O
regulated O
the O
induction O
of O
IE B
genes I
by O
calcium O
ionophore O
. O

A O
later O
result O
of O
inhibition O
of O
this O
activation O
pathway O
by O
p21 B
( I
ras I
) I
was O
down O
- O
regulation O
of O
the O
activity O
of O
the O
transcription B
factor I
AP B
- I
1 I
and O
subsequent O
coordinate O
reductions O
in O
IL B
- I
2 I
gene I
expression O
and O
protein O
production O
. O

The O
mechanism O
of O
action O
of O
DM O
on O
IL B
- I
2R I
alpha I
transcription O
was O
examined O
by O
determining O
the O
mRNA O
levels O
of O
the O
p50 O
subunit O
of O
nuclear O
factor O
kappa O
B O
( O
NF B
- I
kappa I
B I
) O
, O
a O
transcription B
factor I
that O
stimulates O
IL B
- I
2R I
alpha I
gene O
expression O
. O

The O
protein B
- I
tyrosine I
kinase I
ZAP B
- I
70 I
is O
implicated O
, O
together O
with O
the O
Src B
kinase I
p56 B
( I
lck I
) I
, O
in O
controlling O
the O
early O
steps O
of O
the O
T O
- O
cell O
antigen O
receptor O
( O
TCR B
) O
signaling O
cascade O
. O

ORF1 B
consists O
of O
240 O
bp O
that O
would O
encode O
80 O
amino O
acids O
, O
while O
the O
major B
ORF2 I
consists O
of O
648 O
bp O
capable O
of O
coding O
for O
216 O
amino O
acids O
. O

In O
all O
cells O
tested O
, O
IL B
- I
10 I
activated O
Stat1 B
and O
Stat3 B
and O
induced O
the O
formation O
of O
three O
distinct O
DNA B
binding I
complexes I
that O
contained O
different O
combinations O
of O
these O
two O
transcription B
factors I
. O

Using O
a O
structure O
- O
function O
mutagenesis O
approach O
, O
two O
tyrosine O
residues O
( O
Tyr427 O
and O
Tyr477 O
) O
in O
the O
intracellular B
domain I
of O
the O
murine O
IL B
- I
10 I
receptor O
were O
found O
to O
be O
redundantly O
required O
for O
receptor O
function O
and O
for O
activation O
of O
Stat3 B
but O
not O
for O
Stat1 B
or O
Stat5 B
. O

This O
study O
thus O
supports O
the O
concept O
that O
utilization O
of O
distinct O
STAT B
proteins I
by O
different O
cytokine B
receptors I
is O
dependent O
on O
the O
expression O
of O
particular O
ligand O
- O
activatable O
, O
tyrosine B
- I
containing I
STAT I
docking I
sites I
in O
receptor B
intracellular I
domains I
. O

This O
study O
thus O
supports O
the O
concept O
that O
utilization O
of O
distinct O
STAT B
proteins I
by O
different O
cytokine B
receptors I
is O
dependent O
on O
the O
expression O
of O
particular O
ligand O
- O
activatable O
, O
tyrosine B
- I
containing I
STAT I
docking I
sites I
in O
receptor B
intracellular I
domains I
. O

Globin B
genes I
are O
subject O
to O
tissue O
- O
specific O
and O
developmental O
stage O
- O
specific O
regulation O
. O

E3 B
transcripts I
were O
RA O
- O
inducible O
in O
HL60 O
cells O
, O
but O
not O
in O
an O
RA O
- O
resistant O
subclone O
, O
HL60R O
, O
that O
harbors O
a O
mutated O
RAR B
alpha I
gene I
. O

These O
results O
indicate O
that O
E3 B
is O
a O
hematopoietic B
- I
specific I
gene I
that O
is O
an O
immediate O
target O
for O
the O
activated O
RAR B
alpha I
during O
myelopoiesis O
. O

To O
examine O
whether O
an O
active O
negative O
regulatory O
process O
occurs O
, O
we O
created O
a O
reporter B
construct I
containing O
as O
an O
enhancer B
four O
copies O
of O
the O
NF B
- I
AT I
site I
and O
one O
copy O
of O
the O
octamer B
site I
( O
4X B
NF I
- I
AT I
- I
Oct I
) O
. O

To O
examine O
whether O
an O
active O
negative O
regulatory O
process O
occurs O
, O
we O
created O
a O
reporter B
construct I
containing O
as O
an O
enhancer B
four O
copies O
of O
the O
NF B
- I
AT I
site I
and O
one O
copy O
of O
the O
octamer B
site I
( O
4X B
NF I
- I
AT I
- I
Oct I
) O
. O

The O
simplest O
model O
to O
explain O
these O
results O
is O
that O
anergy O
is O
mediated O
by O
a O
complex O
of O
multiple O
transcription B
factors I
that O
exert O
a O
cis O
- O
acting O
dominant O
negative O
regulatory O
effect O
on O
the O
trans O
- O
activation O
of O
the O
IL B
- I
2 I
gene I
. O

The O
identification O
of O
oriP B
and O
the O
EBNA2 B
- I
dependent I
enhancer I
as O
the O
major O
positive O
cis B
elements I
involved O
in O
regulating O
Cp B
activity O
in O
LCL O
suggests O
that O
EBNA B
gene I
transcription O
is O
largely O
autoregulated O
by O
EBNA B
1 I
and O
EBNA B
2 I
. O

The O
identification O
of O
oriP B
and O
the O
EBNA2 B
- I
dependent I
enhancer I
as O
the O
major O
positive O
cis B
elements I
involved O
in O
regulating O
Cp B
activity O
in O
LCL O
suggests O
that O
EBNA B
gene I
transcription O
is O
largely O
autoregulated O
by O
EBNA B
1 I
and O
EBNA B
2 I
. O

The O
identification O
of O
oriP B
and O
the O
EBNA2 B
- I
dependent I
enhancer I
as O
the O
major O
positive O
cis B
elements I
involved O
in O
regulating O
Cp B
activity O
in O
LCL O
suggests O
that O
EBNA B
gene I
transcription O
is O
largely O
autoregulated O
by O
EBNA B
1 I
and O
EBNA B
2 I
. O

The O
identification O
of O
oriP B
and O
the O
EBNA2 B
- I
dependent I
enhancer I
as O
the O
major O
positive O
cis B
elements I
involved O
in O
regulating O
Cp B
activity O
in O
LCL O
suggests O
that O
EBNA B
gene I
transcription O
is O
largely O
autoregulated O
by O
EBNA B
1 I
and O
EBNA B
2 I
. O

Expression O
of O
interleukin B
1beta I
and O
other O
cytokines B
, O
such O
as O
interleukin B
6 I
and O
tumor B
necrosis I
factor I
alpha I
, O
has O
been O
shown O
to O
be O
dependent O
on O
the O
activation O
of O
the O
transcription B
factor I
, O
NFkappaB B
. O

Expression O
of O
interleukin B
1beta I
and O
other O
cytokines B
, O
such O
as O
interleukin B
6 I
and O
tumor B
necrosis I
factor I
alpha I
, O
has O
been O
shown O
to O
be O
dependent O
on O
the O
activation O
of O
the O
transcription B
factor I
, O
NFkappaB B
. O

Expression O
of O
interleukin B
1beta I
and O
other O
cytokines B
, O
such O
as O
interleukin B
6 I
and O
tumor B
necrosis I
factor I
alpha I
, O
has O
been O
shown O
to O
be O
dependent O
on O
the O
activation O
of O
the O
transcription B
factor I
, O
NFkappaB B
. O

All O
cells O
tested O
express O
TAFII105 B
mRNA I
, O
but O
only O
B O
cells O
contain O
significant O
levels O
of O
protein O
associated O
with O
TFIID B
. O

The O
association O
of O
20q B
deletions I
with O
myeloid O
` O
` O
stem O
cell O
' O
' O
disorders O
suggests O
that O
the O
deletions O
mark O
the O
site O
of O
one O
or O
more O
genes O
, O
loss O
or O
inactivation O
of O
which O
plays O
a O
role O
in O
the O
regulation O
of O
normal O
hematopoietic O
progenitors O
. O

Seventeen O
microsatellite B
markers I
that O
span O
the O
common O
deleted O
region O
were O
used O
to O
search O
for O
loss O
of O
heterozygosity O
in O
granulocyte B
DNA I
. O

Seventeen O
microsatellite B
markers I
that O
span O
the O
common O
deleted O
region O
were O
used O
to O
search O
for O
loss O
of O
heterozygosity O
in O
granulocyte B
DNA I
. O

In O
contrast O
to O
MM O
cells O
, O
normal O
splenic O
B O
cells O
express O
dephosphorylated B
pRB I
. O

Although O
CD40 B
ligand I
( O
CD40L B
) O
triggers O
a O
shift O
from O
dephosphorylated O
to O
phosphorylated O
pRB B
and O
proliferation O
of O
B O
cells O
, O
the O
addition O
of O
exogenous O
IL B
- I
6 I
to O
CD40L B
- O
treated O
B O
cells O
does O
not O
alter O
either O
pRB B
or O
proliferation O
, O
as O
observed O
in O
MM O
cells O
. O

Soluble B
factors I
secreted O
by O
activated O
T O
- O
lymphocytes O
modulate O
the O
transcription O
of O
the O
immunosuppressive B
cytokine I
TGF B
- I
beta I
2 I
in O
glial O
cells O
. O

Soluble B
factors I
secreted O
by O
activated O
T O
- O
lymphocytes O
modulate O
the O
transcription O
of O
the O
immunosuppressive B
cytokine I
TGF B
- I
beta I
2 I
in O
glial O
cells O
. O

ALF1 B
transactivated O
transcription O
of O
Akv O
MLV O
through O
the O
two O
E B
( I
gre I
) I
motifs I
equally O
, O
whereas O
E2A B
protein I
required O
the O
promoter O
- O
proximal O
E B
( I
gre I
) I
motif O
. O

Moreover O
, O
ectopic B
Id1 I
repressed O
E B
( I
gre I
) I
- O
directed O
but O
not O
EA B
/ I
S I
- O
directed O
MLV O
transcription O
in O
lymphoid O
cell O
lines O
. O

Correlations O
were O
found O
between O
plasma B
IFN I
alpha I
and O
receptor O
Kd O
on O
monocytes O
of O
AIDS O
- O
GR O
( O
r O
= O
0 O
. O
77 O
) O
and O
between O
IFN B
alpha I
and O
plasma O
cortisol O
in O
the O
same O
group O
( O
r O
= O
0 O
. O
74 O
) O
. O

It O
is O
possible O
that O
the O
CRE B
site I
is O
responsible O
for O
induction O
of O
bcl B
- I
2 I
expression O
in O
other O
cell O
types O
, O
particularly O
those O
in O
which O
protein B
kinase I
C I
is O
involved O
. O

However O
, O
NFATc B
. I
beta I
neither O
bound O
to O
the O
kappa3 B
element I
( O
an O
NFAT B
- I
binding I
site I
) O
in O
the O
tumor B
necrosis I
factor I
- I
alpha I
promoter I
nor O
activated O
the O
tumor B
necrosis I
factor I
- I
alpha I
promoter I
in O
cotransfection O
assays O
. O

Constitutive O
expression O
of O
specific O
interferon B
isotypes I
in O
peripheral O
blood O
leukocytes O
from O
normal O
individuals O
and O
in O
promonocytic O
U937 O
cells O
. O

Constitutive O
expression O
of O
IFN B
- I
alpha5 I
and O
IFN B
- I
beta I
was O
detected O
in O
different O
lymphoid O
cells O
including O
peripheral O
blood O
mononuclear O
cells O
from O
normal O
individuals O
following O
amplification O
of O
IFN B
mRNA I
by O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
and O
direct O
sequencing O
of O
the O
amplified B
product I
. O

Constitutive O
expression O
of O
IFN B
- I
alpha5 I
and O
IFN B
- I
beta I
was O
detected O
in O
different O
lymphoid O
cells O
including O
peripheral O
blood O
mononuclear O
cells O
from O
normal O
individuals O
following O
amplification O
of O
IFN B
mRNA I
by O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
and O
direct O
sequencing O
of O
the O
amplified B
product I
. O

Constitutive O
expression O
of O
IFN B
- I
alpha5 I
and O
IFN B
- I
beta I
was O
detected O
in O
different O
lymphoid O
cells O
including O
peripheral O
blood O
mononuclear O
cells O
from O
normal O
individuals O
following O
amplification O
of O
IFN B
mRNA I
by O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
and O
direct O
sequencing O
of O
the O
amplified B
product I
. O

Thus O
, O
IL B
- I
2 I
- O
induced O
IL B
- I
2R I
alpha I
promoter I
activity O
requires O
a O
complex B
upstream I
element I
, O
which O
appears O
to O
contain O
binding B
sites I
for O
both O
positive B
and I
negative I
regulatory I
factors I
. O

Here O
we O
describe O
the O
isolation O
and O
expression O
of O
a O
cDNA B
encoding O
PTF B
beta I
, O
as O
well O
as O
functional O
studies O
using O
anti B
- I
PTF I
beta I
antibodies I
. O

We O
report O
here O
on O
the O
identification O
of O
a O
17 B
kDa I
variant I
of O
the O
14 B
kDa I
Id I
- I
3 I
protein O
termed O
Id B
- I
3L I
( O
long O
version O
) O
which O
possesses O
a O
unique O
60 B
amino I
acid I
carboxy I
- I
terminus I
generated O
by O
read O
through O
of O
a O
' O
coding B
intron I
' O
and O
alternative O
splicing O
. O

In O
this O
study O
, O
we O
examined O
the O
molecular O
mechanism O
by O
which O
agents O
that O
elevate O
intracellular O
cAMP O
inhibit O
the O
expression O
of O
the O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
) O
, O
tissue B
factor I
, O
endothelial B
leukocyte I
adhesion I
molecule I
- I
1 I
, O
and O
vascular B
cell I
adhesion I
molecule I
- I
1 I
genes I
. O

We O
propose O
that O
direct O
interaction O
between O
the O
glucocorticoid B
receptor I
and O
nuclear B
factor I
- I
kappa I
B I
factors I
is O
at O
least O
a O
partial O
explanation O
for O
the O
effects O
of O
this O
hormone O
in O
inflammatory O
diseases O
. O

Approximately O
40 O
% O
of O
diffuse O
large O
cell O
lymphoma O
are O
associated O
with O
chromosomal O
translocations O
that O
deregulate O
the O
expression O
of O
the O
BCL6 B
gene I
by O
juxtaposing O
heterologous B
promoters I
to O
the O
BCL B
- I
6 I
coding I
domain I
. O

Approximately O
40 O
% O
of O
diffuse O
large O
cell O
lymphoma O
are O
associated O
with O
chromosomal O
translocations O
that O
deregulate O
the O
expression O
of O
the O
BCL6 B
gene I
by O
juxtaposing O
heterologous B
promoters I
to O
the O
BCL B
- I
6 I
coding I
domain I
. O

We O
previously O
suggested O
that O
the O
measurement O
of O
corticosteroid B
receptors I
in O
lymphocytes O
is O
an O
index O
of O
an O
analogous O
pattern O
in O
brain O
. O

Three O
subtypes O
of O
retinoic B
acid I
receptors I
( O
RAR B
) O
, O
termed O
RAR B
alpha I
, O
RAR B
beta I
, O
and O
RAR B
gamma I
, O
have O
been O
described O
. O

Three O
subtypes O
of O
retinoic B
acid I
receptors I
( O
RAR B
) O
, O
termed O
RAR B
alpha I
, O
RAR B
beta I
, O
and O
RAR B
gamma I
, O
have O
been O
described O
. O

Three O
subtypes O
of O
retinoic B
acid I
receptors I
( O
RAR B
) O
, O
termed O
RAR B
alpha I
, O
RAR B
beta I
, O
and O
RAR B
gamma I
, O
have O
been O
described O
. O

In O
spite O
of O
this O
similar O
downstream O
signalling O
, O
IL4 B
and O
IL13 B
used O
a O
different O
set O
of O
Janus B
kinases I
: O
IL13 B
is O
unable O
to O
activate O
JAK1 B
and O
JAK3 B
. O

A O
3 O
' O
- O
- O
> O
5 O
' O
XPB B
helicase I
defect O
in O
repair B
/ I
transcription I
factor I
TFIIH B
of O
xeroderma O
pigmentosum O
group O
B O
affects O
both O
DNA O
repair O
and O
transcription O
. O

DNase B
I I
hypersensitive I
site I
( O
DHS B
) O
mapping O
revealed O
that O
the O
perforin B
locus I
contained O
six O
DHS B
within O
7 O
. O
0 O
kb O
of O
the O
5 B
' I
upstream I
sequence I
( O
- O
7 O
. O
0 O
kb O
) O
and O
two O
DHS B
in O
intron B
2 I
. O

DNase B
I I
hypersensitive I
site I
( O
DHS B
) O
mapping O
revealed O
that O
the O
perforin B
locus I
contained O
six O
DHS B
within O
7 O
. O
0 O
kb O
of O
the O
5 B
' I
upstream I
sequence I
( O
- O
7 O
. O
0 O
kb O
) O
and O
two O
DHS B
in O
intron B
2 I
. O

Chloramphenicol B
acetyltransferase I
( O
CAT B
) O
activities O
directed O
by O
5 B
' I
upstream I
promoter I
were O
detected O
preferentially O
in O
perforin O
- O
expressing O
cell O
lines O
. O

When O
single O
- O
point O
mutation O
was O
introduced O
to O
each O
GC B
box I
, O
EBS B
, O
and O
GT B
box I
in O
PFP9a20 B
, O
at O
least O
3 O
- O
fold O
less O
CAT B
activity O
was O
observed O
in O
CTLL O
- O
R8 O
cells O
. O

When O
single O
- O
point O
mutation O
was O
introduced O
to O
each O
GC B
box I
, O
EBS B
, O
and O
GT B
box I
in O
PFP9a20 B
, O
at O
least O
3 O
- O
fold O
less O
CAT B
activity O
was O
observed O
in O
CTLL O
- O
R8 O
cells O
. O

Instead O
, O
ATF B
- I
2 I
and O
Jun B
proteins I
bind O
to O
the O
composite B
kappa I
3 I
/ I
CRE I
site I
and O
NFATp B
binds O
to O
a O
newly O
identified O
second O
NFAT B
site I
centered O
at O
- B
76 I
nucleotides I
relative O
to O
the O
TNF B
- I
alpha I
transcription I
start I
site I
. O

Instead O
, O
ATF B
- I
2 I
and O
Jun B
proteins I
bind O
to O
the O
composite B
kappa I
3 I
/ I
CRE I
site I
and O
NFATp B
binds O
to O
a O
newly O
identified O
second O
NFAT B
site I
centered O
at O
- B
76 I
nucleotides I
relative O
to O
the O
TNF B
- I
alpha I
transcription I
start I
site I
. O

Thus O
, O
through O
the O
differential O
use O
of O
the O
same O
promoter B
element I
, O
the O
composite B
kappa I
3 I
/ I
CRE I
site I
, O
the O
TNF B
- I
alpha I
gene I
is O
regulated O
in O
a O
cell O
- O
type O
- O
specific O
manner O
in O
response O
to O
the O
same O
extracellular O
signal O
. O

Ligand O
activation O
of O
c B
- I
ErbB I
induced O
the O
tyrosine O
phosphorylation O
, O
DNA O
- O
binding O
, O
and O
reporter B
gene I
transcription O
of O
Stat B
5b I
in O
erythroblasts O
. O

Ligand O
activation O
of O
c B
- I
ErbB I
induced O
the O
tyrosine O
phosphorylation O
, O
DNA O
- O
binding O
, O
and O
reporter B
gene I
transcription O
of O
Stat B
5b I
in O
erythroblasts O
. O

Precise O
alignment B
of I
sites I
required O
for O
mu B
enhancer I
activation O
in O
B O
cells O
. O

The O
lymphocyte B
- I
specific I
immunoglobulin I
mu I
heavy I
- I
chain I
gene I
intronic I
enhancer I
is O
regulated O
by O
multiple O
nuclear B
factors I
. O

The O
previously O
defined O
minimal B
enhancer I
containing O
the O
muA B
, I
muE3 I
, I
and I
muB I
sites I
is O
transactivated O
by O
a O
combination O
of O
the O
ETS B
- I
domain I
proteins I
PU B
. I
1 I
and O
Ets B
- I
1 I
in O
nonlymphoid O
cells O
. O

The O
core O
GGAAs O
of O
the O
muA B
and I
muB I
sites I
are O
separated O
by O
30 O
nucleotides O
, O
suggesting O
that O
ETS B
proteins I
bind O
to O
these O
sites O
from O
these O
same O
side O
of O
the O
DNA O
helix O
. O

Nuclear B
factor I
of I
activated I
T I
cells I
- I
family I
proteins I
( O
NFAT1 B
/ I
NFATp I
, O
NFATc B
, O
NFAT3 B
, O
and O
NFAT4 B
/ I
NFATx I
/ I
NFATc3 I
) O
play O
a O
key O
role O
in O
the O
transcription O
of O
cytokine B
genes I
and O
other O
genes O
during O
the O
immune O
response O
. O

Our O
results O
emphasize O
the O
multiple O
levels O
at O
which O
NFAT O
- O
dependent O
transactivation O
is O
regulated O
, O
and O
predict O
significant O
differences O
in O
the O
architecture O
of O
cooperative O
transcription B
complexes I
containing O
different O
NFAT B
- I
family I
proteins I
. O

This O
revealed O
that O
NF B
- I
kappaB I
generation O
was O
sensitive O
to O
chloroquine O
, O
an O
inhibitor O
of O
acidic B
sphingomyelinase I
, O
but O
not O
to O
the O
phosphatidylinositol B
3 I
- I
kinase I
inhibitor O
, O
wortmannin O
. O

To O
investigate O
the O
presence O
of O
various O
isoforms O
of O
the O
estrogen B
receptor I
( O
ER B
) O
in O
SLE O
we O
isolated O
RNA O
from O
mononuclear O
cells O
of O
lupus O
patients O
and O
normal O
controls O
. O

The O
results O
suggest O
a O
new O
option O
for O
HIV O
gene O
therapy O
; O
bcl B
- I
2 I
muteins I
that O
have O
noncleavable B
alterations I
surrounding O
the O
HIV B
protease I
cleavage I
site I
. O

To O
determine O
the O
contribution O
of O
the O
cytoplasmic B
domain I
of O
the O
IL B
- I
7 I
receptor I
alpha I
chain I
( O
IL B
- I
7R I
alpha I
) O
to O
activation O
of O
STAT B
proteins I
, O
transfectants O
of O
the O
murine O
pro O
- O
B O
cell O
line O
BAF3 O
were O
made O
that O
express O
chimeric B
receptors I
consisting O
of O
the O
extracellular B
domain I
of O
human B
granulocyte I
colony I
- I
stimulating I
factor I
receptor I
( O
G B
- I
CSF I
- I
R I
) O
and O
the O
transmembrane B
and I
intracellular I
domains I
of O
human B
IL I
- I
7R I
alpha I
. O

To O
determine O
the O
contribution O
of O
the O
cytoplasmic B
domain I
of O
the O
IL B
- I
7 I
receptor I
alpha I
chain I
( O
IL B
- I
7R I
alpha I
) O
to O
activation O
of O
STAT B
proteins I
, O
transfectants O
of O
the O
murine O
pro O
- O
B O
cell O
line O
BAF3 O
were O
made O
that O
express O
chimeric B
receptors I
consisting O
of O
the O
extracellular B
domain I
of O
human B
granulocyte I
colony I
- I
stimulating I
factor I
receptor I
( O
G B
- I
CSF I
- I
R I
) O
and O
the O
transmembrane B
and I
intracellular I
domains I
of O
human B
IL I
- I
7R I
alpha I
. O

To O
determine O
the O
contribution O
of O
the O
cytoplasmic B
domain I
of O
the O
IL B
- I
7 I
receptor I
alpha I
chain I
( O
IL B
- I
7R I
alpha I
) O
to O
activation O
of O
STAT B
proteins I
, O
transfectants O
of O
the O
murine O
pro O
- O
B O
cell O
line O
BAF3 O
were O
made O
that O
express O
chimeric B
receptors I
consisting O
of O
the O
extracellular B
domain I
of O
human B
granulocyte I
colony I
- I
stimulating I
factor I
receptor I
( O
G B
- I
CSF I
- I
R I
) O
and O
the O
transmembrane B
and I
intracellular I
domains I
of O
human B
IL I
- I
7R I
alpha I
. O

To O
determine O
the O
contribution O
of O
the O
cytoplasmic B
domain I
of O
the O
IL B
- I
7 I
receptor I
alpha I
chain I
( O
IL B
- I
7R I
alpha I
) O
to O
activation O
of O
STAT B
proteins I
, O
transfectants O
of O
the O
murine O
pro O
- O
B O
cell O
line O
BAF3 O
were O
made O
that O
express O
chimeric B
receptors I
consisting O
of O
the O
extracellular B
domain I
of O
human B
granulocyte I
colony I
- I
stimulating I
factor I
receptor I
( O
G B
- I
CSF I
- I
R I
) O
and O
the O
transmembrane B
and I
intracellular I
domains I
of O
human B
IL I
- I
7R I
alpha I
. O

We O
demonstrate O
that O
CaMKIV B
/ I
Gr I
reconstitutes O
the O
capacity O
of O
the O
cytosolic O
component O
of O
NFAT B
to O
direct O
transcription O
from O
NFAT B
sites I
in O
non O
- O
T O
cells O
. O

This O
was O
identified O
as O
the O
mRNA B
encoding O
the O
transcription B
factor I
egr B
- I
1 I
, O
which O
is O
expressed O
with O
fast O
kinetics O
in O
T O
and O
NK O
cells O
upon O
IL B
- I
2 I
, O
but O
not O
IL B
- I
12 I
, O
stimulation O
. O

However O
, O
the O
transcription O
and O
synthesis O
of O
interleukin B
2 I
and O
other O
delayed O
early O
cytokines B
were O
markedly O
attenuated O
by O
BCL B
- I
2 I
. O

On O
the O
basis O
of O
several O
independent O
assays O
, O
we O
now O
report O
a O
physical O
and O
functional O
interaction O
between O
Tax B
and O
the O
transcription B
factor I
, O
TFIIA B
. O

Inhibition O
of O
transcription B
factor I
Stat1 B
activity O
in O
mononuclear O
cell O
cultures O
and O
T O
cells O
by O
the O
cyclic O
AMP O
signaling O
pathway O
. O

GM B
- I
CSF I
gene I
activation O
in O
T O
cells O
is O
known O
to O
involve O
the O
transcription B
factors I
nuclear B
factor I
- I
kappa I
B I
, O
AP B
- I
1 I
, O
NFAT B
, O
and O
Sp1 O
. O

The O
preferential O
induction O
of O
c B
- I
jun I
by O
H2O2 O
did O
not O
represent O
redox O
stabilization O
of O
mRNA B
transcripts I
, O
and O
oxidative O
signals O
closely O
resembled O
PHA O
/ O
PMA O
stimulation O
by O
effectively O
transactivating O
the O
full O
length O
c B
- I
jun I
promoter O
via O
the O
proximal B
jun1 I
tumor I
promoter I
- I
responsive I
element I
( I
TRE I
) I
- I
like I
promoter I
element I
. O

Many O
of O
Pb O
' O
s O
effects O
on O
the O
immune O
system O
could O
be O
explained O
through O
activation O
of O
the O
transcription B
factor I
, O
NF B
- I
kappa I
B I
. O

Tyrosine B
kinase I
and O
cAMP B
- I
dependent I
protein I
kinase I
activities O
in O
CD40 O
- O
activated O
human O
B O
lymphocytes O
. O

To O
better O
understand O
the O
contribution O
of O
the O
GR B
N I
- I
terminal I
transactivation I
domain I
in O
mediating O
murine O
thymocyte O
apoptosis O
, O
we O
stably O
transfected O
GR B
, O
GR B
variants I
, O
and O
the O
androgen B
receptor I
( O
AR B
) O
into O
receptor O
- O
negative O
S49 O
murine O
thymoma O
cells O
. O

To O
better O
understand O
the O
contribution O
of O
the O
GR B
N I
- I
terminal I
transactivation I
domain I
in O
mediating O
murine O
thymocyte O
apoptosis O
, O
we O
stably O
transfected O
GR B
, O
GR B
variants I
, O
and O
the O
androgen B
receptor I
( O
AR B
) O
into O
receptor O
- O
negative O
S49 O
murine O
thymoma O
cells O
. O

One O
p21ras B
effector O
pathway O
involves O
the O
MAP B
kinase I
ERK B
- I
2 I
, O
and O
we O
have O
examined O
its O
role O
in O
NFAT B
regulation O
. O

Gel O
mobility O
shift O
and O
immunoprecipitation O
analyses O
revealed O
that O
in O
addition O
to O
activating O
STAT3 B
( O
signal B
transducer I
and I
activator I
of I
transcription I
- I
3 I
) O
and O
STAT5 B
, O
IL B
- I
2 I
induced O
tyrosine O
and O
serine O
phosphorylation O
of O
STAT1 B
alpha I
, O
which O
formed O
IFN B
- I
gamma I
- I
activated I
sequence I
- I
binding I
complexes I
by O
itself O
and O
with O
STAT3 B
. O

Although O
IL B
- I
2 I
and O
IFN B
- I
alpha I
activated O
STAT1 B
alpha I
and O
STAT5 B
, O
IL B
- I
2 I
predominantly O
activated O
STAT5 B
, O
while O
IFN B
- I
alpha I
predominantly O
activated O
STAT1 B
alpha I
. O

Although O
IL B
- I
2 I
and O
IFN B
- I
alpha I
activated O
STAT1 B
alpha I
and O
STAT5 B
, O
IL B
- I
2 I
predominantly O
activated O
STAT5 B
, O
while O
IFN B
- I
alpha I
predominantly O
activated O
STAT1 B
alpha I
. O

STAT1 B
alpha I
activation O
by O
IL B
- I
12 I
correlated O
with O
increased O
phosphorylation O
of O
serine O
, O
but O
not O
tyrosine O
. O

Recently O
it O
has O
become O
clear O
that O
these O
cytokines B
activate O
a O
number O
of O
important O
intracellular B
signaling I
molecules I
, O
including O
the O
Janus B
kinases I
JAK1 B
and O
JAK3 B
and O
members O
of O
the O
transcription B
factor I
family I
of O
signal B
transducers I
and O
activators B
of I
transcription I
( O
STATs B
) O
. O

Recently O
it O
has O
become O
clear O
that O
these O
cytokines B
activate O
a O
number O
of O
important O
intracellular B
signaling I
molecules I
, O
including O
the O
Janus B
kinases I
JAK1 B
and O
JAK3 B
and O
members O
of O
the O
transcription B
factor I
family I
of O
signal B
transducers I
and O
activators B
of I
transcription I
( O
STATs B
) O
. O

In O
this O
review O
we O
examine O
the O
structure O
and O
function O
of O
cytokine B
receptors I
and O
the O
signaling O
pathways O
involved O
in O
their O
regulation O
of O
gene O
expression O
. O

Therefore O
, O
we O
analyzed O
the O
expression O
, O
DNA O
binding O
, O
and O
transcriptional O
activity O
of O
the O
endogenous B
RA I
and I
VitD3 I
receptors I
[ O
retinoic B
acid I
receptors I
( O
RARs B
) O
, O
retinoid B
X I
receptors I
( O
RXRs B
) O
, O
and O
VitD3 B
receptor I
( O
VDR B
) O
] O
in O
the O
U O
- O
937 O
cell O
line O
, O
in O
which O
RA O
and O
VitD3 O
induce O
distinct O
monocytic O
differentiation O
pathways O
. O

Southern O
blot O
analysis O
showed O
rearrangement O
of O
BCL6 B
, O
JH B
, O
and O
TCR B
beta I
but O
not O
of O
TCR B
delta I
. O

Southern O
blot O
analysis O
showed O
rearrangement O
of O
BCL6 B
, O
JH B
, O
and O
TCR B
beta I
but O
not O
of O
TCR B
delta I
. O

Latent B
membrane I
protein I
1 I
and O
, O
to O
a O
lesser O
extent O
, O
EBV B
nuclear I
antigen I
2 I
mediated O
the O
increase O
in O
p53 B
levels O
via O
activation O
of O
the O
NF B
- I
kappaB I
transcription B
factor I
. O

Tissue O
- O
specific O
expression O
of O
interleukin B
- I
3 I
( O
IL B
- I
3 I
) O
is O
mediated O
via O
cis B
- I
acting I
elements I
located O
within O
315 O
base O
pairs O
of O
the O
transcription B
start I
. O

In O
chloramphenicol B
acetyltransferase I
assays O
, O
utilizing O
the O
transient O
transfection O
of O
a O
chloramphenicol B
acetyltransferase I
reporter I
plasmid I
containing O
the O
IL B
- I
6 I
gene I
promoter I
, O
IL B
- I
4 I
, O
but O
not O
IL B
- I
10 I
, O
suppressed O
the O
transcriptional O
activity O
of O
the O
IL O
- O
6 O
gene O
promoter O
stimulated O
by O
PMA O
and O
LPS O
. O

We O
compared O
the O
effects O
of O
the O
deactivating B
cytokine I
interleukin B
10 I
( O
IL B
- I
10 I
) O
on O
human O
peripheral O
blood O
mononuclear O
cell O
( O
PBMC O
) O
responses O
to O
lipopolysaccharide O
( O
LPS O
) O
, O
Cryptococcus O
neoformans O
, O
and O
Candida O
albicans O
. O

We O
compared O
the O
effects O
of O
the O
deactivating B
cytokine I
interleukin B
10 I
( O
IL B
- I
10 I
) O
on O
human O
peripheral O
blood O
mononuclear O
cell O
( O
PBMC O
) O
responses O
to O
lipopolysaccharide O
( O
LPS O
) O
, O
Cryptococcus O
neoformans O
, O
and O
Candida O
albicans O
. O

Biochemical O
analysis O
of O
the O
region O
- B
158 I
/ I
- I
90 I
revealed O
a O
binding O
site O
for O
transcription B
factors I
of O
the O
polyomavirus B
enhancer I
- I
binding I
protein I
2 I
/ I
core I
- I
binding I
factor I
( I
PEBP2 I
/ I
CBF I
) I
family I
at O
position B
- I
103 I
. O

Disruption O
of O
the O
PEBP2 B
/ I
CBF I
site I
markedly O
diminished O
the O
role O
of O
the O
PEBP2 B
/ I
CBF I
factors I
in O
the O
constitutive O
transcription O
of O
the O
CD36 B
gene I
. O

Therefore O
, O
a O
STAT1 B
transcription B
factor I
is O
activated O
by O
IFN B
- I
gamma I
synthesized O
and O
released O
upon O
stimulation O
of O
T O
lymphocyte O
populations O
. O

We O
investigated O
oligonucleotide O
- O
directed O
triple O
helix O
formation O
across O
this O
regulatory B
sequence I
as O
a O
potential O
tool O
to O
inhibit O
GM B
- I
CSF I
gene O
transcription O
. O

We O
conclude O
that O
the O
kappaB B
element I
in O
the O
GM B
- I
CSF I
promoter I
plays O
a O
central O
role O
in O
the O
transcriptional O
activation O
of O
the O
endogenous O
GM B
- I
CSF I
gene I
. O

Costimulation O
of O
U1 O
cells O
with O
LPS O
plus O
GM B
- I
CSF I
resulted O
in O
the O
accumulation O
of O
steady O
- O
state O
levels O
of O
HIV B
RNA I
; O
however O
, O
only O
a O
weak O
induction O
of O
HIV B
long I
terminal I
repeat I
- O
driven O
transcription O
, O
which O
was O
not O
associated O
with O
the O
activation O
of O
the O
cellular B
transcription I
factor I
nuclear B
factor I
- I
kappa I
B I
, O
was O
noted O
. O

IL B
- I
12 I
is O
a O
novel O
heterodimeric B
cytokine I
important O
for O
the O
regulation O
and O
differentiation O
of O
lymphocytes O
and O
NK O
cells O
. O

These O
mechanisms O
include O
the O
assembly O
of O
higher B
order I
nucleoprotein I
complexes I
and O
other O
protein O
- O
protein O
interactions O
that O
enhance O
the O
functional O
specificity O
of O
transcriptional B
regulators I
in O
lymphocytes O
. O

Thus O
it O
appears O
that O
there O
may O
often O
be O
malfunction O
of O
the O
normal O
glucocorticoid O
response O
in O
HIV O
- O
infected O
cells O
probably O
due O
to O
altered O
interactions O
between O
the O
glucocorticoid B
receptor I
and O
its O
hormone O
. O

r B
- I
hTBP I
- I
1 I
and O
rhu B
TNFR I
: I
Fc I
also O
decreased O
p24 B
antigen I
synthesized O
by O
U1 O
cells O
in O
response O
to O
other O
stimuli O
, O
including O
phytohemagglutinin B
( I
PHA I
) I
- I
induced I
supernatant I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
, O
interleukin B
- I
6 I
, O
and O
TNF B
. O

Addition O
of O
r B
- I
hTBP I
- I
1 I
to O
U1 O
cells O
during O
the O
last O
4 O
h O
of O
a O
24 O
h O
incubation O
with O
PMA O
still O
inhibited O
p24 B
antigen I
production O
by O
15 O
% O
. O

The O
viral B
protein I
Tax I
was O
likely O
responsible O
for O
this O
higher O
level O
of O
class B
II I
gene I
transcription O
, O
as O
purified B
Tax I
was O
found O
to O
stimulate O
both O
genes O
when O
added O
to O
the O
uninfected O
cell O
extract O
or O
in O
reconstituted O
systems O
. O

We O
have O
generated O
rabbit O
antisera O
against O
this O
putative O
p13MTCP1 B
protein I
and O
screened O
for O
expression O
of O
p13MTCP1 B
normal O
lymphoid O
tissues O
and O
33 O
cases O
of O
immature O
and O
mature O
lymphoid O
T O
- O
cell O
proliferations O
using O
a O
sensitive O
Western O
blot O
assay O
. O

The O
p13MTCP1 B
protein I
was O
detected O
in O
the O
three O
T O
- O
cell O
proliferations O
with O
MTCP1 B
rearrangements I
because O
of O
t O
( O
X O
; O
14 O
) O
translocations O
, O
but O
neither O
in O
normal O
resting O
and O
activated O
lymphocytes O
nor O
in O
the O
other O
T O
- O
cell O
leukemias O
. O

The O
p13MTCP1 B
protein I
was O
detected O
in O
the O
three O
T O
- O
cell O
proliferations O
with O
MTCP1 B
rearrangements I
because O
of O
t O
( O
X O
; O
14 O
) O
translocations O
, O
but O
neither O
in O
normal O
resting O
and O
activated O
lymphocytes O
nor O
in O
the O
other O
T O
- O
cell O
leukemias O
. O

A O
variety O
of O
cytokines B
and O
growth B
factors I
act O
through O
an O
induction O
of O
gene O
expression O
mediated O
by O
a O
family O
of O
latent B
transcription I
factors I
called O
STAT B
( I
signal I
transducers I
and I
activators I
of I
transcription I
) I
proteins I
. O

However O
, O
the O
combined O
stimulation O
did O
not O
result O
in O
enhanced O
p50 B
and O
p65 B
protein I
expression O
. O

The O
effects O
of O
IFN B
- I
gamma I
on O
the O
transcription B
factors I
were O
specific O
, O
since O
no O
change O
was O
observed O
in O
the O
expression O
of O
NF B
- I
IL I
- I
6 I
or O
I B
kappa I
B I
alpha I
, O
the O
inhibitor O
of O
NF B
- I
kappa I
B I
. O

We O
conclude O
that O
the O
effects O
of O
IFN B
- I
gamma I
on O
the O
expression O
of O
the O
transcription B
factors I
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
may O
be O
important O
for O
the O
modulatory O
effects O
of O
IFN B
- I
gamma I
on O
the O
cytokine B
expression O
in O
activated O
human O
monocytes O
. O

We O
have O
previously O
identified O
a O
new O
transcription B
factor I
family I
( O
the O
MNP B
family I
) O
whose O
expression O
is O
crucial O
for O
the O
induction O
of O
MIP B
- I
1 I
alpha I
transcription O
during O
cellular O
activation O
and O
in O
transformed O
B O
cells O
. O

Differentiation O
of O
T O
- O
helper O
lymphocytes O
: O
selective O
regulation O
by O
members O
of O
the O
STAT B
family I
of O
transcription B
factors I
. O

Differentiation O
of O
T O
- O
helper O
lymphocytes O
: O
selective O
regulation O
by O
members O
of O
the O
STAT B
family I
of O
transcription B
factors I
. O

Specific O
docking B
sites I
within O
individual O
cytokine B
receptors I
have O
been O
identified O
for O
almost O
all O
Stat B
proteins I
. O

Specific O
docking B
sites I
within O
individual O
cytokine B
receptors I
have O
been O
identified O
for O
almost O
all O
Stat B
proteins I
. O

Specific O
docking B
sites I
within O
individual O
cytokine B
receptors I
have O
been O
identified O
for O
almost O
all O
Stat B
proteins I
. O

The O
direct O
coupling O
between O
cytokine B
receptor I
and O
transcription B
factor I
helps O
to O
explain O
how O
different O
cytokines B
elicit O
distinct O
patterns O
of O
gene O
expression O
. O

The O
direct O
coupling O
between O
cytokine B
receptor I
and O
transcription B
factor I
helps O
to O
explain O
how O
different O
cytokines B
elicit O
distinct O
patterns O
of O
gene O
expression O
. O

A O
mutant O
Tax B
protein I
deficient O
in O
transactivation O
of O
genes O
by O
the O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
pathway O
was O
unable O
to O
induce O
transcriptional O
activity O
of O
IL B
- I
1alpha I
promoter I
- I
CAT I
constructs I
, O
but O
was O
rescued O
by O
exogenous O
provision O
of O
p65 B
/ I
p50 I
NF B
- I
kappaB I
. O

Electrophoretic O
mobility O
shift O
analyses O
demonstrated O
that O
the O
151 B
- I
bp I
region I
contains O
nuclear B
protein I
binding I
sites I
for O
Sp1 B
, O
PU B
. I
1 I
, O
and O
/ O
or O
Elf B
- I
1 I
, O
and O
a O
novel B
factor I
. O

As O
judged O
by O
supershifting O
the O
DNA B
- I
protein I
complexes I
with O
Abs B
recognizing O
specific O
components O
of O
the O
NF B
- I
kappa I
B I
/ I
Rel I
protein I
family I
, O
the O
p50 B
/ I
p65 I
( O
Rel B
A I
) O
heterodimeric O
form O
of O
NF B
- I
kappa I
B I
is O
primarily O
affected O
. O

Here O
we O
provide O
evidence O
that O
this O
transformation O
is O
the O
result O
of O
double O
infection O
of O
a O
cell O
with O
two O
virions O
, O
the O
P3HR1 B
virus I
genome I
and O
a O
mini B
- I
EBV I
plasmid I
carrying O
the O
chimeric O
EBNA2 B
gene I
. O

It O
remains O
open O
whether O
the O
growth O
retarding O
property O
of O
the O
EBNA2 B
- I
oestrogen I
receptor I
fusion I
protein I
in O
B O
cell O
lymphoma O
lines O
is O
due O
to O
unphysiologically O
high O
expression O
of O
the O
chimeric B
protein I
or O
to O
interference O
with O
a O
cellular O
programme O
driving O
proliferation O
in O
these O
cell O
lines O
. O

These O
results O
indicate O
that O
, O
as O
already O
reported O
for O
the O
IL2Rbeta B
promoter I
, O
GA B
- I
binding I
protein I
is O
an O
essential O
component O
of O
gammac O
basal O
promoter O
activity O
. O

Phorbol O
ester O
treatment O
of O
monocytes O
inhibited O
IFN O
alpha O
- O
stimulated O
tyrosine O
phosphorylation O
of O
the O
transcription B
factors I
Stat1alpha B
, O
Stat2 B
, O
and O
Stat3 B
and O
of O
the O
tyrosine B
kinase I
Tyk2 B
but O
had O
no O
effect O
on O
IFN B
- I
gamma I
activation O
of O
Stat1alpha B
. O

Phorbol O
ester O
treatment O
of O
monocytes O
inhibited O
IFN O
alpha O
- O
stimulated O
tyrosine O
phosphorylation O
of O
the O
transcription B
factors I
Stat1alpha B
, O
Stat2 B
, O
and O
Stat3 B
and O
of O
the O
tyrosine B
kinase I
Tyk2 B
but O
had O
no O
effect O
on O
IFN B
- I
gamma I
activation O
of O
Stat1alpha B
. O

Interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
- B
reporter I
gene I
behavior O
closely O
parallels O
the O
endogenous B
gene I
in O
response O
to O
T B
cell I
receptor I
and O
costimulatory O
signals O
. O

By O
contrast O
, O
AM580 O
is O
not O
effective O
as O
ATRA O
in O
modulating O
the O
expression O
of O
these O
differentiation B
markers I
in O
the O
HL O
- O
60 O
cell O
line O
and O
in O
freshly O
isolated O
granulocytes O
obtained O
from O
the O
peripheral O
blood O
of O
chronic O
myelogenous O
leukemia O
patients O
during O
the O
stable O
phase O
of O
the O
disease O
. O

Binding O
experiments O
, O
using O
COS O
- O
7 O
cells O
transiently O
transfected O
with O
PML B
- I
RAR I
and O
the O
normal O
RAR B
alpha I
, O
show O
that O
AM580 O
has O
a O
lower O
affinity O
than O
ATRA O
for O
both O
receptors O
. O

Nuclear B
factors I
from O
unstimulated O
, O
but O
not O
from O
activated O
cells O
, O
bound O
a O
site O
, O
META B
( I
D I
- I
) I
, O
adjacent O
to O
META B
( I
D I
+ I
) I
. O

Translocation B
breakpoints I
in O
three O
patients O
with O
campomelic O
dysplasia O
and O
autosomal O
sex O
reversal O
map O
more O
than O
130 O
kb O
from O
SOX9 B
. O

Unexpectedly O
, O
the O
17q B
breakpoints I
in O
four O
CMPD1 O
translocation O
cases O
previously O
analyzed O
by O
us O
and O
others O
map O
50 O
kb O
or O
more O
from O
SOX9 B
. O

Both O
CIITA B
and O
Bob1 B
increase O
the O
expression O
from O
the O
DRA B
promoter I
, O
which O
is O
a O
prototypic O
class B
II I
promoter I
. O

Ca2 B
+ I
- I
modulating I
cyclophilin I
ligand I
( O
CAML B
) O
was O
originally O
described O
as O
a O
cyclophilin B
B I
- I
binding I
protein I
whose O
overexpression O
in O
T O
cells O
causes O
a O
rise O
in O
intracellular O
calcium O
, O
thus O
activating O
transcription B
factors I
responsible O
for O
the O
early O
immune O
response O
. O

The O
chromosome B
17 I
breakpoint I
was O
localized O
to O
intron B
2 I
of O
RARA B
by O
Southern O
blotting O
, O
and O
there O
was O
no O
evidence O
at O
the O
molecular O
level O
for O
rearrangement O
at O
PML B
locus I
. O

The O
chromosome B
17 I
breakpoint I
was O
localized O
to O
intron B
2 I
of O
RARA B
by O
Southern O
blotting O
, O
and O
there O
was O
no O
evidence O
at O
the O
molecular O
level O
for O
rearrangement O
at O
PML B
locus I
. O

In O
these O
same O
animals O
, O
E1A B
protein I
was O
detected O
20 O
days O
after O
infection O
in O
two O
and O
47 O
days O
after O
infection O
in O
one O
while O
persistent O
bronchiolitis O
was O
observed O
in O
four O
and O
three O
animals O
20 O
and O
47 O
days O
after O
infection O
, O
respectively O
. O

Cyclic O
AMP O
- B
responsive I
element I
- O
dependent O
activation O
of O
Epstein O
- O
Barr O
virus O
zebra B
promoter I
by O
human O
herpesvirus O
6 O
. O

Mutation O
of O
the O
consensus B
AP I
- I
1 I
/ I
CRE I
site I
within O
ZII B
abolished O
the O
inducibility O
of O
Zp B
by O
HHV O
- O
6 O
, O
whereas O
positioning O
of O
the O
ZII B
domain I
upstream O
of O
the O
beta B
- I
globin I
minimal I
promoter I
conferred O
responsiveness O
following O
HHV O
- O
6 O
infection O
. O

Antibodies O
against O
CRE B
- I
binding I
( I
CREB I
) I
protein I
but O
not O
against O
c B
- I
Fos I
or O
c B
- I
Jun I
were O
able O
to O
supershift O
the O
DNA B
- I
protein I
complex I
, O
identifying O
the O
nature O
of O
the O
transcription B
factor I
which O
binds O
to O
ZII B
as O
a O
member O
of O
the O
CREB B
family I
of I
proteins I
. O

Glucocorticoids O
induced O
down O
- O
regulation O
of O
glucocorticoid B
receptor I
mRNA O
expression O
in O
asthma O
. O

Structure O
/ O
function O
analysis O
of O
various O
Oct B
- I
2a I
effector I
regions I
in O
the O
context O
of O
the O
GAL4 B
DNA I
- I
binding I
domain I
revealed O
that O
Oct B
- I
2a I
contains O
two O
functionally O
different O
activation B
domains I
at O
the O
N B
and I
the I
C I
termini I
. O

Together O
, O
our O
results O
indicate O
that O
occupancy O
of O
the O
viral B
enhancer I
by O
NF B
- I
kappaB I
( I
p50 I
/ I
p65 I
) I
heterodimers I
is O
required O
for O
ongoing O
transcription O
of O
integrated O
HIV O
provirus O
in O
monocytes O
, O
even O
in O
cells O
chronically O
infected O
and O
permanently O
producing O
functional O
HIV B
Tat I
protein I
. O

Two O
explanations O
for O
hyporesponsiveness O
of O
the O
human B
iNOS I
promoter I
to O
LPS O
+ O
/ O
- O
IFN B
- I
gamma I
were O
found O
: O
( O
1 O
) O
multiple O
inactivating O
nucleotide O
substitutions O
in O
the O
human O
counterpart O
of O
the O
enhancer B
element I
that O
has O
been O
shown O
to O
regulate O
LPS O
/ O
IFN B
- I
gamma I
induced O
expression O
of O
the O
mouse B
iNOS I
gene I
; O
and O
( O
2 O
) O
and O
absence O
of O
one O
or O
more O
nuclear B
factors I
in O
human O
macrophages O
( O
e O
. O
g O
. O
, O
an O
LPS B
- I
inducible I
nuclear I
factor I
- I
kappa I
B I
/ I
Rel I
complex I
) O
, O
that O
is O
( O
are O
) O
required O
for O

Two O
explanations O
for O
hyporesponsiveness O
of O
the O
human B
iNOS I
promoter I
to O
LPS O
+ O
/ O
- O
IFN B
- I
gamma I
were O
found O
: O
( O
1 O
) O
multiple O
inactivating O
nucleotide O
substitutions O
in O
the O
human O
counterpart O
of O
the O
enhancer B
element I
that O
has O
been O
shown O
to O
regulate O
LPS O
/ O
IFN B
- I
gamma I
induced O
expression O
of O
the O
mouse B
iNOS I
gene I
; O
and O
( O
2 O
) O
and O
absence O
of O
one O
or O
more O
nuclear B
factors I
in O
human O
macrophages O
( O
e O
. O
g O
. O
, O
an O
LPS B
- I
inducible I
nuclear I
factor I
- I
kappa I
B I
/ I
Rel I
complex I
) O
, O
that O
is O
( O
are O
) O
required O
for O

While O
partial O
variable O
monosomy O
of O
loci O
on O
chromosome B
17p I
can O
not O
be O
excluded O
as O
contributing O
to O
the O
phenotype O
in O
this O
patient O
, O
it O
is O
argued O
that O
the O
major O
likely O
factor O
is O
partial O
functional O
disomy O
of O
sequences O
on O
Xp B
in O
cell O
lineages O
that O
have O
failed O
to O
inactivate O
the O
intact O
X B
chromosome I
. O

While O
partial O
variable O
monosomy O
of O
loci O
on O
chromosome B
17p I
can O
not O
be O
excluded O
as O
contributing O
to O
the O
phenotype O
in O
this O
patient O
, O
it O
is O
argued O
that O
the O
major O
likely O
factor O
is O
partial O
functional O
disomy O
of O
sequences O
on O
Xp B
in O
cell O
lineages O
that O
have O
failed O
to O
inactivate O
the O
intact O
X B
chromosome I
. O

Fas B
ligation O
induces O
apoptosis O
and O
Jun B
kinase I
activation O
independently O
of O
CD45 B
and O
Lck B
in O
human O
T O
cells O
. O

Activation O
of O
macrophages O
by O
bacterial O
lipopolysaccharide O
( O
LPS O
) O
induces O
transcription O
of O
genes O
that O
encode O
for O
proinflammatory B
regulators I
of O
the O
immune O
response O
. O

Deletional O
and O
site O
- O
directed O
mutagenesis O
revealed O
the O
presence O
of O
multiple O
functionally O
critical O
cis B
elements I
within O
this O
region O
, O
one O
of O
which O
was O
a O
nuclear B
factor I
( I
NF I
) I
- I
kappaB I
consensus I
sequence I
. O

This O
is O
the O
first O
description O
, O
to O
our O
knowledge O
, O
of O
regulatory B
elements I
that O
control O
expression O
of O
a O
gene O
encoding O
a O
B7 B
costimulatory I
molecule I
. O

Moreover O
, O
gp120 B
induces O
tyrosine O
phosphorylation O
of O
signal B
transducer I
and I
activator I
of I
transcription I
( O
STAT B
- I
1 I
alpha I
) O
as O
well O
as O
the O
Janus B
kinase I
( O
JAK2 B
) O
in O
glial O
cells O
. O

Interaction O
of O
HTLV B
- I
I I
Tax I
with O
the O
human B
proteasome I
: O
implications O
for O
NF B
- I
kappa I
B I
induction O
. O

We O
identified O
a O
physical O
interaction O
between O
Tax B
and O
the O
HsN3 B
subunit I
of O
the O
human B
proteasome I
. O

We O
identified O
a O
physical O
interaction O
between O
Tax B
and O
the O
HsN3 B
subunit I
of O
the O
human B
proteasome I
. O

The O
shift O
from O
complex B
I I
to O
complex B
II I
seen O
only O
in O
SCM O
- O
1 O
- O
producer O
T O
cell O
lines O
upon O
activation O
was O
completely O
suppressed O
by O
cyclosporin O
A O
. O

The O
shift O
from O
complex B
I I
to O
complex B
II I
seen O
only O
in O
SCM O
- O
1 O
- O
producer O
T O
cell O
lines O
upon O
activation O
was O
completely O
suppressed O
by O
cyclosporin O
A O
. O

The O
importance O
of O
NF B
- I
kappaB I
sites I
was O
confirmed O
by O
using O
vectors O
containing O
wild B
- I
type I
or I
mutant I
kappaB I
sites I
in O
a O
heterologous B
promoter I
. O

Administration O
of O
megakaryocyte B
growth I
and I
development I
factor I
or O
interleukin B
6 I
could O
not O
overcome O
the O
differentiation O
block O
. O

Inhibition O
of O
lipopolysaccharide O
- O
induced O
monocyte B
interleukin I
- I
1 I
receptor I
antagonist O
synthesis O
by O
cortisol O
: O
involvement O
of O
the O
mineralocorticoid B
receptor I
. O

Moreover O
, O
we O
provide O
evidence O
that O
, O
in O
addition O
to O
a O
glucocorticoid B
receptor I
- O
mediated O
effect O
, O
the O
mineralocorticoid B
receptor I
is O
involved O
in O
the O
inhibition O
of O
monocyte O
IL B
- I
1ra I
secretion O
by O
cortisol O
. O

Moreover O
, O
we O
provide O
evidence O
that O
, O
in O
addition O
to O
a O
glucocorticoid B
receptor I
- O
mediated O
effect O
, O
the O
mineralocorticoid B
receptor I
is O
involved O
in O
the O
inhibition O
of O
monocyte O
IL B
- I
1ra I
secretion O
by O
cortisol O
. O

E1A B
oncogene I
induction O
of O
cellular O
susceptibility O
to O
killing O
by O
cytolytic O
lymphocytes O
through O
target O
cell O
sensitization O
to O
apoptotic O
injury O
. O

TCL1 B
oncogene I
expression O
in O
AIDS O
- O
related O
lymphomas O
and O
lymphoid O
tissues O
. O

We O
have O
determined O
that O
the O
JAK B
/ B
STAT I
pathway O
positively O
regulates O
Qp B
activity O
. O

Consistent O
with O
a O
role O
for O
STATs B
in O
Qp B
function O
, O
Qp B
using O
Burkitt O
' O
s O
lymphoma O
Rael O
cells O
and O
cultured O
nasopharyngeal O
carcinoma O
( O
NPC O
) O
cells O
contained O
nuclear O
STAT B
protein I
. O

We O
provide O
evidence O
that O
Zta B
up O
- O
regulation O
of O
p53 B
leads O
to O
p53 B
- O
mediated O
interference O
with O
JAK B
/ B
STAT I
activation O
of O
Qp B
. O

We O
show O
here O
that O
the O
response O
of O
the O
HIV O
- O
1 O
long O
terminal O
repeat O
( O
LTR B
) O
to O
mitogenic O
or O
Tat B
- O
mediated O
activation O
is O
sensitive O
to O
the O
suppressive O
action O
of O
a O
Herpesvirus O
saimiri O
( O
HVS O
) O
- O
transformed O
CD8 O
+ O
T O
cell O
clone O
from O
an O
HIV O
- O
infected O
individual O
and O
supernatants O
from O
CD8 O
+ O
T O
cells O
of O
HIV O
- O
1 O
- O
infected O
asymptomatic O
subjects O
( O
CD4 B
+ I
> O
350 O
/ O
microliters O
) O
. O

We O
find O
that O
recruitment O
of O
EKLF B
to O
5 B
' I
HS2 I
requires O
the O
TATA B
box I
, O
but O
recruitment O
to O
5 B
' I
HS3 I
depends O
on O
the O
CACCC O
and O
TATA B
boxes I
of O
the O
beta B
- I
globin I
promoter I
. O

We O
find O
that O
recruitment O
of O
EKLF B
to O
5 B
' I
HS2 I
requires O
the O
TATA B
box I
, O
but O
recruitment O
to O
5 B
' I
HS3 I
depends O
on O
the O
CACCC O
and O
TATA B
boxes I
of O
the O
beta B
- I
globin I
promoter I
. O

CD40 B
signaling O
activates O
downstream B
effectors I
, O
including O
the O
tyrosine B
protein I
kinase I
, O
Lyn B
, O
the O
phosphatidylinositol B
- I
3 I
- I
kinase I
( O
PI B
- I
3 I
kinase I
) O
, O
and O
the O
transcription O
factor O
, O
NF B
- I
kappa I
B I
. O

CD45 B
- O
dependent O
events O
such O
as O
tyrosine B
phosphorylation I
of O
Shc B
, O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
, O
transcription B
factors I
, O
and O
stimulation O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
and O
of O
CD69 B
and O
CD25 B
surface O
expression O
paralleled O
activation O
of O
the O
tyrosine B
kinases I
lck B
and O
fyn B
. O

CD45 B
- O
dependent O
events O
such O
as O
tyrosine B
phosphorylation I
of O
Shc B
, O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
, O
transcription B
factors I
, O
and O
stimulation O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
and O
of O
CD69 B
and O
CD25 B
surface O
expression O
paralleled O
activation O
of O
the O
tyrosine B
kinases I
lck B
and O
fyn B
. O

CD45 B
- O
dependent O
events O
such O
as O
tyrosine B
phosphorylation I
of O
Shc B
, O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
, O
transcription B
factors I
, O
and O
stimulation O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
and O
of O
CD69 B
and O
CD25 B
surface O
expression O
paralleled O
activation O
of O
the O
tyrosine B
kinases I
lck B
and O
fyn B
. O

Here O
we O
show O
that O
1alpha O
, O
25 O
( O
OH O
) O
2 O
- O
d5 O
- O
previtamin O
D3 O
( O
HF O
) O
, O
JN O
, O
KH1060 O
, O
and O
MC903 O
induce O
expression O
of O
PKC B
alpha I
and O
PKC B
delta I
and O
translocation O
of O
both O
isoforms O
to O
the O
particulate O
fraction O
, O
and O
PKC B
alpha I
to O
the O
nuclear O
fraction O
. O

Here O
we O
show O
that O
1alpha O
, O
25 O
( O
OH O
) O
2 O
- O
d5 O
- O
previtamin O
D3 O
( O
HF O
) O
, O
JN O
, O
KH1060 O
, O
and O
MC903 O
induce O
expression O
of O
PKC B
alpha I
and O
PKC B
delta I
and O
translocation O
of O
both O
isoforms O
to O
the O
particulate O
fraction O
, O
and O
PKC B
alpha I
to O
the O
nuclear O
fraction O
. O

Here O
we O
show O
that O
1alpha O
, O
25 O
( O
OH O
) O
2 O
- O
d5 O
- O
previtamin O
D3 O
( O
HF O
) O
, O
JN O
, O
KH1060 O
, O
and O
MC903 O
induce O
expression O
of O
PKC B
alpha I
and O
PKC B
delta I
and O
translocation O
of O
both O
isoforms O
to O
the O
particulate O
fraction O
, O
and O
PKC B
alpha I
to O
the O
nuclear O
fraction O
. O

Retinoic O
acid O
can O
directly O
modulate O
gene O
expression O
via O
binding O
to O
its O
nuclear B
receptors I
, O
which O
can O
, O
in O
turn O
, O
activate O
transcription O
of O
target B
genes I
. O

Retinoic O
acid O
can O
directly O
modulate O
gene O
expression O
via O
binding O
to O
its O
nuclear B
receptors I
, O
which O
can O
, O
in O
turn O
, O
activate O
transcription O
of O
target B
genes I
. O

Tax B
has O
been O
shown O
to O
transactivate O
several O
cellular B
genes I
. O

Induced O
MIP B
- I
1alpha I
expression O
and O
secretion O
in O
PMA O
/ O
PHA O
stimulated O
tax O
transfected O
cells O
correlate O
with O
the O
noninduction O
of O
MNP B
- I
1 I
transcription B
factor I
, O
which O
is O
intimately O
involved O
in O
downmodulating O
the O
MIP B
- I
1alpha I
gene I
. O

The O
other O
major O
subpopulation O
expressing O
the O
CD4 B
receptor I
, O
namely O
, O
the O
double O
- O
positive O
( O
DP O
) O
CD4 O
( O
+ O
) O
CD8 O
( O
+ O
) O
CD3 O
( O
+ O
/ O
- O
) O
thymocytes O
, O
despite O
the O
entry O
of O
the O
virus O
, O
do O
not O
produce O
a O
significant O
level O
of O
virus O
, O
presumably O
because O
they O
are O
unresponsive O
to O
TNF B
and O
IL B
- I
7 I
. O

Patients O
with O
the O
recessively O
inherited O
disorder O
ataxia O
telangiectasia O
( O
A O
- O
T O
) O
have O
a O
high O
level O
of O
specific O
chromosome B
translocations I
which O
can O
be O
easily O
observed O
in O
peripheral O
T O
cells O
and O
show O
a O
greatly O
increased O
predisposition O
to O
leukaemia O
/ O
lymphoma O
, O
mainly O
of O
T O
cell O
origin O
. O

Compounds O
that O
interfere O
selectively O
with O
the O
calcineurin B
- B
NFAT I
interaction O
without O
affecting O
calcineurin B
phosphatase B
activity O
may O
be O
useful O
as O
therapeutic O
agents O
that O
are O
less O
toxic O
than O
current O
drugs O
. O

Therefore O
, O
we O
investigated O
whether O
IVS1 O
- O
10T O
- O
- O
> O
C O
deleteriously O
affected O
BRCA1 B
splicing O
or O
expression O
, O
and O
thereby O
inactivated O
the O
other O
BRCA1 B
allele I
. O

By O
functionally O
expressing O
receptor B
mutants I
in O
the O
murine O
pro O
- O
B O
cell O
line O
Ba O
/ O
F3 O
, O
we O
could O
show O
that O
phosphorylated O
tyrosine O
residues O
within O
the O
IL B
- I
4R I
alpha I
chain I
are O
dispensable O
for O
IL B
- I
4 I
- O
induced O
STAT5 B
activity O
. O

An O
inhibitory O
, O
` O
` O
dominant O
- O
negative O
, O
' O
' O
form O
of O
the O
calcineurin B
catalytic I
( I
A I
) I
subunit I
was O
prepared O
, O
which O
lacks O
the O
calmodulin B
- I
binding I
domain I
, O
autoinhibitory B
domain I
and O
most O
of O
its O
catalytic O
core O
but O
possesses O
the O
regulatory B
( I
B I
) I
subunit I
binding O
domain O
. O

Immunoprecipitation O
of O
epitope B
- I
labeled I
BKO I
demonstrated O
for O
the O
formation O
of O
a O
tight O
complex O
with O
endogenous B
B I
subunit I
in O
Jurkat O
cells O
, O
consistent O
with O
an O
inhibitory O
mechanism O
that O
involves O
the O
sequestration O
of O
the O
B B
subunit I
. O

Peroxisome B
proliferator I
- I
activated I
receptors I
( O
PPARs B
) O
, O
members O
of O
the O
nuclear B
receptor I
superfamily I
of O
transcription B
factors I
, O
are O
activated O
by O
fatty O
acid O
metabolites O
, O
peroxisome O
proliferators O
, O
and O
thiazolidinediones O
and O
are O
now O
recognized O
as O
important O
mediators O
in O
the O
inflammatory O
response O
. O

Expression O
of O
wild B
- I
type I
SHP1 I
had O
a O
very O
small O
effect O
on O
the O
TCR O
- O
induced O
tyrosine O
phosphorylation O
of O
ZAP B
- I
70 I
and O
Syk B
, O
even O
when O
SHP1 B
was O
overexpressed O
20 O
- O
100 O
- O
fold O
over O
endogenous B
SHP1 I
. O

However O
, O
the O
two O
SH2 B
domains I
of O
SHP1 B
did O
not O
facilitate O
its O
recognition O
of O
ZAP B
- I
70 I
and O
Syk B
as O
substrates O
in O
intact O
cells O
. O

Furthermore O
, O
we O
have O
demonstrated O
that O
both O
C B
/ I
EBPbeta I
and O
GATA B
- I
1 I
can O
bind O
simultaneously O
to O
the O
C O
/ O
EBP O
- O
and O
GATA B
- I
binding I
sites I
in O
the O
MBP B
promoter I
. O

DNase B
I I
footprinting O
identified O
several O
protected O
areas O
including O
Sp1 B
, I
Sp1 I
/ I
AP I
- I
2 I
, I
and I
cAMP I
response I
element I
( I
CRE I
) I
binding I
sites I
within O
the O
201 O
- O
bp O
core O
promoter O
region O
and O
Sp1 B
, I
NRE I
- I
2a I
, I
TCF I
- I
1 I
/ I
LEF I
- I
1 I
, I
and I
Sp1 I
/ I
NF I
- I
AT I
binding I
sites I
in O
the O
upstream B
regulatory I
region I
. O

Electrophoretic O
mobility O
shift O
assay O
analysis O
of O
proteins O
binding O
to O
the O
CRE B
site I
identified O
both O
ATF B
- I
1 I
and O
ATF B
- I
2 I
in O
Jurkat O
cells O
. O

In O
summary O
, O
we O
have O
identified O
a O
tissue B
- I
specific I
regulatory I
region I
5 O
' O
of O
the O
ecto B
- I
5 I
' I
- I
NT I
core I
promoter I
that O
requires O
the O
presence O
of O
a O
functional O
CRE B
site I
within O
the O
basal B
promoter I
for O
its O
suppressive O
activity O
. O

In O
summary O
, O
we O
have O
identified O
a O
tissue B
- I
specific I
regulatory I
region I
5 O
' O
of O
the O
ecto B
- I
5 I
' I
- I
NT I
core I
promoter I
that O
requires O
the O
presence O
of O
a O
functional O
CRE B
site I
within O
the O
basal B
promoter I
for O
its O
suppressive O
activity O
. O

Extracellular O
signal O
- O
regulated O
protein O
kinase O
( O
ERK O
) O
- O
dependent O
and O
ERK O
- O
independent O
pathways O
target O
STAT3 B
on O
serine O
- O
727 O
in O
human O
neutrophils O
stimulated O
by O
chemotactic B
factors I
and O
cytokines B
. O

( O
2 O
- O
Amino O
- O
3 O
' O
- O
methoxyphenyl O
) O
oxanaphthalen O
- O
4 O
- O
one O
( O
PD O
98059 O
) O
, O
an O
inhibitor O
of O
extracellular O
signal B
- I
regulated I
protein I
kinase I
( O
ERK B
) O
activation O
, O
blocked O
the O
serine O
phosphorylation O
of O
STAT3 B
induced O
by O
chemotactic B
factors I
or O
PMA O
. O

These O
foci O
, O
which O
were O
preferentially O
found O
adjacent O
to O
nucleoli O
or O
at O
the O
nuclear O
periphery O
, O
did O
not O
represent O
sites O
of O
active O
transcription O
or O
binding O
of O
GATA B
- I
1 I
to O
consensus B
sites I
in O
the O
beta B
- I
globin I
loci I
. O

After O
exercise O
following O
placebo O
administration O
we O
observed O
increases O
in O
concentrations O
of O
blood O
substrates O
, O
plasma B
adrenocorticotropin I
( O
ACTH B
) O
, O
growth O
hormone O
and O
cortisol O
and O
in O
the O
number O
of O
glucocorticoid B
receptors I
in O
lymphocytes O
without O
changes O
in O
the O
dissociation O
constant O
. O

After O
exercise O
following O
placebo O
administration O
we O
observed O
increases O
in O
concentrations O
of O
blood O
substrates O
, O
plasma B
adrenocorticotropin I
( O
ACTH B
) O
, O
growth O
hormone O
and O
cortisol O
and O
in O
the O
number O
of O
glucocorticoid B
receptors I
in O
lymphocytes O
without O
changes O
in O
the O
dissociation O
constant O
. O

Estrogen B
receptors I
influence O
non O
- O
genomic O
events O
, O
which O
are O
rapid O
in O
onset O
and O
genomic O
events O
, O
which O
are O
longer O
acting O
responses O
. O

Protein B
kinase I
C I
and O
calcineurin B
synergize O
to O
activate O
IkappaB B
kinase I
and O
NF B
- I
kappaB I
in O
T O
lymphocytes O
. O

We O
also O
demonstrate O
that O
the O
IKK B
complex I
, O
but O
not O
p90 B
( I
rsk I
) I
, O
is O
responsible O
for O
the O
in O
vivo O
phosphorylation O
of O
IkappaBalpha B
mediated O
by O
the O
co O
- O
activation O
of O
PKC B
and O
calcineurin B
. O

Additional O
upstream O
gene O
segments O
dramatically O
affected O
B29 B
minimal B
promoter I
activity O
. O

These O
findings O
indicate O
that O
B29 B
gene I
expression O
is O
controlled O
by O
the O
complex O
interplay O
of O
positive O
and O
negative B
regulatory I
elements I
. O

A O
novel O
immunosuppressive B
factor I
in O
bovine O
colostrum O
blocks O
activation O
of O
the O
interleukin B
2 I
gene I
enhancer I
at O
the O
NFAT B
site I
. O

A O
novel O
immunosuppressive B
factor I
in O
bovine O
colostrum O
blocks O
activation O
of O
the O
interleukin B
2 I
gene I
enhancer I
at O
the O
NFAT B
site I
. O

A O
factor O
in O
bovine O
colostrum O
( O
colostrum B
inhibitory I
factor I
, O
CIF B
) O
inhibits O
interleukin B
2 I
( O
IL2 B
) O
production O
in O
activated O
T O
helper O
cells O
by O
blocking O
the O
accumulation O
of O
IL2 B
mRNA I
. O

A O
factor O
in O
bovine O
colostrum O
( O
colostrum B
inhibitory I
factor I
, O
CIF B
) O
inhibits O
interleukin B
2 I
( O
IL2 B
) O
production O
in O
activated O
T O
helper O
cells O
by O
blocking O
the O
accumulation O
of O
IL2 B
mRNA I
. O

Using O
a O
combination O
of O
bacterial O
motility O
assays O
in O
platelet O
extracts O
with O
Escherichia O
coli O
expressing O
the O
Shigella B
IcsA I
protein I
and O
in O
vitro O
analysis O
of O
reconstituted O
systems O
from O
purified B
proteins I
, O
we O
show O
here O
that O
the O
bacterial B
protein I
IcsA I
binds O
N B
- I
WASP I
and O
activates O
it O
in O
a O
Cdc42 B
- O
like O
fashion O
. O

To O
better O
understand O
the O
assembly O
mechanism O
for O
the O
progesterone B
receptor I
( O
PR B
) O
, O
we O
have O
developed O
cell O
- O
free O
systems O
for O
studying O
interactions O
of O
PR B
, O
hsp90 B
, O
and O
other O
associated B
proteins I
. O

To O
better O
understand O
the O
assembly O
mechanism O
for O
the O
progesterone B
receptor I
( O
PR B
) O
, O
we O
have O
developed O
cell O
- O
free O
systems O
for O
studying O
interactions O
of O
PR B
, O
hsp90 B
, O
and O
other O
associated B
proteins I
. O

This O
explains O
, O
in O
part O
, O
the O
known O
effects O
of O
ATP O
and O
molybdate O
on O
assembly O
of O
PR B
complexes I
. O

Since O
NF O
- O
kappaB O
/ O
IkappaB B
system O
regulates O
the O
transcription O
of O
proinflammatory B
genes I
, O
including O
those O
responsible O
for O
ROS O
generation O
, O
we O
tested O
the O
hypothesis O
that O
hydrocortisone O
may O
stimulate O
IkappaB B
production O
thus O
inhibiting O
NF B
- I
kappaB I
translocation O
from O
the O
cytosol O
into O
the O
nucleus O
in O
MNC O
, O
in O
vivo O
. O

Proinflammatory B
cytokines I
such O
as O
IL B
- I
1beta I
and O
TNF B
- I
alpha I
were O
down O
- O
regulated O
by O
GC O
treatment O
. O

Furthermore O
, O
our O
studies O
showed O
association O
of O
the O
IKK B
- I
alpha I
/ I
beta I
heterodimer I
with O
NIK B
, O
IkappaB B
- I
alpha I
and O
- B
epsilon I
in O
unstimulated O
cells O
. O

The O
aim O
of O
this O
study O
was O
to O
examine O
the O
ability O
of O
tumor B
necrosis I
factor I
alpha I
( O
TNFalpha B
, O
a O
proinflammatory B
cytokine I
) O
and O
interleukin B
( I
IL I
) I
- I
10 I
( O
an O
anti B
- I
inflammatory I
cytokine I
) O
to O
differentially O
regulate O
the O
sensitivity O
of O
human O
monocytes O
/ O
macrophages O
to O
glucocorticoids O
. O

Finally O
, O
we O
investigated O
whether O
the O
modulation O
of O
corticosensitivity O
in O
TNFalpha O
- O
and O
IL O
- O
10 O
- O
pretreated O
U937 O
cells O
was O
related O
to O
a O
change O
of O
the O
glucocorticoid B
receptor I
concentration O
and O
affinity O
. O

Because O
NF B
- I
kappa I
B I
contributes O
to O
the O
transcription O
of O
numerous O
inflammatory B
genes I
and O
has O
been O
shown O
to O
be O
a O
molecular O
target O
of O
antiinflammatory O
drugs O
, O
we O
sought O
to O
characterize O
the O
functional O
role O
of O
the O
NF B
- I
kappa I
B I
protein I
complex I
in O
lupus O
T O
cells O
. O

As O
p65 B
complexes I
are O
transcriptionally O
active O
in O
comparison O
to O
the O
p50 O
homodimer O
, O
this O
novel O
finding O
may O
provide O
insight O
on O
the O
origin O
of O
abnormal B
cytokine I
or O
other O
gene O
transcription O
in O
SLE O
patients O
. O

As O
p65 B
complexes I
are O
transcriptionally O
active O
in O
comparison O
to O
the O
p50 O
homodimer O
, O
this O
novel O
finding O
may O
provide O
insight O
on O
the O
origin O
of O
abnormal B
cytokine I
or O
other O
gene O
transcription O
in O
SLE O
patients O
. O

Both O
the O
DNA B
binding I
and O
transactivation B
domains I
of O
PU B
. I
1 I
are O
required O
for O
repression O
and O
both O
domains O
are O
also O
needed O
to O
block O
terminal O
differentiation O
in O
MEL O
cells O
. O

Both O
the O
DNA B
binding I
and O
transactivation B
domains I
of O
PU B
. I
1 I
are O
required O
for O
repression O
and O
both O
domains O
are O
also O
needed O
to O
block O
terminal O
differentiation O
in O
MEL O
cells O
. O

Therefore O
, O
IRF B
- I
1 I
may O
be O
an O
important O
contributor O
to O
IL B
- I
12 I
signaling O
, O
and O
we O
speculate O
that O
the O
defective O
IL B
- I
12 I
responses O
seen O
in O
IRF B
- O
1 O
- O
/ O
- O
mice O
might O
be O
attributable O
, O
in O
part O
, O
to O
the O
absence O
of O
this O
transcription B
factor I
. O

C5a O
- O
induced O
reporter B
gene I
expression O
was O
abolished O
by O
introducing O
mutations O
into O
the O
kappaB B
sites I
and O
by O
coexpression O
of O
a O
dominant B
negative I
IkappaBalpha I
construct I
resistant O
to O
agonist O
- O
induced O
phosphorylation O
. O

C5a O
- O
induced O
reporter B
gene I
expression O
was O
abolished O
by O
introducing O
mutations O
into O
the O
kappaB B
sites I
and O
by O
coexpression O
of O
a O
dominant B
negative I
IkappaBalpha I
construct I
resistant O
to O
agonist O
- O
induced O
phosphorylation O
. O

Pertussis O
toxin O
, O
which O
ADP O
- O
ribosylates O
the O
Gi B
proteins I
known O
to O
couple O
to O
the O
C5a B
receptor I
, O
produced O
minimal O
inhibition O
of O
C5a O
- O
induced O
IL B
- I
8 I
expression O
and O
had O
little O
effect O
on O
C5a O
- O
induced O
calcium O
mobilization O
in O
RAW264 O
. O
7 O
cells O
. O

Pertussis O
toxin O
, O
which O
ADP O
- O
ribosylates O
the O
Gi B
proteins I
known O
to O
couple O
to O
the O
C5a B
receptor I
, O
produced O
minimal O
inhibition O
of O
C5a O
- O
induced O
IL B
- I
8 I
expression O
and O
had O
little O
effect O
on O
C5a O
- O
induced O
calcium O
mobilization O
in O
RAW264 O
. O
7 O
cells O
. O

CD40 B
/ B
CD40 I
ligand O
interactions O
play O
a O
key O
role O
in O
the O
immune O
responses O
of O
B O
lymphocytes O
, O
monocytes O
, O
and O
dendritic O
cells O
. O

The O
transcription B
factor I
NF B
- I
ATc I
that O
controls O
gene O
expression O
in O
T O
lymphocytes O
and O
embryonic O
cardiac O
cells O
is O
expressed O
in O
three O
prominent O
isoforms O
. O

Enhancer O
replacement O
is O
therefore O
an O
effective O
strategy O
to O
target O
expression O
of O
a O
retroviral B
transgene I
to O
a O
specific O
progeny O
of O
transduced O
hematopoietic O
stem O
cells O
. O

Regulation O
of O
Fas B
ligand I
expression O
and O
cell O
death O
by O
apoptosis B
- I
linked I
gene I
4 I
. O

We O
used O
an O
adenoviral O
technique O
of O
blocking O
NF B
- I
kappaB I
through O
overexpression O
of O
the O
inhibitory B
subunit I
IkappaBalpha B
, O
which O
has O
the O
advantage O
that O
it O
can O
be O
used O
in O
the O
diseased O
tissue O
itself O
, O
with O
> O
90 O
% O
of O
the O
synovial O
macrophages O
, O
fibroblasts O
, O
and O
T O
cells O
infected O
. O

Messenger B
RNA I
production O
coding O
for O
IL B
- I
8 I
, O
RANTES B
, O
and O
MCP B
- I
1 I
showed O
parallel O
variations O
to O
the O
production O
of O
the O
correspondent B
proteins I
. O

Messenger B
RNA I
production O
coding O
for O
IL B
- I
8 I
, O
RANTES B
, O
and O
MCP B
- I
1 I
showed O
parallel O
variations O
to O
the O
production O
of O
the O
correspondent B
proteins I
. O

This O
correlated O
with O
the O
initiation O
of O
signaling O
downstream O
of O
Notch O
, O
as O
evidenced O
by O
increased O
levels O
of O
HES B
- I
1 I
transcripts I
in O
co O
- O
cultivated O
T O
cells O
and O
of O
CD23 B
transcripts I
in O
co O
- O
cultivated O
B O
cells O
. O

Our O
results O
demonstrated O
that O
: O
( O
i O
) O
PGN O
induced O
phosphorylation O
of O
the O
transcription B
factors I
ATF B
- I
1 I
and O
CREB B
; O
( O
ii O
) O
ATF B
- I
1 I
and O
CREB B
bound O
DNA O
as O
a O
dimer O
and O
induced O
transcriptional O
activation O
of O
a O
CRE B
reporter I
plasmid I
, O
which O
was O
inhibited O
by O
dominant O
negative O
CREB B
and O
ATF B
- I
1 I
; O
( O
iii O
) O
PGN O
induced O
phosphorylation O
of O
c B
- I
Jun I
, O
protein O
synthesis O
of O
JunB B
and O
c B
- I
Fos I
, O
and O
transcriptional O
activation O
of O
the O
AP B
- I
1 I
reporter I
plasmid I
, O
which O
was O

A O
cell O
culture O
system O
was O
then O
employed O
that O
permitted O
the O
differentiation O
of O
Th B
effectors I
from O
resting O
memory O
T O
cells O
by O
short O
term O
priming O
. O

The O
results O
show O
that O
the O
CYP1A1 B
mRNA I
level O
induced O
by O
UV O
in O
the O
presence O
of O
tryptophan O
was O
higher O
than O
that O
induced O
by O
UV O
alone O
in O
both O
HaCaT O
cells O
and O
lymphocytes O
after O
3 O
h O
of O
incubation O
post O
- O
UV O
irradiation O
. O

This O
shows O
that O
the O
induction O
of O
gene O
expression O
by O
FICZ O
and O
UV O
is O
Ah B
receptor I
dependent O
. O

Thus O
, O
the O
photoproducts O
of O
tryptophan O
are O
suggested O
to O
be O
mediators O
of O
light O
via O
binding O
to O
the O
Ah B
receptor I
and O
as O
such O
also O
could O
have O
a O
role O
in O
light O
- O
regulated O
biological O
rhythms O
. O

Additionally O
, O
virus O
reactivation O
in O
resting O
PBMCs O
infected O
in O
vitro O
with O
HIV O
- O
1 O
was O
found O
to O
be O
specifically O
induced O
by O
ligands O
of O
the O
CDR2 B
- I
loop I
in O
domain B
1 I
( O
D1 B
) O
of O
CD4 B
( O
virus B
envelope I
and I
anti I
- I
CD4 I
monoclonal I
antibodies I
) O
. O

The O
effect O
of O
oestrogens O
on O
oestrogen O
- O
receptive O
organs O
and O
cells O
is O
mediated O
via O
intracellular B
receptors I
( O
ERalpha B
and O
ERbeta B
) O
. O

We O
have O
identified O
an O
E B
box I
around O
- B
260 I
and O
a O
YY1 B
binding I
site I
around O
- B
300 I
relative O
to O
the O
transcription B
start I
site I
. O

We O
have O
identified O
an O
E B
box I
around O
- B
260 I
and O
a O
YY1 B
binding I
site I
around O
- B
300 I
relative O
to O
the O
transcription B
start I
site I
. O

We O
have O
identified O
an O
E B
box I
around O
- B
260 I
and O
a O
YY1 B
binding I
site I
around O
- B
300 I
relative O
to O
the O
transcription B
start I
site I
. O

Furthermore O
, O
PML B
and O
pRb B
105 I
were O
co O
- O
immunoprecipitated O
in O
cellular O
lysates O
derived O
from O
erythroid O
precursors O
indicating O
that O
this O
functional O
interaction O
may O
have O
a O
biochemical O
basis O
. O

These O
data O
suggest O
that O
the O
physiological O
relationship O
between O
binding O
and O
function O
of O
the O
glucocorticoid B
receptor I
is O
disturbed O
in O
MS O
. O

RESULTS O
: O
The O
number O
of O
glucocorticoid B
receptors I
on O
mononuclear O
leukocytes O
( O
MNL O
) O
was O
comparable O
in O
patients O
with O
anorexia O
nervosa O
, O
patients O
with O
active O
Cushing O
' O
s O
disease O
, O
and O
normal O
subjects O
( O
binding O
capacity O
3 O
. O
3 O
+ O
/ O
- O
0 O
. O
23 O
vs O
. O
3 O
. O
7 O
+ O
/ O
- O
0 O
. O
30 O
and O
3 O
. O
5 O
+ O
/ O
- O
0 O
. O
20 O
fmol O
/ O
10 O
( O
6 O
) O
cells O
) O
. O

Different O
sequence O
requirements O
for O
expression O
in O
erythroid O
and O
megakaryocytic O
cells O
within O
a O
regulatory B
element I
upstream O
of O
the O
GATA B
- I
1 I
gene I
. O

We O
have O
localized O
a O
317 O
base O
pair O
cis B
- I
acting I
regulatory I
element I
, O
HS B
I I
, O
associated O
with O
a O
hematopoietic B
- I
specific I
DNase I
I I
hypersensitive I
site I
, O
which O
lies O
approx O
. O

This O
core O
contains O
a O
GATA B
site I
separated O
by O
10 O
base O
pairs O
from O
an O
E B
- I
box I
motif I
. O

In O
addition O
, O
sodium O
salicylate O
and O
additional O
NSAIDs O
used O
at O
concentrations O
that O
activate O
HSF1 B
also O
inhibited O
the O
expression O
of O
other O
monocytic B
genes I
( O
TNF B
- I
alpha I
, O
IL B
- I
1beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
IL B
- I
10 I
, O
ICAM B
- I
1 I
) O
activated O
by O
exposure O
to O
a O
pro O
- O
inflammatory O
stimulus O
( O
lipopolysaccharide O
, O
LPS O
) O
. O

Decidual O
gammadelta O
T O
cells O
, O
which O
significantly O
increase O
in O
number O
during O
pregnancy O
, O
might O
play O
a O
role O
in O
recognition O
of O
fetal B
antigens I
and O
also O
in O
determining O
the O
quality O
of O
the O
response O
to O
these O
antigens B
. O

In O
conclusion O
, O
production O
of O
a O
Th1 B
cytokine I
, O
IFN B
- I
gamma I
, O
by O
HBsAg B
- O
reactive O
cells O
was O
associated O
with O
hepatocyte O
damage O
in O
chronic O
hepatitis O
B O
, O
while O
no O
counteracting O
effect O
of O
Th2 B
cytokines I
produced O
by O
those O
cells O
was O
observed O
. O

In O
conclusion O
, O
production O
of O
a O
Th1 B
cytokine I
, O
IFN B
- I
gamma I
, O
by O
HBsAg B
- O
reactive O
cells O
was O
associated O
with O
hepatocyte O
damage O
in O
chronic O
hepatitis O
B O
, O
while O
no O
counteracting O
effect O
of O
Th2 B
cytokines I
produced O
by O
those O
cells O
was O
observed O
. O

As2O3 O
induced O
PML O
( O
promyelocytic O
leukemia O
) O
protein O
degradation O
but O
did O
not O
modulate O
expression O
of O
cell B
cycle I
- I
related I
proteins I
, O
including O
c B
- I
myc I
, O
retinoblastoma B
protein I
, O
cyclin B
- I
dependent I
kinase I
4 I
, O
cyclin B
D1 I
, O
and O
p53 B
, O
or O
expression O
of O
differentiation B
- I
related I
antigens I
. O

As2O3 O
induced O
PML O
( O
promyelocytic O
leukemia O
) O
protein O
degradation O
but O
did O
not O
modulate O
expression O
of O
cell B
cycle I
- I
related I
proteins I
, O
including O
c B
- I
myc I
, O
retinoblastoma B
protein I
, O
cyclin B
- I
dependent I
kinase I
4 I
, O
cyclin B
D1 I
, O
and O
p53 B
, O
or O
expression O
of O
differentiation B
- I
related I
antigens I
. O

A20 O
can O
be O
regulated O
by O
the O
NF B
- I
kappaB I
transcription B
factor I
, O
which O
is O
known O
to O
be O
activated O
by O
the O
EBV B
LMP I
- I
1 I
protein I
. O

Further O
, O
CTLA B
- I
4 I
engagement O
inhibited O
progression O
through O
the O
cell O
cycle O
by O
inhibiting O
the O
production O
of O
cyclin B
D3 I
, O
cyclin B
- I
dependent I
kinase I
( B
cdk I
) I
4 I
, O
and O
cdk6 B
when O
the O
T O
cells O
were O
stimulated O
with O
anti B
- I
CD3 I
/ I
CD28 I
and O
with O
anti B
- I
CD3 I
alone O
. O

There O
was O
, O
however O
, O
a O
significant O
difference O
in O
the O
amounts O
of O
the O
nuclear B
protein I
, O
REF B
- I
1 I
( O
which O
regulates O
AP B
- I
1 I
DNA O
binding O
by O
altering O
the O
redox O
status O
of O
FOS B
and O
JUN B
proteins I
) O
, O
in O
alveolar O
macrophages O
compared O
with O
monocytes O
. O

There O
was O
, O
however O
, O
a O
significant O
difference O
in O
the O
amounts O
of O
the O
nuclear B
protein I
, O
REF B
- I
1 I
( O
which O
regulates O
AP B
- I
1 I
DNA O
binding O
by O
altering O
the O
redox O
status O
of O
FOS B
and O
JUN B
proteins I
) O
, O
in O
alveolar O
macrophages O
compared O
with O
monocytes O
. O

The O
costimulatory B
molecule I
CD28 B
has O
a O
restricted O
tissue O
distribution O
and O
is O
expressed O
on O
T O
cells O
and O
some O
plasmacytoma O
cells O
. O

In O
the O
culture O
system O
reported O
here O
, O
( O
1 O
) O
the O
growth B
factor I
( O
GF B
) O
stimulus O
induces O
cord O
blood O
( O
CB O
) O
progenitor O
cells O
to O
proliferate O
and O
differentiate O
/ O
mature O
exclusively O
along O
the O
erythroid O
lineage O
; O
( O
2 O
) O
this O
erythropoietic O
wave O
is O
characterized O
by O
less O
than O
4 O
% O
apoptotic O
cells O
; O
( O
3 O
) O
asymmetric O
divisions O
are O
virtually O
absent O
, O
ie O
, O
nonresponsive O
hematopoietic O
progenitors O
with O
no O
erythropoietic O
potential O
are O
forced O
into O
apoptosis O
; O
( O
4 O
) O
the O
system O
is O
cell O
division O
controlled O
( O
cdc O

Single O
- O
cell O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
analysis O
was O
applied O
to O
this O
culture O
system O
to O
investigate O
gene O
expression O
of O
diverse O
receptors B
, O
markers B
of I
differentiation I
, O
and O
transcription B
factors I
( O
EKLF B
, O
GATA B
- I
1 I
, O
GATA B
- I
2 I
, O
p45 B
NF I
- I
E2 I
, O
PU B
. I
1 I
, O
and O
SCL B
/ I
Tal1 I
) O
at O
discrete O
stages O
of O
erythropoietic O
development O
. O

Single O
- O
cell O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
analysis O
was O
applied O
to O
this O
culture O
system O
to O
investigate O
gene O
expression O
of O
diverse O
receptors B
, O
markers B
of I
differentiation I
, O
and O
transcription B
factors I
( O
EKLF B
, O
GATA B
- I
1 I
, O
GATA B
- I
2 I
, O
p45 B
NF I
- I
E2 I
, O
PU B
. I
1 I
, O
and O
SCL B
/ I
Tal1 I
) O
at O
discrete O
stages O
of O
erythropoietic O
development O
. O

In O
T O
lymphocytes O
, O
the O
hematopoietic B
cytokine I
interleukin B
- I
2 I
( O
IL B
- I
2 I
) O
uses O
phosphatidylinositol B
3 I
- I
kinase I
( O
PI B
3 I
- I
kinase I
) O
- O
induced O
signaling O
pathways O
to O
regulate O
E2F B
transcriptional O
activity O
, O
a O
critical O
cell O
cycle O
checkpoint O
. O

These O
include O
the O
Ikaros B
, O
LKLF B
, O
and O
GATA3 B
zinc I
- I
finger I
proteins I
; O
the O
Ets B
, O
CREB B
/ I
ATF I
, O
and O
NF B
- I
kappa I
B I
/ I
Rel I
/ I
NFAT I
transcription I
factors I
; O
the O
Stat B
proteins I
; O
and O
HMG B
box I
transcription I
factors I
such O
as O
LEF1 B
, O
TCF1 B
, O
and O
Sox4 B
. O

Transcription B
factors I
Sp1 B
and O
AP B
- I
2 I
mediate O
induction O
of O
acid B
sphingomyelinase I
during O
monocytic O
differentiation O
. O

Transcription B
factors I
Sp1 B
and O
AP B
- I
2 I
mediate O
induction O
of O
acid B
sphingomyelinase I
during O
monocytic O
differentiation O
. O

A O
PMA B
responsive I
element I
was O
localized O
to O
a O
region O
between O
- B
319 I
and I
- I
219 I
bp I
upstream I
of O
the O
initiation O
codon O
and O
co O
- O
transfections O
with O
transcription B
factor I
expression I
plasmids I
for O
AP B
- I
2 I
and O
Sp1 B
resulted O
in O
augmented O
ASM O
promoter O
activity O
, O
which O
was O
abolished O
when O
the O
binding B
sites I
for O
these O
two O
factors O
were O
deleted O
. O

The O
nature O
of O
the O
nuclear B
factor I
( O
s O
) O
that O
control O
TNF B
- I
alpha I
gene O
transcription O
in O
humans O
remains O
obscure O
, O
although O
NF B
- I
kappaB I
has O
been O
suggested O
. O

Inhibition O
of O
LITAF B
mRNA I
expression O
in O
THP O
- O
1 O
cells O
resulted O
in O
a O
reduction O
of O
TNF B
- I
alpha I
transcripts O
. O

In O
addition O
, O
high O
level O
of O
expression O
of O
LITAF B
mRNA I
was O
observed O
predominantly O
in O
the O
placenta O
, O
peripheral O
blood O
leukocytes O
, O
lymph O
nodes O
, O
and O
the O
spleen O
. O

In O
the O
nucleus O
, O
it O
functions O
as O
a O
dimerization B
cofactor I
of O
HNF1 B
and O
increases O
the O
transcriptional O
activity O
of O
HNF1 B
. O

The O
activation O
of O
STAT3 B
was O
not O
found O
in O
human O
eosinophils O
, O
monocytes O
, O
and O
HL O
- O
60 O
cells O
, O
although O
the O
STAT3 B
protein I
was O
expressed O
in O
these O
cells O
. O

The O
transcription B
factor I
NF B
- I
ATc I
is O
synthesized O
in O
three O
prominent O
isoforms B
. O

However O
, O
p38 B
MAPK I
is O
activated O
strongly O
and O
synergistically O
by O
either O
CD3 B
/ I
CD28 I
coligation O
or O
PMA O
/ O
Ca2 O
+ O
ionophore O
stimulation O
, O
which O
mimics O
TCR B
- O
CD3 B
/ I
CD28 I
- O
mediated O
signaling O
. O

Epo B
caused O
an O
increase O
in O
the O
proportion O
of O
cells O
expressing O
cell O
surface O
glycophorin B
A I
( O
GPA B
) O
and O
up O
- O
regulated O
beta B
- I
and I
gamma I
- I
globin I
by O
several O
fold O
. O

We O
also O
show O
that O
DFX O
treatment O
limits O
the O
in O
vivo O
activation O
of O
NF B
- I
kappaB I
, O
a O
transcription B
factor I
involved O
in O
both O
TNF B
- I
alpha I
gene O
transcription O
and O
TNF B
- I
alpha I
signalling O
( O
P O
< O
0 O
. O
005 O
) O
. O

Gel O
supershift O
assays O
demonstrated O
that O
thrombin B
induced O
binding O
of O
NF B
- I
kappa I
Bp65 I
( O
Rel B
A I
) O
to O
downstream O
NF B
- I
kappa I
B I
site I
of O
the O
ICAM B
- I
1 I
promoter I
. O

Thrombin B
receptor O
activation O
peptide O
, O
a O
14 O
- O
amino O
- O
acid O
peptide O
representing O
the O
new O
NH2 B
terminus I
of O
proteolytically O
activated O
receptor B
- I
1 I
, O
mimicked O
thrombin B
' O
s O
action O
in O
inducing O
ICAM B
- I
1 I
expression O
. O

CONCLUSION O
: O
Our O
results O
show O
that O
the O
tested O
agents O
( O
except O
indomethacin O
) O
are O
inhibitors O
of O
the O
T O
cell O
- O
mediated O
immune O
response O
, O
as O
expected O
, O
that O
aspirin O
is O
an O
effective O
suppressor O
of O
adhesion B
molecule I
expression O
, O
and O
that O
all O
three O
agents O
can O
induce O
Hsp60 B
in O
HUVECs O
. O

However O
, O
we O
detected O
a O
significant O
reduction O
of O
the O
GR B
mRNA I
levels O
in O
the O
endobronchial O
biopsy O
specimens O
after O
FP O
treatment O
( O
36 O
. O
6 O
+ O
/ O
- O
23 O
. O
1 O
and O
25 O
. O
0 O
+ O
/ O
- O
10 O
. O
9 O
amol O
GR B
mRNA I
/ O
microg O
RNA O
, O
respectively O
; O
P O
< O
. O
01 O
) O
. O

However O
, O
we O
detected O
a O
significant O
reduction O
of O
the O
GR B
mRNA I
levels O
in O
the O
endobronchial O
biopsy O
specimens O
after O
FP O
treatment O
( O
36 O
. O
6 O
+ O
/ O
- O
23 O
. O
1 O
and O
25 O
. O
0 O
+ O
/ O
- O
10 O
. O
9 O
amol O
GR B
mRNA I
/ O
microg O
RNA O
, O
respectively O
; O
P O
< O
. O
01 O
) O
. O

In O
the O
peripheral O
blood O
lymphocytes O
an O
even O
more O
striking O
downregulation O
of O
the O
GR O
by O
its O
cognate O
ligand O
was O
documented O
( O
30 O
. O
3 O
+ O
/ O
- O
26 O
. O
5 O
and O
8 O
. O
8 O
+ O
/ O
- O
5 O
amol O
GR B
mRNA I
/ O
microg O
RNA O
, O
respectively O
; O
P O
< O
. O
001 O
) O
, O
possibly O
reflecting O
differences O
in O
glucocorticoid O
sensitivity O
between O
tissues O
. O

The O
action O
of O
glucocorticosteroids O
is O
mediated O
through O
glucocorticoid B
receptors I
present O
in O
the O
cellular O
cytoplasm O
. O

Unexpected O
and O
coordinated O
expression O
of O
Spi B
- I
1 I
, O
Fli B
- I
1 I
, O
and O
megakaryocytic B
genes I
in O
four O
Epo O
- O
dependent O
cell O
lines O
established O
from O
transgenic O
mice O
displaying O
erythroid O
- O
specific O
expression O
of O
a O
thermosensitive B
SV40 I
T I
antigen I
. O

However O
, O
like O
normal O
Ter O
119 O
erythroid O
cells O
, O
these O
Ter O
119 O
positive O
cells O
from O
transgenic O
mice O
still O
expressed O
high O
levels O
of O
beta B
- I
globin I
and O
very O
low O
or O
undetectable O
glycoprotein B
IIb I
and O
platelet B
factor I
4 I
megakaryocytic I
transcripts I
. O

Taken O
together O
, O
these O
data O
indicate O
that O
the O
unexpected O
expression O
of O
megakaryocytic B
genes I
is O
a O
specific O
property O
of O
immortalized O
cells O
that O
can O
not O
be O
explained O
only O
by O
enhanced O
expression O
of O
Spi B
- I
1 I
and I
/ I
or I
Fli I
- I
1 I
genes I
. O

Fludarabine O
caused O
a O
specific O
depletion O
of O
STAT1 B
protein I
( O
and O
mRNA O
) O
but O
not O
of O
other O
STATs B
. O

Spi B
- I
C I
, O
a O
novel O
Ets B
protein I
that O
is O
temporally O
regulated O
during O
B O
lymphocyte O
development O
. O

The O
viral B
protein I
Tax B
induces O
the O
activation O
and O
nuclear O
translocalization O
of O
transcription B
factor I
NF B
- I
kappaB I
, O
which O
is O
proposed O
to O
play O
a O
crucial O
role O
in O
the O
transformation O
of O
T O
cells O
by O
HTLV O
- O
I O
. O

The O
viral B
protein I
Tax B
induces O
the O
activation O
and O
nuclear O
translocalization O
of O
transcription B
factor I
NF B
- I
kappaB I
, O
which O
is O
proposed O
to O
play O
a O
crucial O
role O
in O
the O
transformation O
of O
T O
cells O
by O
HTLV O
- O
I O
. O

The O
most O
characterized O
pathway O
is O
via O
JAK B
- B
STAT I
signaling O
. O

We O
investigated O
the O
MAPk B
kinase I
( O
MKK B
) O
that O
activates O
p38 B
MAPk I
in O
response O
to O
LPS O
, O
the O
p38 B
MAPk I
isoforms I
that O
are O
activated O
as O
part O
of O
this O
pathway O
, O
and O
the O
functional O
responses O
affected O
by O
p38 B
MAPk I
activation O
. O

We O
investigated O
the O
MAPk B
kinase I
( O
MKK B
) O
that O
activates O
p38 B
MAPk I
in O
response O
to O
LPS O
, O
the O
p38 B
MAPk I
isoforms I
that O
are O
activated O
as O
part O
of O
this O
pathway O
, O
and O
the O
functional O
responses O
affected O
by O
p38 B
MAPk I
activation O
. O

We O
investigated O
the O
MAPk B
kinase I
( O
MKK B
) O
that O
activates O
p38 B
MAPk I
in O
response O
to O
LPS O
, O
the O
p38 B
MAPk I
isoforms I
that O
are O
activated O
as O
part O
of O
this O
pathway O
, O
and O
the O
functional O
responses O
affected O
by O
p38 B
MAPk I
activation O
. O

Although O
MKK3 B
, O
MKK4 B
, O
and O
MKK6 B
all O
activated O
p38 B
MAPk I
in O
experimental O
models O
, O
only O
MKK3 B
was O
found O
to O
activate O
recombinant O
p38 B
MAPk I
in O
LPS O
- O
treated O
neutrophils O
. O

Although O
MKK3 B
, O
MKK4 B
, O
and O
MKK6 B
all O
activated O
p38 B
MAPk I
in O
experimental O
models O
, O
only O
MKK3 B
was O
found O
to O
activate O
recombinant O
p38 B
MAPk I
in O
LPS O
- O
treated O
neutrophils O
. O

Electrophoretic O
mobility O
shift O
assays O
showed O
that O
p50 B
/ I
p65 I
/ I
c I
- I
Rel I
and O
STAT B
- I
6 I
are O
effectively O
induced O
by O
CD40L B
and O
IL B
- I
4 I
, O
respectively O
, O
and O
bind O
to O
specific O
DNA B
motifs I
within O
the O
ECS B
. O

In O
contrast O
, O
another O
inducible O
gene O
expression O
of O
monocyte B
chemotactic I
protein I
- I
1 I
( O
a O
CC B
chemokine I
) O
and O
the O
activation O
of O
the O
transcriptional B
factor I
( O
FcRFgamma B
) O
bound O
to O
the O
gamma B
response I
region I
were O
similarly O
or O
less O
abundantly O
induced O
by O
IFNgamma B
treatment O
in O
PMA O
- O
or O
RA O
- O
differentiated O
U937 O
cells O
, O
indicating O
that O
increased O
IP B
- I
10 I
mRNA I
induction O
was O
not O
due O
to O
the O
augmented O
ability O
of O
the O
cells O
to O
respond O
to O
the O
presence O
of O
IFNgamma B
. O

In O
contrast O
, O
another O
inducible O
gene O
expression O
of O
monocyte B
chemotactic I
protein I
- I
1 I
( O
a O
CC B
chemokine I
) O
and O
the O
activation O
of O
the O
transcriptional B
factor I
( O
FcRFgamma B
) O
bound O
to O
the O
gamma B
response I
region I
were O
similarly O
or O
less O
abundantly O
induced O
by O
IFNgamma B
treatment O
in O
PMA O
- O
or O
RA O
- O
differentiated O
U937 O
cells O
, O
indicating O
that O
increased O
IP B
- I
10 I
mRNA I
induction O
was O
not O
due O
to O
the O
augmented O
ability O
of O
the O
cells O
to O
respond O
to O
the O
presence O
of O
IFNgamma B
. O

MDS1 B
/ I
EVI1 I
is O
inappropriately O
activated O
in O
myeloid O
leukemias O
following O
chromosomal O
rearrangements O
involving O
band B
3q26 I
. O

This O
fusion O
protein O
contains O
the O
DNA B
- I
binding I
domain I
of O
the O
transcription B
factor I
AML1 B
fused O
in O
- O
frame O
to O
the O
entire O
MDS1 B
/ I
EVI1 I
with O
the O
exclusion O
of O
its O
first O
12 O
amino O
acids O
. O

This O
effect O
is O
similar O
to O
that O
previously O
described O
by O
others O
for O
32Dcl3 O
cells O
that O
express O
transgenic B
Evil I
. O

Overexpression O
of O
SIT B
in O
Jurkat O
cells O
downmodulates O
T O
cell O
receptor O
- O
and O
phytohemagglutinin O
- O
mediated O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
by O
interfering O
with O
signaling O
processes O
that O
are O
probably O
located O
upstream O
of O
activation O
of O
phospholipase B
C I
. O

Angiotensin B
II I
activates O
the O
proinflammatory B
transcription I
factor I
nuclear B
factor I
- I
kappaB I
in O
human O
monocytes O
. O

ANG B
II I
, O
like O
TNFalpha B
, O
caused O
rapid O
activation O
of O
NF B
- I
kappaB I
in O
human O
mononuclear O
cells O
isolated O
from O
peripheral O
blood O
by O
Ficoll O
density O
gradient O
. O

Because O
these O
induced O
gene O
products O
have O
NF B
- I
kappaB I
sites I
in O
their O
promoter B
regions I
, O
we O
next O
examined O
whether O
there O
was O
an O
up O
- O
regulation O
of O
nuclear O
NF B
- I
kappaB I
levels O
. O

Previous O
characterization O
of O
the O
GPIX B
promoter I
identified O
a O
functional O
Ets O
site O
that O
, O
when O
disrupted O
, O
reduced O
promoter O
activity O
. O

We O
conclude O
from O
these O
studies O
that O
the O
phosphorylation O
of O
TRAF2 B
is O
likely O
to O
play O
an O
important O
role O
in O
regulating O
signaling O
by O
virtue O
of O
its O
ability O
to O
influence O
the O
CD40 B
- B
TRAF2 I
interaction O
. O

Unlike O
the O
proposed O
role O
of O
Cbl B
as O
a O
negative O
regulator O
, O
our O
results O
suggest O
that O
the O
Cbl B
homologue O
Cbl B
- I
b I
has O
a O
positive O
role O
in O
T O
- O
cell O
signaling O
, O
most O
likely O
via O
a O
direct O
interaction O
with O
the O
upstream B
kinase I
Zap B
- I
70 I
. O

As O
a O
result O
of O
its O
transforming O
abilities O
, O
activated B
Ras I
is O
expressed O
in O
a O
great O
number O
of O
cancers O
. O

We O
also O
observed O
an O
increase O
in O
electrophoretic O
mobility O
of O
the O
predominant O
E2F B
components I
, O
DP1 B
and O
E2F4 B
, O
as O
B O
- O
lymphocytes O
progressed O
from O
G0 O
into O
early O
G1 O
. O

The O
transcription B
factors I
PU B
. I
1 I
and O
C B
/ I
EBPalpha I
are O
responsible O
for O
normal O
myeloid O
differentiation O
from O
stem O
cells O
to O
monocytes O
or O
granulocytes O
. O

Despite O
minimal O
discrepancies O
in O
the O
coding B
region I
, O
there O
are O
striking O
tissue O
- O
and O
cell O
type O
- O
specific O
differences O
in O
isoform O
expression O
patterns O
. O

RFLAT B
- I
1 I
: O
a O
new O
zinc B
finger I
transcription I
factor I
that O
activates O
RANTES B
gene I
expression O
in O
T O
lymphocytes O
. O

Furthermore O
, O
these O
oxidative O
stresses O
inhibited O
activity O
of O
calcineurin O
, O
a O
serine O
/ O
threonine B
phosphatase I
that O
regulates O
NFAT B
activation O
. O

Several O
intracellular O
signaling B
proteins I
, O
such O
as O
CBL B
and O
VAV B
, O
were O
phosphorylated O
on O
tyrosine O
in O
response O
to O
CD80 B
, O
CD86 B
, O
and O
anti B
- I
CD28 I
mAb I
. O

However O
, O
CD80 B
and O
CD86 B
also O
induce O
distinct O
signal O
transduction O
pathways O
including O
the O
tyrosine O
phosphorylation O
of O
CD28 B
and O
phospholipase B
Cgamma1 I
and O
the O
SH2 B
- O
dependent O
association O
of O
phosphoinositide B
3 I
- I
kinase I
with O
CD28 B
. O

Glucocorticoid B
receptors I
in O
cord O
blood O
lymphocytes O
of O
healthy O
neonates O
and O
of O
preterms O
suffering O
from O
respiratory O
distress O
syndrome O
. O

We O
measured O
the O
number O
of O
glucocorticoid B
receptors I
( O
GR B
) O
in O
cord O
blood O
lymphocytes O
and O
the O
binding O
affinity O
( O
Kd O
) O
in O
15 O
term O
and O
in O
20 O
preterm O
babies O
. O

The O
aberrant O
CD4 O
( O
- O
) O
CD8 O
( O
- O
) O
T O
cells O
from O
lpr O
/ O
lpr O
and O
gld O
/ O
gld O
mice O
, O
which O
have O
mutations O
in O
the O
genes O
encoding O
Fas B
and O
FasL B
, O
respectively O
, O
have O
an O
activated O
phenotype O
and O
constitutively O
express O
high O
levels O
of O
fasL B
mRNA I
, O
prompting O
us O
to O
ask O
what O
role O
if O
any O
the O
FLRE B
and O
Egr B
family I
proteins I
have O
in O
this O
aberrant O
expression O
of O
fasL B
. O

Although O
overexpressed O
Egr B
- I
1 I
was O
ineffective O
, O
overexpressed O
Egr B
- I
2 I
was O
as O
potent O
as O
Egr B
- I
3 I
in O
inducing O
fasL B
promoter I
- I
dependent I
reporter I
constructs I
in O
T O
cell O
hybridomas O
and O
HeLa O
cells O
, O
and O
both O
up O
- O
regulated O
endogenous O
fasL B
mRNA I
in O
HeLa O
cells O
. O

The O
activity O
of O
the O
CCAAT B
- I
box I
binding I
factor I
NF I
- I
Y I
is O
modulated O
through O
the O
regulated O
expression O
of O
its O
A B
subunit I
during O
monocyte O
to O
macrophage O
differentiation O
: O
regulation O
of O
tissue B
- I
specific I
genes I
through O
a O
ubiquitous O
transcription B
factor I
. O

The O
activity O
of O
the O
CCAAT B
- I
box I
binding I
factor I
NF I
- I
Y I
is O
modulated O
through O
the O
regulated O
expression O
of O
its O
A B
subunit I
during O
monocyte O
to O
macrophage O
differentiation O
: O
regulation O
of O
tissue B
- I
specific I
genes I
through O
a O
ubiquitous O
transcription B
factor I
. O

Deletion O
of O
interdomain B
B I
did O
not O
affect O
the O
ability O
of O
ZAP B
- I
70 I
to O
bind O
to O
the O
receptor O
. O

Oxidants O
, O
transcription B
factors I
, O
and O
intestinal O
inflammation O
. O

The O
regulatory B
regions I
of O
several O
genes O
specifically O
expressed O
in O
B O
cells O
contain O
functional B
binding I
sites I
for O
Oct2 B
. O

These O
target B
genes I
show O
quite O
distinct O
expression O
patterns O
demonstrating O
that O
transcription B
factors I
in O
addition O
to O
Oct2 B
are O
involved O
in O
their O
regulation O
. O

These O
target B
genes I
show O
quite O
distinct O
expression O
patterns O
demonstrating O
that O
transcription B
factors I
in O
addition O
to O
Oct2 B
are O
involved O
in O
their O
regulation O
. O

Fas B
( O
CD95 B
) O
and O
Fas B
ligand I
( O
CD95L B
) O
are O
an O
interacting O
receptor O
- O
ligand O
pair O
required O
for O
immune O
homeostasis O
. O

Although O
resting O
Jurkat O
cells O
express O
Fas B
, O
Fas B
mRNA I
was O
induced O
approximately O
10 O
- O
fold O
in O
2 O
h O
upon O
P O
/ O
I O
stimulation O
. O

Members O
of O
the O
cyclic B
adenosine I
monophosphate I
( I
cAMP I
) I
response I
element I
binding I
( I
CREB I
) I
/ I
activating I
transcription I
factor I
1 I
( I
ATF I
- I
1 I
) I
family I
of O
transcription B
factors I
bind O
three O
21 B
- I
bp I
repeats I
( O
Tax B
- I
responsive I
element I
- I
1 I
, O
or O
TRE B
- I
1 I
) O
within O
the O
viral B
promoter I
and O
are O
important O
for O
basal O
and O
Tax O
- O
mediated O
transcription O
. O

Members O
of O
the O
cyclic B
adenosine I
monophosphate I
( I
cAMP I
) I
response I
element I
binding I
( I
CREB I
) I
/ I
activating I
transcription I
factor I
1 I
( I
ATF I
- I
1 I
) I
family I
of O
transcription B
factors I
bind O
three O
21 B
- I
bp I
repeats I
( O
Tax B
- I
responsive I
element I
- I
1 I
, O
or O
TRE B
- I
1 I
) O
within O
the O
viral B
promoter I
and O
are O
important O
for O
basal O
and O
Tax O
- O
mediated O
transcription O
. O

However O
, O
while O
HUVECs O
contained O
endothelial O
NOS B
protein I
, O
no O
inducible O
NOS B
was O
detected O
in O
either O
tolerant O
or O
nontolerant O
cells O
. O

These O
cells O
, O
stimulated O
by O
an O
agonistic O
monoclonal O
antibody O
against O
CD40 B
or O
by O
transfection O
with O
a O
CD40L B
expression I
vector I
, O
secreted O
p40 B
and O
showed O
enhanced O
p40 B
mRNA I
expression O
. O

Among O
these O
hypersensitive B
sites I
, O
two O
transcriptional B
control I
elements I
were O
found O
, O
one O
in O
the O
first B
intron I
of O
the O
GATA B
- I
3 I
gene I
and O
the O
other O
between B
8 I
. I
3 I
and I
5 I
. I
9 I
kilobases I
5 O
' O
from O
the O
GATA B
- I
3 I
transcriptional I
initiation I
site I
. O

Among O
these O
hypersensitive B
sites I
, O
two O
transcriptional B
control I
elements I
were O
found O
, O
one O
in O
the O
first B
intron I
of O
the O
GATA B
- I
3 I
gene I
and O
the O
other O
between B
8 I
. I
3 I
and I
5 I
. I
9 I
kilobases I
5 O
' O
from O
the O
GATA B
- I
3 I
transcriptional I
initiation I
site I
. O

The O
3 B
' I
- I
CAGGTG I
E I
- I
box I
could O
bind O
USF B
proteins I
, O
the O
ubiquitous B
repressor I
ZEB B
, O
or O
the O
basic B
helix I
- I
loop I
- I
helix I
proteins I
E2A B
and O
HEB B
, O
and O
we O
showed O
that O
a O
competition O
between O
ZEB B
and O
E2A B
/ I
HEB I
proteins I
is O
involved O
in O
the O
silencer O
activity O
. O

The O
3 B
' I
- I
CAGGTG I
E I
- I
box I
could O
bind O
USF B
proteins I
, O
the O
ubiquitous B
repressor I
ZEB B
, O
or O
the O
basic B
helix I
- I
loop I
- I
helix I
proteins I
E2A B
and O
HEB B
, O
and O
we O
showed O
that O
a O
competition O
between O
ZEB B
and O
E2A B
/ I
HEB I
proteins I
is O
involved O
in O
the O
silencer O
activity O
. O

Cutting O
edge O
: O
dominant O
effect O
of O
Ile50Val B
variant I
of O
the O
human B
IL I
- I
4 I
receptor I
alpha I
- I
chain I
in O
IgE B
synthesis O
. O

Regulation O
of O
IL B
- I
4 I
expression O
by O
the O
transcription B
factor I
JunB B
during O
T O
helper O
cell O
differentiation O
. O

The O
present O
study O
was O
designed O
to O
analyze O
the O
roles O
of O
the O
two O
GR B
isoforms I
on O
glucocorticoid O
- O
mediated O
transrepression O
of O
the O
IL B
- I
2 I
gene I
. O

Extinction O
of O
immunoglobulin B
gene I
expression O
in O
B O
cells O
upon O
fusion O
with O
HeLa O
cells O
is O
preceded O
by O
rapid O
nuclear O
depletion O
of O
essential B
transcription I
factors I
and O
is O
accompanied O
by O
widespread O
inactivation O
of O
genes O
expressed O
in O
a O
B O
cell O
- O
specific O
manner O
. O

Evidence O
for O
suppressed O
activity O
of O
the O
transcription B
factor I
NFAT1 B
at O
its O
proximal B
binding I
element I
P0 B
in O
the O
IL B
- I
4 I
promoter I
associated O
with O
enhanced O
IL B
- I
4 I
gene I
transcription O
in O
T O
cells O
of O
atopic O
patients O
. O

GR B
heterocomplexes I
; O
the O
effect O
of O
SML O
cytosol O
on O
GR O
binding O
was O
reproduced O
with O
cytosol O
from O
COS O
cells O
expressing O
squirrel O
monkey O
FKBP51 B
; O
and O
both O
the O
effect O
of O
SML O
cytosol O
on O
GR O
binding O
and O
the O
incorporation O
of O
FKBP51 B
into O
GR B
heterocomplexes I
were O
blocked O
by O
FK506 O
. O

GR B
heterocomplexes I
; O
the O
effect O
of O
SML O
cytosol O
on O
GR O
binding O
was O
reproduced O
with O
cytosol O
from O
COS O
cells O
expressing O
squirrel O
monkey O
FKBP51 B
; O
and O
both O
the O
effect O
of O
SML O
cytosol O
on O
GR O
binding O
and O
the O
incorporation O
of O
FKBP51 B
into O
GR B
heterocomplexes I
were O
blocked O
by O
FK506 O
. O

These O
findings O
indicate O
that O
imbalanced O
expression O
of O
the O
GR B
isoforms I
may O
be O
a O
mechanism O
of O
GC O
resistance O
, O
and O
may O
have O
implications O
for O
tumorigenesis O
by O
enhancing O
cell O
survival O
. O

The O
allele O
- O
specific O
expression O
profiles O
of O
other O
imprinted B
genes I
, O
IGF2 B
and O
H19 B
, O
on O
human B
chromosome I
11 I
were O
constant O
and O
consistent O
with O
those O
in O
other O
tissues O
. O

This O
pro B
- I
IL I
- I
16 I
is O
subsequently O
processed O
to O
the O
mature O
cytokine O
of O
13 B
kDa I
. O

A O
Taq B
I I
polymorphism I
was O
identified O
which O
enabled O
chicken O
IL2 B
to O
be O
mapped O
to O
chromosome B
4 I
, O
linked O
to O
ANX5 B
, O
with O
synteny O
with O
mouse B
chromosome I
3 I
and O
human B
chromosome I
4 I
. O

The O
Megakaryocyte B
/ I
Platelet I
- I
specific I
enhancer I
of O
the O
alpha2beta1 B
integrin I
gene I
: O
two O
tandem O
AP1 B
sites I
and O
the O
mitogen B
- I
activated I
protein I
kinase I
signaling O
cascade O
. O

Transcriptional O
regulation O
of O
the O
alpha2 B
integrin I
gene I
in O
cells O
undergoing O
megakaryocytic O
differentiation O
requires O
a O
core B
promoter I
between O
bp O
- O
30 O
and O
- O
92 O
, O
a O
silencer B
between O
bp O
- O
92 O
and O
- O
351 O
, O
and O
megakaryocytic B
enhancers I
in O
the O
distal B
5 I
' I
flank I
. O

Transcriptional O
regulation O
of O
the O
alpha2 B
integrin I
gene I
in O
cells O
undergoing O
megakaryocytic O
differentiation O
requires O
a O
core B
promoter I
between O
bp O
- O
30 O
and O
- O
92 O
, O
a O
silencer B
between O
bp O
- O
92 O
and O
- O
351 O
, O
and O
megakaryocytic B
enhancers I
in O
the O
distal B
5 I
' I
flank I
. O

Functional O
testosterone B
receptors I
in O
plasma O
membranes O
of O
T O
cells O
. O

Cytoplasmic B
AR I
do O
not O
translocate O
to O
the O
nucleus O
of O
T O
cells O
in O
the O
presence O
of O
testosterone O
, O
in O
contrast O
to O
cytoplasmic B
AR I
in O
human O
cancer O
LNCaP O
cells O
. O

Cytoplasmic B
AR I
do O
not O
translocate O
to O
the O
nucleus O
of O
T O
cells O
in O
the O
presence O
of O
testosterone O
, O
in O
contrast O
to O
cytoplasmic B
AR I
in O
human O
cancer O
LNCaP O
cells O
. O

Limited O
proteolysis O
for O
assaying O
ligand O
binding O
affinities O
of O
nuclear B
receptors I
. O

IL B
- I
10 I
treatment O
prevented O
the O
downregulation O
of O
p27 B
( I
Kip1 I
) O
, O
an O
inhibitory B
protein I
that O
controls O
progression O
out O
of O
the O
G0 O
phase O
of O
the O
cell O
cycle O
. O

Infection O
of O
human O
monocytes O
with O
influenza O
A O
virus O
induces O
a O
broad O
range O
of O
proinflammatory B
cytokines I
and O
mononuclear O
cell O
attracting O
chemokines B
before O
the O
infected O
cells O
undergo O
apoptosis O
. O

In O
conclusion O
, O
the O
long O
- O
term O
regulation O
of O
transcription B
factor I
gene O
expression O
in O
non O
- O
proliferating O
cells O
seems O
to O
be O
of O
minor O
importance O
after O
influenza O
infection O
since O
in O
apoptosisprone O
cells O
an O
immediate O
availability O
of O
transcription B
factor I
proteins I
is O
required O
. O

The O
importance O
of O
BCL2 B
and O
Stat3 B
on O
IL B
- I
6 I
- O
induced O
macrophage O
- O
differentiation O
and O
apoptosis O
was O
studied O
with O
1A9 O
- O
M O
cells O
expressing O
human B
BCL2 I
or O
a O
dominant O
- O
negative O
form O
of O
Stat3 B
, O
respectively O
. O

Interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
is O
a O
chemokine B
that O
belongs O
to O
the O
alpha B
- I
chemokine I
or O
CXC B
subfamily I
and O
is O
produced O
by O
a O
wide O
variety O
of O
human O
cells O
, O
including O
monocytes O
and O
polymorphonuclear O
cells O
( O
PMN O
) O
. O

Therefore O
we O
investigated O
the O
properties O
and O
function O
of O
the O
glucocorticoid B
receptors I
( O
GR B
) O
in O
FMS O
patients O
and O
compared O
the O
results O
with O
those O
of O
healthy O
persons O
and O
patients O
with O
chronic O
low O
back O
pain O
( O
LBP O
a O
localized O
pain O
condition O
) O
. O

The O
suggested O
roles O
of O
the O
downstream B
3 I
' I
regions I
acting O
as O
a O
Locus B
Control I
Region I
( O
LCR B
) O
, O
have O
allowed O
comparisons O
to O
be O
made O
between O
the O
regulation O
of O
the O
IgH B
locus I
with O
other O
model O
systems O
whose O
gene O
expression O
is O
governed O
by O
LCR B
activity O
. O

MATERIALS O
AND O
METHODS O
: O
Peptides O
derived O
from O
oncogenic B
proteins I
were O
screened O
for O
the O
presence O
of O
HLA B
binding I
motifs I
; O
actual O
binding O
were O
evaluated O
by O
HLA O
stabilization O
experiments O
using O
transfectants O
and O
specific O
anti B
- I
HLA I
antibodies I
. O

RESULTS O
: O
We O
identified O
peptides O
derived O
from O
EWS B
/ I
FLI I
- I
1 I
fusion I
protein I
and O
from O
mutated B
K I
- I
RAS I
protein I
( O
encompassing O
respectively O
the O
fusion B
point I
and O
the O
mutation O
at O
position B
12 I
) O
that O
showed O
binding B
motif I
for O
HLA B
- I
Cw I
* I
0702 I
and O
HLA B
- I
A3 I
respectively O
. O

RESULTS O
: O
We O
identified O
peptides O
derived O
from O
EWS B
/ I
FLI I
- I
1 I
fusion I
protein I
and O
from O
mutated B
K I
- I
RAS I
protein I
( O
encompassing O
respectively O
the O
fusion B
point I
and O
the O
mutation O
at O
position B
12 I
) O
that O
showed O
binding B
motif I
for O
HLA B
- I
Cw I
* I
0702 I
and O
HLA B
- I
A3 I
respectively O
. O

RESULTS O
: O
We O
identified O
peptides O
derived O
from O
EWS B
/ I
FLI I
- I
1 I
fusion I
protein I
and O
from O
mutated B
K I
- I
RAS I
protein I
( O
encompassing O
respectively O
the O
fusion B
point I
and O
the O
mutation O
at O
position B
12 I
) O
that O
showed O
binding B
motif I
for O
HLA B
- I
Cw I
* I
0702 I
and O
HLA B
- I
A3 I
respectively O
. O

We O
eliminate O
both O
Stat5 B
and O
Raf B
/ B
MEK I
pathways O
from O
E2F B
regulation O
. O

Although O
experimental O
evidence O
is O
lacking O
, O
lytic O
viral O
DNA O
replication O
is O
believed O
to O
remove O
modifications O
or O
binding B
factors I
from O
the O
genome O
which O
serve O
to O
repress O
late O
gene O
expression O
during O
latency O
or O
the O
early O
lytic O
cycle O
. O

Thus O
, O
replication O
of O
the O
transcriptional B
template I
is O
not O
a O
prerequisite O
for O
expression O
with O
late O
kinetics O
, O
a O
finding O
inconsistent O
with O
the O
current O
models O
which O
posit O
a O
cis O
- O
active O
relationship O
between O
lytic O
EBV O
DNA O
replication O
and O
late O
gene O
expression O
. O

This O
induction O
of O
C B
/ I
EBP I
epsilon I
mRNA I
expression O
is O
transcriptionally O
mediated O
and O
occurs O
in O
the O
absence O
of O
synthesis O
of O
additional O
protein B
factors I
. O

Both O
have O
been O
shown O
to O
be O
transcription B
factors I
. O

The O
estrogen B
receptor I
( O
ER B
) O
repressed O
erythroid O
differentiation O
and O
erythroid B
- I
specific I
gene I
expression O
. O

These O
bHLH B
antagonists I
are O
induced O
during O
a O
mitogenic O
signalling O
response O
, O
and O
they O
function O
by O
sequestering O
their O
bHLH B
targets I
in O
inactive B
heterodimers I
that O
are O
unable O
to O
bind O
to O
specific O
gene B
regulatory I
( I
E I
box I
) I
sequences I
. O

These O
bHLH B
antagonists I
are O
induced O
during O
a O
mitogenic O
signalling O
response O
, O
and O
they O
function O
by O
sequestering O
their O
bHLH B
targets I
in O
inactive B
heterodimers I
that O
are O
unable O
to O
bind O
to O
specific O
gene B
regulatory I
( I
E I
box I
) I
sequences I
. O

These O
bHLH B
antagonists I
are O
induced O
during O
a O
mitogenic O
signalling O
response O
, O
and O
they O
function O
by O
sequestering O
their O
bHLH B
targets I
in O
inactive B
heterodimers I
that O
are O
unable O
to O
bind O
to O
specific O
gene B
regulatory I
( I
E I
box I
) I
sequences I
. O

In O
the O
mouse O
embryo O
, O
mNFATc B
transcript I
was O
strongly O
expressed O
in O
thymus O
, O
lung O
and O
submandibular O
gland O
and O
weakly O
in O
skeletal O
muscle O
and O
heart O
suggesting O
that O
mNFATc B
may O
have O
a O
role O
both O
in O
embryogenesis O
and O
in O
mature O
T O
cells O
. O

These O
data O
indicate O
that O
the O
TRE B
- I
like I
cAMP I
- I
responsive I
DSE I
sites I
within O
the O
5 B
' I
- I
untranslated I
leader I
can O
mediate O
the O
transcriptional O
cooperativity O
between O
TNFalpha B
and O
the O
cAMP O
/ B
PKA I
pathway O
. O

PURPOSE O
: O
To O
clarify O
the O
relationship O
between O
the O
glucocorticoid B
receptor I
and O
the O
effectiveness O
of O
glucocorticoid O
therapy O
in O
patients O
with O
ulcerative O
colitis O
, O
we O
investigated O
the O
number O
and O
apparent O
dissociation O
constant O
of O
glucocorticoid B
receptor I
in O
peripheral O
blood O
mononuclear O
leukocytes O
of O
patients O
with O
ulcerative O
colitis O
. O

PURPOSE O
: O
To O
clarify O
the O
relationship O
between O
the O
glucocorticoid B
receptor I
and O
the O
effectiveness O
of O
glucocorticoid O
therapy O
in O
patients O
with O
ulcerative O
colitis O
, O
we O
investigated O
the O
number O
and O
apparent O
dissociation O
constant O
of O
glucocorticoid B
receptor I
in O
peripheral O
blood O
mononuclear O
leukocytes O
of O
patients O
with O
ulcerative O
colitis O
. O

The O
apparent O
dissociation O
constant O
of O
the O
glucocorticoid B
receptors I
from O
the O
nonresponders O
, O
responders O
, O
and O
healthy O
controls O
were O
7 O
. O
03 O
( O
range O
, O
5 O
. O
66 O
- O
10 O
) O
, O
4 O
. O
27 O
( O
range O
, O
4 O
- O
5 O
. O
13 O
) O
, O
and O
6 O
. O
18 O
( O
range O
, O
5 O
. O
86 O
- O
6 O
. O
74 O
) O
nM O
, O
respectively O
. O

Nonresponders O
had O
a O
significant O
increase O
both O
in O
the O
number O
of O
binding B
sites I
and O
in O
the O
apparent O
dissociation O
constant O
compared O
with O
responders O
( O
P O
= O
0 O
. O
045 O
; O
P O
= O
0 O
. O
029 O
) O
. O

Cooperation O
of O
binding B
sites I
for O
STAT6 B
and O
NF B
kappa I
B I
/ I
rel I
in O
the O
IL B
- I
4 I
- O
induced O
up O
- O
regulation O
of O
the O
human B
IgE I
germline I
promoter I
. O

In O
cells O
that O
have O
been O
preincubated O
to O
lower O
mRNA O
levels O
, O
there O
is O
a O
transient O
increase O
in O
G0S2 B
mRNA I
, O
peaking O
between O
1 O
- O
2 O
h O
, O
in O
response O
to O
Concanavalin O
- O
A O
( O
ConA O
) O
, O
or O
to O
the O
combination O
of O
phorbol O
ester O
( O
TPA O
) O
, O
and O
the O
calcium O
ionophore O
, O
ionomycin O
. O

Here O
we O
report O
a O
real O
- O
time O
study O
of O
factor O
/ O
DNA O
interactions O
using O
a O
surface O
plasmon O
resonance O
approach O
and O
further O
characterization O
of O
recovered B
proteins I
involved O
in O
this O
interaction O
. O

This O
result O
, O
confirmed O
by O
competitions O
with O
each O
GATA B
site I
, O
demonstrated O
the O
higher O
relative O
affinity O
( O
at O
least O
sevenfold O
) O
of O
site O
3 O
. O

The O
role O
of O
the O
viral B
trans I
- I
activator I
Tax I
protein I
in O
the O
induction O
of O
VCAM B
- I
1 I
was O
first O
indicated O
by O
the O
detection O
of O
this O
adhesion B
molecule I
on O
Jurkat O
T O
- O
cell O
clones O
stably O
expressing O
the O
tax O
gene O
. O

The O
effect O
of O
Tax B
on O
VCAM B
- I
1 I
gene O
transcription O
was O
next O
confirmed O
in O
JPX O
- O
9 O
cells O
, O
a O
subclone O
of O
Jurkat O
cells O
, O
carrying O
the O
tax B
sequences I
under O
the O
control O
of O
an O
inducible B
promoter I
. O

The O
effect O
of O
Tax B
on O
VCAM B
- I
1 I
gene O
transcription O
was O
next O
confirmed O
in O
JPX O
- O
9 O
cells O
, O
a O
subclone O
of O
Jurkat O
cells O
, O
carrying O
the O
tax B
sequences I
under O
the O
control O
of O
an O
inducible B
promoter I
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM B
- I
1 I
promoter I
performed O
with O
chloramphenicol B
acetyltransferase I
constructs I
revealed O
that O
Tax B
was O
trans O
activating O
the O
VCAM B
- I
1 I
promoter I
via O
two O
NF B
- I
kappaB I
sites I
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM B
- I
1 I
gene I
promoter I
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax B
- O
induced O
expression O
of O
this O
adhesion B
molecule I
. O

Interleukin B
2 I
( O
IL B
- I
2 I
) O
induces O
tyrosine O
phosphorylation O
of O
STATs B
3 I
and I
5 I
( O
signal O
transducer O
and O
activator O
of O
transcription O
) O
. O

IL B
- I
2 I
and O
T B
cell I
antigen I
receptor I
complex I
induction O
of O
STAT3alpha B
serine O
727 O
phosphorylation O
is O
dependent O
on O
the O
activity O
of O
the O
MEK B
/ B
ERK I
pathway O
. O

These O
results O
thus O
show O
that O
STAT3 B
proteins I
are O
targets O
for O
multiple O
kinase O
pathways O
in O
T O
cells O
and O
can O
integrate O
signals O
from O
both O
cytokine B
receptors I
and O
antigen B
receptors I
. O

These O
results O
thus O
show O
that O
STAT3 B
proteins I
are O
targets O
for O
multiple O
kinase O
pathways O
in O
T O
cells O
and O
can O
integrate O
signals O
from O
both O
cytokine B
receptors I
and O
antigen B
receptors I
. O

These O
results O
thus O
show O
that O
STAT3 B
proteins I
are O
targets O
for O
multiple O
kinase O
pathways O
in O
T O
cells O
and O
can O
integrate O
signals O
from O
both O
cytokine B
receptors I
and O
antigen B
receptors I
. O

The O
composite B
PU I
. I
1 I
and I
Pip I
site I
likely O
accounts O
for O
both O
lineage O
and O
stage O
- O
specific O
expression O
of O
CD20 B
whereas O
the O
CD20 B
E I
box I
binding I
proteins I
enhance O
overall O
promoter O
activity O
and O
may O
link O
the O
promoter O
to O
a O
distant B
enhancer I
. O

Thus O
, O
the O
reduction O
of O
CN B
activity O
observed O
in O
CsA O
- O
treated O
patients O
is O
accompanied O
by O
a O
similar O
degree O
of O
reduction O
in O
lymphocyte B
gene I
activation O
, O
and O
accounts O
for O
the O
immunosuppression O
observed O
. O

The O
transcription B
factor I
NF B
- I
kappa I
B I
is O
maintained O
in O
an O
inactive O
cytoplasmic O
state O
by O
I B
kappa I
B I
inhibitors I
. O

Intragenic O
TSG101 B
deletions O
in O
RNA B
transcripts I
were O
frequently O
found O
in O
all O
types O
of O
samples O
. O

Production O
of O
IL B
- I
2 I
requires O
the O
formation O
of O
transcription B
factors I
involved O
in O
the O
IL B
- I
2 I
- I
gene I
regulation O
. O

The O
visualization O
of O
heavy B
and I
light I
chain I
genes I
in O
B O
- O
lymphoid O
cells O
showed O
that O
the O
three O
Ig B
genes I
are O
differentially O
and O
nonrandomly O
distributed O
in O
different O
nuclear O
subvolumes O
: O
the O
kappa B
genes I
were O
found O
to O
be O
preferentially O
confined O
to O
an O
outer O
nuclear O
volume O
, O
whereas O
the O
gamma B
and I
lambda I
genes I
consistently O
occupied O
more O
central O
positions O
within O
the O
nucleus O
, O
the O
lambda B
genes I
being O
more O
interior O
when O
compared O
with O
the O
gamma B
genes I
. O

The O
visualization O
of O
heavy B
and I
light I
chain I
genes I
in O
B O
- O
lymphoid O
cells O
showed O
that O
the O
three O
Ig B
genes I
are O
differentially O
and O
nonrandomly O
distributed O
in O
different O
nuclear O
subvolumes O
: O
the O
kappa B
genes I
were O
found O
to O
be O
preferentially O
confined O
to O
an O
outer O
nuclear O
volume O
, O
whereas O
the O
gamma B
and I
lambda I
genes I
consistently O
occupied O
more O
central O
positions O
within O
the O
nucleus O
, O
the O
lambda B
genes I
being O
more O
interior O
when O
compared O
with O
the O
gamma B
genes I
. O

The O
visualization O
of O
heavy B
and I
light I
chain I
genes I
in O
B O
- O
lymphoid O
cells O
showed O
that O
the O
three O
Ig B
genes I
are O
differentially O
and O
nonrandomly O
distributed O
in O
different O
nuclear O
subvolumes O
: O
the O
kappa B
genes I
were O
found O
to O
be O
preferentially O
confined O
to O
an O
outer O
nuclear O
volume O
, O
whereas O
the O
gamma B
and I
lambda I
genes I
consistently O
occupied O
more O
central O
positions O
within O
the O
nucleus O
, O
the O
lambda B
genes I
being O
more O
interior O
when O
compared O
with O
the O
gamma B
genes I
. O

The O
visualization O
of O
heavy B
and I
light I
chain I
genes I
in O
B O
- O
lymphoid O
cells O
showed O
that O
the O
three O
Ig B
genes I
are O
differentially O
and O
nonrandomly O
distributed O
in O
different O
nuclear O
subvolumes O
: O
the O
kappa B
genes I
were O
found O
to O
be O
preferentially O
confined O
to O
an O
outer O
nuclear O
volume O
, O
whereas O
the O
gamma B
and I
lambda I
genes I
consistently O
occupied O
more O
central O
positions O
within O
the O
nucleus O
, O
the O
lambda B
genes I
being O
more O
interior O
when O
compared O
with O
the O
gamma B
genes I
. O

Transcription B
factor I
NF B
- I
kappa I
B I
must O
be O
released O
from O
cytoplasmic B
inhibitory I
molecules I
( O
I B
kappa I
Bs I
) O
in O
order O
to O
move O
to O
the O
nucleus O
and O
to O
activate O
its O
target B
genes I
. O

Transcription B
factor I
NF B
- I
kappa I
B I
must O
be O
released O
from O
cytoplasmic B
inhibitory I
molecules I
( O
I B
kappa I
Bs I
) O
in O
order O
to O
move O
to O
the O
nucleus O
and O
to O
activate O
its O
target B
genes I
. O

TCR B
beta I
analysis O
showed O
that O
while O
there O
was O
loop O
length O
restriction O
in O
the O
putative O
peptide O
contact O
site O
of O
all O
responding O
beta B
chains I
, O
diverse O
and O
unique O
( O
non O
- O
recurrent O
) O
TCR O
beta O
clonotypes O
were O
selected O
in O
individuals O
during O
primary O
infection O
and O
continued O
to O
emerge O
after O
long O
- O
term O
virus O
exposure O
. O

TCR B
beta I
analysis O
showed O
that O
while O
there O
was O
loop O
length O
restriction O
in O
the O
putative O
peptide O
contact O
site O
of O
all O
responding O
beta B
chains I
, O
diverse O
and O
unique O
( O
non O
- O
recurrent O
) O
TCR O
beta O
clonotypes O
were O
selected O
in O
individuals O
during O
primary O
infection O
and O
continued O
to O
emerge O
after O
long O
- O
term O
virus O
exposure O
. O

A O
threonine O
residue O
at O
position B
234 I
, O
previously O
shown O
to O
be O
important O
for O
CD40 B
association O
with O
TNF B
receptor I
- I
associated I
factor I
2 I
( O
TRAF2 B
) O
, O
TRAF3 B
, O
and O
TRAF5 B
, O
was O
not O
required O
for O
NF B
- I
kappa I
B I
activation O
. O

NF B
- I
kappa I
B I
activation O
was O
independent O
of O
the O
transmembrane B
domain I
of O
CD40 B
, O
suggesting O
that O
it O
is O
independent O
of O
p23 B
, O
a O
molecule O
that O
associates O
with O
CD40 B
in O
a O
region O
other O
than O
the O
cytoplasmic B
domain I
. O

NF B
- I
kappa I
B I
activation O
was O
independent O
of O
the O
transmembrane B
domain I
of O
CD40 B
, O
suggesting O
that O
it O
is O
independent O
of O
p23 B
, O
a O
molecule O
that O
associates O
with O
CD40 B
in O
a O
region O
other O
than O
the O
cytoplasmic B
domain I
. O

As O
shown O
by O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
and O
electrophoretic O
mobility O
shift O
assay O
, O
respectively O
, O
treatment O
with O
CsA O
leads O
to O
decreased O
TF B
mRNA I
expression O
and O
reduced O
activation O
of O
the O
NF B
- I
kappaB I
transcription I
factor I
, O
which O
is O
known O
to O
contribute O
to O
the O
induction O
of O
the O
TF B
promotor I
in O
human O
monocytes O
. O

As O
shown O
by O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
and O
electrophoretic O
mobility O
shift O
assay O
, O
respectively O
, O
treatment O
with O
CsA O
leads O
to O
decreased O
TF B
mRNA I
expression O
and O
reduced O
activation O
of O
the O
NF B
- I
kappaB I
transcription I
factor I
, O
which O
is O
known O
to O
contribute O
to O
the O
induction O
of O
the O
TF B
promotor I
in O
human O
monocytes O
. O

These O
data O
suggest O
that O
IL B
- I
2 I
and O
IL B
- I
7 I
induce O
assembly O
of O
STAT B
heterodimers I
in O
a O
similar O
manner O
and O
that O
subsequent O
cellular O
responses O
may O
be O
driven O
by O
induction O
of O
similar O
sets O
of O
genes B
. O

The O
POU B
transcription I
factors I
Oct B
- I
1 I
and O
Oct B
- I
2 I
regulate O
the O
activity O
of O
octamer B
- I
dependent I
promoters I
, O
including O
those O
that O
direct O
transcription O
from O
rearranged O
immunoglobulin B
genes I
. O

We O
show O
here O
that O
helenalin O
, O
and O
, O
to O
a O
much O
lesser O
degree O
, O
11alpha O
, O
13 O
- O
dihydrohelenalin O
and O
chamissonolid O
, O
inhibit O
activation O
of O
transcription B
factor I
NF B
- I
kappaB I
. O

The O
tax B
protein I
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
mediates O
the O
transactivation O
of O
the O
c B
- I
sis I
/ I
platelet I
- I
derived I
growth I
factor I
- I
B I
promoter I
through O
interactions O
with O
the O
zinc B
finger I
transcription I
factors I
Sp1 B
and O
NGFI B
- I
A I
/ I
Egr I
- I
1 I
. O

In O
most O
cells O
, O
Rel B
/ I
NF I
- I
kappa I
B I
transcription B
factors I
appear O
to O
mediate O
survival O
signals O
that O
protect O
cells O
from O
apoptosis O
; O
however O
, O
under O
some O
circumstances O
, O
activation O
of O
these O
factors O
may O
also O
promote O
apoptosis O
. O

Proteins O
of O
the O
ATF O
/ O
CREB B
class O
of O
transcription B
factors I
stimulate O
gene O
expression O
of O
several O
cell B
growth I
- I
related I
genes I
through O
protein B
kinase I
A I
- I
related I
cAMP I
response I
elements I
. O

One O
ATF B
/ I
CRE I
motif I
is O
located O
in O
the O
distal B
promoter I
at O
the O
nuclear B
matrix I
- I
associated I
Site I
IV I
, O
and O
the O
second O
motif O
is O
present O
in O
the O
proximal B
promoter I
at O
Site B
I I
. O

One O
ATF B
/ I
CRE I
motif I
is O
located O
in O
the O
distal B
promoter I
at O
the O
nuclear B
matrix I
- I
associated I
Site I
IV I
, O
and O
the O
second O
motif O
is O
present O
in O
the O
proximal B
promoter I
at O
Site B
I I
. O

One O
ATF B
/ I
CRE I
motif I
is O
located O
in O
the O
distal B
promoter I
at O
the O
nuclear B
matrix I
- I
associated I
Site I
IV I
, O
and O
the O
second O
motif O
is O
present O
in O
the O
proximal B
promoter I
at O
Site B
I I
. O

Site O
- O
directed O
mutational O
studies O
demonstrate O
that O
Site B
I I
and O
Site B
IV I
together O
support O
ATF1 O
- O
and O
CREB O
- O
induced O
trans O
- O
activation O
of O
the O
H4 B
promoter I
. O

Site O
- O
directed O
mutational O
studies O
demonstrate O
that O
Site B
I I
and O
Site B
IV I
together O
support O
ATF1 O
- O
and O
CREB O
- O
induced O
trans O
- O
activation O
of O
the O
H4 B
promoter I
. O

Site O
- O
directed O
mutational O
studies O
demonstrate O
that O
Site B
I I
and O
Site B
IV I
together O
support O
ATF1 O
- O
and O
CREB O
- O
induced O
trans O
- O
activation O
of O
the O
H4 B
promoter I
. O

This O
reversal O
of O
apoptosis O
almost O
to O
the O
control O
level O
by O
inhibitor O
of O
NF B
- I
kappa I
B I
activation O
may O
indicate O
involvement O
of O
this O
signaling B
molecule I
in O
MTBE O
and O
benzene O
induction O
of O
programmed O
cell O
death O
. O

Northern O
blot O
analysis O
of O
SR B
- I
BP I
gene O
expression O
revealed O
a O
single O
transcript O
of O
2 B
kilobases I
which O
was O
widely O
expressed O
among O
organs O
, O
with O
the O
highest O
abundance O
in O
liver O
and O
the O
lowest O
abundance O
in O
brain O
. O

Neither O
the O
PLC B
gamma I
1 I
overexpression O
induced O
by O
IFN B
nor O
the O
increased O
hydrolytic O
activity O
of O
the O
enzyme B
appear O
to O
be O
affected O
by O
pretreatment O
of O
the O
cells O
with O
the O
protein O
tyrosine B
kinase I
inhibitor O
genistein O
, O
which O
is O
known O
to O
prevent O
the O
association O
of O
ISGF3 B
components O
. O

These O
results O
suggest O
that O
in O
human O
T O
lymphocytes O
IFN B
- I
beta I
can O
activate O
other O
transcription B
factor I
( O
s O
) O
distinct O
from O
ISGF3 B
to O
regulate O
PLC B
gamma I
1 I
expression O
. O

Moreover O
, O
anti B
- I
TNF I
- I
alpha I
inhibited O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
- O
driven O
transcription O
of O
a O
reporter B
gene I
in O
primary O
T O
cells O
in O
response O
to O
activation O
, O
either O
in O
the O
presence O
or O
the O
absence O
of O
HIV B
- I
1 I
Tat I
. O

These O
results O
indicate O
that O
JAK2 B
/ B
STAT5 I
activation O
is O
a O
common O
JAK B
/ B
STAT I
pathway O
for O
hIL B
- I
5 I
- O
mediated O
signal O
in O
these O
cells O
. O

These O
results O
indicate O
that O
JAK2 B
/ B
STAT5 I
activation O
is O
a O
common O
JAK B
/ B
STAT I
pathway O
for O
hIL B
- I
5 I
- O
mediated O
signal O
in O
these O
cells O
. O

PURPOSE O
: O
To O
demonstrate O
that O
leukocyte O
adhesion O
to O
cultured O
corneal O
endothelial O
cells O
is O
mediated O
by O
the O
CD18 B
antigen I
, O
and O
to O
determine O
whether O
dexamethasone O
directly O
suppresses O
adhesion O
by O
inhibiting O
activation O
of O
nuclear B
factor I
kappa I
B I
( O
NFkappaB B
) O
. O

The O
pp52 B
promoter I
contains O
an O
initiator O
specifying O
the O
unique O
5 B
' I
terminus I
of O
pp52 B
mRNA I
, O
tandem O
pairs O
of O
Ets B
and I
SP1 I
motifs I
, O
and O
a O
lone B
C I
/ I
EBP I
motif I
. O

The O
pp52 B
promoter I
contains O
an O
initiator O
specifying O
the O
unique O
5 B
' I
terminus I
of O
pp52 B
mRNA I
, O
tandem O
pairs O
of O
Ets B
and I
SP1 I
motifs I
, O
and O
a O
lone B
C I
/ I
EBP I
motif I
. O

BACKGROUND O
: O
Recent O
studies O
have O
raised O
the O
hypothesis O
that O
glucocorticoids O
could O
diminish O
the O
ability O
of O
endothelial O
cells O
to O
direct O
leukocyte O
traffic O
into O
inflamed O
tissues O
by O
inhibiting O
expression O
of O
the O
adhesion B
molecules I
endothelial B
- I
leukocyte I
adhesion I
molecule I
- I
1 I
and O
intercellular B
adhesion I
molecule I
- I
1 I
. O

These O
defects O
are O
paralleled O
by O
an O
impaired O
ability O
to O
produce O
Th1 B
cytokines I
( O
IL B
- I
2 I
and O
IFN B
- I
gamma I
) O
. O

The O
class B
II I
- I
specific I
transcription I
factors I
RFX B
and O
CIITA B
are O
also O
required O
for O
expression O
, O
as O
cell O
lines O
deficient O
in O
these O
factors O
failed O
to O
allow O
transcription O
from O
the O
DM B
promoters I
. O

In O
addition O
, O
in O
vivo O
footprint O
analysis O
showed O
the O
putative O
X B
and I
Y I
boxes I
to O
be O
occupied O
by O
transcription B
factors I
in O
wild O
- O
type O
B O
cells O
, O
but O
not O
in O
RFX O
- O
deficient O
B O
cells O
. O

Critical O
cytoplasmic B
domains I
of O
human B
interleukin I
- I
9 I
receptor I
alpha I
chain I
in O
interleukin B
- O
9 O
- O
mediated O
cell O
proliferation O
and O
signal O
transduction O
. O

We O
report O
the O
identification O
and O
characterization O
of O
simple B
tandem I
repeat I
DNA I
polymorphisms I
in O
the O
genes O
encoding O
HNF B
- I
3alpha I
, O
- B
3beta I
, O
- B
3gamma I
, O
- B
4gamma I
, O
and O
- B
6 I
and O
the O
mapping O
of O
HNF B
- I
6 I
to O
chromosome B
bands I
15q21 B
. I
1 I
- I
21 I
. I
2 I
by O
fluorescence O
in O
situ O
hybridization O
. O

We O
report O
the O
identification O
and O
characterization O
of O
simple B
tandem I
repeat I
DNA I
polymorphisms I
in O
the O
genes O
encoding O
HNF B
- I
3alpha I
, O
- B
3beta I
, O
- B
3gamma I
, O
- B
4gamma I
, O
and O
- B
6 I
and O
the O
mapping O
of O
HNF B
- I
6 I
to O
chromosome B
bands I
15q21 B
. I
1 I
- I
21 I
. I
2 I
by O
fluorescence O
in O
situ O
hybridization O
. O

We O
report O
the O
identification O
and O
characterization O
of O
simple B
tandem I
repeat I
DNA I
polymorphisms I
in O
the O
genes O
encoding O
HNF B
- I
3alpha I
, O
- B
3beta I
, O
- B
3gamma I
, O
- B
4gamma I
, O
and O
- B
6 I
and O
the O
mapping O
of O
HNF B
- I
6 I
to O
chromosome B
bands I
15q21 B
. I
1 I
- I
21 I
. I
2 I
by O
fluorescence O
in O
situ O
hybridization O
. O

We O
report O
the O
identification O
and O
characterization O
of O
simple B
tandem I
repeat I
DNA I
polymorphisms I
in O
the O
genes O
encoding O
HNF B
- I
3alpha I
, O
- B
3beta I
, O
- B
3gamma I
, O
- B
4gamma I
, O
and O
- B
6 I
and O
the O
mapping O
of O
HNF B
- I
6 I
to O
chromosome B
bands I
15q21 B
. I
1 I
- I
21 I
. I
2 I
by O
fluorescence O
in O
situ O
hybridization O
. O

We O
report O
the O
identification O
and O
characterization O
of O
simple B
tandem I
repeat I
DNA I
polymorphisms I
in O
the O
genes O
encoding O
HNF B
- I
3alpha I
, O
- B
3beta I
, O
- B
3gamma I
, O
- B
4gamma I
, O
and O
- B
6 I
and O
the O
mapping O
of O
HNF B
- I
6 I
to O
chromosome B
bands I
15q21 B
. I
1 I
- I
21 I
. I
2 I
by O
fluorescence O
in O
situ O
hybridization O
. O

From O
analyses O
of O
mice O
deficient O
in O
transcription B
factor I
genes I
and O
from O
the O
characterizations O
of O
chromosome B
breakpoints I
in O
human O
leukemias O
, O
it O
has O
become O
evident O
that O
transcription B
factors I
are O
important O
regulators O
of O
hematopoiesis O
. O

From O
analyses O
of O
mice O
deficient O
in O
transcription B
factor I
genes I
and O
from O
the O
characterizations O
of O
chromosome B
breakpoints I
in O
human O
leukemias O
, O
it O
has O
become O
evident O
that O
transcription B
factors I
are O
important O
regulators O
of O
hematopoiesis O
. O

With O
the O
use O
of O
specific B
antibodies I
we O
have O
determined O
the O
composition O
of O
each O
complex O
using O
electrophoretic O
mobility O
shift O
assays O
. O

c B
- I
Myb I
and O
Ets B
proteins I
synergize O
to O
overcome O
transcriptional O
repression O
by O
ZEB B
. O

ETS1 B
is O
a O
transcription B
factor I
of O
the O
ETS B
family I
that O
is O
expressed O
in O
T O
cells O
. O

ETS1 B
is O
a O
transcription B
factor I
of O
the O
ETS B
family I
that O
is O
expressed O
in O
T O
cells O
. O

In O
fact O
, O
mAb B
L243 I
but O
not O
the O
staphylococcal B
superantigens I
, O
staphylococcal B
exotoxin I
toxic I
shock I
syndrome I
toxin I
- I
I I
or O
staphylococcal B
enterotoxin I
B I
, O
regulate O
the O
NF B
- I
kappa I
B I
binding O
activity O
. O

In O
fact O
, O
mAb B
L243 I
but O
not O
the O
staphylococcal B
superantigens I
, O
staphylococcal B
exotoxin I
toxic I
shock I
syndrome I
toxin I
- I
I I
or O
staphylococcal B
enterotoxin I
B I
, O
regulate O
the O
NF B
- I
kappa I
B I
binding O
activity O
. O

Fusion O
proteins O
involving O
the O
retinoic O
acid O
receptor B
alpha I
( O
RAR B
alpha I
) O
and O
the O
PML B
or O
PLZF B
nuclear I
protein I
are O
the O
genetic O
markers O
of O
acute O
promyelocytic O
leukemias O
( O
APLs O
) O
. O

Fusion O
proteins O
involving O
the O
retinoic O
acid O
receptor B
alpha I
( O
RAR B
alpha I
) O
and O
the O
PML B
or O
PLZF B
nuclear I
protein I
are O
the O
genetic O
markers O
of O
acute O
promyelocytic O
leukemias O
( O
APLs O
) O
. O

Therefore O
, O
while O
the O
total O
plasma B
sialyltransferase I
: O
cortisol O
ratio O
reflects O
HPA O
axis O
function O
, O
alterations O
in O
specific O
isozyme O
activity O
may O
also O
be O
associated O
with O
other O
CNS O
disease O
states O
. O

Using O
a O
previously O
described O
mutant O
of O
the O
Jurkat O
T O
cell O
line O
, O
we O
show O
that O
proximal O
signaling O
events O
dependent O
on O
the O
presence O
of O
the O
CD45 B
tyrosine I
phosphatase I
are O
required O
for O
TCR B
- O
stimulated O
CD95 B
ligand I
expression O
. O

Together O
, O
these O
studies O
begin O
a O
dissection O
of O
the O
biochemical O
events O
that O
lead O
to O
expression O
of O
CD95 B
ligand I
, O
a O
required O
step O
for O
TCR B
- O
induced O
apoptosis O
. O

The O
Eed B
- O
mediated O
transcriptional O
effects O
are O
likely O
to O
reflect O
the O
interaction O
of O
Eed B
with O
multiple O
molecular O
partners O
, O
including O
K B
protein I
. O

When O
macrophages O
were O
pretreated O
with O
low O
doses O
of O
IFN B
- I
gamma I
and O
then O
stimulated O
with O
IFN B
- I
alpha I
, O
clearly O
enhanced O
formation O
of O
specific O
transcription B
factor I
complexes O
was O
detected O
. O

Activation O
and O
regulation O
of O
NF B
- I
kappa I
B I
are O
tightly O
controlled O
by O
a O
group O
of O
inhibitory B
proteins I
( O
I B
kappa I
B I
) O
that O
sequester O
NF B
- I
kappa I
B I
in O
the O
cytoplasm O
of O
immune O
/ O
inflammatory O
effector O
cells O
. O

A O
combination O
of O
differential O
splicing O
and O
alternative O
use O
of O
promoters B
generates O
four O
mRNA B
isoforms I
, O
of O
2 O
. O
6 O
kb O
and O
1 O
. O
3 O
- O
1 O
. O
5 O
kb O
in O
size O
. O

Recent O
studies O
have O
revealed O
that O
interactions O
between O
transcription B
factors I
play O
an O
important O
role O
in O
regulation O
of O
gene O
expression O
in O
eukaryotic O
cells O
. O

Triggering O
of O
the O
T B
- I
cell I
receptor I
- I
CD3 I
complex I
activates O
two O
major O
signal O
cascades O
in O
T O
lymphocytes O
, O
( O
i O
) O
Ca2 O
+ O
- O
dependent O
signal O
cascades O
and O
( O
ii O
) O
protein B
kinase I
cascades O
. O

Functional O
analysis O
of O
monocytic O
THP O
- O
1 O
cells O
transfected O
with O
plasmids B
containing O
various O
lengths O
of O
TNF B
- I
alpha I
promoter I
localized O
enhancer B
elements I
in O
a O
region O
( O
- B
182 I
to I
- I
37 I
base I
pairs I
( O
bp O
) O
) O
that O
were O
required O
for O
optimal O
transcription O
of O
the O
TNF B
- I
alpha I
gene I
in O
response O
to O
LPS O
. O

In O
unstimulated O
THP O
- O
1 O
, O
CRE B
- I
binding I
protein I
and O
, O
to O
a O
lesser O
extent O
, O
c B
- I
Jun I
complexes I
were O
found O
to O
bind O
to O
the O
CRE B
site I
. O

The O
CRE B
and I
kappaB3 I
sites I
in O
region B
II I
together O
conferred O
strong O
LPS O
responsiveness O
to O
a O
heterologous B
promoter I
, O
whereas O
individually O
they O
failed O
to O
provide O
transcriptional O
activation O
. O

The O
CRE B
and I
kappaB3 I
sites I
in O
region B
II I
together O
conferred O
strong O
LPS O
responsiveness O
to O
a O
heterologous B
promoter I
, O
whereas O
individually O
they O
failed O
to O
provide O
transcriptional O
activation O
. O

However O
, O
these O
plasmids B
produced O
transcriptional O
activity O
in O
HeLa O
cells O
only O
in O
conjunction O
with O
interferon B
gamma I
stimulation O
, O
a O
condition O
in O
which O
expression O
of O
both O
CIITA B
and O
class B
II I
major I
histocompatibility I
complex I
surface I
proteins I
are O
induced O
. O

Acute O
promyelocytic O
leukemia O
( O
APL O
) O
is O
associated O
with O
reciprocal O
chromosomal O
translocations O
involving O
the O
retinoic B
acid I
receptor I
alpha I
( I
RARalpha I
) I
locus I
on O
chromosome B
17 I
. O

The O
resulting O
fusion B
genes I
encode O
the O
two O
structurally O
unique O
PML B
/ I
RARalpha I
and O
RARalpha B
/ I
PML I
fusion I
proteins I
as O
well O
as O
aberrant B
PML I
gene I
products I
, O
the O
respective O
pathogenetic O
roles O
of O
which O
have O
not O
been O
elucidated O
. O

Binding B
sites I
at O
the O
core O
region O
show O
little O
conservation O
with O
consensus B
sites I
. O

Binding B
sites I
at O
the O
core O
region O
show O
little O
conservation O
with O
consensus B
sites I
. O

While O
the O
activation O
of O
JAK2 B
, O
Shc B
, O
Erk B
, O
and O
STAT5 B
proteins I
correlated O
with O
hGM B
- I
CSF I
- O
mediated O
cell O
growth O
, O
cellular O
differentiation O
occurred O
in O
the O
absence O
of O
activation O
of O
these O
signal O
transduction O
pathways O
. O

Molecular O
cloning O
and O
characterization O
of O
a O
cDNA B
, O
CHEMR1 B
, O
encoding O
a O
chemokine B
receptor I
with O
a O
homology O
to O
the O
human B
C I
- I
C I
chemokine I
receptor I
, O
CCR B
- I
4 I
. O

To O
understand O
the O
mechanisms O
underlined O
in O
this O
regulation O
in O
normal O
human O
cells O
, O
we O
have O
analysed O
in O
vivo O
protein O
- O
DNA O
interactions O
at O
the O
Cyclin B
A I
locus O
in O
primary O
T O
lymphocytes O
. O

The O
third O
site O
was O
occupied O
in O
quiescent O
cells O
or O
in O
cells O
stimulated O
by O
anti B
CD2 I
or O
anti B
CD28 I
alone O
. O

The O
third O
site O
was O
occupied O
in O
quiescent O
cells O
or O
in O
cells O
stimulated O
by O
anti B
CD2 I
or O
anti B
CD28 I
alone O
. O

Human B
immunodeficiency I
virus I
type I
1 I
( I
HIV I
- I
1 I
) I
Tat I
, O
an O
early O
regulatory B
protein I
that O
is O
critical O
for O
viral O
gene O
expression O
and O
replication O
, O
transactivates O
the O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
via O
its O
binding O
to O
the O
transactivation B
response I
element I
( O
TAR B
) O
and O
, O
along O
with O
other O
cellular O
factors O
, O
increases O
viral O
transcription O
initiation O
and O
elongation O
. O

In O
this O
study O
, O
a O
combined O
pharmacologic O
and O
genetic O
strategy O
using O
two O
PKC B
( O
NF B
- I
kappa I
B I
) O
inhibitors O
, O
pentoxifylline O
( O
PTX O
) O
and O
Go O
- O
6976 O
, O
and O
a O
stably O
expressed O
anti B
- I
Tat I
single I
- I
chain I
intracellular I
antibody I
( O
sFv B
intrabody I
) O
was O
employed O
to O
obtain O
cooperative O
inhibition O
of O
both O
HIV O
- O
1 O
LTR B
- O
driven O
gene O
expression O
and O
HIV O
- O
1 O
replication O
. O

CD28 B
is O
an O
important O
costimulatory B
molecule I
in O
the O
activation O
of O
human O
T O
cells O
. O

The O
aim O
of O
this O
research O
was O
to O
test O
the O
hypothesis O
that O
a O
causal O
relationship O
exists O
between O
the O
level O
of O
expression O
of O
G B
( I
S I
) I
alpha I
and O
induction O
of O
the O
adenylyl B
cyclase I
( O
AC O
) O
cascade O
. O

We O
report O
here O
that O
ectopic O
expression O
of O
CIITA B
cDNAs I
derived O
by O
reverse O
transcriptase O
polymerase O
chain O
reaction O
from O
clone O
13 O
do O
not O
restore O
expression O
of O
HLA B
- I
DQ I
in O
another O
CIITA O
- O
deficient O
cell O
line O
, O
RJ2 O
. O
2 O
. O
5 O
. O

The O
cytokines B
interleukin B
( I
IL I
) I
- I
4 I
and O
IL B
- I
13 I
play O
a O
critical O
role O
in O
inducing O
Cepsilon B
germline I
transcripts I
and O
IgE B
isotype I
switching O
in O
human O
B O
cells O
. O

We O
show O
that O
ligand O
- O
induced O
homodimerization O
of O
chimeric B
surface I
receptors I
consisting O
of O
the O
extracellular B
and I
transmembrane I
domains I
of O
the O
erythropoietin B
receptor I
and O
of O
the O
intracellular B
domain I
of O
IL B
- I
4Ralpha I
induces O
Janus B
kinase I
1 I
( O
Jak1 B
) O
activation O
, O
STAT6 B
activation O
, O
and O
Cepsilon B
germline I
transcripts I
in O
human O
B O
cell O
line O
BJAB O
. O

We O
show O
that O
ligand O
- O
induced O
homodimerization O
of O
chimeric B
surface I
receptors I
consisting O
of O
the O
extracellular B
and I
transmembrane I
domains I
of O
the O
erythropoietin B
receptor I
and O
of O
the O
intracellular B
domain I
of O
IL B
- I
4Ralpha I
induces O
Janus B
kinase I
1 I
( O
Jak1 B
) O
activation O
, O
STAT6 B
activation O
, O
and O
Cepsilon B
germline I
transcripts I
in O
human O
B O
cell O
line O
BJAB O
. O

To O
understand O
the O
molecular O
mechanisms O
controlling O
CD19 B
gene O
expression O
, O
we O
isolated O
and O
functionally O
characterized O
the O
CD19 B
promoter I
using O
in O
vivo O
footprinting O
, O
gel O
shift O
assays O
, O
and O
transfection O
studies O
. O

Treatment O
of O
cells O
expressing O
the O
chimeric B
receptor I
kit B
/ I
IL I
- I
4R I
alpha I
with O
SCF B
induces O
activation O
of O
the O
IL B
- I
4R I
alpha I
- I
associated I
kinase I
JAK B
- I
1 I
and O
the O
transcription B
factor I
STAT6 B
. O

Treatment O
of O
cells O
expressing O
the O
chimeric B
receptor I
kit B
/ I
IL I
- I
4R I
alpha I
with O
SCF B
induces O
activation O
of O
the O
IL B
- I
4R I
alpha I
- I
associated I
kinase I
JAK B
- I
1 I
and O
the O
transcription B
factor I
STAT6 B
. O

Dose O
- O
dependence O
studies O
using O
histamine O
and O
dimaprit O
showed O
that O
the O
EC50 O
values O
for O
cAMP O
production O
and O
c B
- I
fos I
increase O
were O
similar O
, O
suggesting O
that O
cAMP O
might O
be O
involved O
in O
c B
- I
fos I
induction O
via O
H2 B
receptors I
. O

The O
present O
work O
shows O
that O
the O
primary O
CD8 O
+ O
CTL O
response O
to O
EBV O
in O
infectious O
mononucleosis O
patients O
contains O
multiple O
lytic O
antigen O
- O
specific O
reactivities O
at O
levels O
at O
least O
as O
high O
as O
those O
seen O
against O
latent B
antigens I
; O
similar O
reactivities O
are O
also O
detectable O
in O
CTL O
memory O
. O

Clonal O
analysis O
revealed O
individual O
responses O
to O
the O
two O
immediate B
early I
proteins I
BZLF1 B
and O
BRLF1 B
, O
and O
to O
three O
( O
BMLF1 B
, O
BMRF1 B
, O
and O
BALF2 B
) O
of O
the O
six O
early B
proteins I
tested O
. O

Bacterially O
expressed O
RP1 B
protein I
revealed O
specific O
binding O
to O
wild B
- I
type I
but O
not O
to O
mutated B
APC I
protein I
. O

We O
show O
for O
human O
Jurkat O
T O
leukemia O
cells O
, O
as O
well O
as O
human O
and O
mouse O
primary O
T O
lymphocytes O
, O
that O
this O
inhibitory O
effect O
is O
accompanied O
by O
an O
impaired O
nuclear O
translocation O
of O
the O
Rel B
proteins I
c B
- I
Rel I
, O
RelA B
/ I
p65 I
and O
NF B
- I
kappa I
B1 I
/ I
p50 I
, O
whereas O
the O
nuclear O
appearance O
of O
RelB B
remains O
unaffected O
. O

Accordingly O
, O
immunoblot O
experiments O
showed O
that O
amongst O
NF B
- I
kappa I
B I
/ B
Rel I
proteins I
, O
RelA B
and O
p50 B
are O
mobilized O
to O
the O
nucleus O
following O
microglial O
cell O
stimulation O
with O
A O
beta O
( O
25 O
- O
35 O
) O
plus O
IFN B
gamma I
. O

Collectively O
, O
these O
findings O
indicate O
that O
NF B
- I
kappa I
B I
activation O
might O
constitute O
one O
of O
the O
mechanisms O
underlying O
the O
inducible O
expression O
of O
kappa B
B I
- I
dependent I
genes I
in O
microglia O
stimulated O
by O
A O
beta O
peptides O
and O
IFN B
gamma I
, O
or O
by O
LPS O
. O

We O
isolated O
a O
new O
mouse B
gene I
that O
is O
highly O
expressed O
in O
thymocytes O
, O
testis O
, O
and O
brain O
. O

The O
serum O
also O
detected O
a O
170 B
- I
kD I
protein I
that O
seems O
to O
be O
a O
mouse O
homologue O
of O
human B
BAF170 I
. O

To O
evaluate O
the O
physiologic O
plausibility O
of O
these O
claims O
, O
we O
compared O
the O
abundance O
of O
the O
VDR B
mRNA I
in O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
between O
different O
VDR B
genotypes I
using O
a O
quantitative O
reverse O
transcribed O
polymerase O
chain O
reaction O
- O
based O
method O
. O

To O
evaluate O
the O
physiologic O
plausibility O
of O
these O
claims O
, O
we O
compared O
the O
abundance O
of O
the O
VDR B
mRNA I
in O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
between O
different O
VDR B
genotypes I
using O
a O
quantitative O
reverse O
transcribed O
polymerase O
chain O
reaction O
- O
based O
method O
. O

The O
concentration O
of O
the O
VDR B
mRNA I
, O
corrected O
for O
the O
number O
of O
monocytes O
, O
was O
similar O
among O
the O
three O
genotype O
groups O
, O
as O
were O
the O
other O
variables O
examined O
: O
serum B
calcitriol I
, O
serum B
osteocalcin I
, O
and O
vertebral O
and O
hip O
bone O
density O
. O

The O
concentration O
of O
the O
VDR B
mRNA I
, O
corrected O
for O
the O
number O
of O
monocytes O
, O
was O
similar O
among O
the O
three O
genotype O
groups O
, O
as O
were O
the O
other O
variables O
examined O
: O
serum B
calcitriol I
, O
serum B
osteocalcin I
, O
and O
vertebral O
and O
hip O
bone O
density O
. O

The O
concentration O
of O
the O
VDR B
mRNA I
, O
corrected O
for O
the O
number O
of O
monocytes O
, O
was O
similar O
among O
the O
three O
genotype O
groups O
, O
as O
were O
the O
other O
variables O
examined O
: O
serum B
calcitriol I
, O
serum B
osteocalcin I
, O
and O
vertebral O
and O
hip O
bone O
density O
. O

Unexpectedly O
, O
a O
second O
, O
stronger O
RBP B
- I
Jkappa I
- I
binding I
site I
, O
which O
lies O
within O
the O
intracellular B
domain I
close O
to O
the O
transmembrane O
region O
and O
significantly O
augments O
association O
with O
RBP B
- I
Jkappa I
, O
was O
not O
needed O
for O
oncogenesis O
or O
for O
transcriptional O
activation O
. O

These O
studies O
have O
indicated O
that O
the O
individual O
repeats O
are O
not O
identical O
with O
respect O
to O
the O
cellular B
factors I
with O
which O
they O
interact O
. O

Induction O
of O
STAT3 B
is O
inhibited O
by O
both O
the O
serine O
/ O
threonine O
protein O
kinase O
inhibitor O
H O
- O
7 O
and O
the O
immunosuppressive O
drug O
rapamycin O
and O
requires O
de O
novo O
protein O
synthesis O
, O
demonstrating O
novel O
coupling O
between O
sIg B
and O
STAT B
proteins I
that O
differs O
from O
the O
classical O
paradigm O
for O
STAT B
induction O
by O
cytokine B
receptors I
. O

Induction O
of O
STAT3 B
is O
inhibited O
by O
both O
the O
serine O
/ O
threonine O
protein O
kinase O
inhibitor O
H O
- O
7 O
and O
the O
immunosuppressive O
drug O
rapamycin O
and O
requires O
de O
novo O
protein O
synthesis O
, O
demonstrating O
novel O
coupling O
between O
sIg B
and O
STAT B
proteins I
that O
differs O
from O
the O
classical O
paradigm O
for O
STAT B
induction O
by O
cytokine B
receptors I
. O

This O
effect O
was O
specifically O
due O
to O
Tat B
, O
since O
Jurkat O
and O
U937 O
cells O
cotransfected O
either O
with O
tat B
cDNA I
in O
antisense O
orientation O
( O
tat B
/ I
AS I
) O
, O
tat B
carrying O
a O
mutation O
in O
the O
aminoacid B
cys22 I
- I
gly22 I
( O
tat B
22 I
/ I
S I
) O
or O
with O
the O
backbone B
vector I
alone I
( O
pRPneo B
- I
SL3 I
) O
did O
not O
show O
any O
significant O
difference O
in O
c B
- I
fos I
promoter I
activity O
as O
compared O
to O
cells O
transfected O
with O
FC3 B
plasmid I
alone O
. O

This O
effect O
was O
specifically O
due O
to O
Tat B
, O
since O
Jurkat O
and O
U937 O
cells O
cotransfected O
either O
with O
tat B
cDNA I
in O
antisense O
orientation O
( O
tat B
/ I
AS I
) O
, O
tat B
carrying O
a O
mutation O
in O
the O
aminoacid B
cys22 I
- I
gly22 I
( O
tat B
22 I
/ I
S I
) O
or O
with O
the O
backbone B
vector I
alone I
( O
pRPneo B
- I
SL3 I
) O
did O
not O
show O
any O
significant O
difference O
in O
c B
- I
fos I
promoter I
activity O
as O
compared O
to O
cells O
transfected O
with O
FC3 B
plasmid I
alone O
. O

c B
- I
Fos I
protein O
was O
shown O
essential O
for O
an O
optimal O
transactivation O
of O
the O
HIV O
- O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
by O
Tat B
: O
incubation O
of O
Jurkat O
cells O
with O
antisense O
, O
but O
not O
sense O
, O
c O
- O
fos O
oligonucleotides O
significantly O
reduced O
either O
the O
Tat B
- O
enhanced O
expression O
of O
an O
LTR B
- I
CAT I
reporter I
construct I
or O
the O
levels O
of O
gag B
p24 I
in O
the O
culture O
supernatants O
of O
Jurkat O
cells O
and O
PBMC O
acutely O
infected O
with O
HIV O
- O
1 O
. O

Previously O
, O
we O
showed O
that O
fibroblast O
conditioned O
medium O
( O
FCM O
) O
is O
able O
to O
inhibit O
both O
TNF B
mRNA I
accumulation O
and O
protein O
release O
in O
peripheral O
blood O
- O
derived O
human O
monocytes O
( O
PBM O
) O
stimulated O
with O
lipopolysaccharide O
( O
LPS O
) O
. O

Two O
main O
pieces O
of O
data O
prompted O
us O
to O
focus O
on O
the O
activation O
of O
the O
platelet B
fibrinogen I
receptor I
, O
the O
alphaIIbbeta3 B
integrin I
. O

Immunoblot O
and O
flow O
cytometry O
analysis O
revealed O
a O
limited O
proteolysis O
of O
the O
carboxyl B
terminus I
of O
the O
alphaIIb B
subunit I
heavy I
chain I
( O
alphaIIbH B
) O
, O
as O
judged O
by O
the O
disappearance O
of O
the O
epitope O
for O
the O
monoclonal B
antibody I
PMI I
- I
1 I
. O

The O
suppression O
of O
productive O
LAI O
replication O
in O
naive O
T O
cells O
is O
not O
due O
to O
differential O
expression O
of O
viral B
coreceptors I
, O
nor O
is O
it O
due O
to O
inhibition O
of O
activation O
of O
the O
important O
HIV O
transcription B
factors I
, O
nuclear B
factor I
- I
kappaB I
and O
activator B
protein I
- I
1 I
. O

The O
suppression O
of O
productive O
LAI O
replication O
in O
naive O
T O
cells O
is O
not O
due O
to O
differential O
expression O
of O
viral B
coreceptors I
, O
nor O
is O
it O
due O
to O
inhibition O
of O
activation O
of O
the O
important O
HIV O
transcription B
factors I
, O
nuclear B
factor I
- I
kappaB I
and O
activator B
protein I
- I
1 I
. O

Our O
results O
demonstrate O
that O
PMLRAR B
alpha I
impairs O
neutrophil O
differentiation O
and O
initiates O
the O
development O
of O
APL O
. O

Finally O
, O
reactivation O
of O
tumor O
- O
suppressor O
gene O
expression O
through O
pharmacologic O
inhibition O
of O
DNA B
methyltransferase I
and O
resultant O
DNA O
demethylation O
appears O
to O
be O
a O
promising O
new O
avenue O
of O
therapy O
in O
acute O
leukemia O
. O

In O
earlier O
studies O
, O
we O
have O
identified O
the O
transcription B
factors I
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
as O
molecular O
targets O
for O
oxidative O
signalling O
processes O
during O
cell O
cycle O
entry O
, O
and O
have O
shown O
that O
oxidative O
signalling O
is O
involved O
in O
the O
regulation O
of O
early O
changes O
in O
gene O
expression O
during O
the O
G0 O
to O
G1 O
phase O
transition O
. O

Using O
the O
yeast O
two O
- O
hybrid O
system O
to O
screen O
for O
proteins O
which O
interact O
with O
Tax1 B
, O
we O
isolated O
the O
B B
subunit I
of O
the O
CCAAT B
binding I
protein I
NF B
- I
Y I
from O
a O
HeLa B
cDNA I
library I
. O

The O
interaction O
of O
Tax1 B
with O
NF B
- I
YB I
was O
specific O
in O
that O
NF B
- I
YB I
did O
not O
interact O
with O
a O
variety O
of O
other O
transcription B
factors I
, O
including O
human B
immunodeficiency I
virus I
Tat I
, O
human B
papillomavirus I
E6 I
, O
and O
Bicoid B
, O
or O
with O
the O
M7 B
( I
amino I
acids I
29CP I
- I
AS I
) I
Tax1 I
mutant I
. O

Using O
a O
mitogenically B
incompetent I
human I
G I
- I
CSFR I
mutant I
in O
which O
Pro639 O
and O
Pro641 O
were O
substituted O
by O
alanine O
, O
the O
box B
1 I
PDP I
motif I
was O
found O
to O
be O
required O
for O
activation O
of O
Jak B
kinases I
, O
tyrosine O
phosphorylation O
of O
the O
G B
- I
CSFR I
, O
and O
recruitment O
of O
Stat B
proteins I
. O

Using O
a O
mitogenically B
incompetent I
human I
G I
- I
CSFR I
mutant I
in O
which O
Pro639 O
and O
Pro641 O
were O
substituted O
by O
alanine O
, O
the O
box B
1 I
PDP I
motif I
was O
found O
to O
be O
required O
for O
activation O
of O
Jak B
kinases I
, O
tyrosine O
phosphorylation O
of O
the O
G B
- I
CSFR I
, O
and O
recruitment O
of O
Stat B
proteins I
. O

Activation O
of O
the O
Jak B
- B
Stat I
pathway O
correlates O
with O
proliferative O
signaling O
by O
the O
G B
- I
CSFR I
and O
requires O
the O
membrane B
- I
proximal I
box I
1 I
PXP I
motif I
, O
which O
is O
conserved O
in O
members O
of O
the O
cytokine B
receptor I
superfamily I
. O

The O
function O
of O
LEF B
- I
1 I
is O
dependent O
, O
in O
part O
, O
on O
the O
HMG B
domain I
that O
induces O
a O
sharp O
bend O
in O
the O
DNA O
helix O
, O
and O
on O
an O
activation B
domain I
that O
stimulates O
transcription O
only O
in O
a O
specific O
context O
of O
other O
enhancer B
- I
binding I
proteins I
. O

The O
function O
of O
LEF B
- I
1 I
is O
dependent O
, O
in O
part O
, O
on O
the O
HMG B
domain I
that O
induces O
a O
sharp O
bend O
in O
the O
DNA O
helix O
, O
and O
on O
an O
activation B
domain I
that O
stimulates O
transcription O
only O
in O
a O
specific O
context O
of O
other O
enhancer B
- I
binding I
proteins I
. O

In O
parallel O
with O
the O
decreased O
cytokine B
generation O
, O
each O
cytokine B
mRNA I
was O
less O
expressed O
in O
the O
presence O
of O
10 O
( O
- O
5 O
) O
M O
Azeptin O
. O

Using O
anti B
- I
C I
/ I
EBPbeta I
( O
NF B
- I
IL6 I
) O
, O
anti B
- I
C I
/ I
EBPdelta I
( O
NF B
- I
IL6beta I
) O
, O
anti B
- I
NF I
- I
ATc I
, O
anti B
- I
NF I
- I
ATp I
, O
anti B
- I
Fos I
, O
and O
anti B
- I
Jun I
Abs I
we O
demonstrate O
that O
the O
previously O
identified O
PRE B
- I
I I
binding I
factor I
POS B
- I
1 I
is O
composed O
of O
different O
transcription B
factors I
in O
different O
Th O
cell O
subsets O
. O

Different O
cytokines B
activate O
transcription O
at O
the O
appropriate O
germline B
promoter I
. O

The O
results O
described O
here O
indicate O
that O
cognate O
interaction O
of O
B O
cells O
recognizing O
DNA O
or O
DNA B
- I
associated I
proteins I
and O
T O
cells O
recognizing O
T B
antigen I
had O
taken O
place O
as O
a O
consequence O
of O
complex O
formation O
between O
T B
ag I
and O
DNA O
in O
vivo O
in O
the O
context O
of O
polyomavirus O
reactivations O
. O

The O
results O
described O
here O
indicate O
that O
cognate O
interaction O
of O
B O
cells O
recognizing O
DNA O
or O
DNA B
- I
associated I
proteins I
and O
T O
cells O
recognizing O
T B
antigen I
had O
taken O
place O
as O
a O
consequence O
of O
complex O
formation O
between O
T B
ag I
and O
DNA O
in O
vivo O
in O
the O
context O
of O
polyomavirus O
reactivations O
. O

Cell O
- O
to O
- O
cell O
contact O
activates O
the O
long B
terminal I
repeat I
of O
human O
immunodeficiency O
virus O
1 O
through O
its O
kappaB B
motif I
. O

Identification O
of O
nucleotide B
sequences I
that O
regulate O
transcription O
of O
the O
MCF13 O
murine O
leukemia O
virus O
long B
terminal I
repeat I
in O
activated O
T O
cells O
. O

By O
contrast O
, O
the O
binding O
activity O
of O
the O
NF B
- I
kappa I
( I
B I
) I
and O
EGR B
- I
1 I
transcription B
factors I
was O
little O
affected O
. O

Stimulation O
of O
CD2 B
or O
TCR B
/ I
CD3 I
induced O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
, O
the O
binding B
site I
of O
which O
is O
included O
in O
the O
IL B
- I
2 I
gene I
promoter I
. O

Nuclear B
transcription I
factor I
kB I
( O
NF B
- I
kappa I
B I
) O
is O
a O
ubiquitous B
transcription I
factor I
and O
pleiotropic B
regulator I
of O
numerous O
genes O
involved O
in O
the O
immune O
and O
inflammatory O
responses O
. O

This O
transcription B
factor I
is O
activated O
via O
the O
selective O
phosphorylation O
, O
ubiquination O
and O
degradation O
of O
its O
inhibitor B
protein I
I I
- I
kB I
thereby O
allowing O
translocation O
of O
NF B
- I
kappa I
B I
into O
the O
nucleus O
where O
it O
upregulates O
the O
transcription O
of O
a O
variety O
of O
adhesion B
molecules I
( O
e O
. O
g O
. O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
) O
, O
cytokines B
( O
TNF B
, O
IL B
- I
1 I
, O
IL B
- I
6 I
) O
and O
enzymes B
( O
iNOS B
) O
. O

This O
transcription B
factor I
is O
activated O
via O
the O
selective O
phosphorylation O
, O
ubiquination O
and O
degradation O
of O
its O
inhibitor B
protein I
I I
- I
kB I
thereby O
allowing O
translocation O
of O
NF B
- I
kappa I
B I
into O
the O
nucleus O
where O
it O
upregulates O
the O
transcription O
of O
a O
variety O
of O
adhesion B
molecules I
( O
e O
. O
g O
. O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
) O
, O
cytokines B
( O
TNF B
, O
IL B
- I
1 I
, O
IL B
- I
6 I
) O
and O
enzymes B
( O
iNOS B
) O
. O

Based O
upon O
work O
from O
our O
laboratory O
, O
we O
propose O
that O
inhibition O
of O
NF B
- I
kappa I
B I
activation O
produces O
significant O
anti O
inflammatory O
activity O
which O
may O
be O
mediated O
by O
the O
inhibition O
of O
transcription O
of O
certain O
pro B
- I
inflammatory I
mediators I
and O
adhesion B
molecules I
. O

Generation O
of O
cytotoxic O
T O
lymphocytes O
against O
immunorecessive B
epitopes I
after O
multiple O
immunizations O
with O
adenovirus O
vectors O
is O
dependent O
on O
haplotype O
. O

Interaction O
of O
transcription B
factors I
RFX1 B
and O
MIBP1 B
with O
the O
gamma B
motif I
of O
the O
negative B
regulatory I
element I
of O
the O
hepatitis B
B I
virus I
core I
promoter I
. O

Interaction O
of O
transcription B
factors I
RFX1 B
and O
MIBP1 B
with O
the O
gamma B
motif I
of O
the O
negative B
regulatory I
element I
of O
the O
hepatitis B
B I
virus I
core I
promoter I
. O

In O
addition O
, O
RFX1 B
can O
bind O
simultaneously O
, O
most O
likely O
as O
a O
heterodimer B
, O
with O
the O
transcription B
factor I
MIBP1 B
to O
NRE B
gamma I
. O

In O
addition O
, O
RFX1 B
can O
bind O
simultaneously O
, O
most O
likely O
as O
a O
heterodimer B
, O
with O
the O
transcription B
factor I
MIBP1 B
to O
NRE B
gamma I
. O

The O
ZEBRA B
protein I
from O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
activates O
a O
switch O
from O
the O
latent O
to O
the O
lytic O
expression O
program O
of O
the O
virus O
. O

The O
additional O
function O
that O
is O
required O
for O
initiation O
of O
the O
lytic O
viral O
life O
cycle O
is O
likely O
to O
require O
phosphorylation O
of O
serine O
186 O
of O
the O
ZEBRA B
protein I
, O
which O
may O
influence O
either O
DNA O
recognition O
or O
transcriptional O
activation O
of O
lytic B
viral I
promoters I
in O
a O
chromatinized B
viral I
episome I
. O

CONCLUSIONS O
: O
The O
reduction O
of O
symptoms O
due O
to O
topical O
fluticasone O
propionate O
in O
patients O
with O
rhinitis O
and O
allergy O
to O
house O
dust O
mite O
is O
not O
correlated O
with O
the O
characteristics O
of O
the O
glucocorticoid B
receptor I
. O

Activation O
of O
Ras O
and O
mitogen B
- I
activated I
protein I
kinase I
pathway O
by O
terminal B
complement I
complexes I
is O
G B
protein I
dependent O
. O

Mutants O
of O
type O
5 O
adenovirus O
( O
Ad5 O
) O
with O
reiterated B
DNA I
sequences I
in O
the O
E1a B
region I
appeared O
in O
a O
human O
T O
- O
lymphocyte O
cell O
line O
, O
Molt O
- O
4 O
, O
persistently O
infected O
with O
H5sub304 O
, O
a O
deletion O
/ O
substitution O
mutant O
that O
has O
a O
wild O
- O
type O
phenotype O
in O
viral O
replication O
. O

There O
was O
not O
any O
DNA O
homology O
between O
the O
breakpoints O
in O
the O
second O
exon B
and O
the O
inserting B
sequences I
( O
starting O
at O
nt O
532 O
, O
710 O
, O
or O
792 O
) O
. O

The O
observed O
E1a B
reiterations I
provide O
a O
model O
to O
gain O
insight O
into O
understanding O
the O
evolutionary O
events O
of O
some O
, O
if O
not O
all O
, O
adenovirus O
types O
during O
many O
years O
of O
symbiotic O
, O
persistent O
relationship O
in O
human O
tonsils O
and O
adenoids O
and O
possibly O
other O
lymphoid O
organs O
. O

These O
results O
link O
regulatory B
factors I
critical O
to O
T O
cell O
commitment O
directly O
to O
HIV O
- O
1 O
replication O
. O

eTh2 O
cells O
are O
the O
major O
source O
of O
IL B
- I
4 I
, O
while O
gamma B
interferon I
is O
produced O
by O
eTh1 O
cells O
. O

However O
, O
although O
NFAT B
DNA O
binding O
is O
similarly O
induced O
in O
both O
eTh1 O
and O
eTh2 O
cells O
upon O
antigen O
stimulation O
, O
only O
the O
NFAT B
complexes I
present O
in O
eTh2 O
cells O
are O
able O
to O
mediate O
high O
- O
level O
transcription O
, O
and O
relatively O
little O
NFAT B
transcriptional O
activity O
was O
induced O
in O
eTh1 O
cells O
. O

V3 B
loop I
of O
human O
immunodeficiency O
virus O
type O
1 O
suppresses O
interleukin B
2 I
- O
induced O
T O
cell O
growth O
[ O
published O
erratum O
appears O
in O
AIDS O
Res O
Hum O
Retroviruses O
1997 O
May O
1 O
; O
13 O
( O
7 O
) O
: O
633 O
] O

V3 B
loop I
of O
human O
immunodeficiency O
virus O
type O
1 O
suppresses O
interleukin B
2 I
- O
induced O
T O
cell O
growth O
[ O
published O
erratum O
appears O
in O
AIDS O
Res O
Hum O
Retroviruses O
1997 O
May O
1 O
; O
13 O
( O
7 O
) O
: O
633 O
] O

V3 B
- I
BH10 I
neither O
blocked O
radiolabeled O
IL B
- I
2 I
binding O
to O
IL B
- I
2 I
receptors I
nor O
affected O
tyrosyl O
phosphorylation O
of O
several O
cellular B
proteins I
( O
p120 B
, O
p98 B
, O
p96 B
, O
p54 B
, O
and O
p38 B
) O
, O
which O
is O
immediately O
induced O
by O
IL B
- I
2 I
stimulation O
. O

The O
predominant O
E2F B
complex I
in O
human O
primary O
haemopoietic O
cells O
and O
in O
AML O
blasts O
contains O
E2F B
- I
4 I
, O
DP B
- I
1 I
and O
p130 B
. O

Associated O
with O
its O
inhibitor O
, O
I B
kappaB I
, O
NF B
- I
kappaB I
resides O
as O
an O
inactive O
form O
in O
the O
cytoplasm O
. O

The O
transduction O
pathways O
that O
lead O
to O
I B
kappaB I
inactivation O
remain O
poorly O
understood O
. O

In O
order O
to O
evaluate O
the O
conditions O
for O
optimal O
expression O
and O
immunogenicity O
of O
varicella B
- I
zoster I
virus I
( I
VZV I
) I
proteins I
in O
a O
herpes O
simplex O
virus O
- O
1 O
( O
HSV O
- O
1 O
) O
vector O
, O
we O
selected O
the O
VZV B
glycoprotein I
E I
( O
gE B
) O
, O
encoded O
by O
ORF B
68 I
and O
the O
VZV B
product I
of O
ORF B
62 I
, O
an O
immediate B
- I
early I
major I
tegument I
protein I
( O
IE62 B
) O
. O

In O
order O
to O
evaluate O
the O
conditions O
for O
optimal O
expression O
and O
immunogenicity O
of O
varicella B
- I
zoster I
virus I
( I
VZV I
) I
proteins I
in O
a O
herpes O
simplex O
virus O
- O
1 O
( O
HSV O
- O
1 O
) O
vector O
, O
we O
selected O
the O
VZV B
glycoprotein I
E I
( O
gE B
) O
, O
encoded O
by O
ORF B
68 I
and O
the O
VZV B
product I
of O
ORF B
62 I
, O
an O
immediate B
- I
early I
major I
tegument I
protein I
( O
IE62 B
) O
. O

In O
order O
to O
evaluate O
the O
conditions O
for O
optimal O
expression O
and O
immunogenicity O
of O
varicella B
- I
zoster I
virus I
( I
VZV I
) I
proteins I
in O
a O
herpes O
simplex O
virus O
- O
1 O
( O
HSV O
- O
1 O
) O
vector O
, O
we O
selected O
the O
VZV B
glycoprotein I
E I
( O
gE B
) O
, O
encoded O
by O
ORF B
68 I
and O
the O
VZV B
product I
of O
ORF B
62 I
, O
an O
immediate B
- I
early I
major I
tegument I
protein I
( O
IE62 B
) O
. O

Immunoblot O
analysis O
and O
immunoperoxidase O
staining O
of O
infected O
cell O
monolayers O
demonstrated O
vector O
expression O
of O
VZV B
proteins I
. O

When O
tested O
in O
cytotoxicity O
assays O
using O
T O
- O
lymphocytes O
from O
VZV O
immune O
human O
donors O
, O
the O
range O
of O
precursor O
frequencies O
for O
T O
- O
lymphocytes O
that O
recognized O
VZV B
gE I
or O
VZV B
IE62 I
was O
similar O
whether O
these O
proteins O
were O
expressed O
by O
HSV O
- O
1 O
or O
a O
vaccinia O
vector O
. O

When O
tested O
in O
cytotoxicity O
assays O
using O
T O
- O
lymphocytes O
from O
VZV O
immune O
human O
donors O
, O
the O
range O
of O
precursor O
frequencies O
for O
T O
- O
lymphocytes O
that O
recognized O
VZV B
gE I
or O
VZV B
IE62 I
was O
similar O
whether O
these O
proteins O
were O
expressed O
by O
HSV O
- O
1 O
or O
a O
vaccinia O
vector O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
the O
active O
form O
of O
NF B
- I
AT1 I
is O
also O
present O
in O
the O
nuclei O
of O
HTLV O
- O
I O
- O
transformed O
T O
cells O
that O
express O
the O
Tax B
protein I
. O

The O
requirement O
of O
another O
regulatory B
element I
called O
CLE0 B
, O
which O
lies O
downstream O
of O
the O
- B
70 I
GATA I
site I
, O
was O
also O
demonstrated O
. O

NO O
is O
produced O
from O
at O
least O
three O
different O
NO B
synthase I
( I
NOS I
) I
isoforms I
: O
neuronal B
NOS I
( O
nNOS B
) O
, O
endothelial B
NOS I
, O
and O
immunologic B
NOS I
( O
iNOS B
) O
. O

NO O
is O
produced O
from O
at O
least O
three O
different O
NO B
synthase I
( I
NOS I
) I
isoforms I
: O
neuronal B
NOS I
( O
nNOS B
) O
, O
endothelial B
NOS I
, O
and O
immunologic B
NOS I
( O
iNOS B
) O
. O

NO O
is O
produced O
from O
at O
least O
three O
different O
NO B
synthase I
( I
NOS I
) I
isoforms I
: O
neuronal B
NOS I
( O
nNOS B
) O
, O
endothelial B
NOS I
, O
and O
immunologic B
NOS I
( O
iNOS B
) O
. O

Pyrrolidine O
dithiocarbamate O
( O
PDTC O
) O
is O
an O
inhibitor O
of O
NF B
kappaB I
in O
most O
cells O
; O
however O
, O
we O
show O
that O
PDTC O
is O
also O
a O
potent O
scavenger O
of O
NO O
through O
formation O
of O
mononitrosyl O
iron O
complexes O
with O
PDTC O
. O

Contrary O
to O
the O
results O
in O
Jurkat O
cells O
, O
PDTC O
did O
not O
inhibit O
tumor B
necrosis I
factor I
- I
alpha I
- O
induced O
NF B
kappaB I
activation O
in O
astrocytes O
; O
instead O
PDTC O
itself O
induces O
NF B
kappaB I
activation O
in O
astrocytes O
, O
and O
this O
may O
be O
related O
to O
scavenging O
of O
endogenously O
produced O
NO O
by O
the O
PDTC O
iron O
complex O
. O

Contrary O
to O
the O
results O
in O
Jurkat O
cells O
, O
PDTC O
did O
not O
inhibit O
tumor B
necrosis I
factor I
- I
alpha I
- O
induced O
NF B
kappaB I
activation O
in O
astrocytes O
; O
instead O
PDTC O
itself O
induces O
NF B
kappaB I
activation O
in O
astrocytes O
, O
and O
this O
may O
be O
related O
to O
scavenging O
of O
endogenously O
produced O
NO O
by O
the O
PDTC O
iron O
complex O
. O

In O
astrocytes O
PDTC O
also O
dramatically O
induces O
the O
NF B
kappaB I
- I
dependent I
enzyme I
, O
iNOS B
, O
supporting O
the O
physiologic O
relevance O
of O
endogenous O
NO O
regulation O
of O
NF B
kappaB I
. O

EGF O
treatment O
induced O
IgM B
production O
in O
cells O
transfected O
with O
an O
intact O
gp130 B
cytoplasmic I
tail I
, O
but O
not O
in O
untransfected O
cells O
or O
cells O
transfected O
with O
a O
cytoplasmic B
tail I
lacking O
all O
four O
signal B
transducers I
and I
activators I
of I
transcription I
( I
Stat I
) I
binding I
sites I
. O

This O
cis B
element I
binds O
a O
protein O
complex O
referred O
to O
as O
HRF B
( O
heme B
- I
responsive I
factor I
) O
, O
which O
is O
greatly O
enhanced O
both O
in O
heme O
- O
treated O
FLCs O
and O
during O
monocyte O
- O
to O
- O
macrophage O
differentiation O
. O

One O
of O
the O
latter O
elements O
, O
the O
IgH B
3 I
' I
enhancer I
, O
is O
of O
particular O
interest O
: O
( O
1 O
) O
it O
is O
B O
cell O
- O
specific O
and O
active O
only O
in O
late O
B O
cell O
development O
; O
( O
2 O
) O
in O
rodent O
plasmacytomas O
and O
in O
some O
human O
Burkitt O
' O
s O
lymphomas O
it O
is O
part O
of O
a O
locus B
control I
region I
( O
LCR B
) O
that O
is O
involved O
in O
deregulation O
of O
the O
c B
- I
myc I
oncogene I
as O
a O
result O
of O
translocation O
into O
the O
IgH B
locus I
; O
and O
( O
3 O
) O
it O
has O
been O
implicated O
in O
the O
mechanisms O
that O
control O
Ig B
gene I
class I
switch O
recombination O

Reactive O
oxygen O
species O
( O
ROS O
) O
such O
as O
hydrogen O
peroxide O
serve O
as O
second O
messengers O
in O
the O
induction O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
, O
and O
hence O
in O
the O
activation O
and O
replication O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
in O
human O
cells O
. O

The O
transcriptional B
regulatory I
elements I
of O
many O
inducible B
T I
- I
cell I
genes I
contain O
adjacent O
or O
overlapping B
binding I
sites I
for O
the O
Ets B
and I
NF I
- I
kappaB I
/ I
NFAT I
families I
of O
transcription B
factors I
. O

From O
AML1 B
gene I
, O
two O
representative O
forms O
of O
proteins O
, O
AML1a B
and O
AML1b B
, O
are O
produced O
by O
an O
alternative O
splicing O
. O

When O
introduced O
into O
interleukin B
3 I
( O
IL B
- I
3 I
) O
- O
dependent O
mouse O
pro O
- O
B O
lymphocytes O
, O
E2A B
- I
HLF I
prevents O
apoptosis O
induced O
by O
growth B
factor I
deprivation O
, O
suggesting O
that O
IL B
- I
3 I
mediates O
cell O
survival O
through O
activation O
of O
a O
transcription B
factor I
whose O
activity O
can O
be O
constitutively O
replaced O
by O
the O
chimeric B
oncoprotein I
. O

When O
introduced O
into O
interleukin B
3 I
( O
IL B
- I
3 I
) O
- O
dependent O
mouse O
pro O
- O
B O
lymphocytes O
, O
E2A B
- I
HLF I
prevents O
apoptosis O
induced O
by O
growth B
factor I
deprivation O
, O
suggesting O
that O
IL B
- I
3 I
mediates O
cell O
survival O
through O
activation O
of O
a O
transcription B
factor I
whose O
activity O
can O
be O
constitutively O
replaced O
by O
the O
chimeric B
oncoprotein I
. O

When O
introduced O
into O
interleukin B
3 I
( O
IL B
- I
3 I
) O
- O
dependent O
mouse O
pro O
- O
B O
lymphocytes O
, O
E2A B
- I
HLF I
prevents O
apoptosis O
induced O
by O
growth B
factor I
deprivation O
, O
suggesting O
that O
IL B
- I
3 I
mediates O
cell O
survival O
through O
activation O
of O
a O
transcription B
factor I
whose O
activity O
can O
be O
constitutively O
replaced O
by O
the O
chimeric B
oncoprotein I
. O

When O
introduced O
into O
interleukin B
3 I
( O
IL B
- I
3 I
) O
- O
dependent O
mouse O
pro O
- O
B O
lymphocytes O
, O
E2A B
- I
HLF I
prevents O
apoptosis O
induced O
by O
growth B
factor I
deprivation O
, O
suggesting O
that O
IL B
- I
3 I
mediates O
cell O
survival O
through O
activation O
of O
a O
transcription B
factor I
whose O
activity O
can O
be O
constitutively O
replaced O
by O
the O
chimeric B
oncoprotein I
. O

The O
expression O
and O
binding O
activity O
of O
the O
Nfil3 B
protein I
( O
also O
called O
E4bp4 B
) O
, O
but O
not O
of O
Hlf B
, O
Dbp B
, O
or O
Tef B
, O
was O
found O
to O
be O
regulated O
by O
IL B
- I
3 I
in O
mouse O
pro O
- O
B O
cell O
lines O
( O
Baf O
- O
3 O
and O
FL5 O
. O
12 O
) O
. O

A O
specific O
p38 B
MAPk I
inhibitor O
( O
SK O
& O
F O
86002 O
) O
blocked O
superoxide O
anion O
production O
in O
response O
to O
FMLP B
and O
reduced O
adhesion O
and O
chemotaxis O
in O
response O
to O
PAF B
or O
FMLP B
. O

Co O
- O
ligation O
of O
the O
A6H B
antigen O
and O
the O
CD3 B
complex I
induced O
expression O
of O
the O
transcription B
factor I
AP B
- I
1 I
in O
CD4 O
+ O
T O
cells O
, O
whereas O
no O
increase O
in O
NF B
- I
kappa I
B I
and O
octamer B
- I
binding I
( I
Oct I
) I
proteins I
was O
seen O
compared O
to O
T O
cells O
stimulated O
with O
anti B
- I
CD3 I
alone O
. O

Co O
- O
ligation O
of O
the O
A6H B
antigen O
and O
the O
CD3 B
complex I
induced O
expression O
of O
the O
transcription B
factor I
AP B
- I
1 I
in O
CD4 O
+ O
T O
cells O
, O
whereas O
no O
increase O
in O
NF B
- I
kappa I
B I
and O
octamer B
- I
binding I
( I
Oct I
) I
proteins I
was O
seen O
compared O
to O
T O
cells O
stimulated O
with O
anti B
- I
CD3 I
alone O
. O

Molecular O
differences O
of O
the O
A6H B
molecule I
or O
distinct O
regulation O
of O
the O
A6H B
transduced O
AP B
- I
1 I
activation O
pathway O
may O
exist O
in O
CD4 O
+ O
and O
CD8 O
+ O
T O
cell O
subpopulations O
. O

Expressions O
of O
human O
and O
squirrel O
monkey O
glucocorticoid B
receptors I
and O
a O
squirrel B
monkey I
receptor I
in O
which O
Phe774 O
was O
mutated O
to O
Leu O
( O
F774L O
) O
were O
similar O
. O

The O
gamma B
( I
c I
) I
subunit I
can O
be O
employed O
in O
receptor B
complexes I
for O
IL B
- I
2 I
, I
- I
4 I
, I
- I
7 I
, I
- I
9 I
, I
and I
- I
15 I
, O
and O
the O
multiple O
signaling O
defects O
that O
would O
result O
from O
a O
defective O
gamma B
( I
c I
) I
chain I
in O
these O
receptors O
are O
proposed O
to O
cause O
the O
severe O
phenotype O
of O
X O
- O
SCID O
patients O
. O

By O
screening O
a O
T O
cell O
cDNA B
library I
, O
we O
identified O
a O
novel B
ets I
transcription I
factor I
that O
binds O
RBTN B
- I
2 I
. O

When O
immunoglobulin O
( O
Ig O
) O
- O
secreting O
plasmacytomas O
are O
fused O
to O
a O
T O
- O
cell O
lymphoma O
, O
Ig B
gene I
expression O
ceases O
in O
greater O
than O
95 O
% O
of O
the O
resulting O
hybrids O
. O

Disturbance O
of O
both O
the O
immune O
surveillance O
as O
well O
as O
viral B
gene I
regulation O
may O
result O
in O
EBV O
- O
associated O
disease O
. O

To O
investigate O
in O
vivo O
regulatory O
mechanisms O
that O
control O
the O
population O
of O
type O
2 O
T O
cells O
and O
disease O
susceptibility O
, O
we O
have O
created O
lines O
of O
transgenic O
mice O
in O
which O
expression O
of O
a O
chimeric B
cytokine I
receptor I
( O
the O
mouse B
interleukin I
2 I
receptor I
beta I
chain I
[ I
IL I
- I
2Rbeta I
] I
extracellular I
domain I
fused O
to O
the O
cytoplasmic B
tail I
of O
IL B
- I
4Ralpha I
) O
is O
targeted O
to O
the O
T O
lymphoid O
lineage O
using O
the O
proximal B
lck I
promoter I
. O

We O
have O
recently O
cloned O
the O
carboxylesterase B
upstream I
sequence I
and O
showed O
its O
basal B
promoter I
activity O
in O
CHO O
cells O
. O

The O
role O
of O
the O
Ikaros B
gene I
in O
lymphocyte O
development O
and O
homeostasis O
. O

Substitution O
mutations O
in O
this O
consensus B
sequence I
eliminate O
binding O
of O
the O
inducible B
factor I
. O

Substitution O
mutations O
in O
this O
consensus B
sequence I
eliminate O
binding O
of O
the O
inducible B
factor I
. O

A O
novel O
transcription B
factor I
regulates O
expression O
of O
the O
vacuolar B
H I
+ I
- I
ATPase I
B2 I
subunit I
through O
AP B
- I
2 I
sites I
during O
monocytic O
differentiation O
. O

In O
mobility O
shift O
assays O
, O
a O
nuclear B
factor I
from O
THP O
- O
1 O
and O
U O
- O
937 O
cells O
was O
identified O
that O
binds O
to O
several O
AP B
- I
2 I
response I
elements I
within O
the O
B2 B
promoter I
, O
but O
does O
not O
react O
with O
AP B
- I
2 I
antibodies I
, O
and O
has O
a O
DNA B
sequence I
binding O
affinity O
profile O
that O
differs O
from O
AP B
- I
2 I
. O

In O
mobility O
shift O
assays O
, O
a O
nuclear B
factor I
from O
THP O
- O
1 O
and O
U O
- O
937 O
cells O
was O
identified O
that O
binds O
to O
several O
AP B
- I
2 I
response I
elements I
within O
the O
B2 B
promoter I
, O
but O
does O
not O
react O
with O
AP B
- I
2 I
antibodies I
, O
and O
has O
a O
DNA B
sequence I
binding O
affinity O
profile O
that O
differs O
from O
AP B
- I
2 I
. O

In O
mobility O
shift O
assays O
, O
a O
nuclear B
factor I
from O
THP O
- O
1 O
and O
U O
- O
937 O
cells O
was O
identified O
that O
binds O
to O
several O
AP B
- I
2 I
response I
elements I
within O
the O
B2 B
promoter I
, O
but O
does O
not O
react O
with O
AP B
- I
2 I
antibodies I
, O
and O
has O
a O
DNA B
sequence I
binding O
affinity O
profile O
that O
differs O
from O
AP B
- I
2 I
. O

Both O
BZLF1 B
and I
BRLF1 I
immediate I
- I
early I
transcripts I
, O
but O
not O
BMLF1 B
transcript I
, O
could O
be O
detected O
in O
individual O
CD4 O
+ O
and O
CD8 O
+ O
T O
cells O
infected O
with O
EBV O
. O

Pharmacologic O
blockade O
of O
endogenous B
NFAT I
activity O
by O
FK506 O
or O
CsA O
inhibited O
synthesis O
of O
reverse O
transcription O
and O
also O
potently O
blocked O
HIV O
- O
1 O
replication O
. O

The O
first O
step O
in O
the O
nuclear O
import O
process O
is O
recognition O
of O
a O
nuclear B
localization I
sequence I
( O
NLS B
) O
within O
the O
karyophilic B
protein I
by O
a O
cytoplasmic B
receptor I
such O
as O
the O
importin B
( I
karyopherin I
) I
- I
alpha I
subunit I
. O

The O
first O
step O
in O
the O
nuclear O
import O
process O
is O
recognition O
of O
a O
nuclear B
localization I
sequence I
( O
NLS B
) O
within O
the O
karyophilic B
protein I
by O
a O
cytoplasmic B
receptor I
such O
as O
the O
importin B
( I
karyopherin I
) I
- I
alpha I
subunit I
. O

NLS B
peptide O
- O
mediated O
disruption O
of O
the O
nuclear O
import O
of O
these O
transcription B
factors I
results O
in O
inhibition O
of O
I O
kappa O
B O
alpha O
and O
IL O
- O
2 O
gene O
expression O
, O
processes O
dependent O
on O
NF B
- I
kappa I
B I
or O
the O
combination O
of O
NF B
- I
kappa I
B I
, O
AP B
- I
1 I
, O
and O
NFAT B
. O

The O
discrepancy O
in O
the O
degree O
of O
inhibition O
by O
membrane O
extracts O
and O
NK O
cells O
with O
mutant B
TNFRI I
suggests O
that O
additional O
pathways O
are O
utilized O
by O
NK O
cells O
to O
activate O
EC O

Ras B
- O
dependent O
, O
Ca2 O
+ O
- O
stimulated O
activation O
of O
nuclear B
factor I
of I
activated I
T I
cells I
by O
a O
constitutively O
active O
Cbl B
mutant I
in O
T O
cells O
. O

Quantitative O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
showed O
an O
increase O
in O
steady O
- O
state O
TNF B
- I
alpha I
mRNA I
after O
3 O
to O
4 O
hours O
of O
cross O
- O
linking O
. O

These O
data O
indicate O
specific O
modulation O
of O
the O
CREB B
/ I
ATF I
- I
1 I
family I
of O
transcription B
factors I
by O
the O
CD2 B
signalling O
pathway O
and O
suggest O
CD2 B
receptor O
modulation O
of O
CRE B
- O
mediated O
transcription O
following O
ligand O
engagement O
( O
e O
. O
g O
. O
cell O
- O
to O
- O
cell O
contact O
) O
. O

In O
addition O
, O
X O
- O
ray O
activation O
of O
HIV B
- I
1 I
LTR I
in O
transiently O
or O
stably O
transfected O
cell O
lines O
is O
inhibited O
by O
a O
potent O
antioxidant O
drug O
, O
pyrrolidine O
dithiocarbamate O
and O
by O
another O
drug O
, O
known O
for O
its O
role O
in O
the O
trapping O
of O
growth B
factors I
, O
suramin O
. O

Restoration O
of O
the O
CCAAT B
box I
at O
- B
70 I
bp I
, O
or O
insertion O
of O
an O
EKLF B
binding I
site I
at O
- B
85 I
bp I
or O
- B
95 I
bp I
in O
the O
promoter B
significantly O
increased O
delta O
globin O
gene O
expression O
in O
hAEC O
. O

Evidence O
suggests O
that O
IL B
- I
10 I
may O
inhibit O
activation O
of O
the O
transcription B
factor I
nuclear B
factor I
- I
kappaB I
( O
NF B
- I
kappaB I
) O
through O
an O
unknown O
mechanism O
. O

Down O
- O
regulation O
of O
human O
granzyme B
B I
expression O
by O
glucocorticoids O
. O

These O
results O
indicate O
that O
dexamethasone O
is O
able O
to O
abrogate O
the O
transcriptional O
activity O
of O
the O
human B
granzyme I
B I
gene I
promoter I
by O
inhibiting O
the O
binding O
of O
nuclear B
factors I
at O
the O
AP B
- I
1 I
and I
Ikaros I
sites I
. O

In O
contrast O
, O
a O
significant O
correlation O
between O
NGAL B
expression O
in O
breast O
cancer O
was O
found O
with O
several O
other O
markers O
of O
poor O
prognosis O
, O
including O
estrogen O
and O
progesterone B
receptor I
- O
negative O
status O
and O
high O
proliferation O
( O
S O
- O
phase O
fraction O
) O
. O

These O
studies O
revealed O
that O
the O
major B
protein I
in O
extracts O
of O
PMN O
activated O
by O
G B
- I
CSF I
to O
bind O
the O
high B
- I
affinity I
serum I
- I
inducible I
element I
( O
hSIE B
) O
is O
a O
72 B
- I
kDa I
protein I
that O
cross O
- O
reacts O
with O
Stat3 B
monoclonal I
antibody I
, O
which O
we O
have O
designated O
Stat3gamma B
. O

Since O
the O
AES B
proteins I
are O
part O
of O
a O
set O
of O
transcriptional O
repressors O
encoded O
by O
the O
Enhancer B
of I
split I
[ I
E I
( I
spl I
) I
] I
genes I
, O
and O
since O
these O
repressors O
are O
activated O
to O
suppress O
cell O
differentiation O
in O
response O
to O
Notch B
receptors I
signalling O
, O
the O
AES O
peptides O
may O
represent O
a O
novel O
class O
of O
self B
- I
antigens I
that O
deserve O
further O
consideration O
as O
tumor B
Ag I
in O
epithelial O
cancers O
. O

Since O
the O
AES B
proteins I
are O
part O
of O
a O
set O
of O
transcriptional O
repressors O
encoded O
by O
the O
Enhancer B
of I
split I
[ I
E I
( I
spl I
) I
] I
genes I
, O
and O
since O
these O
repressors O
are O
activated O
to O
suppress O
cell O
differentiation O
in O
response O
to O
Notch B
receptors I
signalling O
, O
the O
AES O
peptides O
may O
represent O
a O
novel O
class O
of O
self B
- I
antigens I
that O
deserve O
further O
consideration O
as O
tumor B
Ag I
in O
epithelial O
cancers O
. O

Since O
the O
AES B
proteins I
are O
part O
of O
a O
set O
of O
transcriptional O
repressors O
encoded O
by O
the O
Enhancer B
of I
split I
[ I
E I
( I
spl I
) I
] I
genes I
, O
and O
since O
these O
repressors O
are O
activated O
to O
suppress O
cell O
differentiation O
in O
response O
to O
Notch B
receptors I
signalling O
, O
the O
AES O
peptides O
may O
represent O
a O
novel O
class O
of O
self B
- I
antigens I
that O
deserve O
further O
consideration O
as O
tumor B
Ag I
in O
epithelial O
cancers O
. O

Glucocorticoid B
receptors I
( O
GR B
) O
and O
3 O
- O
O O
- O
methyl O
- O
D O
glucose O
( O
3 O
- O
O O
- O
MG O
) O
transport O
were O
determined O
in O
mononuclear O
leukocytes O
( O
MNL O
) O
from O
11 O
abdominal O
obese O
subjects O
, O
10 O
pituitary O
- O
dependent O
Cushing O
' O
s O
syndrome O
( O
Cushing O
' O
s O
disease O
) O
and O
10 O
healthy O
controls O
. O

Since O
the O
protein O
has O
a O
homeodomain B
and O
can O
activate O
transcription O
, O
it O
probably O
exerts O
at O
least O
some O
of O
its O
effects O
in O
vivo O
by O
regulation O
of O
target B
genes I
. O

We O
investigated O
the O
function O
of O
the O
evolutionary O
conserved O
X2 B
box I
in O
the O
promoter B
of O
the O
HLA B
- I
DRA I
gene I
from O
the O
human B
major I
histocompatibility I
complex I
( O
MHC B
) O
in O
resting O
and O
activated O
B O
cells O
. O

Thymocytes O
control O
the O
CD4 B
gene I
differently O
from O
mature O
T O
lymphocytes O
. O

In O
order O
to O
elucidate O
possible O
mechanisms O
underlying O
endothelial O
cell O
activation O
by O
xenogeneic O
serum O
, O
we O
focussed O
on O
transcription B
factor I
NF I
- I
kappa I
B I
, O
a O
central O
regulator O
for O
the O
induction O
of O
different O
genes O
, O
including O
adhesive B
molecules I
and O
chemoattractants B
. O

Plasma O
TPO B
levels O
are O
regulated O
by O
the O
platelet O
and O
megakaryocyte O
mass O
through O
Mpl B
receptor I
binding O
, O
internalization O
and O
degradation O
. O

The O
Mpl B
receptor I
is O
a O
member O
of O
the O
hematopoietin B
receptor I
superfamily I
lacking O
intrinsic O
kinase O
activity O
. O

Promoter O
analysis O
revealed O
that O
a O
GATA B
site I
in O
a O
cryptic B
promoter I
in O
the O
second B
intron I
was O
essential O
and O
sufficient O
for O
the O
TAL1 O
- O
and O
LMO O
- O
dependent O
transcriptional O
activation O
, O
and O
GATA3 B
binds O
to O
this O
site O
. O

Promoter O
analysis O
revealed O
that O
a O
GATA B
site I
in O
a O
cryptic B
promoter I
in O
the O
second B
intron I
was O
essential O
and O
sufficient O
for O
the O
TAL1 O
- O
and O
LMO O
- O
dependent O
transcriptional O
activation O
, O
and O
GATA3 B
binds O
to O
this O
site O
. O

Promoter O
analysis O
revealed O
that O
a O
GATA B
site I
in O
a O
cryptic B
promoter I
in O
the O
second B
intron I
was O
essential O
and O
sufficient O
for O
the O
TAL1 O
- O
and O
LMO O
- O
dependent O
transcriptional O
activation O
, O
and O
GATA3 B
binds O
to O
this O
site O
. O

X B
chromosome I
inactivation O
patterns O
in O
normal O
females O
. O

Since O
one O
of O
the O
two O
X B
chromosomes I
is O
randomly O
inactivated O
at O
an O
early O
stage O
of O
female O
embryonic O
development O
, O
X B
- I
linked I
markers I
have O
been O
used O
to O
study O
the O
origin O
and O
development O
of O
various O
neoplastic O
disorders O
in O
affected O
heterozygous O
women O
; O
clonality O
assays O
have O
provided O
a O
useful O
tool O
to O
the O
understanding O
of O
the O
mechanisms O
underlying O
the O
development O
of O
neoplasia O
. O

These O
motifs O
are O
regulatory B
sequences I
within O
the O
so O
- O
called O
AU B
- I
rich I
elements I
( O
AREs B
) O
often O
found O
in O
3 B
' I
untranslated I
regions I
of O
genes O
such O
as O
cytokines B
, O
proto B
- I
oncogenes I
, O
and O
transcription B
factors I
. O

These O
motifs O
are O
regulatory B
sequences I
within O
the O
so O
- O
called O
AU B
- I
rich I
elements I
( O
AREs B
) O
often O
found O
in O
3 B
' I
untranslated I
regions I
of O
genes O
such O
as O
cytokines B
, O
proto B
- I
oncogenes I
, O
and O
transcription B
factors I
. O

The O
nuclear B
factor I
- I
kappa I
B I
( I
NF I
- I
kappaB I
) I
family I
of O
transcription B
factors I
regulates O
genes O
involved O
in O
inflammation O
, O
cell O
proliferation O
, O
and O
cell O
differentiation O
. O

At O
the O
same O
time O
there O
was O
no O
change O
in O
the O
level O
of O
expression O
of O
the O
cell B
surface I
antigenes I
CD33 B
, O
CD34 B
, O
CD45 B
, O
CD71 B
and O
glycophorin B
A I
. O

Here O
, O
we O
demonstrate O
through O
the O
use O
of O
intracellular O
staining O
that O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
is O
expressed O
in O
LCLs O
and O
investigate O
the O
influence O
of O
the O
individual O
latent B
proteins I
on O
the O
expression O
of O
IL B
- I
1beta I
. O

Recent O
studies O
, O
however O
, O
demonstrate O
that O
the O
transcribed O
5 B
' I
- I
untranslated I
leader I
region I
( O
5 B
' I
- I
UTR I
) O
also O
contains O
important O
transcriptional B
elements I
. O

These O
regulatory B
elements I
situated O
downstream O
of O
transcription O
interact O
with O
constitutive O
and O
inducible O
transcription B
factors I
, O
mediate O
transmission O
of O
cellular O
activation O
signals O
, O
and O
are O
important O
for O
efficient O
HIV O
- O
1 O
transcription O
and O
replication O
. O

These O
regulatory B
elements I
situated O
downstream O
of O
transcription O
interact O
with O
constitutive O
and O
inducible O
transcription B
factors I
, O
mediate O
transmission O
of O
cellular O
activation O
signals O
, O
and O
are O
important O
for O
efficient O
HIV O
- O
1 O
transcription O
and O
replication O
. O

Regulation O
of O
PAK O
activation O
and O
the O
T O
cell O
cytoskeleton O
by O
the O
linker B
protein I
SLP B
- I
76 I
. O

LOX B
- I
1 I
is O
an O
endothelial B
receptor I
for O
oxidized B
low I
- I
density I
lipoprotein I
that O
plays O
essential O
roles O
in O
atherogenesis O
. O

GATA B
- I
3 I
represses O
gp91phox B
gene I
expression O
in O
eosinophil O
- O
committed O
HL O
- O
60 O
- O
C15 O
cells O
. O

Receptors O
for O
the O
Fc B
portion I
of O
immunoglobulin B
molecules I
( O
FcR B
) O
present O
on O
leukocyte O
cell O
membranes O
mediate O
a O
large O
number O
of O
cellular O
responses O
that O
are O
very O
important O
in O
host O
defense O
, O
including O
phagocytosis O
, O
cell O
cytotoxicity O
, O
production O
and O
secretion O
of O
inflammatory B
mediators I
, O
and O
modulation O
of O
the O
immune O
response O
. O

Receptors O
for O
the O
Fc B
portion I
of O
immunoglobulin B
molecules I
( O
FcR B
) O
present O
on O
leukocyte O
cell O
membranes O
mediate O
a O
large O
number O
of O
cellular O
responses O
that O
are O
very O
important O
in O
host O
defense O
, O
including O
phagocytosis O
, O
cell O
cytotoxicity O
, O
production O
and O
secretion O
of O
inflammatory B
mediators I
, O
and O
modulation O
of O
the O
immune O
response O
. O

Receptors O
for O
the O
Fc B
portion I
of O
immunoglobulin B
molecules I
( O
FcR B
) O
present O
on O
leukocyte O
cell O
membranes O
mediate O
a O
large O
number O
of O
cellular O
responses O
that O
are O
very O
important O
in O
host O
defense O
, O
including O
phagocytosis O
, O
cell O
cytotoxicity O
, O
production O
and O
secretion O
of O
inflammatory B
mediators I
, O
and O
modulation O
of O
the O
immune O
response O
. O

Cross O
- O
linking O
of O
FcR B
, O
on O
the O
THP O
- O
1 O
monocytic O
cell O
line O
, O
by O
immune B
complexes I
resulted O
in O
both O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
and O
interleukin B
1 I
production O
. O

Cross O
- O
linking O
of O
FcR B
, O
on O
the O
THP O
- O
1 O
monocytic O
cell O
line O
, O
by O
immune B
complexes I
resulted O
in O
both O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
and O
interleukin B
1 I
production O
. O

Cross O
- O
linking O
of O
FcR B
, O
on O
the O
THP O
- O
1 O
monocytic O
cell O
line O
, O
by O
immune B
complexes I
resulted O
in O
both O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappaB I
and O
interleukin B
1 I
production O
. O

BCL B
- I
6 I
mutations O
in O
normal O
germinal O
center O
B O
cells O
: O
evidence O
of O
somatic O
hypermutation O
acting O
outside O
Ig B
loci I
. O

Neither O
the O
E12 B
nor O
the O
E47 B
product O
of O
the O
E2A B
gene I
nor O
the O
wild B
- I
type I
HLF I
protein I
was O
able O
to O
protect O
the O
cells O
from O
apoptosis O
induced O
by O
IL B
- I
3 I
deprivation O
. O

Surprisingly O
, O
different O
combinations O
of O
disabling O
mutations O
within O
the O
HLF B
bZIP I
domain I
had O
little O
effect O
on O
the O
antiapoptotic O
property O
of O
the O
chimeric B
protein I
, O
so O
long O
as O
the O
amino O
- O
terminal O
portion O
of O
E2A B
remained O
intact O
. O

These O
results O
suggest O
that O
1 O
) O
lipid O
A O
myristoyl O
fatty O
acid O
, O
although O
it O
is O
important O
for O
the O
induction O
of O
inflammatory B
cytokine I
production O
by O
human O
monocytes O
, O
is O
not O
necessary O
for O
the O
induction O
of O
Mn B
SOD I
, O
2 O
) O
endotoxin B
- O
mediated O
induction O
of O
Mn B
SOD I
and O
inflammatory O
cytokines B
are O
regulated O
, O
at O
least O
in O
part O
, O
through O
different O
signal O
transduction O
pathways O
, O
and O
3 O
) O
failure O
of O
the O
mutant B
endotoxin I
to O
induce O
tumor B
necrosis I
factor I
- I
alpha I
production O
is O
, O
at O
least O
in O
part O
, O
due O
to O
its O
inability O
to O
activate O
mitogen B
- I
activated I
protein I
kinase I
. O

These O
results O
suggest O
that O
1 O
) O
lipid O
A O
myristoyl O
fatty O
acid O
, O
although O
it O
is O
important O
for O
the O
induction O
of O
inflammatory B
cytokine I
production O
by O
human O
monocytes O
, O
is O
not O
necessary O
for O
the O
induction O
of O
Mn B
SOD I
, O
2 O
) O
endotoxin B
- O
mediated O
induction O
of O
Mn B
SOD I
and O
inflammatory O
cytokines B
are O
regulated O
, O
at O
least O
in O
part O
, O
through O
different O
signal O
transduction O
pathways O
, O
and O
3 O
) O
failure O
of O
the O
mutant B
endotoxin I
to O
induce O
tumor B
necrosis I
factor I
- I
alpha I
production O
is O
, O
at O
least O
in O
part O
, O
due O
to O
its O
inability O
to O
activate O
mitogen B
- I
activated I
protein I
kinase I
. O

These O
results O
suggest O
that O
1 O
) O
lipid O
A O
myristoyl O
fatty O
acid O
, O
although O
it O
is O
important O
for O
the O
induction O
of O
inflammatory B
cytokine I
production O
by O
human O
monocytes O
, O
is O
not O
necessary O
for O
the O
induction O
of O
Mn B
SOD I
, O
2 O
) O
endotoxin B
- O
mediated O
induction O
of O
Mn B
SOD I
and O
inflammatory O
cytokines B
are O
regulated O
, O
at O
least O
in O
part O
, O
through O
different O
signal O
transduction O
pathways O
, O
and O
3 O
) O
failure O
of O
the O
mutant B
endotoxin I
to O
induce O
tumor B
necrosis I
factor I
- I
alpha I
production O
is O
, O
at O
least O
in O
part O
, O
due O
to O
its O
inability O
to O
activate O
mitogen B
- I
activated I
protein I
kinase I
. O

These O
results O
suggest O
that O
1 O
) O
lipid O
A O
myristoyl O
fatty O
acid O
, O
although O
it O
is O
important O
for O
the O
induction O
of O
inflammatory B
cytokine I
production O
by O
human O
monocytes O
, O
is O
not O
necessary O
for O
the O
induction O
of O
Mn B
SOD I
, O
2 O
) O
endotoxin B
- O
mediated O
induction O
of O
Mn B
SOD I
and O
inflammatory O
cytokines B
are O
regulated O
, O
at O
least O
in O
part O
, O
through O
different O
signal O
transduction O
pathways O
, O
and O
3 O
) O
failure O
of O
the O
mutant B
endotoxin I
to O
induce O
tumor B
necrosis I
factor I
- I
alpha I
production O
is O
, O
at O
least O
in O
part O
, O
due O
to O
its O
inability O
to O
activate O
mitogen B
- I
activated I
protein I
kinase I
. O

Characterization O
of O
cytokine B
differential O
induction O
of O
STAT B
complexes I
in O
primary O
human O
T O
and O
NK O
cells O
. O

A O
regulatory B
element I
in O
the O
CD95 B
( I
APO I
- I
1 I
/ I
Fas I
) I
ligand I
promoter I
is O
essential O
for O
responsiveness O
to O
TCR B
- O
mediated O
activation O
. O

The O
DNA O
sequence O
at O
- B
120 I
also O
contains O
two O
DNA B
motifs I
homologous O
to O
the O
binding O
site O
for O
NF B
- I
AT I
. O

The O
DNA O
sequence O
at O
- B
120 I
also O
contains O
two O
DNA B
motifs I
homologous O
to O
the O
binding O
site O
for O
NF B
- I
AT I
. O

The O
chemokine B
receptor I
, O
BLR1 B
, O
is O
a O
major O
regulator O
of O
the O
microenvironmental O
homing O
of O
B O
cells O
in O
lymphoid O
organs O
. O

Activation O
of O
the O
CD4 B
promoter I
occurs O
in O
the O
presence O
of O
the O
viral O
DNA O
polymerase O
inhibitor O
phosphonoformic O
acid O
, O
which O
limits O
expression O
to O
the O
immediate B
- I
early I
and I
early I
classes I
of I
viral I
genes I
. O

Both O
Tax B
- O
mediated O
apoptosis O
and O
oxidative O
stress O
can O
be O
potently O
suppressed O
by O
antioxidants O
, O
as O
is O
seen O
with O
the O
administration O
of O
recombinant B
thioredoxin I
( O
adult B
T I
cell I
leukemia I
- I
derived I
factor I
) O
or O
pyrrolidine O
dithiocarbamate O
. O

[ O
Molecular O
mechanism O
of O
cytokine B
gene I
expression O
in O
Th1 O
and O
Th2 O
] O

Among O
them O
, O
both O
the O
activation O
of O
PKC O
/ O
Ras O
- O
and O
CaM O
/ O
CN O
- O
mediated O
pathways O
play O
a O
central O
role O
in O
the O
signal O
transduction O
of O
cytokine B
gene I
expression O
. O

Activation O
of O
T O
cells O
results O
in O
the O
rapid O
calcineurin B
- O
dependent O
translocation O
of O
NFAT B
transcription B
factors I
from O
the O
cytoplasm O
to O
the O
nucleus O
. O

Unexpectedly O
, O
we O
found O
that O
conventional O
procedures O
employed O
to O
prepare O
cellular O
extracts O
cause O
the O
release O
of O
proteolytic O
activities O
that O
are O
normally O
stored O
in O
intracellular O
granules O
, O
resulting O
in O
the O
degradation O
of O
various O
NF B
- I
kappaB I
/ I
Rel I
and O
STAT B
proteins I
. O

In O
addition O
, O
the O
procedure O
described O
herein O
could O
prove O
useful O
in O
other O
cell O
types O
that O
express O
high O
levels O
of O
endogenous B
proteases I
. O

As O
NF B
- I
kappa I
B I
is O
a O
critical O
transcription B
factor I
in O
the O
control O
of O
IL B
- I
2 I
expression O
, O
we O
next O
analysed O
its O
nuclear O
translocation O
in O
neonatal O
and O
adult O
T O
cells O
using O
the O
electrophoretic O
mobility O
shift O
assay O
and O
, O
because O
induction O
of O
reactive O
oxygen O
intermediates O
( O
ROI O
) O
is O
required O
for O
the O
activation O
of O
NF B
- I
kappa I
B I
, O
we O
also O
analysed O
levels O
of O
intracellular O
ROI O
in O
these O
cells O
using O
the O
ROI O
- O
reactive O
fluorochrome O
DCFH O
- O
DA O
and O
flow O
cytometry O
. O

Are O
there O
effects O
of O
CyA O
and O
FK O
506 O
all O
attributable O
to O
CN O
inhibition O
, O
and O
how O
much O
of O
them O
are O
mediated O
through O
the O
NFATC B
family I
of O
transcription B
factors I
? O

Are O
there O
effects O
of O
CyA O
and O
FK O
506 O
all O
attributable O
to O
CN O
inhibition O
, O
and O
how O
much O
of O
them O
are O
mediated O
through O
the O
NFATC B
family I
of O
transcription B
factors I
? O

Simultaneous O
analysis O
of O
close O
to O
600 B
genes I
indicated O
highest O
increase O
in O
the O
expression O
of O
certain O
transcription B
, I
differentiation I
and I
proliferation I
factors I
. O

It O
is O
unknown O
which O
Stat3 B
isoform I
( O
s O
) O
is O
activated O
in O
response O
to O
interleukin B
( I
IL I
) I
- I
2 I
and O
IL B
- I
15 I
. O

Our O
results O
suggest O
that O
the O
TNFalpha B
gene I
could O
be O
one O
of O
the O
targets O
of O
NF B
- I
kappaB I
in O
EBV O
infected O
cells O
and O
that O
NF O
- O
kappaB O
protects O
EBV O
- O
infected O
cells O
from O
apoptosis O
induced O
by O
TNFalpha B
, O
which O
may O
favour O
the O
proliferative O
effect O
of O
this O
cytokine B
. O

The O
eosinophilic O
characteristics O
of O
YJ O
cells O
were O
confirmed O
by O
histochemical O
staining O
with O
Fast O
- O
Green O
/ O
Neutral O
- O
Red O
and O
by O
the O
expression O
of O
mRNAs B
for O
eosinophil B
- I
associated I
granule I
proteins I
, O
eosinophil B
cationic I
protein I
( O
ECP B
) O
, O
eosinophil B
- I
derived I
neurotoxin I
( O
EDN B
) O
, O
eosinophil B
peroxidase I
( O
EPO B
) O
, O
and O
major B
basic I
protein I
( O
MBP B
) O
, O
and O
for O
the O
Charcot B
- I
Leyden I
crystal I
( I
CLC I
) I
protein I
. O

The O
expression O
of O
genes O
for O
transcription B
factors I
involved O
in O
myeloid O
differentiation O
was O
evaluated O
by O
Northern O
blot O
analysis O
. O

The O
characterization O
of O
CIITA B
mutants I
that O
are O
able O
to O
discriminate O
between O
promoters O
with O
or O
without O
the O
W B
box I
strongly O
suggests O
that O
CIITA B
requires O
such O
interactions O
for O
function O
. O

The O
characterization O
of O
CIITA B
mutants I
that O
are O
able O
to O
discriminate O
between O
promoters O
with O
or O
without O
the O
W B
box I
strongly O
suggests O
that O
CIITA B
requires O
such O
interactions O
for O
function O
. O

Recently O
, O
it O
was O
suggested O
that O
activation O
of O
the O
alpha B
isoform I
of O
PPAR B
by O
the O
potent O
proinflammatory O
mediator O
leukotriene O
B4 O
( O
LTB4 O
) O
enhanced O
degradation O
of O
this O
eicosanoid O
, O
offersuggesting O
a O
new O
aspect O
of O
down O
- O
regulation O
of O
inflammation O
. O

Identification O
of O
transcription B
factors I
expressed O
during O
ATRA O
- O
induced O
neutrophil O
differentiation O
of O
HL60 O
cells O
. O

Interleukin B
- I
4 I
and I
- I
13 I
induce O
upregulation O
of O
the O
murine O
macrophage O
12 B
/ I
15 I
- I
lipoxygenase I
activity I
: O
evidence O
for O
the O
involvement O
of O
transcription B
factor I
STAT6 B
. O

Interferon B
- I
gamma I
- I
induced I
factor I
binding O
to O
the O
interleukin B
- I
4 I
- I
responsive I
element I
of O
CD23b B
promoter I
in O
human O
tonsillar O
mononuclear O
cells O
: O
role O
in O
transient O
up O
- O
regulation O
of O
the O
interleukin B
- I
4 I
- I
induced I
CD23b I
mRNA I
. O

Mutations O
of O
sites O
that O
suppress O
NF B
- I
AT I
binding O
impair O
the O
induction O
and O
strong O
NF B
- I
ATp I
- O
mediated O
transactivation O
of O
the O
CD25 B
promoter I
in O
T O
cells O
. O

Antibodies B
to O
Duffy B
antigens I
are O
responsible O
for O
some O
cases O
of O
transfusion O
incompatibility O
and O
newborn O
hemolytic O
disease O
. O

The O
Duffy B
protein I
is O
a O
receptor O
for O
the O
Plasmodium B
vivax I
erythrocyte I
- I
binding I
protein I
and O
is O
also O
a O
receptor O
for O
various O
chemokines B
( O
thus O
renamed O
Duffy B
Antigen I
Receptor I
for I
Chemokines I
[ O
DARC B
] O
) O
. O

The O
Fy O
( O
a O
- O
b O
- O
) O
phenotype O
has O
been O
associated O
with O
a O
mutation O
in O
the O
FY B
* I
B I
promoter I
at O
the O
GATA B
box I
that O
abolishes O
the O
expression O
of O
erythrocyte B
Duffy I
protein I
. O

The O
functions O
of O
NFAT B
proteins I
are O
directly O
controlled O
by O
the O
calcium B
- I
and I
calmodulin I
- I
dependent I
phosphatase I
calcineurin B
. O

Expression O
of O
the O
IL B
- I
2 I
gene I
requires O
activation O
of O
T O
cells O
through O
stimulation O
of O
the O
TCR B
and O
costimulation O
through O
accessory B
receptors I
. O

The O
transcription B
factors I
active O
at O
the O
IL B
- I
2 I
promoter I
were O
differentially O
influenced O
: O
upon O
down O
- O
modulation O
of O
okadaic B
acid I
- I
sensitive I
phosphatases I
, O
transactivation O
by O
octamer O
, O
NF B
- I
kappa I
B I
, O
and O
NF B
of I
activated I
T I
cells I
proteins I
was O
abrogated O
, O
while O
transactivation O
by O
AP B
- I
1 I
proteins I
was I
even I
enhanced I
. I

The O
nuclear B
receptor I
PPARgamma B
- O
bigger O
than O
fat O
. O

We O
have O
determined O
how O
the O
phosphorylation O
of O
the O
retinoblastoma B
family I
( O
pRb B
, O
p107 B
, O
and O
p130 B
) O
is O
governed O
in O
individual O
cell O
cycle O
phases O
of O
Daudi O
B O
- O
cells O
during O
cell O
cycle O
exit O
triggered O
by O
alpha B
- I
interferon I
( O
alpha B
- I
IFN I
) O
. O

p130 B
, O
predominantly O
in O
Form O
1 O
, O
and O
hypophosphorylated B
pRb I
bind O
an O
E2F B
DNA I
binding I
site I
; O
p130 B
complexes O
E2F B
- I
4 I
, O
whereas O
pRb B
binds O
both O
E2F O
- O
4 O
and O
E2F B
- I
1 I
. O

In O
contrast O
, O
v B
- I
myb I
reduces O
MRP14 B
promoter I
activity O
. O

This O
pathway O
resulted O
in O
the O
induction O
of O
the O
transcription B
factors I
NF B
- I
kappa I
B I
, O
NF B
- I
AT I
, O
and O
proteins O
binding O
to O
the O
CD28 B
response O
element O
of O
the O
IL B
- I
2 I
promoter I
. O

In O
contrast O
to O
the O
differential O
signaling O
of O
BW B
828 I
and O
9 B
. I
3 I
in O
resting O
T O
cells O
, O
the O
two O
mAbs O
exhibited O
a O
similar O
pattern O
of O
early O
signaling O
events O
in O
activated O
T O
cells O
and O
Jurkat O
cells O
( O
p56 B
( I
lck I
) I
activation O
, O
association O
of O
phosphatidylinositol B
3 I
- I
kinase I
with O
CD28 B
) O
, O
indicating O
that O
the O
signaling O
capacity O
of O
CD28 B
changes O
with O
activation O
. O

Metabolic O
labeling O
combined O
with O
pulse O
- O
chase O
experiments O
and O
biochemical O
analysis O
showed O
that O
the O
majority O
of O
class B
II I
molecules I
in O
infected O
cells O
became O
resistant O
to O
endoglycosidase B
H I
, O
consistent O
with O
normal O
Golgi O
processing O
. O

Analyzed O
DNA B
sequences I
included O
delta B
and I
beta I
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
500 I
to I
+ I
50bp I
( O
promoter B
regions I
) O
, O
truncated O
delta O
and O
beta B
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
250 I
to I
+ I
50 I
bp I
, O
and O
chimeric B
promoter I
constructions I
, O
which O
consisted O
of O
a O
distal O
delta B
or I
beta I
fragment I
fused O
to O
a O
proximal B
beta I
or I
delta I
sequence I
. O

Analyzed O
DNA B
sequences I
included O
delta B
and I
beta I
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
500 I
to I
+ I
50bp I
( O
promoter B
regions I
) O
, O
truncated O
delta O
and O
beta B
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
250 I
to I
+ I
50 I
bp I
, O
and O
chimeric B
promoter I
constructions I
, O
which O
consisted O
of O
a O
distal O
delta B
or I
beta I
fragment I
fused O
to O
a O
proximal B
beta I
or I
delta I
sequence I
. O

In O
CAT B
reporter I
constructions I
no O
appreciable O
level O
of O
CAT B
activity O
was O
supported O
by O
the O
beta B
globin I
promoter I
, O
and O
only O
low O
level O
activity O
by O
the O
delta B
promoter I
. O

Fusion O
of O
the O
upstream B
portion I
of O
the O
delta B
promoter I
to O
the O
truncated O
beta B
globin I
promoter I
yielded O
a O
modest O
increase O
in O
promoter O
strength O
relative O
to O
the O
truncated B
beta I
gene I
promoter I
, O
indicating O
the O
presence O
of O
a O
positive B
transcriptional I
element I
( O
s O
) O
in O
the O
upstream B
delta I
globin I
regulatory I
region I
. O

Fusion O
of O
the O
upstream B
portion I
of O
the O
delta B
promoter I
to O
the O
truncated O
beta B
globin I
promoter I
yielded O
a O
modest O
increase O
in O
promoter O
strength O
relative O
to O
the O
truncated B
beta I
gene I
promoter I
, O
indicating O
the O
presence O
of O
a O
positive B
transcriptional I
element I
( O
s O
) O
in O
the O
upstream B
delta I
globin I
regulatory I
region I
. O

NFAT B
regulates O
transcription O
of O
a O
number O
of O
cytokine O
and O
other O
immunoregulatory B
genes I
. O

This O
transactivation O
sequence O
is O
altered O
by O
tissue O
- O
specific O
alternative O
splicing O
in O
newly O
isolated O
NFATx B
isoforms I
, O
resulting O
in O
lower O
transactivation O
activity O
in O
Jurkat O
T O
cells O
. O

We O
show O
that O
the O
function O
of O
such O
closely O
related O
proteins O
can O
be O
distinguished O
in O
vivo O
by O
matching O
point O
mutations O
in O
5 B
' I
HS3 I
with O
amino O
acid O
changes O
in O
the O
zinc B
fingers I
of O
Sp1 B
and O
EKLF B
. O

Expression O
of O
either O
BZLF1 B
or O
BRLF1 B
triggers O
expression O
of O
the O
other O
immediate B
- I
early I
factor I
, O
and O
together O
these O
activators O
act O
individually O
or O
in O
synergy O
on O
downstream B
targets I
to O
activate O
the O
viral O
lytic O
cycle O
. O

We O
first O
demonstrate O
, O
in O
human O
and O
mouse O
intraspecies O
hybrids O
, O
the O
coordinate O
suppression O
of O
MHC B
class I
II I
, O
Ii B
( O
invariant B
chain I
) O
and O
HLA B
- I
DM I
gene I
transcription O
, O
and O
the O
release O
of O
the O
silencing O
by O
the O
addition O
of O
interferon B
gamma I
. O

We O
first O
demonstrate O
, O
in O
human O
and O
mouse O
intraspecies O
hybrids O
, O
the O
coordinate O
suppression O
of O
MHC B
class I
II I
, O
Ii B
( O
invariant B
chain I
) O
and O
HLA B
- I
DM I
gene I
transcription O
, O
and O
the O
release O
of O
the O
silencing O
by O
the O
addition O
of O
interferon B
gamma I
. O

Transient O
transfection O
analysis O
with O
target B
plasmids I
containing O
either O
DRA B
promoter I
( O
wild O
- O
type O
or O
mutated O
) O
or O
TPA B
response I
elements I
demonstrated O
that O
pretreatment O
with O
the O
selective O
PKC B
inhibitor O
GF O
109203X O
repressed O
TPA O
- O
mediated O
activation O
. O

Transient O
transfection O
analysis O
with O
target B
plasmids I
containing O
either O
DRA B
promoter I
( O
wild O
- O
type O
or O
mutated O
) O
or O
TPA B
response I
elements I
demonstrated O
that O
pretreatment O
with O
the O
selective O
PKC B
inhibitor O
GF O
109203X O
repressed O
TPA O
- O
mediated O
activation O
. O

Together O
, O
these O
results O
show O
that O
activated O
HLA B
- I
DRA I
expression O
in O
response O
to O
TPA O
treatment O
is O
strictly O
dependent O
on O
PKC B
activation O
acting O
on O
the O
X2 B
box I
of O
the O
DRA B
promoter I
and O
that O
selective O
inhibition O
of O
PKC B
enzymatic O
activity O
does O
not O
influence O
subcellular O
localization O
of O
expressed O
PKC B
isoenzymes I
. O

Together O
, O
these O
results O
show O
that O
activated O
HLA B
- I
DRA I
expression O
in O
response O
to O
TPA O
treatment O
is O
strictly O
dependent O
on O
PKC B
activation O
acting O
on O
the O
X2 B
box I
of O
the O
DRA B
promoter I
and O
that O
selective O
inhibition O
of O
PKC B
enzymatic O
activity O
does O
not O
influence O
subcellular O
localization O
of O
expressed O
PKC B
isoenzymes I
. O

Together O
, O
these O
results O
show O
that O
activated O
HLA B
- I
DRA I
expression O
in O
response O
to O
TPA O
treatment O
is O
strictly O
dependent O
on O
PKC B
activation O
acting O
on O
the O
X2 B
box I
of O
the O
DRA B
promoter I
and O
that O
selective O
inhibition O
of O
PKC B
enzymatic O
activity O
does O
not O
influence O
subcellular O
localization O
of O
expressed O
PKC B
isoenzymes I
. O

These O
synthetic O
ligands O
specifically O
inhibit O
DNA O
- O
binding O
of O
each O
transcription B
factor I
and O
HIV O
type O
1 O
transcription O
in O
cell O
- O
free O
assays O
. O

Although O
bacterial O
lipopolysaccharides O
( O
LPS O
) O
and O
several O
other O
microbial O
agonists O
can O
bind O
to O
mCD14 B
( O
membrane B
CD14 I
) O
, O
a O
cell O
- O
surface O
receptor O
found O
principally O
on O
monocytes O
and O
neutrophils O
, O
host O
- O
derived O
mCD14 B
ligands O
are O
poorly O
defined O
. O

To O
differentiate O
whether O
the O
RA O
effect O
was O
mediated O
by O
RA B
receptors I
alpha I
, I
beta I
, I
and I
gamma I
, O
the O
expression O
of O
the O
retinoic B
acid I
receptors I
( O
RAR B
) O
was O
examined O
by O
reverse B
transcriptase I
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
. O

Recently O
, O
we O
have O
reported O
that O
the O
tumor B
necrosis I
factor I
and O
interleukin B
1 I
signaling O
pathways O
activate O
two O
kinases O
, O
IKK1 B
and O
IKK2 B
. O

IL B
- I
7 I
did O
not O
maintain O
v B
- I
Abl I
- O
mediated O
differentiation O
arrest O
of O
the O
pre O
- O
B O
cells O
, O
as O
activation O
of O
NF B
- I
kappaB I
and O
RAG B
gene I
transcription O
was O
unaffected O
by O
IL B
- I
7 I
. O

Functional O
analysis O
of O
the O
promoter O
by O
transient O
transfection O
assays O
indicated O
that O
synergistic O
action O
between O
an O
SP B
- I
1 I
- I
like I
element I
at O
- O
21 O
/ O
- O
12 O
, O
a O
GATA B
site I
at O
- O
59 O
/ O
- O
54 O
, O
and O
a O
novel B
regulatory I
element I
, O
CPRE B
( O
- O
GGACTACAG B
- O
) O
at O
- O
49 O
/ O
- O
41 O
, O
is O
essential O
for O
the O
promoter O
activity O
in O
murine O
erythroleukemia O
( O
MEL O
) O
cells O
. O

Nuclear B
receptors I
are O
important O
regulators O
of O
erythroid O
cell O
development O
. O

T O
lymphocytes O
from O
6 O
of O
the O
14 O
patients O
also O
exhibited O
an O
increased O
expression O
of O
the O
dual O
specificity B
phosphatase I
, O
map B
kinase I
phosphatase I
- I
1 I
( O
MKP B
- I
1 I
) O
. O

We O
studied O
the O
number O
of O
glucocorticoid B
receptors I
and O
dissociation O
constant O
in O
isolated O
human O
lymphocytes O
as O
well O
as O
blood O
concentrations O
of O
hormones O
produced O
by O
the O
hypothalamic O
- O
hypophyseal O
- O
adrenocortical O
system O
in O
three O
experimental O
series O
: O
at O
normal O
( O
17 O
subjects O
) O
, O
decreased O
( O
10 O
subjects O
, O
a O
360 O
- O
d O
head O
- O
down O
bed O
rest O
) O
and O
increased O
( O
8 O
subjects O
, O
physical O
exercise O
on O
bicycle O
ergometer O
) O
levels O
of O
motor O
activity O
. O

Uncoupling O
of O
nonreceptor O
tyrosine B
kinases I
from O
PLC B
- I
gamma1 I
in O
an O
SLP O
- O
76 O
- O
deficient O
T O
cell O
. O

Data O
obtained O
by O
electrophoretic O
mobility O
shift O
assay O
suggested O
that O
the O
activated B
Stat I
- I
3 I
protein I
associates O
with O
the O
human B
serum I
- I
inducible I
element I
( I
hSIE I
) I
DNA I
- I
probe I
derived O
from O
the O
interferon B
- I
gamma I
activated I
site I
( O
GAS B
) O
in O
the O
c B
- I
fos I
promoter I
, O
a O
common O
DNA O
sequence O
for O
Stat B
protein I
binding O
. O

We O
further O
demonstrate O
that O
0 O
. O
1 O
- O
0 O
. O
5 O
microM O
DMDTC O
inhibits O
intracellular O
IL B
- I
2 I
production O
and O
decreases O
surface O
expression O
of O
CD25 B
( O
the O
alpha B
subunit I
of O
the O
IL B
- I
2 I
receptor I
) O
in O
T O
cells O
stimulated O
with O
phorbol O
ester O
. O

Using O
deletion B
constructs I
, O
we O
have O
defined O
an O
active B
promoter I
region I
of O
1056 O
bp O
. O

To O
determine O
whether O
the O
acquisition O
of O
antitumor O
function O
during O
ex O
vivo O
activation O
is O
associated O
with O
modifications O
in O
signal O
transduction O
capacity O
, O
the O
protein O
tyrosine B
kinases I
p56lck B
and O
p59fyn B
and O
proteins O
of O
the O
NF B
- I
kappaB I
family I
were O
analyzed O
in O
tumor O
- O
draining O
LN O
T O
cells O
. O

In O
contrast O
, O
the O
cytoplasmic O
levels O
of O
c B
- I
Rel I
and O
Rel B
A I
were O
normal O
in O
freshly O
isolated O
tumor O
- O
draining O
LN O
, O
as O
was O
nuclear O
kappaB B
DNA O
- O
binding O
activity O
induced O
by O
anti B
- I
CD3 I
mAb I
or O
phorbol O
myristate O
acetate O
. O

BACKGROUND O
: O
The O
class B
II I
transactivator I
( O
CIITA B
) O
is O
a O
bi B
- I
or I
multifunctional I
domain I
protein I
that O
acts O
as O
a O
transcriptional B
activator I
and O
plays O
a O
critical O
role O
in O
the O
expression O
of O
MHC B
class I
II I
genes I
. O

Transient O
transfectants O
of O
the O
porcine O
B O
- O
cell O
line O
L23 O
with O
the O
mutated O
CIITA B
constructs I
were O
tested O
for O
the O
suppression O
of O
constitutive O
SLA O
- O
DR O
and O
SLA O
- O
DQ O
expression O
. O

Mononuclear O
phagocytes O
play O
an O
important O
role O
in O
atherosclerosis O
and O
its O
sequela O
plaque O
rupture O
in O
part O
by O
their O
secretion O
of O
matrix B
metalloproteinases I
( O
MMPs B
) O
, O
including O
MMP B
- I
9 I
. O

In O
addition O
, O
PPARgamma B
mRNA I
expression O
in O
U937 O
cells O
increased O
during O
phorbol O
12 O
- O
myristate O
13 O
acetate O
- O
induced O
differentiation O
. O

A O
recent O
study O
showed O
a O
MLL B
/ I
AF10 I
fusion I
in O
all O
cases O
of O
AML O
with O
t B
( I
10 I
; I
11 I
) I
and O
various O
breakpoints O
on O
chromosome B
11 I
ranging O
from O
q13 B
to O
q23 B
. O

Dominant B
negative I
mutants I
of O
NIK B
, O
IKKalpha B
, O
or O
IKKbeta B
substantially O
inhibited O
NF B
- I
kappaB I
activation O
by O
LMP1 B
or O
by O
each O
of O
its O
effector B
sites I
. O

In O
addition O
, O
transcriptional O
activity O
of O
IL B
- I
2 I
and O
metallothionein B
enhancer I
and I
promoter I
regions I
and O
transcription B
factors I
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
NF B
- I
AT I
were O
analyzed O
by O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
and O
electrophoretic O
mobility O
shift O
assays O
, O
respectively O
. O

In O
addition O
, O
transcriptional O
activity O
of O
IL B
- I
2 I
and O
metallothionein B
enhancer I
and I
promoter I
regions I
and O
transcription B
factors I
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
NF B
- I
AT I
were O
analyzed O
by O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
and O
electrophoretic O
mobility O
shift O
assays O
, O
respectively O
. O

Because O
the O
GATA B
- I
1 I
gene I
is O
located O
on O
the O
X B
chromosome I
, O
which O
is O
randomly O
inactivated O
in O
every O
cell O
, O
heterozygous O
females O
can O
bear O
either O
an O
active O
wild O
- O
type O
or O
mutant O
( O
referred O
to O
as O
GATA B
- I
1 I
. I
05 I
) O
GATA B
- I
1 I
allele O
, O
consequently O
leading O
to O
variable O
anemic O
severity O
. O

Differential O
regulation O
of O
the O
Janus B
kinase I
- B
STAT I
pathway O
and O
biologic O
function O
of O
IL B
- I
13 I
in O
primary O
human O
NK O
and O
T O
cells O
: O
a O
comparative O
study O
with O
IL B
- I
4 I
. O

Differential O
regulation O
of O
the O
Janus B
kinase I
- B
STAT I
pathway O
and O
biologic O
function O
of O
IL B
- I
13 I
in O
primary O
human O
NK O
and O
T O
cells O
: O
a O
comparative O
study O
with O
IL B
- I
4 I
. O

We O
observed O
that O
Abs O
directed O
against O
unique O
domains O
of O
STAT6 B
have O
differential O
effects O
on O
complexes O
in O
T O
cells O
but O
not O
in O
NK O
cells O
, O
suggesting O
different O
STAT6 B
isoforms I
. O

To O
study O
the O
influence O
of O
NFkappaB B
activity O
on O
apoptosis O
mediated O
by O
TRAIL B
, O
CD95 O
, O
TNFalpha B
, O
or O
doxorubicin O
, O
NFkappaB B
activation O
was O
inhibited O
using O
the O
proteasome B
inhibitor O
N O
- O
acetyl O
- O
L O
- O
leucinyl O
- O
L O
- O
leucinyl O
- O
L O
- O
norleucinal O
or O
transient O
overexpression O
of O
mutant B
IkappaBalpha I
. O

However O
, O
its O
interactions O
with O
these O
histone B
acetyltransferases I
are O
not O
equivalent O
, O
as O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
utilize O
EKLF B
as O
a O
substrate O
for O
in O
vitro O
acetylation O
within O
its O
trans O
- O
activation B
region I
. O

However O
, O
its O
interactions O
with O
these O
histone B
acetyltransferases I
are O
not O
equivalent O
, O
as O
CBP B
and O
p300 B
, O
but O
not O
P B
/ I
CAF I
, O
utilize O
EKLF B
as O
a O
substrate O
for O
in O
vitro O
acetylation O
within O
its O
trans O
- O
activation B
region I
. O

There O
were O
no O
notable O
differences O
in O
the O
ER B
transcripts I
between O
patients O
and O
healthy O
controls O
. O

Variant O
receptor O
transcripts O
lacking O
exon B
5 I
or O
exon B
7 I
, O
which O
encodes O
the O
hormone O
binding O
domain O
, O
were O
identified O
in O
the O
majority O
of O
the O
cells O
. O

Variant O
receptor O
transcripts O
lacking O
exon B
5 I
or O
exon B
7 I
, O
which O
encodes O
the O
hormone O
binding O
domain O
, O
were O
identified O
in O
the O
majority O
of O
the O
cells O
. O

These O
stimuli O
also O
induced O
the O
stress O
- O
activated O
kinase O
pathway O
( O
SAPK B
/ B
JNK I
) O
, O
which O
was O
required O
for O
the O
maximal O
induction O
of O
apoptosis O
. O

These O
findings O
suggest O
that O
LTR B
sequence I
changes O
can O
significantly O
affect O
basal O
LTR B
function O
and O
transcription B
factor I
recruitment O
, O
which O
may O
, O
in O
turn O
, O
alter O
the O
course O
of O
viral O
replication O
in O
cells O
of O
CNS O
and O
immune O
system O
origin O
. O

These O
findings O
suggest O
that O
LTR B
sequence I
changes O
can O
significantly O
affect O
basal O
LTR B
function O
and O
transcription B
factor I
recruitment O
, O
which O
may O
, O
in O
turn O
, O
alter O
the O
course O
of O
viral O
replication O
in O
cells O
of O
CNS O
and O
immune O
system O
origin O
. O

Molecular O
genetic O
characterization O
of O
the O
variant B
allele I
can O
serve O
as O
a O
primary O
tool O
for O
diagnosis O
and O
subsequent O
therapy O
, O
and O
can O
provide O
a O
basis O
for O
distinguishing O
heterozygous O
carriers O
in O
familial O
androgen O
resistance O
. O

Elf B
- I
1 I
binds O
exclusively O
to O
the O
underphosphorylated O
form O
of O
Rb B
and O
fails O
to O
bind O
to O
Rb B
mutants I
derived O
from O
patients O
with O
retinoblastoma O
. O

Transcriptional O
activation O
of O
the O
macrophage B
colony I
- I
stimulating I
factor I
gene I
by O
IL B
- I
2 I
is O
associated O
with O
secretion O
of O
bioactive O
macrophage B
colony I
- I
stimulating I
factor I
protein I
by O
monocytes O
and O
involves O
activation O
of O
the O
transcription B
factor I
NF B
- I
kappa I
B I
. O

Transcriptional O
activation O
of O
the O
M B
- I
CSF I
gene I
by O
IL B
- I
2 I
is O
preceded O
by O
enhanced O
binding O
activity O
of O
the O
transcription B
factor I
NF B
- I
kappa I
B I
to O
its O
recognition O
sequence O
in O
the O
5 O
' O
regulatory O
enhancer O
region O
of O
the O
M B
- I
CSF I
gene I
. O

We O
localized O
the O
LAM O
- O
, O
lipopolysaccharide O
( O
LPS O
) O
- O
, O
and O
TNF B
- I
alpha I
- B
inducible I
promoter I
activity O
to O
a O
- O
131 O
/ O
+ O
15 O
( O
positions O
- O
131 O
to O
+ O
15 O
) O
DNA O
fragment O
of O
the O
IL B
- I
1 I
beta I
gene I
by O
deletion O
analysis O
and O
chloramphenicol B
acetyltransferase I
assay O
. O

Additionally O
, O
Nef O
expressing O
cells O
were O
transiently O
transfected O
with O
a O
plasmid O
in O
which O
HIV B
- I
1 I
AP I
- I
1 I
DNA I
recognition I
sequences I
were O
cloned O
downstream O
of O
the O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
gene O
. O

Two O
transcriptional O
elements O
in O
the O
TSP B
1 I
promoter O
, O
a O
distal O
element O
at O
- O
1280 O
and O
a O
proximal O
element O
at O
- O
65 O
, O
were O
required O
for O
the O
response O
of O
the O
human O
TSP O
1 O
gene O
to O
serum O
. O

Here O
we O
have O
investigated O
the O
transcriptional O
regulation O
of O
the O
gamma B
chain I
gene O
by O
analyzing O
the O
2 B
. I
5 I
- I
kilobase I
sequence I
upstream O
of O
the O
transcription O
start O
site O
. O

However O
, O
the O
tissue O
specificity O
of O
this O
promoter B
is O
only O
partial O
because O
it O
is O
active O
in O
all O
of O
the O
hematopoietic O
cells O
tested O
here O
, O
regardless O
of O
whether O
they O
constitutively O
express O
Fc O
epsilon O
RI O
- O
gamma B
chain I
transcripts O
. O

We O
have O
demonstrated O
earlier O
that O
the O
crosslinkage O
of O
the O
CD3 B
/ I
TCR I
complex I
with O
the O
CD2 B
antigen I
results O
in O
the O
proliferation O
of O
normal O
human O
T O
cells O
. O

This O
was O
accompanied O
by O
downregulation O
of O
two O
transcription B
factors I
normally O
expressed O
in O
erythroid O
, O
mast O
and O
megakaryocyte O
lineages O
. O

Northern O
analysis O
demonstrated O
coordinate O
downregulation O
of O
alpha B
globin I
and O
gamma B
globin I
in O
addition O
to O
the O
two O
lineage O
- O
restricted O
transcription B
factors I
, O
SCL B
and O
GATA B
- I
1 I
. O

Northern O
analysis O
demonstrated O
coordinate O
downregulation O
of O
alpha B
globin I
and O
gamma B
globin I
in O
addition O
to O
the O
two O
lineage O
- O
restricted O
transcription B
factors I
, O
SCL B
and O
GATA B
- I
1 I
. O

Northern O
analysis O
demonstrated O
coordinate O
downregulation O
of O
alpha B
globin I
and O
gamma B
globin I
in O
addition O
to O
the O
two O
lineage O
- O
restricted O
transcription B
factors I
, O
SCL B
and O
GATA B
- I
1 I
. O

Surface O
marker O
analysis O
showed O
that O
HMBA O
- O
induced O
cells O
expressed O
reduced O
levels O
of O
glycophorin B
A I
, O
CD5 B
, O
CD7 B
and O
CD11b B
. O

To O
determine O
whether O
the O
defect O
in O
the O
patient O
' O
s O
T O
lymphocytes O
involved O
a O
trans B
- I
acting I
factor I
common O
to O
the O
affected O
lymphokine B
genes I
, O
we O
examined O
the O
ability O
of O
nuclear B
factors I
from O
the O
patient O
' O
s O
T O
lymphocytes O
to O
bind O
response O
elements O
present O
in O
the O
regulatory B
region I
of O
IL2 B
. O

To O
determine O
whether O
the O
defect O
in O
the O
patient O
' O
s O
T O
lymphocytes O
involved O
a O
trans B
- I
acting I
factor I
common O
to O
the O
affected O
lymphokine B
genes I
, O
we O
examined O
the O
ability O
of O
nuclear B
factors I
from O
the O
patient O
' O
s O
T O
lymphocytes O
to O
bind O
response O
elements O
present O
in O
the O
regulatory B
region I
of O
IL2 B
. O

To O
determine O
whether O
the O
defect O
in O
the O
patient O
' O
s O
T O
lymphocytes O
involved O
a O
trans B
- I
acting I
factor I
common O
to O
the O
affected O
lymphokine B
genes I
, O
we O
examined O
the O
ability O
of O
nuclear B
factors I
from O
the O
patient O
' O
s O
T O
lymphocytes O
to O
bind O
response O
elements O
present O
in O
the O
regulatory B
region I
of O
IL2 B
. O

In O
contrast O
, O
the O
binding O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
to O
its O
response O
element O
in O
the O
IL2 B
enhancer I
and O
to O
an O
NF B
- I
AT I
- I
like I
response I
element I
present O
in O
the O
IL4 B
enhancer I
was O
abnormal O
. O

In O
contrast O
, O
the O
binding O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
to O
its O
response O
element O
in O
the O
IL2 B
enhancer I
and O
to O
an O
NF B
- I
AT I
- I
like I
response I
element I
present O
in O
the O
IL4 B
enhancer I
was O
abnormal O
. O

Instead O
, O
they O
form O
tight O
complexes O
with O
two O
different O
classes O
of O
abundant O
cytosolic B
receptors I
called O
immunophilins B
upon O
entering O
the O
cell O
, O
and O
consequently O
inhibit O
their O
peptidyl B
prolyl I
cis I
- I
trans I
isomerase I
activities O
. O

p105 B
and O
p98 B
precursor B
proteins I
play O
an O
active O
role O
in O
NF B
- I
kappa I
B I
- O
mediated O
signal O
transduction O
. O

The O
eukaryotic O
transcription B
factor I
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
participates O
in O
many O
parts O
of O
the O
genetic O
program O
mediating O
T O
lymphocyte O
activation O
and O
growth O
. O

A O
cell B
- I
type I
- I
independent I
lipopolysaccharide I
( I
LPS I
) I
- I
responsive I
enhancer I
element I
located O
between O
- B
3757 I
and I
- I
2729 I
bp I
upstream I
from O
the O
transcription B
start I
site I
( O
cap B
site I
) O
consisted O
of O
at O
least O
six O
discrete O
subregions O
which O
were O
essential O
to O
the O
maximal O
induction O
by O
LPS O
in O
transfected O
monocytes O
. O

The O
3H O
- O
thymidine O
uptake O
procedure O
was O
employed O
, O
incorporating O
multiple O
microbiological B
antigens I
. O

Expression O
of O
PILOT B
, O
a O
putative O
transcription B
factor I
, O
requires O
two O
signals O
and O
is O
cyclosporin O
A O
sensitive O
in O
T O
cells O
. O

The O
PILOT B
protein O
has O
a O
calculated O
M O
( O
r O
) O
of O
42 O
. O
6 O
kDa O
and O
contains O
three O
zinc B
fingers I
of O
the O
C2H2 B
- I
type I
at O
the O
carboxyl B
- I
terminus I
which O
are O
highly O
homologous O
to O
the O
zinc B
finger I
regions I
of O
the O
transcription B
factors I
EGR1 B
, O
EGR2 B
, O
and O
pAT B
133 I
. O

The O
PILOT B
protein O
has O
a O
calculated O
M O
( O
r O
) O
of O
42 O
. O
6 O
kDa O
and O
contains O
three O
zinc B
fingers I
of O
the O
C2H2 B
- I
type I
at O
the O
carboxyl B
- I
terminus I
which O
are O
highly O
homologous O
to O
the O
zinc B
finger I
regions I
of O
the O
transcription B
factors I
EGR1 B
, O
EGR2 B
, O
and O
pAT B
133 I
. O

The O
PILOT B
protein O
has O
a O
calculated O
M O
( O
r O
) O
of O
42 O
. O
6 O
kDa O
and O
contains O
three O
zinc B
fingers I
of O
the O
C2H2 B
- I
type I
at O
the O
carboxyl B
- I
terminus I
which O
are O
highly O
homologous O
to O
the O
zinc B
finger I
regions I
of O
the O
transcription B
factors I
EGR1 B
, O
EGR2 B
, O
and O
pAT B
133 I
. O

NF B
- I
kappa I
B I
is O
a O
pleiotropic B
regulator I
of O
a O
variety O
of O
genes O
implicated O
in O
the O
cellular O
response O
to O
injury O
. O

Transcriptional O
regulation O
of O
interleukin B
3 I
( O
IL3 B
) O
in O
primary O
human O
T O
lymphocytes O
. O

We O
have O
previously O
found O
that O
NFKB2 B
( I
p49 I
/ I
p52 I
) I
acts O
in O
concert O
with O
RelA B
( I
p65 I
) I
to O
stimulate O
the O
HIV B
enhancer I
in O
Jurkat O
T O
- O
leukemia O
cells O
. O

Somewhat O
unexpectedly O
, O
the O
constitutive O
p21ras B
activity O
did O
not O
cause O
an O
increased O
DNA O
binding O
of O
transcription B
factors I
PEA1 B
( O
AP1 B
) O
, O
PEA3 B
, O
Oct B
- I
2 I
or O
NF B
- I
kB I

Competition O
with O
an O
AP B
- I
1 I
motif I
or O
with O
anti B
- I
Jun I
and O
anti B
- I
Fos I
antibodies I
abolished O
binding O
to O
the O
NFAT B
motif I
in O
both O
T O
and O
B O
cells O
, O
indicating O
that O
Jun O
and O
Fos O
are O
critical O
for O
NFAT B
complex I
formation O
in O
both O
cell O
types O
. O

Competition O
with O
an O
AP B
- I
1 I
motif I
or O
with O
anti B
- I
Jun I
and O
anti B
- I
Fos I
antibodies I
abolished O
binding O
to O
the O
NFAT B
motif I
in O
both O
T O
and O
B O
cells O
, O
indicating O
that O
Jun O
and O
Fos O
are O
critical O
for O
NFAT B
complex I
formation O
in O
both O
cell O
types O
. O

However O
, O
when O
combined O
with O
unstimulated O
B O
or O
T O
cell O
extracts O
, O
full O
- O
length O
, O
but O
not O
truncated O
, O
Jun O
/ O
Fos O
heterodimers O
were O
able O
to O
form O
an O
NFAT B
complex I
, O
indicating O
the O
presence O
of O
a O
constitutively B
expressed I
nuclear I
factor I
( O
s O
) O
in O
B O
and O
T O
cells O
necessary O
for O
the O
formation O
of O
the O
NFAT B
complex I
in O
both O
cell O
types O
. O

However O
, O
when O
combined O
with O
unstimulated O
B O
or O
T O
cell O
extracts O
, O
full O
- O
length O
, O
but O
not O
truncated O
, O
Jun O
/ O
Fos O
heterodimers O
were O
able O
to O
form O
an O
NFAT B
complex I
, O
indicating O
the O
presence O
of O
a O
constitutively B
expressed I
nuclear I
factor I
( O
s O
) O
in O
B O
and O
T O
cells O
necessary O
for O
the O
formation O
of O
the O
NFAT B
complex I
in O
both O
cell O
types O
. O

Differential O
autoregulation O
of O
glucocorticoid B
receptor I
expression O
in O
human O
T O
- O
and O
B O
- O
cell O
lines O
. O

In O
contrast O
to O
the O
decrease O
in O
GR B
mRNA I
seen O
in O
IM O
- O
9 O
cells O
after O
treatment O
with O
1 O
microM O
dexamethasone O
for O
16 O
- O
18 O
h O
, O
treatment O
of O
6TG1 O
. O
1 O
cells O
resulted O
in O
an O
8 O
- O
fold O
increase O
in O
GR B
mRNA I
, O
as O
determined O
by O
Northern O
blot O
and O
RNase B
protection O
analysis O
, O
with O
a O
corresponding O
3 O
- O
to O
4 O
- O
fold O
increase O
in O
GR B
protein I
. O

In O
contrast O
to O
the O
decrease O
in O
GR B
mRNA I
seen O
in O
IM O
- O
9 O
cells O
after O
treatment O
with O
1 O
microM O
dexamethasone O
for O
16 O
- O
18 O
h O
, O
treatment O
of O
6TG1 O
. O
1 O
cells O
resulted O
in O
an O
8 O
- O
fold O
increase O
in O
GR B
mRNA I
, O
as O
determined O
by O
Northern O
blot O
and O
RNase B
protection O
analysis O
, O
with O
a O
corresponding O
3 O
- O
to O
4 O
- O
fold O
increase O
in O
GR B
protein I
. O

In O
contrast O
to O
the O
decrease O
in O
GR B
mRNA I
seen O
in O
IM O
- O
9 O
cells O
after O
treatment O
with O
1 O
microM O
dexamethasone O
for O
16 O
- O
18 O
h O
, O
treatment O
of O
6TG1 O
. O
1 O
cells O
resulted O
in O
an O
8 O
- O
fold O
increase O
in O
GR B
mRNA I
, O
as O
determined O
by O
Northern O
blot O
and O
RNase B
protection O
analysis O
, O
with O
a O
corresponding O
3 O
- O
to O
4 O
- O
fold O
increase O
in O
GR B
protein I
. O

Induction O
of O
CD8 B
antigen I
and O
suppressor O
activity O
by O
glucocorticoids O
in O
a O
CEM O
human O
leukemic O
cell O
clone O
. O

IFN B
- O
MCP O
was O
not O
inhibited O
by O
infection O
with O
dl343 O
, O
despite O
the O
production O
of O
large O
amounts O
of O
both O
early O
( O
E1B B
, O
p55 B
) O
and O
late O
( O
hexon B
) O
Ad B
proteins I
. O

Nuclear B
factor I
of I
activated I
T I
cells I
( O
NF B
- I
AT I
) O
is O
a O
transcriptional B
activator I
involved O
in O
the O
induction O
of O
IL B
- I
2 I
gene O
expression O
. O

Mutual O
regulation O
of O
the O
transcriptional B
activator I
NF B
- I
kappa I
B I
and O
its O
inhibitor O
, O
I B
kappa I
B I
- I
alpha I
. O

In O
previous O
transfection O
analyses O
using O
the O
chloramphenicol B
acetyltransferase I
reporter B
gene I
system O
, O
we O
determined O
that O
linker O
substitution O
( O
LS O
) O
mutations O
between O
- B
201 I
and I
- I
130 I
( O
relative O
to O
the O
transcription O
start O
site O
) O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
caused O
moderate O
decreases O
in O
LTR B
transcriptional O
activity O
in O
a O
T O
- O
cell O
line O
( O
S O
. O
L O
. O
Zeichner O
, O
J O
. O
Y O
. O
H O
. O
Kim O
, O
and O
J O
. O
C O
. O
Alwine O
, O
J O
. O
Virol O
. O
65 O
: O
2436 O
- O
2444 O
, O
1991 O
) O
. O

In O
previous O
transfection O
analyses O
using O
the O
chloramphenicol B
acetyltransferase I
reporter B
gene I
system O
, O
we O
determined O
that O
linker O
substitution O
( O
LS O
) O
mutations O
between O
- B
201 I
and I
- I
130 I
( O
relative O
to O
the O
transcription O
start O
site O
) O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
caused O
moderate O
decreases O
in O
LTR B
transcriptional O
activity O
in O
a O
T O
- O
cell O
line O
( O
S O
. O
L O
. O
Zeichner O
, O
J O
. O
Y O
. O
H O
. O
Kim O
, O
and O
J O
. O
C O
. O
Alwine O
, O
J O
. O
Virol O
. O
65 O
: O
2436 O
- O
2444 O
, O
1991 O
) O
. O

If O
GATA O
- O
1 O
- O
red O
cells O
were O
available O
, O
the O
analyses O
would O
involve O
the O
actual O
transcription O
of O
or O
chromatin O
structure O
surrounding O
the O
globin B
genes I
. O

Groups O
1 O
and O
2 O
have O
a O
serine B
- I
rich I
region I
and O
an O
` O
` O
arginine B
element I
` O
` O
( O
RRLPIF B
) O
at O
the O
carboxyl B
terminus I
. O

Groups O
1 O
and O
2 O
have O
a O
serine B
- I
rich I
region I
and O
an O
` O
` O
arginine B
element I
` O
` O
( O
RRLPIF B
) O
at O
the O
carboxyl B
terminus I
. O

One O
enigmatic O
aspect O
of O
GATA B
factor I
expression O
is O
that O
several O
GATA B
proteins I
, O
which O
ostensibly O
share O
the O
same O
DNA B
- I
binding I
site I
specificity O
, O
are O
coexpressed O
in O
erythroid O
cells O
. O

One O
enigmatic O
aspect O
of O
GATA B
factor I
expression O
is O
that O
several O
GATA B
proteins I
, O
which O
ostensibly O
share O
the O
same O
DNA B
- I
binding I
site I
specificity O
, O
are O
coexpressed O
in O
erythroid O
cells O
. O

Within O
this O
region O
, O
we O
define O
a O
minimal B
promoter I
( O
- O
62 O
to O
+ O
54 O
) O
that O
displays O
erythroid O
- O
specific O
activity O
and O
contains O
two O
DNA O
binding O
sites O
. O

Mutations O
and O
deletions O
of O
both O
sites O
indicate O
that O
only O
the O
association O
of O
CCACC B
/ I
Sp1 I
and O
GATA B
binding I
sites I
can O
drive O
efficient O
and O
tissue O
- O
specific O
expression O
of O
this O
R B
- I
PK I
minimal B
promoter I
. O

To O
test O
this O
hypothesis O
, O
a O
more O
sensitive O
and O
specific O
polymerase O
chain O
reaction O
( O
PCR O
) O
assay O
was O
developed O
to O
detect O
adenovirus B
DNA I
. O

HIV O
- O
1 O
activation O
and O
expression O
was O
quantitated O
by O
reverse B
transcriptase I
assay O
. O

A O
reporter B
gene I
under O
the O
control O
of O
a O
T B
- I
cell I
antigen I
receptor I
element I
was O
activated O
in O
Jurkat O
cells O
by O
antigen O
receptor O
triggering O
or O
by O
a O
combination O
of O
phorbol O
myristate O
acetate O
, O
which O
activates O
protein B
kinase I
C I
, O
and O
a O
calcium O
ionophore O
. O

Both O
these O
signals O
were O
necessary O
for O
expression O
of O
the O
reporter B
gene I
. O

When O
co O
- O
transfected O
with O
a O
construct O
capable O
of O
overexpressing O
the O
tyrosine B
kinase I
p59fyn B
, O
the O
reporter B
gene I
was O
activated O
by O
PMA B
alone O
. O

When O
co O
- O
transfected O
with O
a O
construct O
capable O
of O
overexpressing O
the O
tyrosine B
kinase I
p59fyn B
, O
the O
reporter B
gene I
was O
activated O
by O
PMA B
alone O
. O

Globin B
chains I
( O
alpha B
, O
beta B
and O
gamma B
) O
were O
clearly O
detectable O
by O
affinity O
chromatography O
in O
UT B
- I
7 I
Epo I
but O
not O
in O
UT O
- O
7 O
cells O
. O

Recent O
isolation O
of O
the O
CD11b B
promoter I
shows O
that O
92 O
base O
pairs O
( O
bp O
) O
of O
5 B
' I
- I
flanking I
DNA I
are O
sufficient O
to O
direct O
myeloid O
- O
specific O
expression O
of O
a O
reporter B
gene I
. O

Recent O
isolation O
of O
the O
CD11b B
promoter I
shows O
that O
92 O
base O
pairs O
( O
bp O
) O
of O
5 B
' I
- I
flanking I
DNA I
are O
sufficient O
to O
direct O
myeloid O
- O
specific O
expression O
of O
a O
reporter B
gene I
. O

R7 O
- O
57 O
reporter O
cells O
, O
on O
the O
other O
hand O
, O
signaled O
induced O
activity O
of O
the O
lytic B
origin I
of I
EBV I
replication I
( O
ori B
Lyt I
) O
. O

This O
indicates O
an O
increase O
in O
either O
episomal B
DNA I
or O
concatameric B
linear I
DNA I
. O

Cell O
- O
specific O
bifunctional O
role O
of O
Jun B
oncogene I
family I
members I
on O
glucocorticoid B
receptor I
- O
dependent O
transcription O
. O

Here O
we O
report O
that O
this O
interference O
is O
cell O
specific O
, O
as O
TPA O
augmented O
dexamethasone O
- O
induced O
transcriptional O
activation O
of O
the O
MMTV B
LTR I
in O
several O
T O
cell O
lines O
but O
was O
inhibitory O
in O
NIH O
- O
3T3 O
fibroblasts O
. O

Cross O
competition O
experiments O
with O
an O
octamer O
sequence O
from O
the O
Ig O
heavy O
chain O
promoter O
, O
the O
BAT B
box I
, O
and O
a O
TA O
- O
rich O
sequence O
present O
in O
the O
CD21 B
promoter I
revealed O
that O
all O
three O
sequences O
bound O
the O
same O
nuclear B
proteins I
suggesting O
that O
the O
BAT B
box I
binding I
proteins I
were O
Oct B
- I
1 I
and O
Oct B
- I
2 I
. O

Cross O
competition O
experiments O
with O
an O
octamer O
sequence O
from O
the O
Ig O
heavy O
chain O
promoter O
, O
the O
BAT B
box I
, O
and O
a O
TA O
- O
rich O
sequence O
present O
in O
the O
CD21 B
promoter I
revealed O
that O
all O
three O
sequences O
bound O
the O
same O
nuclear B
proteins I
suggesting O
that O
the O
BAT B
box I
binding I
proteins I
were O
Oct B
- I
1 I
and O
Oct B
- I
2 I
. O

Cross O
competition O
experiments O
with O
an O
octamer O
sequence O
from O
the O
Ig O
heavy O
chain O
promoter O
, O
the O
BAT B
box I
, O
and O
a O
TA O
- O
rich O
sequence O
present O
in O
the O
CD21 B
promoter I
revealed O
that O
all O
three O
sequences O
bound O
the O
same O
nuclear B
proteins I
suggesting O
that O
the O
BAT B
box I
binding I
proteins I
were O
Oct B
- I
1 I
and O
Oct B
- I
2 I
. O

Despite O
this O
lower O
affinity O
, O
a O
trimer O
of O
the O
BAT B
box I
sequence I
was O
as O
efficiently O
transactivated O
by O
an O
Oct B
- I
2 I
expression I
vector I
as O
was O
a O
trimer O
of O
the O
octamer B
sequence I
in O
HeLa O
cells O
. O

One O
cDNA B
clone I
of O
a O
primary O
response O
gene O
, O
expressed O
upon O
macrophage O
differentiation O
, O
encoded O
for O
Egr B
- I
1 I
, O
a O
zinc B
finger I
transcription I
factor I
. O

Agents O
which O
increased O
cAMP O
levels O
, O
including O
cholera O
toxin O
, O
pertussis O
toxin O
, O
dibutyryl O
cAMP O
, O
and O
isoproterenol O
mimicked O
the O
actions O
of O
MM B
- I
LDL I
. O

Cotransfection O
of O
an O
hGATA B
- I
3 I
expression I
plasmid I
with O
a O
reporter B
plasmid I
whose O
transcription O
is O
directed O
by O
the O
HIV B
- I
1 I
LTR I
resulted O
in O
6 O
- O
to O
10 O
- O
fold O
stimulation O
of O
LTR B
- O
mediated O
transcription O
, O
whereas O
site O
specific O
mutation O
of O
these O
GATA B
sites I
resulted O
in O
virtual O
abrogation O
of O
the O
activation O
by O
hGATA B
- I
3 I
. O

Cotransfection O
of O
an O
hGATA B
- I
3 I
expression I
plasmid I
with O
a O
reporter B
plasmid I
whose O
transcription O
is O
directed O
by O
the O
HIV B
- I
1 I
LTR I
resulted O
in O
6 O
- O
to O
10 O
- O
fold O
stimulation O
of O
LTR B
- O
mediated O
transcription O
, O
whereas O
site O
specific O
mutation O
of O
these O
GATA B
sites I
resulted O
in O
virtual O
abrogation O
of O
the O
activation O
by O
hGATA B
- I
3 I
. O

Partial O
amino O
acid O
sequences O
obtained O
from O
purified O
EBF B
were O
used O
to O
isolate O
cDNA B
clones I
, O
which O
by O
multiple O
criteria O
encode O
EBF B
. O

Deletions O
delineated O
a O
carboxy B
- I
terminal I
dimerization I
region I
containing O
two O
repeats O
of O
15 O
amino O
acids O
that O
show O
similarity O
with O
the O
dimerization B
domains I
of O
basic B
- I
helix I
- I
loop I
- I
helix I
proteins I
. O

The O
detection O
of O
this O
protein O
selectively O
in O
extracts O
of O
lymphoid O
cells O
correlates O
with O
the O
presence O
of O
the O
E B
box I
- O
binding O
activity O
LEF1 B
/ I
BCF1 I
in O
these O
cells O
; O
this O
binding O
activity O
was O
previously O
shown O
to O
be O
efficiently O
recognized O
by O
antiserum O
directed O
against O
E2A B
gene I
products I
. O

Furthermore O
, O
we O
evaluated O
the O
mineralocorticoid B
receptor I
( O
MR B
) O
count O
in O
mononuclear O
leukocytes O
in O
the O
2 O
groups O
. O

The O
divergent O
effects O
of O
hemin O
and O
TPA O
on O
gene O
expression O
in O
K562 O
cells O
are O
mediated O
, O
in O
part O
, O
by O
their O
contrasting O
effects O
on O
the O
transcription B
factor I
NF B
- I
E2 I
. O

The O
CD19 B
protein I
is O
expressed O
on O
the O
surface O
of O
all O
B O
- O
lymphoid O
cells O
with O
the O
exception O
of O
terminally O
differentiated O
plasma O
cells O
and O
has O
been O
implicated O
as O
a O
signal O
- O
transducing O
receptor O
in O
the O
control O
of O
proliferation O
and O
differentiation O
. O

In O
addition O
, O
BSAP B
was O
found O
to O
be O
the O
only O
abundant O
DNA O
- O
binding O
activity O
of O
B O
- O
cell O
nuclear O
extracts O
that O
interacts O
with O
the O
CD19 B
promoter I
. O

Based O
on O
these O
results O
we O
estimate O
a O
5 O
- O
10 O
% O
difference O
in O
virus O
production O
of O
the O
LTR B
variants I
when O
compared O
to O
that O
of O
wild O
- O
type O
. O

The O
helix B
- I
loop I
- I
helix I
( I
HLH I
) I
proteins I
are O
a O
family O
of O
transcription B
factors I
that O
include O
proteins O
critical O
to O
differentiation O
and O
development O
in O
species O
ranging O
from O
plants O
to O
mammals O
. O

Glucocorticoid B
receptor I
in O
patients O
with O
lupus O
nephritis O
: O
relationship O
between O
receptor O
levels O
in O
mononuclear O
leukocytes O
and O
effect O
of O
glucocorticoid O
therapy O
. O

We O
investigated O
the O
clinical O
significance O
of O
glucocorticoid B
receptor I
determination O
in O
20 O
patients O
with O
systemic O
lupus O
erythematosus O
( O
SLE O
) O
who O
afterwards O
developed O
nephrotic O
syndrome O
. O

Improvement O
in O
urinary O
protein O
excretion O
and O
in O
disease O
activity O
, O
which O
was O
scored O
according O
to O
the O
SLE O
Disease O
Activity O
Index O
system O
of O
the O
University O
of O
Toronto O
, O
closely O
related O
to O
the O
glucocorticoid B
receptor I
concentrations O
in O
MNL O
isolated O
from O
the O
corresponding O
patients O
. O

We O
conclude O
that O
a O
specific O
nuclear O
translocation O
mechanism O
exists O
for O
calcitriol O
in O
both O
cell O
types O
examined O
, O
most O
likely O
due O
to O
translocation O
of O
receptor B
proteins I
after O
hormone O
binding O
. O

The O
long B
terminal I
repeat I
( I
LTR I
) I
region I
of O
HIV B
proviral I
DNA I
contains O
binding O
sites O
for O
nuclear B
factor I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
and O
this O
transcriptional B
activator I
appears O
to O
regulate O
HIV O
activation O
. O

REV B
LTRs I
work O
efficiently O
in O
human O
lymphoid O
cells O
, O
and O
are O
viable O
alternatives O
to O
promoters B
commonly O
used O
for O
expression O
of O
cloned B
genes I
. O

REV B
LTRs I
work O
efficiently O
in O
human O
lymphoid O
cells O
, O
and O
are O
viable O
alternatives O
to O
promoters B
commonly O
used O
for O
expression O
of O
cloned B
genes I
. O

Treatment O
of O
human O
B O
lymphocytes O
with O
an O
optimal O
concentration O
of O
okadaic O
acid O
, O
an O
inhibitor O
of O
phosphatases B
1 I
and I
2A I
, O
resulted O
in O
the O
induction O
of O
the O
transcription B
factor I
, O
AP B
- I
1 I
and O
a O
marked O
increase O
in O
NF B
- I
kappa I
B I
levels O
. O

These O
data O
show O
that O
aged O
subjects O
have O
reductions O
of O
corticosteroid B
receptors I
that O
are O
not O
associated O
with O
increase O
of O
related O
steroids O
and O
that O
this O
situation O
probably O
represents O
a O
concomitant O
of O
the O
normal O
aging O
process O
. O

IL B
- I
4 I
secreted O
by O
activated O
T O
cells O
is O
a O
pleiotropic B
cytokine I
affecting O
growth O
and O
differentiation O
of O
diverse O
cell O
types O
such O
as O
T O
cells O
, O
B O
cells O
, O
and O
mast O
cells O
. O

A O
T B
cell I
- I
specific I
protein I
Neg B
- I
1 I
and O
a O
ubiquitous B
protein I
Neg B
- I
2 I
binding O
to O
NRE B
- I
I I
and O
NRE B
- I
II I
, O
respectively O
, O
were O
identified O
. O

The O
addition O
of O
antisense O
oligonucleotides O
to O
c B
- I
fos I
significantly O
inhibited O
IL B
6 I
- O
induced O
IgM B
production O
by O
SKW O
6 O
. O
4 O
cells O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
whereas O
control O
oligonucleotides O
had O
no O
inhibitory O
effect O
. O

In O
this O
article O
, O
transcriptional O
regulation O
of O
the O
archetypal B
T I
- I
cell I
- I
specific I
gene I
, O
alpha B
TCR I
, O
is O
discussed O
. O

Analysis O
of O
the O
p50 B
and O
p65 B
subunits I
of O
the O
NF B
- I
kappa I
B I
transcription I
factor I
complex I
has O
revealed O
that O
both O
proteins O
can O
interact O
with O
related O
DNA O
sequences O
through O
either O
homo O
- O
or O
heterodimer O
formation O
. O

Immunoglobulin B
molecules I
on O
the O
surface O
of O
a O
B O
lymphocyte O
are O
the O
endogenous O
` O
` O
receptors O
' O
' O
to O
which O
specific O
antigens O
bind O
. O

Because O
of O
the O
efficient O
binding O
of O
TG B
by O
surrogate B
receptors I
on O
non O
- O
T O
cells O
, O
we O
assessed O
the O
ability O
of O
such O
cells O
to O
present O
TG B
to O
T O
cells O
. O

GM2 B
defines O
a O
binding B
site I
for O
protein O
( O
s O
) O
whose O
binding O
is O
inducible O
by O
PMA O
. O

In O
vivo O
footprint O
analysis O
of O
the O
HLA B
- I
DRA I
gene I
promoter I
: O
cell O
- O
specific O
interaction O
at O
the O
octamer B
site I
and O
up O
- O
regulation O
of O
X O
box O
binding O
by O
interferon B
gamma I
. O

In O
vivo O
footprint O
analysis O
of O
the O
HLA B
- I
DRA I
gene I
promoter I
: O
cell O
- O
specific O
interaction O
at O
the O
octamer B
site I
and O
up O
- O
regulation O
of O
X O
box O
binding O
by O
interferon B
gamma I
. O

Therefore O
, O
we O
describe O
a O
microtitre O
assay O
system O
for O
glucocorticoid B
receptors I
which O
is O
a O
whole O
- O
cell O
competitive O
binding O
radioassay O
using O
[ O
3H O
] O
- O
dexamethasone O
as O
radioligand O
. O

Thus O
enabled O
to O
perform O
the O
test O
on O
multiple O
blood O
samples O
in O
parallel O
, O
we O
investigated O
cardiac O
infarction O
patients O
over O
a O
12 O
- O
day O
period O
to O
test O
if O
glucocorticoid B
receptor I
binding O
is O
altered O
in O
this O
' O
stressful O
' O
disease O
. O

On O
the O
first O
day O
of O
the O
disease O
, O
glucocorticoid B
receptor I
capacity O
was O
significantly O
decreased O
without O
alteration O
of O
the O
receptor O
- O
ligand O
affinity O
, O
whereas O
on O
days O
4 O
and O
12 O
the O
number O
of O
receptor O
sites O
was O
normal O
again O
. O

CsA O
was O
found O
not O
to O
inhibit O
lck B
gene O
expression O
, O
nor O
the O
activity O
of O
the O
lck B
gene I
product O
. O

The O
IL B
- I
2 I
promoter I
contains O
binding B
sites I
for O
nuclear B
factors I
including O
NFAT B
- I
1 I
, O
Oct B
, O
NF B
- I
kappa I
B I
, O
and O
AP B
- I
1 I
, O
which O
are O
all O
potentially O
sensitive O
to O
activation O
of O
PKC B
. O

The O
IL B
- I
2 I
promoter I
contains O
binding B
sites I
for O
nuclear B
factors I
including O
NFAT B
- I
1 I
, O
Oct B
, O
NF B
- I
kappa I
B I
, O
and O
AP B
- I
1 I
, O
which O
are O
all O
potentially O
sensitive O
to O
activation O
of O
PKC B
. O

It O
is O
, O
however O
, O
still O
unclear O
whether O
LTB4 O
acts O
in O
this O
regard O
directly O
or O
indirectly O
by O
stimulating O
the O
release O
of O
chemotactic O
and O
inflammatory B
cytokines I
. O

We O
furthermore O
demonstrate O
that O
this O
process O
involves O
activation O
of O
the O
transcription B
factor I
NF B
- I
chi I
B I
and O
, O
to O
a O
lesser O
extent O
, O
of O
NF B
- I
IL6 I
, O
while O
the O
activity O
of O
the O
transcription B
factor I
AP B
- I
1 I
, O
shown O
to O
otherwise O
confer O
IL B
- I
6 I
inducibility O
, O
appeared O
to O
be O
unaffected O
by O
LTB4 O
. O

We O
furthermore O
demonstrate O
that O
this O
process O
involves O
activation O
of O
the O
transcription B
factor I
NF B
- I
chi I
B I
and O
, O
to O
a O
lesser O
extent O
, O
of O
NF B
- I
IL6 I
, O
while O
the O
activity O
of O
the O
transcription B
factor I
AP B
- I
1 I
, O
shown O
to O
otherwise O
confer O
IL B
- I
6 I
inducibility O
, O
appeared O
to O
be O
unaffected O
by O
LTB4 O
. O

The O
insertion O
was O
not O
required O
for O
Fc B
gamma I
RII I
to O
modulate O
surface B
immunoglobulin I
- O
triggered O
B O
- O
cell O
activation O
. O

Second O
is O
a O
controlled O
phase O
of O
TCR B
gene I
rearrangement O
. O

It O
seems O
that O
the O
rearrangement O
of O
the O
TCR B
gamma I
loci I
in O
the O
gamma O
delta O
lineage O
may O
not O
always O
take O
place O
at O
a O
developmental O
stage O
strictly O
equivalent O
to O
the O
rearrangement O
of O
TCR B
beta I
in O
the O
alpha O
beta O
lineage O
, O
and O
it O
is O
not O
clear O
just O
how O
early O
the O
two O
lineages O
diverge O
. O

Together O
, O
these O
findings O
suggest O
that O
the O
nuclear O
localization O
signal O
and O
transactivation B
domain I
of O
NF B
- I
kappa I
B I
p65 I
constitute O
a O
bipartite O
system O
that O
is O
critically O
involved O
in O
the O
inhibitory O
function O
of O
I B
kappa I
B I
/ I
MAD I
- I
3 I
. O

We O
have O
biochemically O
and O
functionally O
characterized O
a O
new O
transcription B
factor I
, O
NP B
- I
TCII I
, O
which O
is O
present O
in O
nuclei O
from O
unstimulated O
T O
and O
B O
lymphocytes O
but O
is O
not O
found O
in O
nonhematopoietic O
cells O
. O

[ O
3H O
] O
Thymidine O
incorporation O
was O
decreased O
dose O
- O
dependently O
by O
dexamethasone O
in O
controls O
and O
patients O
; O
the O
effect O
was O
significantly O
blunted O
( O
P O
less O
than O
0 O
. O
05 O
) O
in O
group O
1 O
patients O
, O
which O
suggests O
that O
activation O
of O
glucocorticoid B
receptor I
is O
impaired O
as O
a O
result O
of O
the O
glucocorticoid B
receptor I
abnormality O
. O

[ O
3H O
] O
Thymidine O
incorporation O
was O
decreased O
dose O
- O
dependently O
by O
dexamethasone O
in O
controls O
and O
patients O
; O
the O
effect O
was O
significantly O
blunted O
( O
P O
less O
than O
0 O
. O
05 O
) O
in O
group O
1 O
patients O
, O
which O
suggests O
that O
activation O
of O
glucocorticoid B
receptor I
is O
impaired O
as O
a O
result O
of O
the O
glucocorticoid B
receptor I
abnormality O
. O

After O
the O
DNA B
fragment I
containing O
the O
CAG B
repeats I
is O
amplified O
by O
the O
polymerase O
chain O
reaction O
, O
a O
primer O
extension O
is O
carried O
out O
; O
the O
extension O
of O
the O
end B
- I
labelled I
reverse I
primer I
adjacent O
to O
3 B
' I
end I
of O
CAG B
repeats I
stops O
at O
the O
first O
T O
after O
CAG B
repeats I
with O
the O
incorporation O
of O
dideoxy O
ATP O
in O
the O
reaction O
mixture O
. O

After O
the O
DNA B
fragment I
containing O
the O
CAG B
repeats I
is O
amplified O
by O
the O
polymerase O
chain O
reaction O
, O
a O
primer O
extension O
is O
carried O
out O
; O
the O
extension O
of O
the O
end B
- I
labelled I
reverse I
primer I
adjacent O
to O
3 B
' I
end I
of O
CAG B
repeats I
stops O
at O
the O
first O
T O
after O
CAG B
repeats I
with O
the O
incorporation O
of O
dideoxy O
ATP O
in O
the O
reaction O
mixture O
. O

After O
the O
DNA B
fragment I
containing O
the O
CAG B
repeats I
is O
amplified O
by O
the O
polymerase O
chain O
reaction O
, O
a O
primer O
extension O
is O
carried O
out O
; O
the O
extension O
of O
the O
end B
- I
labelled I
reverse I
primer I
adjacent O
to O
3 B
' I
end I
of O
CAG B
repeats I
stops O
at O
the O
first O
T O
after O
CAG B
repeats I
with O
the O
incorporation O
of O
dideoxy O
ATP O
in O
the O
reaction O
mixture O
. O

After O
the O
DNA B
fragment I
containing O
the O
CAG B
repeats I
is O
amplified O
by O
the O
polymerase O
chain O
reaction O
, O
a O
primer O
extension O
is O
carried O
out O
; O
the O
extension O
of O
the O
end B
- I
labelled I
reverse I
primer I
adjacent O
to O
3 B
' I
end I
of O
CAG B
repeats I
stops O
at O
the O
first O
T O
after O
CAG B
repeats I
with O
the O
incorporation O
of O
dideoxy O
ATP O
in O
the O
reaction O
mixture O
. O

It O
is O
evident O
that O
assembly O
of O
the O
surface B
domain I
of O
TF B
with O
VIIa B
to O
form O
the O
binary O
TF B
. I
VIIa I
complex I
induces O
a O
significant O
increase O
in O
the O
Kcat O
of O
the O
catalytic B
domain I
of O
VIIa B
for O
small O
peptidyl O
substrates O
and O
more O
profoundly O
for O
protein B
substrate I
. O

It O
is O
evident O
that O
assembly O
of O
the O
surface B
domain I
of O
TF B
with O
VIIa B
to O
form O
the O
binary O
TF B
. I
VIIa I
complex I
induces O
a O
significant O
increase O
in O
the O
Kcat O
of O
the O
catalytic B
domain I
of O
VIIa B
for O
small O
peptidyl O
substrates O
and O
more O
profoundly O
for O
protein B
substrate I
. O

It O
is O
evident O
that O
assembly O
of O
the O
surface B
domain I
of O
TF B
with O
VIIa B
to O
form O
the O
binary O
TF B
. I
VIIa I
complex I
induces O
a O
significant O
increase O
in O
the O
Kcat O
of O
the O
catalytic B
domain I
of O
VIIa B
for O
small O
peptidyl O
substrates O
and O
more O
profoundly O
for O
protein B
substrate I
. O

The O
endothelium O
plays O
a O
critical O
role O
in O
inflammation O
by O
directing O
circulating O
leukocytes O
into O
extravascular O
tissues O
by O
expressing O
adhesive B
molecules I
for O
leukocytes O
[ O
e O
. O
g O
. O
, O
endothelial B
- I
leukocyte I
adhesion I
molecule I
1 I
( O
ELAM B
- I
1 I
) O
and O
intercellular B
adhesion I
molecule I
1 I
( O
ICAM B
- I
1 I
) O
] O
. O

In O
contrast O
, O
sodium O
salicylate O
( O
1 O
mM O
) O
inhibited O
neither O
adhesion O
nor O
expression O
of O
these O
adhesion B
molecules I
. O

These O
studies O
suggest O
that O
antagonism O
by O
dexamethasone O
of O
endotoxin B
- O
induced O
inflammation O
is O
a O
specific O
instance O
of O
the O
general O
biological O
principle O
that O
the O
glucocorticoid B
receptor I
is O
a O
hormone O
- O
dependent O
regulator O
of O
transcription O
. O

Later O
, O
the O
expression O
of O
the O
BSAP B
gene I
shifts O
to O
the O
fetal O
liver O
where O
it O
correlates O
with O
the O
onset O
of O
B O
lymphopoiesis O
. O

NF B
- I
kappa I
B I
is O
a O
protein B
complex I
which O
functions O
in O
concert O
with O
the O
tat B
- I
I I
gene I
product I
to O
stimulate O
human O
immunodeficiency O
virus O
( O
HIV O
) O
transcription O
. O

Little O
effect O
was O
observed O
with O
50 B
- I
kDa I
forms I
of O
p105 B
NF B
- I
kappa I
B I
or O
rel B
, O
in O
combination O
with O
p65 B
or O
full B
- I
length I
c I
- I
rel I
, O
which O
do O
not O
stimulate O
the O
HIV B
enhancer I
in O
these O
cells O
. O

This O
protein O
is O
distinct O
from O
other O
members O
of O
the O
steroid B
/ I
thyroid I
hormone I
receptor I
family I
including O
the O
COUP B
protein I
which O
has O
a O
closely O
related O
DNA O
binding O
specificity O
. O

A O
Tat B
- I
responsive I
element I
is O
found O
upstream O
within O
the O
viral B
promoter I
that O
in O
glial O
- O
derived O
cell O
lines O
allows O
transactivation O
in O
the O
absence O
of O
TAR B
. O

The O
promoter O
of O
the O
major B
histocompatibility I
class I
II I
gene I
DRA B
contains O
an O
octamer B
element I
( O
ATTTGCAT O
) O
that O
is O
required O
for O
efficient O
DRA B
expression O
in O
B O
cells O
. O

In O
vitro O
transcription O
analysis O
using O
protein O
fractions O
enriched O
for O
the O
octamer O
- O
binding O
protein O
OTF B
- I
2 I
demonstrate O
a O
positive O
functional O
role O
for O
OTF B
- I
2 I
in O
DRA B
gene I
transcription O
. O

Recombinant B
OTF I
- I
2 I
protein I
produced O
by O
in O
vitro O
transcription O
/ O
translation O
could O
also O
enhance O
DRA B
gene I
transcription O
in O
vitro O
. O

However O
, O
the O
increase O
in O
ISGF3 B
activity O
ultimately O
correlates O
with O
the O
accumulation O
of O
ISGF3 B
gamma I
induced O
by O
IFN B
- I
alpha I
or O
IFN B
- I
gamma I
. O

Glucocorticoid B
receptor I
and O
inhibition O
of O
3 O
- O
O O
- O
methyl O
- O
D O
- O
glucose O
uptake O
by O
glucocorticoids O
in O
peripheral O
blood O
leukocytes O
from O
normal O
humans O
: O
correlation O
between O
receptor O
level O
and O
hormone O
effect O
in O
vitro O
. O

A O
DNA B
probe I
that O
spanned O
a O
domain O
conserved O
among O
the O
proto B
- I
oncogene I
c I
- I
rel I
, O
the O
Drosophila B
morphogen I
dorsal I
, O
and O
the O
p50 B
DNA I
binding I
subunit I
of O
NF B
- I
kappa I
B I
was O
generated O
from O
Jurkat B
T I
cell I
complementary I
DNA I
with O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
and O
degenerate O
oligonucleotides O
. O

In O
vitro O
transcription O
and O
translation O
of O
the O
complementary B
DNA I
resulted O
in O
the O
synthesis O
of O
a O
protein O
with O
an O
apparent O
molecular O
size O
of O
65 B
kilodaltons I
( O
kD O
) O
. O

In O
vitro O
transcription O
and O
translation O
of O
the O
complementary B
DNA I
resulted O
in O
the O
synthesis O
of O
a O
protein O
with O
an O
apparent O
molecular O
size O
of O
65 B
kilodaltons I
( O
kD O
) O
. O

This O
erbA B
- I
binding I
site I
confers O
thyroid O
hormone O
responsiveness O
to O
a O
heterologous B
promoter I
in O
transient O
expression O
experiments O
and O
is O
a O
target O
for O
efficient O
down O
- O
regulation O
of O
CAII B
transcription O
by O
the O
v B
- I
erbA I
oncoprotein I
. O

The O
effect O
is O
mediated O
by O
the O
NF B
- I
kappa I
B I
transcription B
factor I
which O
is O
potently O
and O
rapidly O
activated O
by O
an O
H2O2 O
treatment O
of O
cells O
from O
its O
inactive B
cytoplasmic I
form I
. O

ROI O
appear O
to O
serve O
as O
messengers O
mediating O
directly O
or O
indirectly O
the O
release O
of O
the O
inhibitory B
subunit I
I B
kappa I
B I
from O
NF B
- I
kappa I
B I
. O

Inhibition O
of O
transcription B
factors I
belonging O
to O
the O
rel B
/ I
NF I
- I
kappa I
B I
family I
by O
a O
transdominant B
negative I
mutant I
. O

A O
mutant O
of O
KBF1 B
/ I
p50 I
( O
delta B
SP I
) O
, O
unable O
to O
bind O
to O
DNA O
but O
able O
to O
form O
homo O
- O
or O
heterodimers B
, O
has O
been O
constructed O
. O

One O
gene O
of O
interest O
is O
the O
glycoprotein B
IIb I
( I
GPIIb I
) I
gene I
; O
GPIIb B
, O
the O
alpha B
subunit I
of O
the O
platelet B
cytoadhesin I
GPIIb I
- I
IIIa I
, O
is O
produced O
in O
megakaryocytes O
at O
an O
early O
stage O
of O
the O
differentiation O
, O
whereas O
the O
other O
subunit O
of O
this O
complex O
, O
GPIIIa B
, O
is O
expressed O
in O
other O
cells O
. O

No O
relationship O
could O
be O
established O
between O
glucocorticoid B
receptor I
binding O
and O
antidepressant O
medication O
. O

These O
data O
support O
the O
view O
of O
an O
impaired O
ligand O
- O
induced O
plasticity O
of O
glucocorticoid B
receptor I
regulation O
rather O
than O
the O
hypothesis O
of O
decreased O
glucocorticoid B
receptor I
numbers O
during O
depression O
. O

These O
data O
support O
the O
view O
of O
an O
impaired O
ligand O
- O
induced O
plasticity O
of O
glucocorticoid B
receptor I
regulation O
rather O
than O
the O
hypothesis O
of O
decreased O
glucocorticoid B
receptor I
numbers O
during O
depression O
. O

Circadian O
rhythm O
in O
glucocorticoid B
receptor I
( O
GR B
) O
was O
studied O
in O
the O
rat O
liver O
and O
human O
peripheral O
leukocytes O
. O

The O
conversion O
of O
the O
TCEd B
to O
a O
' B
perfect I
' I
NF I
- I
kB I
binding I
site I
leads O
to O
a O
tighter O
binding O
of O
NF B
- I
kB I
to O
TCEd B
DNA I
and O
, O
as O
a O
functional O
consequence O
, O
to O
the O
activity O
of O
the O
' B
converted I
' I
TCEd I
motifs I
in O
HeLa O
cells O
. O

Glucocorticoid B
receptor I
characteristics O
in O
monocytes O
of O
patients O
with O
corticosteroid O
- O
resistant O
bronchial O
asthma O
. O

In O
lymphocytes O
activated O
either O
by O
PHA B
or O
OKT3 B
( O
but O
not O
in O
resting O
cells O
) O
, O
a O
50 B
- I
kDa I
species I
cross O
- O
reacting O
with O
a O
monoclonal B
antibody I
against O
the O
intestinal B
vitamin I
D I
receptor I
was O
detected O
. O

Previously O
, O
a O
nuclear B
factor I
, O
IRF B
- I
1 I
( O
interferon B
regulatory I
factor I
1 I
) O
, O
which O
binds O
to O
type B
I I
IFN I
and O
some O
IFN B
- I
inducible I
gene I
promoters I
, O
was O
identified O
and O
cloned O
. O

A O
dimerization B
cofactor I
of O
HNF B
- I
1 I
alpha I
( O
DCoH B
) O
was O
identified O
that O
displayed O
a O
restricted O
tissue O
distribution O
and O
did O
not O
bind O
to O
DNA O
, O
but O
, O
rather O
, O
selectively O
stabilized O
HNF B
- I
1 I
alpha I
dimers I
. O

The O
nuclear O
extracts O
from O
resting O
and O
induced O
ML O
- O
1 O
cells O
contain O
proteins O
binding O
specifically O
to O
the O
AP B
- I
1 I
, I
AP I
- I
2 I
, I
and I
NF I
kappa I
B I
sequence I
located O
within O
the O
TNF B
promoter I
. O

Transforming B
growth I
factor I
- I
beta I
suppresses O
human B
B I
lymphocyte I
Ig I
production O
by O
inhibiting O
synthesis O
and O
the O
switch O
from O
the O
membrane B
form I
to O
the O
secreted B
form I
of O
Ig B
mRNA I
. O

Transforming B
growth I
factor I
- I
beta I
suppresses O
human B
B I
lymphocyte I
Ig I
production O
by O
inhibiting O
synthesis O
and O
the O
switch O
from O
the O
membrane B
form I
to O
the O
secreted B
form I
of O
Ig B
mRNA I
. O

Transforming B
growth I
factor I
- I
beta I
suppresses O
human B
B I
lymphocyte I
Ig I
production O
by O
inhibiting O
synthesis O
and O
the O
switch O
from O
the O
membrane B
form I
to O
the O
secreted B
form I
of O
Ig B
mRNA I
. O

NF B
- I
E1 I
is O
also O
the O
human B
homologue I
of O
the O
mouse B
delta I
protein I
, O
which O
binds O
to O
ribosomal B
protein I
gene I
promoters I
. O

Cotransfection O
studies O
with O
this O
cDNA B
indicate O
that O
it O
can O
repress O
basal B
promoter I
activity O
. O

An O
upstream B
segment I
contains O
tandem B
dinucleotide I
repeats I
( B
CT I
) I
19 I
/ I
( I
CA I
) I
16 I
. O

There O
is O
a O
suitably O
located O
TATA B
box I
, O
but O
potential O
sites O
for O
CCAAT B
- I
box I
binding I
factors I
are O
far O
upstream O
, O
embedded O
in O
a O
42 B
- I
nucleotide I
repeat I
element I
. O

The O
activity O
of O
dihydropyrimidine B
dehydrogenase I
( O
DPD B
) O
, O
the O
initial O
enzyme B
of O
pyrimidine O
( O
and O
FUra O
) O
catabolism O
, O
in O
peripheral O
blood O
mononuclear O
cells O
was O
measured O
in O
each O
subject O
by O
a O
specific O
radiometric O
assay O
using O
FUra O
as O
the O
substrate O
. O

TCF B
- I
1 I
alpha I
is O
currently O
unique O
among O
the O
newly O
emerging O
family O
of O
DNA B
- I
binding I
regulatory I
proteins I
that O
share O
the O
HMG B
motif I
in O
that O
it O
is O
a O
highly B
tissue I
- I
specific I
RNA I
polymerase I
II I
transcription B
factor I
. O

TCF B
- I
1 I
alpha I
is O
currently O
unique O
among O
the O
newly O
emerging O
family O
of O
DNA B
- I
binding I
regulatory I
proteins I
that O
share O
the O
HMG B
motif I
in O
that O
it O
is O
a O
highly B
tissue I
- I
specific I
RNA I
polymerase I
II I
transcription B
factor I
. O

We O
describe O
the O
isolation O
and O
characterization O
of O
multiple B
cDNAs I
encoding O
mouse B
Oct2 I
from O
a O
mature O
B O
- O
cell O
line O
and O
we O
show O
that O
a O
variety O
of O
isoforms O
of O
this O
transcription B
factor I
is O
generated O
from O
a O
single O
gene O
by O
an O
alternative O
splicing O
mechanism O
. O

We O
describe O
the O
isolation O
and O
characterization O
of O
multiple B
cDNAs I
encoding O
mouse B
Oct2 I
from O
a O
mature O
B O
- O
cell O
line O
and O
we O
show O
that O
a O
variety O
of O
isoforms O
of O
this O
transcription B
factor I
is O
generated O
from O
a O
single O
gene O
by O
an O
alternative O
splicing O
mechanism O
. O

We O
describe O
the O
isolation O
and O
characterization O
of O
multiple B
cDNAs I
encoding O
mouse B
Oct2 I
from O
a O
mature O
B O
- O
cell O
line O
and O
we O
show O
that O
a O
variety O
of O
isoforms O
of O
this O
transcription B
factor I
is O
generated O
from O
a O
single O
gene O
by O
an O
alternative O
splicing O
mechanism O
. O

In O
cotransfection O
experiments O
we O
show O
that O
all O
the O
isoforms B
are O
able O
to O
activate O
an O
octamer B
containing O
promoter B
element I
in O
fibroblasts O
revealing O
an O
unexpected O
functional O
redundancy O
. O

The O
decrease O
of O
the O
number O
of O
glucocorticoid B
receptors I
in O
patients O
with O
type O
IIa O
hyperlipidemia O
seems O
to O
be O
a O
compensatory O
response O
of O
cells O
culminating O
in O
activation O
of O
endogenous O
cholesterol O
synthesis O
. O

Formation O
of O
the O
protein B
- I
DNA I
complex I
with O
the O
C26 B
subfragment I
was O
positively O
affected O
by O
p40tax B
. O

We O
have O
generated O
a O
monoclonal B
antibody I
, O
BZ1 B
, O
to O
BZLF1 B
which O
reacts O
in O
immunohistology O
, O
immunoblotting O
, O
and O
immunoprecipitation O
and O
which O
recognizes O
both O
the O
active B
, I
dimeric I
form I
and O
the O
inactive B
, I
monomeric I
form I
of O
the O
protein O
. O

The O
hormone B
receptors I
of O
the O
primary O
tumor O
were O
known O
in O
15 O
( O
ER B
) O
and O
14 O
( O
PR B
) O
patients O
, O
respectively O
. O

[ O
Regulatory O
effect O
of O
insulin B
on O
glucocorticoid B
receptor I
in O
human O
peripheral O
leukocytes O
] O

Over O
the O
past O
decade O
it O
has O
become O
clear O
that O
glucocorticosteroid B
receptors I
play O
a O
significant O
role O
in O
the O
mechanism O
of O
glucocorticosteroid O
action O
. O

Glucocorticosteroid B
receptors I
on O
leukocytes O
of O
patients O
with O
SLE O
were O
significantly O
higher O
than O
in O
healthy O
controls O
( O
4419 O
+ O
/ O
- O
306 O
vs O
3369 O
+ O
/ O
- O
196 O
, O
p O
less O
than O
0 O
. O
005 O
) O
. O

The O
insertion O
of O
multiple O
copies O
of O
the O
binding B
site I
for O
the O
former O
or O
latter O
factor O
into O
a O
heterologous B
promoter I
reduced O
the O
promoter O
activity O
to O
one O
- O
tenth O
or O
one O
- O
third O
, O
respectively O
. O

The O
insertion O
of O
multiple O
copies O
of O
the O
binding B
site I
for O
the O
former O
or O
latter O
factor O
into O
a O
heterologous B
promoter I
reduced O
the O
promoter O
activity O
to O
one O
- O
tenth O
or O
one O
- O
third O
, O
respectively O
. O

In O
contrast O
, O
mild O
oxidation O
with O
glucose B
oxidase I
selectively O
inhibits O
p75 B
and O
p85 B
binding O
while O
not O
blocking O
p50 B
and O
p55 B
interactions O
. O

[ O
Changes O
in O
leucocytic O
estrogen B
receptor I
levels O
in O
patients O
with O
climacteric O
syndrome O
and O
therapeutic O
effect O
of O
liuwei O
dihuang O
pills O
] O

The O
numbers O
of O
estrogen B
receptor I
( O
ER B
) O
in O
human O
peripheral O
leucocytes O
in O
22 O
women O
with O
climacteric O
syndrome O
were O
measured O
by O
radioligand O
method O
. O

Addition O
of O
KCl O
resulted O
in O
less O
DNA O
binding O
either O
due O
to O
blockage O
of O
DNA O
- O
receptor B
complex I
formation O
or O
disruption O
of O
the O
complexes O
. O

Oligonucleotides O
containing O
the O
consensus B
GRE I
were O
the O
most O
efficient O
competitors O
, O
and O
fragments O
containing O
regulatory B
sequences I
from O
glucocorticoid B
- I
repressible I
genes I
were O
somewhat O
competitive O
, O
whereas O
single O
stranded O
oligonucleotides O
were O
unable O
to O
compete O
for O
mouse B
mammary I
tumor I
virus I
- I
long I
terminal I
repeat I
DNA O
binding O
, O
except O
when O
competitor O
was O
present O
at O
extremely O
high O
concentrations O
. O

Oligonucleotides O
containing O
the O
consensus B
GRE I
were O
the O
most O
efficient O
competitors O
, O
and O
fragments O
containing O
regulatory B
sequences I
from O
glucocorticoid B
- I
repressible I
genes I
were O
somewhat O
competitive O
, O
whereas O
single O
stranded O
oligonucleotides O
were O
unable O
to O
compete O
for O
mouse B
mammary I
tumor I
virus I
- I
long I
terminal I
repeat I
DNA O
binding O
, O
except O
when O
competitor O
was O
present O
at O
extremely O
high O
concentrations O
. O

Role O
for O
the O
Epstein B
- I
Barr I
virus I
nuclear I
antigen I
2 I
in O
viral B
promoter I
switching O
during O
initial O
stages O
of O
infection O
. O

These O
studies O
have O
been O
extended O
to O
show O
that O
( O
i O
) O
a O
mutant O
EBV O
strain O
lacking O
the O
gene O
encoding O
EBNA B
2 I
fails O
to O
switch O
from O
Wp O
to O
Cp B
usage O
in O
primary O
B O
lymphocytes O
, O
although O
the O
virus O
contains O
a O
functional O
Cp B
; O
( O
ii O
) O
a O
region O
from O
- B
429 I
to I
- I
245 I
base I
pairs I
upstream O
of O
Cp B
is O
essential O
for O
Cp B
activity O
in O
B O
lymphocytes O
, O
but O
only O
in O
the O
context O
of O
upstream B
and I
downstream I
sequences I
; O
( O
iii O
) O
this O
region O
contains O
an O
EBNA B
2 I
- I
dependent I
enhancer I
; O
and O
( O
iv O
) O
DNase B
I I
protection O
employing O
nuclear O
extracts O
from O
B O
and O

These O
studies O
have O
been O
extended O
to O
show O
that O
( O
i O
) O
a O
mutant O
EBV O
strain O
lacking O
the O
gene O
encoding O
EBNA B
2 I
fails O
to O
switch O
from O
Wp O
to O
Cp B
usage O
in O
primary O
B O
lymphocytes O
, O
although O
the O
virus O
contains O
a O
functional O
Cp B
; O
( O
ii O
) O
a O
region O
from O
- B
429 I
to I
- I
245 I
base I
pairs I
upstream O
of O
Cp B
is O
essential O
for O
Cp B
activity O
in O
B O
lymphocytes O
, O
but O
only O
in O
the O
context O
of O
upstream B
and I
downstream I
sequences I
; O
( O
iii O
) O
this O
region O
contains O
an O
EBNA B
2 I
- I
dependent I
enhancer I
; O
and O
( O
iv O
) O
DNase B
I I
protection O
employing O
nuclear O
extracts O
from O
B O
and O

Five O
T O
- O
cell O
clones O
specific O
for O
a O
T B
- I
cell I
epitope I
located O
at O
the O
carboxyterminal B
region I
of O
HBxAg B
were O
established O
and O
found O
to O
belong O
to O
the O
CD2 O
/ O
CD4 O
- O
positive O
, O
CD8 O
- O
negative O
subtype O
. O

Plasma O
cortisol O
concentration O
and O
blood O
leukocyte O
content O
of O
glucocorticoid B
receptors I
( O
GCR B
) O
were O
assayed O
in O
20 O
patients O
with O
deficiency O
syndromes O
, O
10 O
cold O
in O
property O
( O
deficiency O
- O
cold O
) O
, O
the O
other O
10 O
hot O
in O
property O
( O
deficiency O
- O
heat O
) O
, O
and O
also O
in O
10 O
healthy O
individuals O
as O
normal O
control O
for O
the O
purpose O
of O
investigating O
the O
nature O
of O
cold O
and O
heat O
syndromes O
. O

This O
tight O
correlation O
between O
c B
- I
jun I
expression O
, O
the O
generation O
of O
AP B
- I
1 I
activity O
, O
and O
differentiation O
suggests O
a O
critical O
role O
for O
this O
gene O
and O
transcriptional B
complex I
during O
this O
process O
. O

A O
transcription B
factor I
, O
NF B
- I
AT I
, O
which O
is O
essential O
for O
early O
T O
- O
cell O
gene O
activation O
, O
seems O
to O
be O
a O
specific O
target O
of O
cyclosporin O
A O
and O
FK506 O
action O
because O
transcription O
directed O
by O
this O
protein O
is O
blocked O
in O
T O
cells O
treated O
with O
these O
drugs O
, O
with O
little O
or O
no O
effect O
on O
other O
transcription B
factors I
such O
as O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
. O

A O
transcription B
factor I
, O
NF B
- I
AT I
, O
which O
is O
essential O
for O
early O
T O
- O
cell O
gene O
activation O
, O
seems O
to O
be O
a O
specific O
target O
of O
cyclosporin O
A O
and O
FK506 O
action O
because O
transcription O
directed O
by O
this O
protein O
is O
blocked O
in O
T O
cells O
treated O
with O
these O
drugs O
, O
with O
little O
or O
no O
effect O
on O
other O
transcription B
factors I
such O
as O
AP B
- I
1 I
and O
NF B
- I
kappa I
B I
. O

Glucocorticoid B
receptors I
in O
lymphocytes O
in O
anorexia O
nervosa O
. O

CONCLUSIONS O
Hypercortisolaemia O
does O
not O
down O
- O
regulate O
the O
lymphocyte O
glucocorticoid B
receptors I
in O
anorexia O
nervosa O
and O
a O
post O
- O
receptor O
defect O
might O
be O
involved O
in O
peripheral O
tissue O
resistance O
to O
the O
effects O
of O
glucocorticoid O
hormones O
in O
undernutrition O
. O

The O
induction O
of O
AP1 B
by O
okadaic O
acid O
suggests O
that O
protein B
phosphatases I
1 I
and I
2A I
( O
PP1 B
and O
PP2A B
) O
may O
be O
involved O
in O
T O
cell O
activation O
as O
important O
negative O
regulators O
of O
the O
transcription B
factor I
AP1 B
. O

Northern O
blot O
analysis O
of O
polyadenylated B
RNA I
purified O
from O
activated O
human O
B O
cells O
revealed O
a O
single B
mRNA I
transcript I
of O
approximately O
2 O
. O
3 O
kb O
. O

There O
is O
a O
single O
methionine B
codon I
- I
initiated I
open I
reading I
frame I
of O
1 O
, O
458 O
nt O
in O
frame O
with O
a O
homeobox B
and O
a O
CAX B
repeat I
, O
and O
the O
open B
reading I
frame I
is O
predicted O
to O
encode O
a O
protein O
of O
51 O
, O
659 O
daltons O
. O

Tandem O
copies O
of O
this O
67 B
- I
bp I
MnlI I
- I
AluI I
fragment I
, O
when O
fused O
to O
the O
chloramphenicol B
acetyltransferase I
gene I
driven O
by O
the O
conalbumin B
promoter I
, O
stimulated O
transcription O
in O
B O
cells O
but O
not O
in O
Jurkat O
T O
cells O
or O
HeLa O
cells O
. O

In O
agreement O
with O
the O
results O
of O
gel O
retardation O
assays O
, O
tandem O
copies O
of O
the O
E6 B
motif I
stimulated O
transcription O
in O
ARH77 O
and O
Raji O
cells O
but O
not O
in O
Jurkat O
or O
HeLa O
cells O
. O

Interestingly O
, O
the O
MnlI B
- I
AluI I
fragment I
could O
suppress O
the O
basal O
- O
level O
activity O
of O
the O
conalbumin B
promoter I
in O
both O
Jurkat O
and O
HeLa O
cells O
. O

From O
information O
available O
in O
the O
literature O
on O
the O
substrate O
specificity O
of O
the O
three O
enzymes B
, O
it O
is O
clear O
that O
a O
cysteine O
is O
not O
accepted O
in O
any O
of O
the O
S2 B
, I
S1 I
, I
S1 I
' I
, I
and I
S2 I
' I
subsites I
of O
cathepsin B
B I
and I
L I
, O
and O
not O
in O
the O
S1 B
and O
S1 B
' I
subsites O
of O
cathepsin B
D I
. O

From O
information O
available O
in O
the O
literature O
on O
the O
substrate O
specificity O
of O
the O
three O
enzymes B
, O
it O
is O
clear O
that O
a O
cysteine O
is O
not O
accepted O
in O
any O
of O
the O
S2 B
, I
S1 I
, I
S1 I
' I
, I
and I
S2 I
' I
subsites I
of O
cathepsin B
B I
and I
L I
, O
and O
not O
in O
the O
S1 B
and O
S1 B
' I
subsites O
of O
cathepsin B
D I
. O

Starting O
with O
a O
replication O
- O
incompetent O
molecular O
clone O
of O
human O
immunodeficiency O
virus O
type O
1 O
, O
lacking O
all O
the O
NF B
- I
kappa I
B I
and I
Sp1 I
binding I
sites I
present O
in O
the O
native B
long I
terminal I
repeat I
( O
LTR B
) O
, O
proviruses O
containing O
reconstructed B
LTRs I
with O
individual O
or O
combinations O
of O
NF B
- I
kappa I
B I
and I
Sp1 I
elements I
were O
generated O
and O
evaluated O
for O
their O
capacity O
to O
produce O
virus O
progeny O
following O
transfection O
- O
cocultivation O
. O

The O
human B
interferon I
beta I
( I
IFN I
- I
beta I
) I
regulatory I
element I
consists O
of O
multiple O
enhanson B
domains I
which O
are O
targets O
for O
transcription B
factors I
involved O
in O
inducible O
expression O
of O
the O
promoter B
. O

The O
human B
interferon I
beta I
( I
IFN I
- I
beta I
) I
regulatory I
element I
consists O
of O
multiple O
enhanson B
domains I
which O
are O
targets O
for O
transcription B
factors I
involved O
in O
inducible O
expression O
of O
the O
promoter B
. O

A O
2 O
- O
4 O
- O
fold O
increase O
in O
IFN B
- I
beta I
promoter I
transcription O
was O
observed O
in O
Sendai O
virus O
induced O
extracts O
, O
and O
deletion O
of O
PRDI B
and O
PRDII B
elements I
decreased O
this O
induced O
level O
of O
transcription O
. O

Furthermore O
, O
while O
PMA O
activation O
was O
inhibited O
by O
the O
PKC B
inhibitor O
staurosporin O
, O
the O
TNF B
alpha I
effect O
was O
unchanged O
. O

The O
fusion B
cDNA I
results O
from O
an O
interstitial O
deletion O
between O
a O
previously O
unknown B
locus I
, O
SIL B
( O
SCL B
interrupting I
locus I
) O
, O
and O
the O
5 B
' I
untranslated I
region I
of O
SCL B
. O

The O
fusion B
cDNA I
results O
from O
an O
interstitial O
deletion O
between O
a O
previously O
unknown B
locus I
, O
SIL B
( O
SCL B
interrupting I
locus I
) O
, O
and O
the O
5 B
' I
untranslated I
region I
of O
SCL B
. O

Thus O
, O
in O
lymphocytes O
, O
growth B
- I
affecting I
genes I
other O
than O
immune B
receptors I
risk O
rearrangements O
. O

A O
closely O
related O
( O
if O
not O
identical O
) O
protein O
is O
found O
in O
both O
a O
human O
megakaryocytic O
cell O
line O
and O
purified O
human O
megakaryocytes O
; O
it O
binds O
to O
promoter B
regions I
of O
two O
megakaryocytic B
- I
specific I
genes I
. O

[ O
Glucocorticoid B
receptors I
in O
peripheral O
blood O
lymphocytes O
of O
patients O
with O
bronchial O
asthma O
] O

Quantitation O
of O
glucocorticoid B
receptors I
( O
GCR B
) O
and O
the O
study O
of O
their O
affinity O
for O
glucocorticosteroids O
( O
GCS O
) O
were O
made O
in O
peripheral O
blood O
lymphocytes O
of O
bronchial O
asthma O
( O
BA O
) O
patients O
in O
consideration O
of O
GCR B
treatment O
and O
serum O
levels O
of O
endogenous O
cortisol O
. O

Retroviral O
mediated O
transfer O
and O
expression O
of O
exogenous B
genes I
in O
primary O
lymphoid O
cells O
: O
assaying O
for O
a O
viral O
transactivator B
activity O
in O
normal O
and O
malignant O
cells O
. O

Incidence O
of O
HLA B
antigens I
was O
determined O
in O
94 O
of O
them O
. O

ER B
content O
in O
lymphocytes O
of O
each O
sample O
was O
expressed O
by O
both O
fmol O
/ O
mg O
of O
lymphocyte B
cytosolic I
protein I
and O
fmol O
/ O
micrograms O
of O
lymphocyte B
DNA I
. O

We O
used O
mouse O
embryonic O
stem O
( O
ES O
) O
cells O
to O
study O
globin B
gene I
expression O
and O
switching O
in O
vitro O
. O

When O
the O
human B
epsilon I
- I
or I
beta I
- I
globin I
genes I
driven O
by O
the O
dominant B
control I
region I
( O
DCR B
) O
are O
introduced O
into O
this O
system O
, O
the O
human B
epsilon I
- I
globin I
gene I
, O
in O
contrast O
to O
the O
beta B
- I
globin I
gene I
, O
is O
not O
deregulated O
by O
the O
presence O
of O
the O
DCR B
and O
is O
expressed O
strictly O
as O
an O
embryonic B
gene I
. O

However O
, O
one O
palindrome B
, O
either O
alone O
or O
duplicated O
, O
or O
the O
overlapping B
palindromes I
did O
not O
respond O
to O
R O
. O

[ O
Hormonal O
interactions O
and O
glucocorticoid B
receptors I
in O
patients O
with O
the O
nephrotic O
syndrome O
] O

These O
studies O
detected O
two O
novel B
domains I
referred O
to O
as O
L1 B
and O
L2 B
with O
a O
variety O
of O
lymphoid O
but O
not O
HeLa O
extracts O
. O

The O
defensin B
sensitivities O
of O
Salmonella O
typhimurium O
strains O
with O
mutations O
in O
the O
phoP B
/ I
phoQ I
two I
- I
component I
virulence I
regulon I
were O
tested O
by O
using O
purified B
defensins I
NP B
- I
1 I
and O
NP B
- I
2 I
. O

The O
predicted O
periplasmic B
domain I
of O
the O
PhoQ B
protein I
contained O
a O
markedly O
anionic O
domain O
that O
could O
interact O
with O
cationic B
proteins I
and O
that O
could O
be O
responsible O
for O
resistance O
to O
defensin B
. O

The O
predicted O
periplasmic B
domain I
of O
the O
PhoQ B
protein I
contained O
a O
markedly O
anionic O
domain O
that O
could O
interact O
with O
cationic B
proteins I
and O
that O
could O
be O
responsible O
for O
resistance O
to O
defensin B
. O

The O
predicted O
periplasmic B
domain I
of O
the O
PhoQ B
protein I
contained O
a O
markedly O
anionic O
domain O
that O
could O
interact O
with O
cationic B
proteins I
and O
that O
could O
be O
responsible O
for O
resistance O
to O
defensin B
. O

The O
two O
proteins O
differ O
by O
a O
14 B
- I
amino I
acid I
serine I
- I
rich I
insertion I
present O
in O
one O
of O
the O
CREB B
isoforms I
. O

Competition O
experiments O
did O
not O
reveal O
any O
high B
- I
affinity I
binding I
site I
for O
BSAP B
in O
known O
regulatory B
regions I
of O
immunoglobulin B
and I
class I
II I
major I
histocompatibility I
( I
MHC I
) I
genes I
, O
suggesting O
that O
BSAP B
is O
a O
regulator O
of O
a O
different O
set O
of O
B B
- I
lymphoid I
- I
specific I
genes I
. O

It O
appears O
that O
the O
B O
cell O
- O
specific O
expression O
of O
Ig B
genes I
is O
mediated O
at O
least O
in O
part O
by O
cell O
type B
- I
specific I
Oct I
factors I
, O
and O
that O
there O
are O
both O
quantitative O
and O
qualitative O
differences O
between O
Oct B
- I
1 I
and O
Oct B
- I
2 I
factors I
. O

Many O
of O
these O
may O
be O
created O
by O
alternative O
splicing O
of O
a O
primary B
transcript I
of O
one O
Oct O
factor O
gene O
and O
may O
serve O
a O
specific O
function O
in O
the O
fine O
tuning O
of O
gene O
expression O
. O

A O
study O
was O
made O
of O
adrenocortical O
function O
by O
measuring O
blood O
plasma O
cortisol O
concentration O
and O
amount O
of O
glucocorticoid B
receptors I
in O
lymphocytes O
as O
well O
as O
thyroid O
function O
by O
measuring O
blood O
plasma O
triidothyronine O
and O
thyroxine O
concentration O
in O
58 O
bronchial O
asthma O
children O
aged O
1 O
to O
14 O
years O
. O

Multiple B
regulatory I
elements I
in O
the O
human B
immunodeficiency I
virus I
long I
terminal I
repeat I
( O
HIV B
LTR I
) O
are O
required O
for O
activation O
of O
HIV O
gene O
expression O
. O

Results O
in O
all O
cell O
lines O
indicated O
that O
mutations O
of O
the O
SP1 B
, O
TATA B
and O
the O
TAR O
loop O
and O
stem O
secondary O
structure O
resulted O
in O
marked O
decreases O
in O
gene O
expression O
while O
mutations O
of O
the O
enhancer B
motif I
or O
TAR B
primary I
sequence I
resulted O
in O
only O
slight O
decreases O
. O

Inducible O
nuclear B
factor I
binding O
to O
the O
kappa B
B I
elements I
of O
the O
human B
immunodeficiency I
virus I
enhancer I
in O
T O
cells O
can O
be O
blocked O
by O
cyclosporin O
A O
in O
a O
signal O
- O
dependent O
manner O
. O

Curiously O
, O
the O
TCF B
- I
1 I
alpha I
binding O
element O
was O
inactive O
in O
vivo O
when O
removed O
from O
its O
neighboring O
elements O
on O
the O
TCR B
alpha I
enhancer I
and O
positioned O
in O
one O
or O
more O
copies O
upstream O
of O
a O
heterologous B
promoter I
. O

A O
powerful O
enhancer O
has O
been O
mapped O
to O
an O
18 B
- I
bp I
DNA I
segment I
located O
11 O
kb O
5 O
' O
to O
the O
human B
epsilon I
- I
globin I
gene I
within O
the O
dominant B
control I
or O
locus B
- I
activating I
region I
. O

In O
addition O
to O
these O
elements O
, O
we O
identified O
a O
second O
regulatory B
element I
, O
the O
N B
element I
with O
the O
sequence O
5 O
' O
- O
GGAACCTCCCCC O
- O
3 O
' O
. O

In O
addition O
to O
these O
elements O
, O
we O
identified O
a O
second O
regulatory B
element I
, O
the O
N B
element I
with O
the O
sequence O
5 O
' O
- O
GGAACCTCCCCC O
- O
3 O
' O
. O

NF B
- I
kappa I
B I
as O
inducible O
transcriptional B
activator I
of O
the O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
gene I
. O

The O
same O
agents O
induce O
transcription O
from O
the O
interleukin B
- I
2 I
receptor I
alpha I
- I
chain I
and I
interleukin I
- I
2 I
genes I
, O
depending O
on O
promoter B
elements I
that O
bind O
the O
inducible B
transcription I
factor I
NF B
- I
kappa I
B I
( O
or O
an O
NF B
- I
kappa I
B I
- I
like I
factor I
) O
. O

Similar O
constructs O
controlled O
by O
NF B
- I
kappa I
B I
or O
the O
entire O
interleukin B
- I
2 I
enhancer I
show O
bimodal O
expression O
patterns O
during O
induction O
, O
suggesting O
that O
thresholds O
set O
by O
the O
concentration O
of O
transcription B
factors I
may O
be O
a O
common O
property O
of O
inducible B
genes I
. O

Similar O
constructs O
controlled O
by O
NF B
- I
kappa I
B I
or O
the O
entire O
interleukin B
- I
2 I
enhancer I
show O
bimodal O
expression O
patterns O
during O
induction O
, O
suggesting O
that O
thresholds O
set O
by O
the O
concentration O
of O
transcription B
factors I
may O
be O
a O
common O
property O
of O
inducible B
genes I
. O

In O
lymphoid O
cells O
, O
only O
the O
upstream B
sequences I
are O
required O
for O
transactivation O
by O
the O
Z B
/ I
R I
combination O
, O
and O
the O
AP B
- I
1 I
site I
is O
dispensable O
. O

This O
effect O
was O
comparable O
to O
or O
even O
stronger O
than O
the O
effect O
of O
a O
mutation O
in O
the O
OCTA B
site I
. O

Both O
HIV O
- O
2 O
and O
CMV B
transactivators I
enhance O
HIV O
- O
2 O
gene O
expression O
by O
transcriptional O
activation O
involving O
transcript O
initiation O
as O
well O
as O
elongation O
, O
with O
CMV B
transactivator I
affecting O
elongation O
more O
than O
the O
initiation O
. O

Both O
HIV O
- O
2 O
and O
CMV B
transactivators I
enhance O
HIV O
- O
2 O
gene O
expression O
by O
transcriptional O
activation O
involving O
transcript O
initiation O
as O
well O
as O
elongation O
, O
with O
CMV B
transactivator I
affecting O
elongation O
more O
than O
the O
initiation O
. O

Transcription B
factor I
IID I
( O
TFIID B
) O
binds O
to O
the O
TATA B
box I
promoter I
element I
and O
regulates O
the O
expression O
of O
most O
eukaryotic B
genes I
transcribed O
by O
RNA B
polymerase I
II I
. O

Complementary B
DNA I
( O
cDNA B
) O
encoding O
a O
human B
TFIID I
protein I
has O
been O
cloned O
. O

Elevated O
glucocorticoid B
receptor I
concentrations O
before O
and O
after O
glucocorticoid O
therapy O
in O
peripheral O
mononuclear O
leukocytes O
of O
patients O
with O
atopic O
dermatitis O
. O

Patients O
with O
AD O
( O
n O
= O
15 O
) O
exhibited O
significantly O
more O
glucocorticoid B
receptors I
( O
GR B
) O
per O
cell O
than O
the O
control O
group O
( O
n O
= O
22 O
) O
, O
while O
the O
GR B
affinity O
did O
not O
differ O
. O

Human O
T O
- O
cell O
leukemia O
virus O
types O
I O
( O
HTLV O
- O
I O
) O
and O
II O
( O
HTLV O
- O
II O
) O
have O
two O
nonstructural B
trans I
- I
acting I
regulatory I
genes I
, O
tax B
and O
rex B
, O
located O
in O
the O
3 B
' I
region I
of O
the O
viral B
genome I
. O

Rex B
acts O
posttranscriptionall O
to O
facilitate O
accumulation O
of O
full O
- O
length O
gag B
/ I
pol I
and O
singly O
spliced O
env B
mRNA I
in O
the O
cytoplasm O
of O
HTLV O
- O
infected O
cells O
. O

By O
using O
an O
infectious O
molecular O
clone O
of O
HTLV O
- O
II O
, O
we O
investigated O
the O
importance O
of O
the O
internal O
ATGs O
of O
the O
rex B
gene I
on O
Rex B
protein O
production O
and O
function O
. O

The O
' B
octamer I
' I
sequence I
, O
ATGCAAAT O
or O
its O
complement O
ATTTGCAT O
, O
is O
a O
key O
element O
for O
the O
transcriptional O
regulation O
of O
immunoglobulin B
genes I
in O
B O
- O
lymphocytes O
as O
well O
as O
a O
number O
of O
housekeeping B
genes I
in O
all O
cell O
types O
. O

The O
' B
octamer I
' I
sequence I
, O
ATGCAAAT O
or O
its O
complement O
ATTTGCAT O
, O
is O
a O
key O
element O
for O
the O
transcriptional O
regulation O
of O
immunoglobulin B
genes I
in O
B O
- O
lymphocytes O
as O
well O
as O
a O
number O
of O
housekeeping B
genes I
in O
all O
cell O
types O
. O

In O
lymphocytes O
, O
the O
octamer B
- I
binding I
protein I
Oct B
- I
2A I
and O
variants O
thereof O
are O
thought O
to O
contribute O
to O
the O
B B
- I
cell I
specific I
gene I
expression O
, O
while O
the O
ubiquitous O
protein O
Oct O
- O
1 O
seems O
to O
control O
general O
octamer B
site I
- O
dependent O
transcription O
. O

All O
immunoglobulin B
genes I
contain O
a O
conserved O
octanucleotide B
promoter I
element I
, O
ATGCAAAT O
, O
which O
has O
been O
shown O
to O
be O
required O
for O
their O
normal O
B O
- O
cell O
- O
specific O
transcription O
. O

Addition O
of O
a O
highly O
enriched O
preparation O
of O
OTF B
- I
1 I
made O
from O
one O
of O
these O
pre O
- O
B O
cells O
or O
from O
HeLa O
cells O
specifically O
stimulated O
in O
vitro O
transcription O
of O
an O
immunoglobulin B
gene I
. O

In O
vitro O
binding O
of O
aldosterone O
to O
mineralocorticoid B
receptors I
on O
human O
mononuclear O
leukocytes O
( O
HML O
) O
and O
its O
effects O
on O
the O
intracellular O
sodium O
and O
potassium O
concentrations O
of O
HML O
have O
already O
been O
described O
. O

The O
number O
of O
mineralocorticoid B
receptors I
/ O
cell O
were O
within O
or O
close O
to O
the O
normal O
range O
( O
n O
= O
9 O
) O
. O

The O
transcription O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
is O
under O
the O
control O
of O
cellular B
proteins I
that O
bind O
to O
the O
viral B
long I
terminal I
repeat I
( O
LTR B
) O
. O

This O
similarity O
in O
expression O
and O
the O
fact O
that O
NFAT B
- I
1 I
has O
been O
shown O
to O
bind O
functional B
sequences I
in O
HIV B
- I
LTR I
suggest O
a O
role O
for O
NFAT B
- I
1 I
in O
dermal O
activation O
of O
the O
HIV B
- I
LTR I
. O

A O
novel O
T B
- I
cell I
protein I
recognized O
the O
palindromic B
sequence I
within O
site B
B I
and O
also O
bound O
estrogen B
- I
or I
thyroid I
hormone I
- I
response I
elements I
with O
lower O
affinity O
. O

A O
novel O
T B
- I
cell I
protein I
recognized O
the O
palindromic B
sequence I
within O
site B
B I
and O
also O
bound O
estrogen B
- I
or I
thyroid I
hormone I
- I
response I
elements I
with O
lower O
affinity O
. O

The O
effects O
of O
a O
competitive O
progesterone O
antagonist O
( O
RU486 O
) O
and O
a O
specific O
glucocorticoid B
receptor I
blocker O
( O
RU43044 O
) O
were O
tested O
on O
the O
release O
of O
a O
blocking B
factor I
by O
progesterone O
- O
treated O
pregnancy O
lymphocytes O
. O

The O
effects O
of O
a O
competitive O
progesterone O
antagonist O
( O
RU486 O
) O
and O
a O
specific O
glucocorticoid B
receptor I
blocker O
( O
RU43044 O
) O
were O
tested O
on O
the O
release O
of O
a O
blocking B
factor I
by O
progesterone O
- O
treated O
pregnancy O
lymphocytes O
. O

A O
mutant B
LTR I
containing O
four O
base O
pair O
substitutions O
in O
the O
ets B
- I
1 I
binding I
site I
was O
constructed O
and O
was O
shown O
to O
have O
reduced O
binding O
in O
vitro O
. O

Proteins O
of O
the O
Ras B
superfamily I
are O
likely O
to O
be O
involved O
in O
a O
variety O
of O
normal O
phagocyte O
functions O
through O
their O
ability O
to O
modulate O
the O
assembly O
of O
actin B
filaments I
, O
direct O
vesicle O
trafficking O
and O
fusion O
, O
and O
so O
forth O
. O

Proteins O
of O
the O
Ras B
superfamily I
are O
likely O
to O
be O
involved O
in O
a O
variety O
of O
normal O
phagocyte O
functions O
through O
their O
ability O
to O
modulate O
the O
assembly O
of O
actin B
filaments I
, O
direct O
vesicle O
trafficking O
and O
fusion O
, O
and O
so O
forth O
. O

Further O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
inhibited O
the O
transcriptional O
activity O
of O
NF B
- I
kappa I
B I
in O
Jurkat O
cells O
transiently O
transfected O
with O
a O
construct B
containing O
four O
tandem B
repeats I
of O
the O
NF B
- I
kappa I
B I
binding I
sequence I
of O
the O
immunoglobulin B
kappa I
light I
chain I
gene I
linked O
to O
the O
chloramphenicol B
acetyltransferase I
reporter I
gene I
. O

The O
MZF B
- I
1 I
binding I
sites I
are O
present O
in O
the O
promoters B
of O
several O
genes B
expressed O
during O
myeloid O
differentiation O
, O
including O
the O
CD34 B
promoter I
. O

Nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
regulates O
transcription O
of O
a O
number O
of O
cytokine B
genes I
, O
and O
NFAT B
DNA O
binding O
activity O
is O
stimulated O
following O
T O
cell O
activation O
. O

Activation O
and O
expression O
of O
the O
nuclear B
factors I
of O
activated O
T O
cells O
, O
NFATp B
and O
NFATc B
, O
in O
human O
natural O
killer O
cells O
: O
regulation O
upon O
CD16 B
ligand O
binding O
. O

Since O
many O
cytokines B
that O
activate O
Jak B
kinases I
also O
lead O
to O
the O
tyrosine O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Stat B
family I
of O
transcription B
factors I
, O
the O
ability O
of O
IL B
- I
2 I
to O
trigger O
Stat O
phosphorylation O
was O
examined O
. O

Since O
many O
cytokines B
that O
activate O
Jak B
kinases I
also O
lead O
to O
the O
tyrosine O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Stat B
family I
of O
transcription B
factors I
, O
the O
ability O
of O
IL B
- I
2 I
to O
trigger O
Stat O
phosphorylation O
was O
examined O
. O

Since O
many O
cytokines B
that O
activate O
Jak B
kinases I
also O
lead O
to O
the O
tyrosine O
phosphorylation O
and O
activation O
of O
members O
of O
the O
Stat B
family I
of O
transcription B
factors I
, O
the O
ability O
of O
IL B
- I
2 I
to O
trigger O
Stat O
phosphorylation O
was O
examined O
. O

Exposure O
of O
activated O
human O
T O
lymphocytes O
or O
of O
a O
natural O
killer O
cell O
line O
( O
NKL O
) O
to O
IL B
- I
2 I
leads O
to O
the O
phosphorylation O
of O
Stat1 B
alpha I
, O
Stat1 O
beta O
, O
and O
Stat3 B
, O
as O
well O
as O
of O
two O
Stat B
- I
related I
proteins I
, O
p94 B
and O
p95 B
. O

These O
Stat B
proteins I
were O
found O
to O
translocate O
to O
the O
nucleus O
and O
to O
bind O
to O
a O
specific B
DNA I
sequence I
. O

Results O
indicated O
that O
( O
i O
) O
constitutive O
c B
- I
fos I
transcript I
levels O
are O
significantly O
higher O
in O
patients O
subsequently O
responding O
to O
IFN B
- I
alpha I
therapy O
( O
p O
< O
0 O
. O
01 O
) O
and O
positively O
correlated O
with O
the O
proportion O
of O
lymphocytes O
( O
r O
= O
0 O
. O
6895 O
, O
p O
< O
0 O
. O
01 O
) O
and O
negatively O
with O
the O
proportion O
of O
immature O
cells O
( O
r O
= O
- O
0 O
. O
568 O
, O
p O
< O
0 O
. O
01 O
) O
contained O
in O
the O
pbmc O
preparations O
tested O
, O
( O
ii O
) O
constitutive B
mRNA I
levels O
of O
the O
hybrid B
bcr I
/ I
abl I
, O
c B
- I
myc I
and O
p53 B
are O

Yet O
, O
IL B
- I
2 I
- O
driven O
proliferation O
remained O
profoundly O
inhibited O
, O
suggesting O
that O
signaling O
events O
other O
than O
Jak3 B
/ B
Stat I
activation O
had O
also O
been O
changed O
following O
SE B
stimulation O
. O

Moreover O
, O
the O
induction O
of O
both O
Jak B
1 I
and I
3 I
, O
and O
STAT B
5 I
activity O
strongly O
correlated O
with O
the O
growth O
- O
promoting O
effects O
of O
IL B
- I
7 I
, O
suggesting O
that O
this O
signal O
transduction O
mechanism O
may O
play O
a O
key O
role O
in O
IL B
- I
7 I
- O
induced O
proliferation O
. O

Tepoxalin O
also O
inhibits O
the O
activation O
of O
NF B
kappa I
B I
, O
a O
transcription B
factor I
which O
acts O
on O
several O
cytokine B
genes I
. O

Tepoxalin O
also O
inhibits O
the O
activation O
of O
NF B
kappa I
B I
, O
a O
transcription B
factor I
which O
acts O
on O
several O
cytokine B
genes I
. O

Finally O
, O
by O
studying O
a O
further O
series O
of O
patients O
, O
we O
could O
confirm O
that O
the O
decrease O
in O
Rap1 B
protein I
expression O
in O
heart O
failure O
, O
whatever O
its O
extent O
, O
was O
variable O
, O
and O
could O
strictly O
correlate O
the O
expression O
of O
Rap1 B
protein I
with O
the O
stimulatory O
effect O
of O
C B
. I
Sub I
. I
on O
Ca2 O
+ O
transport O
. O

Finally O
, O
by O
studying O
a O
further O
series O
of O
patients O
, O
we O
could O
confirm O
that O
the O
decrease O
in O
Rap1 B
protein I
expression O
in O
heart O
failure O
, O
whatever O
its O
extent O
, O
was O
variable O
, O
and O
could O
strictly O
correlate O
the O
expression O
of O
Rap1 B
protein I
with O
the O
stimulatory O
effect O
of O
C B
. I
Sub I
. I
on O
Ca2 O
+ O
transport O
. O

Activation O
through O
the O
Ca2 O
+ O
/ O
calcineurin B
pathway O
is O
essential O
to O
the O
transcription O
of O
many O
cytokine B
genes I
. O

Results O
from O
site O
- O
directed O
mutations O
and O
electrophoretic O
mobility O
shift O
assays O
strongly O
suggest O
that O
this O
sequence O
mediates O
the O
ionomycin O
- O
induced O
activation O
of O
the O
TCRG B
enhancer I
. O

Our O
studies O
provide O
an O
explanation O
for O
a O
previous O
observation O
that O
TCRG B
mRNA I
levels O
, O
but O
not O
mRNA O
levels O
for O
T B
cell I
receptor I
alpha I
and I
- I
beta I
, O
are O
increased O
by O
ionomycin O
treatment O
. O

Coexpression O
of O
NF B
- I
kappa I
B I
/ I
Rel I
and O
Sp1 B
transcription B
factors I
in O
human O
immunodeficiency O
virus O
1 O
- O
induced O
, O
dendritic O
cell O
- O
T O
- O
cell O
syncytia O
. O

Nonetheless O
, O
a O
membrane B
- I
proximal I
region I
of O
human O
IL B
- I
2R I
beta I
( O
Asn240 B
- I
Leu335 I
) O
was O
critical O
for O
JAK3 B
activation O
, O
and O
the O
amount O
of O
JAK3 B
present O
in O
activated O
IL B
- I
2 I
receptor I
complexes I
increased O
with O
time O
, O
suggesting O
that O
stabilization O
of O
JAK3 B
binding O
to O
the O
receptor B
complex I
relies O
on O
both O
IL B
- I
2R I
beta I
and O
IL B
- I
2R I
gamma I
. O

In O
most O
cases O
, O
the O
transcriptional B
factor I
NF B
- I
kappa I
B I
is O
a O
heterodimer B
consisting O
of O
two O
subunits O
, O
p50 B
and O
p65 B
, O
which O
are O
encoded O
by O
two O
distinct O
genes O
of O
the O
Rel B
family I
. O

In O
most O
cases O
, O
the O
transcriptional B
factor I
NF B
- I
kappa I
B I
is O
a O
heterodimer B
consisting O
of O
two O
subunits O
, O
p50 B
and O
p65 B
, O
which O
are O
encoded O
by O
two O
distinct O
genes O
of O
the O
Rel B
family I
. O

It O
has O
been O
suggested O
that O
the O
ubiquitin B
- B
proteasome I
system O
is O
involved O
in O
the O
process O
; O
however O
, O
the O
specific O
enzymes B
involved O
and O
the O
mechanism O
of O
limited O
proteolysis O
, O
in O
which O
half O
of O
the O
molecule O
is O
spared O
, O
have O
been O
obscure O
. O

This O
novel O
enzyme O
is O
distinct O
from O
E6 B
- I
AP I
, O
the O
p53 B
- I
conjugating I
ligase I
, O
and O
from O
E3 B
alpha I
, O
the O
` B
` I
N I
- I
end I
rule I
' I
' I
ligase I
. O

Before O
treatment O
, O
the O
number O
of O
androgen B
receptors I
was O
higher O
in O
the O
luteal O
than O
in O
the O
follicular O
phase O
. O

By O
DNA O
cotransfection O
experiments O
, O
we O
also O
demonstrate O
that O
AML B
- I
1B I
can O
increase O
the O
activity O
of O
a O
short O
osteocalcin B
promoter I
through O
its O
binding O
to O
OSE2 O
. O

IBR B
is O
a O
503 B
- I
amino I
- I
acid I
- I
long I
acidic I
protein I
which O
is O
99 O
. O
0 O
% O
identical O
to O
the O
recently O
reported O
human B
NRF I
- I
1 I
/ I
alpha I
- I
Pal I
factor I
and O
highly O
related O
to O
the O
invertebrate O
transcription B
factors I
P3A2 B
and O
erected B
wing I
gene I
product I
( O
EWG B
) O
. O

The O
lack O
of O
Jak3 B
expression O
correlated O
with O
impaired O
B O
cell O
signaling O
, O
as O
demonstrated O
by O
the O
inability O
of O
IL B
- I
4 I
to O
activate O
Stat6 B
in O
the O
EBV O
- O
transformed O
cell O
line O
from O
the O
patient O
. O
These O
observations O
indicate O
that O
the O
functions O
of O
gamma B
c I
are O
dependent O
on O
Jak3 B
and O
that O
Jak3 B
is O
essential O
for O
lymphoid O
development O
and O
signaling O
. O

Sequence O
analysis O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
CD69 B
gene I
revealed O
the O
presence O
of O
a O
potential O
TATA B
element I
30 B
base I
pairs I
upstream I
of O
the O
major O
transcription B
initiation I
site I
and O
several O
putative O
binding O
sequences O
for O
inducible O
transcription B
factors I
( O
NF B
- I
kappa I
B I
, O
Egr B
- I
1 I
, O
AP B
- I
1 I
) O
, O
which O
might O
mediate O
the O
inducible O
expression O
of O
this O
gene O
. O

Sequence O
analysis O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
CD69 B
gene I
revealed O
the O
presence O
of O
a O
potential O
TATA B
element I
30 B
base I
pairs I
upstream I
of O
the O
major O
transcription B
initiation I
site I
and O
several O
putative O
binding O
sequences O
for O
inducible O
transcription B
factors I
( O
NF B
- I
kappa I
B I
, O
Egr B
- I
1 I
, O
AP B
- I
1 I
) O
, O
which O
might O
mediate O
the O
inducible O
expression O
of O
this O
gene O
. O

Sequence O
analysis O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
CD69 B
gene I
revealed O
the O
presence O
of O
a O
potential O
TATA B
element I
30 B
base I
pairs I
upstream I
of O
the O
major O
transcription B
initiation I
site I
and O
several O
putative O
binding O
sequences O
for O
inducible O
transcription B
factors I
( O
NF B
- I
kappa I
B I
, O
Egr B
- I
1 I
, O
AP B
- I
1 I
) O
, O
which O
might O
mediate O
the O
inducible O
expression O
of O
this O
gene O
. O

The O
exon B
- I
intron I
structure I
of O
the O
5 B
' I
portion I
of O
the O
thromboxane B
receptor I
gene I
was O
determined O
initially O
by O
comparing O
the O
nucleotide B
sequence I
of O
the O
5 B
' I
flanking I
genomic I
clone I
with O
that O
of O
a O
novel B
human I
uterine I
thromboxane I
receptor I
cDNA I
that O
extended O
the O
mRNA B
141 B
bp I
further I
upstream I
than O
the O
previously B
identified I
human I
placental I
cDNA I
. O

Proteins O
in O
the O
first O
group O
contain O
multiple O
HMG B
boxes I
, O
are O
non O
- O
sequence O
- O
specific O
, O
and O
recognize O
structural O
features O
as O
found O
in O
cruciform B
DNA I
and O
cross B
- I
over I
DNA I
. O

Proteins O
in O
the O
first O
group O
contain O
multiple O
HMG B
boxes I
, O
are O
non O
- O
sequence O
- O
specific O
, O
and O
recognize O
structural O
features O
as O
found O
in O
cruciform B
DNA I
and O
cross B
- I
over I
DNA I
. O

The O
abundant O
chromosomal B
protein I
HMG B
- I
1 I
belongs O
to O
this O
subgroup O
. O

As O
in O
HMG1B B
, O
the O
overall O
structure O
of O
the O
Sox B
- I
4 I
HMG B
box I
is O
L O
- O
shaped O
and O
is O
maintained O
by O
a O
cluster O
of O
conserved O
, O
mainly O
aromatic O
residues O
. O

We O
have O
analyzed O
the O
expression O
of O
TCL1 B
mRNA I
and O
protein B
in O
peripheral O
blood O
lymphocytes O
( O
PBLs O
) O
from O
four O
AT O
cases O
and O
from O
healthy O
controls O
. O

We O
found O
that O
the O
TCL1 B
gene I
was O
overexpressed O
in O
the O
PBLs O
of O
an O
AT O
patient O
with O
a O
large O
clonal O
T O
- O
cell O
population O
exhibiting O
the O
t O
( O
14 O
; O
14 O
) O
translocation O
but O
not O
in O
the O
lymphocytes O
of O
the O
other O
cases O
. O

Fluorescence O
in O
situ O
hybridization O
of O
the O
TCL1 B
genomic I
locus I
to O
lymphocyte O
metaphases O
from O
the O
AT O
patient O
with O
the O
T O
- O
cell O
clonal O
expansion O
showed O
that O
the O
breakpoint O
of O
the O
t O
( O
14 O
; O
14 O
) O
translocation O
lies O
within O
the O
TCL1 B
locus I
and O
is O
accompanied O
by O
an O
inverted O
duplication O
of O
the O
distal B
part I
of O
chromosome B
14 I
. O

Fluorescence O
in O
situ O
hybridization O
of O
the O
TCL1 B
genomic I
locus I
to O
lymphocyte O
metaphases O
from O
the O
AT O
patient O
with O
the O
T O
- O
cell O
clonal O
expansion O
showed O
that O
the O
breakpoint O
of O
the O
t O
( O
14 O
; O
14 O
) O
translocation O
lies O
within O
the O
TCL1 B
locus I
and O
is O
accompanied O
by O
an O
inverted O
duplication O
of O
the O
distal B
part I
of O
chromosome B
14 I
. O

Fluorescence O
in O
situ O
hybridization O
of O
the O
TCL1 B
genomic I
locus I
to O
lymphocyte O
metaphases O
from O
the O
AT O
patient O
with O
the O
T O
- O
cell O
clonal O
expansion O
showed O
that O
the O
breakpoint O
of O
the O
t O
( O
14 O
; O
14 O
) O
translocation O
lies O
within O
the O
TCL1 B
locus I
and O
is O
accompanied O
by O
an O
inverted O
duplication O
of O
the O
distal B
part I
of O
chromosome B
14 I
. O

Since O
expression O
of O
the O
viruses O
is O
in O
large O
part O
regulated O
by O
the O
sequence B
elements I
in O
their O
long B
terminal I
repeats I
( O
LTRs B
) O
, O
this O
study O
was O
directed O
to O
an O
analysis O
of O
the O
regulatory B
elements I
in O
the O
HIV B
- I
2 I
LTR I
. O

Since O
expression O
of O
the O
viruses O
is O
in O
large O
part O
regulated O
by O
the O
sequence B
elements I
in O
their O
long B
terminal I
repeats I
( O
LTRs B
) O
, O
this O
study O
was O
directed O
to O
an O
analysis O
of O
the O
regulatory B
elements I
in O
the O
HIV B
- I
2 I
LTR I
. O

A O
comparison O
with O
the O
Stat B
proteins I
induced O
by O
interferon B
- I
gamma I
, O
PRL B
, O
and O
IL B
- I
6 I
in O
T47D O
mammary O
tumor O
cells O
was O
made O
. O

A O
number O
of O
the O
ETS B
family I
of O
transcription B
factors I
are O
expressed O
in O
T O
cells O
, O
including O
ETS1 B
and O
ELF1 B
. O

A O
number O
of O
the O
ETS B
family I
of O
transcription B
factors I
are O
expressed O
in O
T O
cells O
, O
including O
ETS1 B
and O
ELF1 B
. O

Using O
varying O
conditions O
, O
three O
distinct O
complexes O
were O
shown O
to O
interact O
specifically O
with O
the O
NIP B
region I
, O
although O
only O
one O
correlates O
with O
repressor O
activity O
. O

Functional O
specificity O
for O
repression O
matches O
the O
DNA O
binding O
specificity O
of O
complex B
3 I
; O
both O
repressor O
activity O
and O
complex B
3 I
binding O
require O
the O
consensus B
sequence I
CTCACNTNC O
. O

Functional O
specificity O
for O
repression O
matches O
the O
DNA O
binding O
specificity O
of O
complex B
3 I
; O
both O
repressor O
activity O
and O
complex B
3 I
binding O
require O
the O
consensus B
sequence I
CTCACNTNC O
. O

Functional O
specificity O
for O
repression O
matches O
the O
DNA O
binding O
specificity O
of O
complex B
3 I
; O
both O
repressor O
activity O
and O
complex B
3 I
binding O
require O
the O
consensus B
sequence I
CTCACNTNC O
. O

It O
binds O
the O
so O
- O
called O
Pu B
box I
, O
an O
important O
tissue B
- I
specific I
regulatory I
DNA I
element I
present O
in O
a O
number O
of O
genes O
expressed O
in O
these O
cell O
lineages O
. O

Protein O
phosphorylation O
has O
an O
important O
role O
in O
the O
regulation O
of O
these O
two O
factors O
: O
( O
1 O
) O
it O
induces O
the O
transactivating O
capacity O
of O
the O
AP B
- I
1 I
protein I
c B
- I
Jun I
; O
and O
( O
2 O
) O
it O
is O
involved O
in O
the O
release O
of O
the O
cytoplasmic B
inhibitor I
, O
I B
kappa I
B I
, O
from O
NF B
- I
kappa I
B I
, O
allowing O
translocation O
of O
the O
latter O
into O
the O
nucleus O
. O

Elevated O
levels O
of O
several O
inflammatory B
cytokines I
have O
been O
detected O
in O
the O
sera O
of O
HIV O
- O
1 O
- O
infected O
individuals O
. O

We O
measured O
steroid O
mediated O
lysis O
, O
receptor O
number O
and O
induction O
of O
glutamine B
synthetase I
in O
the O
transfected O
cells O
. O

The O
DNA B
binding I
region I
specifying O
high O
affinity O
for O
GRE B
sites I
is O
required O
. O

Full O
- O
length O
cDNAs B
and O
genomic B
clones I
were O
isolated O
, O
and O
the O
gene O
structure O
was O
determined O
. O
Comparison O
of O
the O
deduced O
amino O
acids O
shows O
88 O
% O
sequence O
identity O
between O
mouse B
and I
human I
BOB I
. I
1 I
/ I
OBF I
. I
1 I
. O

The O
NH2 B
- I
terminal I
126 I
amino I
acids I
of O
BOB B
. I
1 I
/ I
OBF I
. I
1 I
are O
both O
essential O
and O
sufficient O
for O
interaction O
with O
the O
POU B
domains I
of O
either O
Oct1 B
or O
Oct2 B
. O

As O
this O
phosphorylation O
was O
independent O
of O
protein B
kinase I
C I
activity O
, O
we O
tested O
whether O
a O
calcium B
/ I
calmodulin I
- I
dependent I
protein I
kinase I
( O
CaM B
kinase I
) O
might O
phosphorylate O
the O
Ets B
- I
1 I
protein I
after O
elevation O
of O
intracellular O
free O
calcium O
concentrations O
. O

In O
all O
cell O
lines O
investigated O
, O
the O
NF B
- I
kappa I
B I
complexes I
induced O
following O
CD30 B
engagement O
were O
shown O
to O
contain O
p50 B
NF I
- I
kappa I
B1 I
, O
p65 B
RelA I
, O
and O
possibly O
other O
transcription B
factors I
. O

In O
all O
cell O
lines O
investigated O
, O
the O
NF B
- I
kappa I
B I
complexes I
induced O
following O
CD30 B
engagement O
were O
shown O
to O
contain O
p50 B
NF I
- I
kappa I
B1 I
, O
p65 B
RelA I
, O
and O
possibly O
other O
transcription B
factors I
. O

Estrogen B
and O
progesterone B
receptors I
in O
vernal O
keratoconjunctivitis O
. O

RESULTS O
: O
Both O
the O
epithelium O
and O
subepithelium O
of O
the O
tarsal O
and O
bulbar O
conjunctiva O
of O
patients O
with O
VKC O
, O
but O
not O
those O
of O
four O
nonatopic O
control O
subjects O
, O
showed O
intense O
positive O
staining O
for O
estrogen O
and O
progesterone B
receptors I
. O

Because O
HLA B
class I
II I
molecules I
present O
antigen O
to O
T B
cell I
receptors I
( O
TCRs B
) O
, O
we O
have O
searched O
for O
a O
TCR B
gene I
associated O
with O
the O
production O
of O
anti B
- I
Ro I
( I
SSA I
) I
antibodies I
. O

This O
RFLP B
pair I
occurs O
in O
76 O
% O
of O
patients O
with O
Ro B
( I
SSA I
) I
precipitins O
, O
84 O
% O
of O
anti O
- O
Ro B
( I
SSA I
) I
- O
positive O
patients O
lacking O
La B
( I
SSB I
) I
precipitins B
, O
but O
only O
41 O
% O
of O
the O
patients O
lacking O
both O
precipitins B
( O
P O
= O
0 O
. O
0004 O
) O
. O

The O
majority O
of O
patients O
who O
have O
these O
RFLPs B
and O
HLA B
class I
II I
antigens I
previously O
associated O
with O
the O
anti O
- O
Ro B
( I
SSA I
) I
response O
make O
this O
antibody O
, O
suggesting O
that O
interactions O
between O
products O
of O
these O
loci B
occur I
in O
response O
to O
Ro B
( I
SSA I
) I
. O

However O
, O
while O
IL2 B
expression O
requires O
the O
contribution O
of O
Ca O
( O
2 O
+ O
) O
- O
and O
protein B
kinase I
C I
- O
dependent O
signals O
, O
we O
report O
that O
activation O
of O
human B
IL4 I
transcription O
through O
the O
Ca O
( O
2 O
+ O
) O
- O
dependent O
pathway O
is O
diminished O
by O
protein B
kinase I
C I
stimulation O
in O
Jurkat O
T O
cells O
. O

The O
present O
study O
demonstrates O
that O
triggering O
of O
complement B
receptors I
CR1 B
( O
CD35 B
) O
and O
CR3 B
( O
CD11b B
/ I
CD18 I
) O
enhances O
viral O
replication O
in O
HIV O
- O
infected O
human O
monocytic O
cells O
. O

Monocytic O
cell O
lines O
and O
normal O
peripheral O
blood O
monocytes O
were O
infected O
with O
HIV O
- O
1 O
in O
vitro O
and O
cultured O
in O
the O
presence O
or O
absence O
of O
F B
( I
ab I
' I
) I
2 I
fragments I
of O
monoclonal B
anti I
- I
CR1 I
or O
anti B
- I
CR3 I
Abs I
or O
with O
C3 B
fragments I
. O

Unresponsiveness O
to O
gamma B
interferon I
for O
activation O
of O
this O
pathway O
may O
explain O
impaired O
transcriptional O
responses O
in O
leishmania O
- O
infected O
cells O
. O

To O
understand O
the O
role O
of O
MARs B
in O
IgH B
enhancer I
regulation O
, O
we O
have O
identified O
a O
novel O
MAR B
- I
binding I
protein I
, O
MAR B
- I
BP1 I
, O
from O
soluble O
nuclear O
matrix O
preparations O
based O
on O
its O
ability O
to O
bind O
to O
the O
MARs B
associated O
with O
the O
IgH B
enhancer I
. O

To O
understand O
the O
role O
of O
MARs B
in O
IgH B
enhancer I
regulation O
, O
we O
have O
identified O
a O
novel O
MAR B
- I
binding I
protein I
, O
MAR B
- I
BP1 I
, O
from O
soluble O
nuclear O
matrix O
preparations O
based O
on O
its O
ability O
to O
bind O
to O
the O
MARs B
associated O
with O
the O
IgH B
enhancer I
. O

The O
GM B
- I
CSF I
receptor I
alpha I
promoter I
contains O
an O
important O
functional O
site O
between O
positions O
- O
53 O
and O
- O
41 O
as O
identified O
by O
deletion O
analysis O
of O
reporter B
constructs I
. O

In O
addition O
, O
HU O
stimulates O
the O
synthesis O
of O
fetal B
hemoglobin I
in O
sickle O
cell O
anemia O
patients O
. O

Because O
NF B
- I
kappa I
B I
activates O
many O
immunoregulatory B
genes I
in O
response O
to O
pro O
- O
inflammatory O
stimuli O
, O
the O
inhibition O
of O
its O
activity O
can O
be O
a O
major O
component O
of O
the O
anti O
- O
inflammatory O
activity O
of O
glucocorticoids O
. O

The O
5 B
' I
flanking I
DNA I
also O
contains O
a O
cluster O
of O
three O
binding B
sites I
for O
the O
GATA B
family I
of O
transcription B
factors I
. O

The O
5 B
' I
flanking I
DNA I
also O
contains O
a O
cluster O
of O
three O
binding B
sites I
for O
the O
GATA B
family I
of O
transcription B
factors I
. O

The O
5 B
' I
flanking I
DNA I
also O
contains O
a O
cluster O
of O
three O
binding B
sites I
for O
the O
GATA B
family I
of O
transcription B
factors I
. O

The O
Id2 B
mRNA I
was O
abundantly O
expressed O
in O
5 O
/ O
12 O
T O
- O
cell O
and O
3 O
/ O
4 O
B O
- O
cell O
lines O
, O
and O
Id3 B
mRNA I
was O
detected O
in O
4 O
/ O
12 O
T O
- O
cell O
and O
3 O
/ O
4 O
B O
- O
cell O
lines O
. O

The O
Id2 B
mRNA I
was O
abundantly O
expressed O
in O
5 O
/ O
12 O
T O
- O
cell O
and O
3 O
/ O
4 O
B O
- O
cell O
lines O
, O
and O
Id3 B
mRNA I
was O
detected O
in O
4 O
/ O
12 O
T O
- O
cell O
and O
3 O
/ O
4 O
B O
- O
cell O
lines O
. O

In O
addition O
, O
resting O
PBL O
constitutively O
expressed O
prominent O
levels O
of O
Id2 B
mRNA I
, O
but O
not O
Id3 B
mRNA I
. O

In O
addition O
, O
resting O
PBL O
constitutively O
expressed O
prominent O
levels O
of O
Id2 B
mRNA I
, O
but O
not O
Id3 B
mRNA I
. O

Here O
, O
we O
report O
that O
a O
family O
of O
anti O
- O
inflammatory O
agents O
, O
known O
as O
the O
salicylates O
, O
inhibited O
LPS O
induction O
of O
TF O
activity O
and O
TF B
gene I
transcription O
in O
human O
monocytes O
and O
monocytic O
THP O
- O
1 O
cells O
at O
clinically O
relevant O
doses O
. O

In O
contrast O
, O
two O
other O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
, O
ibuprofen O
and O
indomethacin O
, O
did O
not O
inhibit O
LPS O
induction O
of O
the O
TF B
gene I
. O

As O
neutralizing B
anti I
- I
IL I
- I
6 I
Abs I
effectively O
down O
- O
regulated O
the O
early O
induction O
of O
STAT B
proteins I
and O
as O
exogenously O
added O
IL B
- I
6 I
rapidly O
activated O
DNA O
binding O
similar O
to O
TCR B
- O
mediated O
bindings O
, O
it O
can O
be O
concluded O
that O
IL B
- I
6 I
is O
the O
factor O
responsible O
for O
the O
activation O
of O
STAT B
proteins I
in O
a O
primary O
T O
cell O
response O
. O

As O
neutralizing B
anti I
- I
IL I
- I
6 I
Abs I
effectively O
down O
- O
regulated O
the O
early O
induction O
of O
STAT B
proteins I
and O
as O
exogenously O
added O
IL B
- I
6 I
rapidly O
activated O
DNA O
binding O
similar O
to O
TCR B
- O
mediated O
bindings O
, O
it O
can O
be O
concluded O
that O
IL B
- I
6 I
is O
the O
factor O
responsible O
for O
the O
activation O
of O
STAT B
proteins I
in O
a O
primary O
T O
cell O
response O
. O

We O
conclude O
that O
transcription O
activation O
by O
LEF B
- I
1 I
in O
vitro O
is O
a O
chromatin B
- O
dependent O
process O
that O
requires O
a O
functional O
trans B
- I
activation I
domain I
in O
addition O
to O
the O
HMG B
domain I
. O

Immunoprecipitation O
of O
the O
gp B
160 I
- O
induced O
nuclear O
extracts O
with O
polyclonal B
antibodies I
to O
Fos B
and O
Jun B
proteins I
indicates O
that O
AP B
- I
1 I
complex I
is O
comprised O
of O
members O
of O
these O
family O
of O
proteins O
. O

Immunoprecipitation O
of O
the O
gp B
160 I
- O
induced O
nuclear O
extracts O
with O
polyclonal B
antibodies I
to O
Fos B
and O
Jun B
proteins I
indicates O
that O
AP B
- I
1 I
complex I
is O
comprised O
of O
members O
of O
these O
family O
of O
proteins O
. O

Immunoprecipitation O
of O
the O
gp B
160 I
- O
induced O
nuclear O
extracts O
with O
polyclonal B
antibodies I
to O
Fos B
and O
Jun B
proteins I
indicates O
that O
AP B
- I
1 I
complex I
is O
comprised O
of O
members O
of O
these O
family O
of O
proteins O
. O

